,text,src,Type,misc,ID,ann_section,ann_source,class
1,seasonal allergic rhinitis ( SAR ) .,1,Abstract,ss_p,10070173,test,gold,p
2,budesonide Turbuhaler,1,Abstract,ss_i,10070173,test,gold,i
3,budesonide aqua,1,Abstract,ss_i,10070173,test,gold,i
4,budesonide Turbuhaler,1,Abstract,hl_i,10070173,test,gold,i
5,budesonide aqua,1,Abstract,hl_i,10070173,test,gold,i
6,patients ' preferences for the two nasal devices,2,Abstract,ss_o,10070173,test,gold,o
7,quality of life .,2,Abstract,ss_o,10070173,test,gold,o
8,patients ' preferences,2,Abstract,hl_o,10070173,test,gold,o
9,quality of life .,2,Abstract,hl_o,10070173,test,gold,o
11,"Ontario , Quebec and Manitoba .",4,Abstract,ss_p,10070173,test,gold,p
12,"Two hundred and eighty-four out-patients with SAR , who were symptomatic during the ragweed season , volunteered for enrolment ( 243 randomized ) .",5,Abstract,ss_p,10070173,test,gold,p
13,Two hundred and eighty-four out-patients,5,Abstract,hl_p,10070173,test,gold,p
14,SAR,5,Abstract,hl_p,10070173,test,gold,p
15,symptomatic during the ragweed season,5,Abstract,hl_p,10070173,test,gold,p
16,243,5,Abstract,hl_p,10070173,test,gold,p
17,Mean daily nasal symptom scores,6,Abstract,ss_o,10070173,test,gold,o
18,Mean daily nasal symptom scores,6,Abstract,hl_o,10070173,test,gold,o
19,eye symptoms .,7,Abstract,ss_o,10070173,test,gold,o
20,eye symptoms .,7,Abstract,hl_o,10070173,test,gold,o
21,budesonide .,8,Abstract,ss_i,10070173,test,gold,i
22,budesonide .,8,Abstract,hl_i,10070173,test,gold,i
23,nasal and non-nasal adverse events,9,Abstract,ss_o,10070173,test,gold,o
24,epistaxis,9,Abstract,ss_o,10070173,test,gold,o
25,headache .,9,Abstract,ss_o,10070173,test,gold,o
26,nasal and non-nasal adverse events,9,Abstract,hl_o,10070173,test,gold,o
27,epistaxis,9,Abstract,hl_o,10070173,test,gold,o
28,headache .,9,Abstract,hl_o,10070173,test,gold,o
29,Turbuhaler,10,Abstract,ss_i,10070173,test,gold,i
30,unpleasant taste,10,Abstract,ss_o,10070173,test,gold,o
31,nasal irritation,10,Abstract,ss_o,10070173,test,gold,o
32,Turbuhaler,10,Abstract,hl_i,10070173,test,gold,i
33,nasal irritation,10,Abstract,hl_o,10070173,test,gold,o
34,Turbuhaler,11,Abstract,ss_i,10070173,test,gold,i
35,aqua spray,11,Abstract,ss_i,10070173,test,gold,i
36,Turbuhaler,11,Abstract,hl_i,10070173,test,gold,i
37,aqua spray,11,Abstract,hl_i,10070173,test,gold,i
38,quality of life,12,Abstract,ss_o,10070173,test,gold,o
39,quality of life,12,Abstract,hl_o,10070173,test,gold,o
40,SAR .,13,Abstract,ss_p,10070173,test,gold,p
41,budesonide aqua,13,Abstract,ss_i,10070173,test,gold,i
42,budesonide Turbuhaler,13,Abstract,ss_i,10070173,test,gold,i
43,safe,13,Abstract,ss_o,10070173,test,gold,o
44,efficacious,13,Abstract,ss_o,10070173,test,gold,o
45,SAR .,13,Abstract,hl_p,10070173,test,gold,p
46,budesonide aqua,13,Abstract,hl_i,10070173,test,gold,i
47,budesonide Turbuhaler,13,Abstract,hl_i,10070173,test,gold,i
48,safe,13,Abstract,hl_o,10070173,test,gold,o
49,efficacious,13,Abstract,hl_o,10070173,test,gold,o
50,budesonide powder,14,Abstract,ss_i,10070173,test,gold,i
51,Turbuhaler,14,Abstract,ss_i,10070173,test,gold,i
52,aqua,14,Abstract,ss_i,10070173,test,gold,i
53,budesonide powder,14,Abstract,hl_i,10070173,test,gold,i
54,Turbuhaler,14,Abstract,hl_i,10070173,test,gold,i
55,aqua,14,Abstract,hl_i,10070173,test,gold,i
56,seasonal allergic rhinitis .,0,Title,ss_p,10070173,test,gold,p
57,budesonide Turbuhaler,0,Title,ss_i,10070173,test,gold,i
58,budesonide aqua,0,Title,ss_i,10070173,test,gold,i
59,seasonal allergic rhinitis .,0,Title,hl_p,10070173,test,gold,p
60,budesonide Turbuhaler,0,Title,hl_i,10070173,test,gold,i
61,budesonide aqua,0,Title,hl_i,10070173,test,gold,i
62,tonsillectomy with or without adenoidectomy in children .,0,Abstract,ss_p,10390665,test,gold,p
63,granisetron,0,Abstract,ss_i,10390665,test,gold,i
64,perphenazine,0,Abstract,ss_i,10390665,test,gold,i
65,efficacy,0,Abstract,ss_o,10390665,test,gold,o
66,tonsillectomy with or without adenoidectomy,0,Abstract,hl_p,10390665,test,gold,p
67,children,0,Abstract,hl_p,10390665,test,gold,p
68,granisetron,0,Abstract,hl_i,10390665,test,gold,i
69,perphenazine,0,Abstract,hl_i,10390665,test,gold,i
70,efficacy,0,Abstract,hl_o,10390665,test,gold,o
71,"90 paediatric patients , ASA I , aged 4-10 years",1,Abstract,ss_p,10390665,test,gold,p
72,granisetron,1,Abstract,ss_i,10390665,test,gold,i
73,perphenazine,1,Abstract,ss_i,10390665,test,gold,i
74,90 paediatric patients,1,Abstract,hl_p,10390665,test,gold,p
75,ASA I,1,Abstract,hl_p,10390665,test,gold,p
76,aged 4-10 years,1,Abstract,hl_p,10390665,test,gold,p
77,granisetron,1,Abstract,hl_i,10390665,test,gold,i
78,perphenazine,1,Abstract,hl_i,10390665,test,gold,i
80,granisetron,3,Abstract,ss_i,10390665,test,gold,i
81,perphenazine,3,Abstract,ss_i,10390665,test,gold,i
82,"complete response , defined as no emesis with no need for another rescue antiemetic",3,Abstract,ss_o,10390665,test,gold,o
83,granisetron,3,Abstract,hl_i,10390665,test,gold,i
84,perphenazine,3,Abstract,hl_i,10390665,test,gold,i
85,"complete response , defined as no emesis with no need for another rescue antiemetic",3,Abstract,hl_o,10390665,test,gold,o
86,corresponding incidence,4,Abstract,ss_o,10390665,test,gold,o
87,corresponding incidence,4,Abstract,hl_o,10390665,test,gold,o
88,adverse events,5,Abstract,ss_o,10390665,test,gold,o
89,adverse events,5,Abstract,hl_o,10390665,test,gold,o
90,children undergoing general anaesthesia for tonsillectomy .,6,Abstract,ss_p,10390665,test,gold,p
91,granisetron,6,Abstract,ss_i,10390665,test,gold,i
92,perphenazine,6,Abstract,ss_i,10390665,test,gold,i
93,long-term prevention of post-operative vomiting,6,Abstract,ss_o,10390665,test,gold,o
94,children undergoing general anaesthesia for tonsillectomy,6,Abstract,hl_p,10390665,test,gold,p
95,granisetron,6,Abstract,hl_i,10390665,test,gold,i
96,perphenazine,6,Abstract,hl_i,10390665,test,gold,i
97,long-term prevention,6,Abstract,hl_o,10390665,test,gold,o
98,post-operative vomiting,6,Abstract,hl_o,10390665,test,gold,o
99,children .,0,Title,ss_p,10390665,test,gold,p
100,granisetron,0,Title,ss_i,10390665,test,gold,i
101,perphenazine,0,Title,ss_i,10390665,test,gold,i
102,Anti-emetic efficacy,0,Title,ss_o,10390665,test,gold,o
103,prevention,0,Title,ss_o,10390665,test,gold,o
104,children .,0,Title,hl_p,10390665,test,gold,p
105,granisetron,0,Title,hl_i,10390665,test,gold,i
106,perphenazine,0,Title,hl_i,10390665,test,gold,i
107,Anti-emetic efficacy,0,Title,hl_o,10390665,test,gold,o
108,prevention,0,Title,hl_o,10390665,test,gold,o
109,Somatostatin,0,Abstract,ss_i,10475150,test,gold,i
110,regulation of melatonin secretion .,0,Abstract,ss_o,10475150,test,gold,o
111,Somatostatin,0,Abstract,hl_i,10475150,test,gold,i
112,melatonin secretion .,0,Abstract,hl_o,10475150,test,gold,o
113,somatostatin,1,Abstract,ss_i,10475150,test,gold,i
114,regulatory influence on melatonin secretion,1,Abstract,ss_o,10475150,test,gold,o
115,somatostatin,1,Abstract,hl_i,10475150,test,gold,i
116,melatonin secretion,1,Abstract,hl_o,10475150,test,gold,o
117,"8 healthy volunteers , and 6 women with untreated primary hypothyroidism",2,Abstract,ss_p,10475150,test,gold,p
118,nocturnal melatonin secretion,2,Abstract,ss_o,10475150,test,gold,o
119,8 healthy volunteers,2,Abstract,hl_p,10475150,test,gold,p
120,6 women,2,Abstract,hl_p,10475150,test,gold,p
121,untreated primary hypothyroidism,2,Abstract,hl_p,10475150,test,gold,p
122,nocturnal melatonin secretion,2,Abstract,hl_o,10475150,test,gold,o
123,saline,3,Abstract,ss_i,10475150,test,gold,i
124,octreotide ( Sandostatin ;,3,Abstract,ss_i,10475150,test,gold,i
125,saline,3,Abstract,hl_i,10475150,test,gold,i
126,octreotide ( Sandostatin ;,3,Abstract,hl_i,10475150,test,gold,i
127,healthy volunteers,4,Abstract,ss_p,10475150,test,gold,p
128,octreotide,4,Abstract,ss_i,10475150,test,gold,i
129,saline .,4,Abstract,ss_i,10475150,test,gold,i
130,melatonin secretion,4,Abstract,ss_o,10475150,test,gold,o
131,healthy volunteers,4,Abstract,hl_p,10475150,test,gold,p
132,octreotide,4,Abstract,hl_i,10475150,test,gold,i
133,saline .,4,Abstract,hl_i,10475150,test,gold,i
134,melatonin secretion,4,Abstract,hl_o,10475150,test,gold,o
135,urinary excretion of melatonin,5,Abstract,ss_o,10475150,test,gold,o
136,urinary excretion of melatonin,5,Abstract,hl_o,10475150,test,gold,o
137,healthy controls,6,Abstract,ss_p,10475150,test,gold,p
138,octreotide,6,Abstract,ss_i,10475150,test,gold,i
139,octreotide,6,Abstract,ss_i,10475150,test,gold,i
140,saline ;,6,Abstract,ss_i,10475150,test,gold,i
141,GH secretion,6,Abstract,ss_o,10475150,test,gold,o
142,octreotide,6,Abstract,hl_i,10475150,test,gold,i
143,octreotide,6,Abstract,hl_i,10475150,test,gold,i
144,saline ;,6,Abstract,hl_i,10475150,test,gold,i
145,GH secretion,6,Abstract,hl_o,10475150,test,gold,o
146,The patients with hypothyroidism,7,Abstract,ss_p,10475150,test,gold,p
147,octreotide,7,Abstract,ss_i,10475150,test,gold,i
148,saline .,7,Abstract,ss_i,10475150,test,gold,i
149,nocturnal melatonin secretion,7,Abstract,ss_o,10475150,test,gold,o
150,patients with hypothyroidism,7,Abstract,hl_p,10475150,test,gold,p
151,octreotide,7,Abstract,hl_i,10475150,test,gold,i
152,saline .,7,Abstract,hl_i,10475150,test,gold,i
153,nocturnal melatonin secretion,7,Abstract,hl_o,10475150,test,gold,o
154,Urinary excretion of melatonin,8,Abstract,ss_o,10475150,test,gold,o
155,Urinary excretion of melatonin,8,Abstract,hl_o,10475150,test,gold,o
156,octreotide,9,Abstract,ss_i,10475150,test,gold,i
157,octreotide,9,Abstract,ss_i,10475150,test,gold,i
158,saline ;,9,Abstract,ss_i,10475150,test,gold,i
159,octreotide,9,Abstract,ss_i,10475150,test,gold,i
160,somatostatin .,9,Abstract,ss_i,10475150,test,gold,i
161,total nocturnal secretion of TSH,9,Abstract,ss_o,10475150,test,gold,o
162,octreotide,9,Abstract,hl_i,10475150,test,gold,i
163,octreotide,9,Abstract,hl_i,10475150,test,gold,i
164,saline ;,9,Abstract,hl_i,10475150,test,gold,i
165,octreotide,9,Abstract,hl_i,10475150,test,gold,i
166,somatostatin .,9,Abstract,hl_i,10475150,test,gold,i
167,total nocturnal secretion of TSH,9,Abstract,hl_o,10475150,test,gold,o
168,normal subjects and in patients with primary hypothyroidism,10,Abstract,ss_p,10475150,test,gold,p
169,somatostatin -- in,10,Abstract,ss_i,10475150,test,gold,i
170,octreotide -- fails,10,Abstract,ss_i,10475150,test,gold,i
171,somatostatin,10,Abstract,ss_i,10475150,test,gold,i
172,nocturnal secretion and urinary excretion of melatonin,10,Abstract,ss_o,10475150,test,gold,o
173,regulator of melatonin secretion,10,Abstract,ss_o,10475150,test,gold,o
174,normal subjects and in patients with primary hypothyroidism,10,Abstract,hl_p,10475150,test,gold,p
175,somatostatin,10,Abstract,hl_i,10475150,test,gold,i
176,octreotide,10,Abstract,hl_i,10475150,test,gold,i
177,somatostatin,10,Abstract,hl_i,10475150,test,gold,i
178,nocturnal secretion and urinary excretion of melatonin,10,Abstract,hl_o,10475150,test,gold,o
179,healthy volunteers and in patients with primary hypothyroidism .,0,Title,ss_p,10475150,test,gold,p
180,somatostatin ( octreotide ),0,Title,ss_i,10475150,test,gold,i
181,regulation of melatonin secretion,0,Title,ss_o,10475150,test,gold,o
182,healthy volunteers and in patients with primary hypothyroidism .,0,Title,hl_p,10475150,test,gold,p
183,somatostatin ( octreotide ),0,Title,hl_i,10475150,test,gold,i
184,melatonin secretion,0,Title,hl_o,10475150,test,gold,o
185,soy,0,Abstract,ss_i,10578479,test,gold,i
186,hormonal effects,0,Abstract,ss_o,10578479,test,gold,o
187,soy,0,Abstract,hl_i,10578479,test,gold,i
188,soy,1,Abstract,ss_i,10578479,test,gold,i
189,soy,1,Abstract,ss_i,10578479,test,gold,i
190,sex hormone metabolism,1,Abstract,ss_o,10578479,test,gold,o
191,menstrual function or serum sex hormones,1,Abstract,ss_o,10578479,test,gold,o
192,soy,1,Abstract,hl_i,10578479,test,gold,i
193,sex hormone metabolism,1,Abstract,hl_o,10578479,test,gold,o
194,"36 premenopausal women , 20 of whom used OC .",2,Abstract,ss_p,10578479,test,gold,p
195,soy,2,Abstract,ss_i,10578479,test,gold,i
196,36 premenopausal women,2,Abstract,hl_p,10578479,test,gold,p
197,20,2,Abstract,hl_p,10578479,test,gold,p
198,used OC,2,Abstract,hl_p,10578479,test,gold,p
199,soy,2,Abstract,hl_i,10578479,test,gold,i
200,normal diet,3,Abstract,ss_i,10578479,test,gold,i
201,soy beverage,3,Abstract,ss_i,10578479,test,gold,i
202,soy beverage,3,Abstract,hl_i,10578479,test,gold,i
203,soy,4,Abstract,ss_i,10578479,test,gold,i
204,"serum estrone , estradiol , sex hormone-binding globulin , dehydroepiandrosterone sulfate , prolactin , or progesterone concentrations",4,Abstract,ss_o,10578479,test,gold,o
205,soy,4,Abstract,hl_i,10578479,test,gold,i
206,"serum estrone , estradiol , sex hormone-binding globulin , dehydroepiandrosterone sulfate , prolactin , or progesterone concentrations",4,Abstract,hl_o,10578479,test,gold,o
207,menstrual cycle length or the urinary estrogen metabolite ratio of 2-hydroxyestrone to 16 alpha-hydroxyestrone,5,Abstract,ss_o,10578479,test,gold,o
208,menstrual cycle length or the urinary estrogen metabolite ratio of 2-hydroxyestrone to 16 alpha-hydroxyestrone,5,Abstract,hl_o,10578479,test,gold,o
209,urinary estrogen metabolites,6,Abstract,ss_o,10578479,test,gold,o
210,urinary estrogen metabolites,6,Abstract,hl_o,10578479,test,gold,o
211,premenopausal OC or non-OC users .,7,Abstract,ss_p,10578479,test,gold,p
212,soy,7,Abstract,ss_i,10578479,test,gold,i
213,"menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio",7,Abstract,ss_o,10578479,test,gold,o
214,premenopausal OC,7,Abstract,hl_p,10578479,test,gold,p
215,non-OC users .,7,Abstract,hl_p,10578479,test,gold,p
216,soy,7,Abstract,hl_i,10578479,test,gold,i
217,"menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio",7,Abstract,hl_o,10578479,test,gold,o
218,premenopausal women .,0,Title,ss_p,10578479,test,gold,p
219,soy,0,Title,ss_i,10578479,test,gold,i
220,sex hormone metabolism,0,Title,ss_o,10578479,test,gold,o
221,premenopausal women .,0,Title,hl_p,10578479,test,gold,p
222,soy,0,Title,hl_i,10578479,test,gold,i
223,sex hormone metabolism,0,Title,hl_o,10578479,test,gold,o
225,non-root substance removing curettes,1,Abstract,ss_i,10589810,test,gold,i
226,plastic curettes,2,Abstract,ss_i,10589810,test,gold,i
227,clinical effects,2,Abstract,ss_o,10589810,test,gold,o
228,clinical effects,2,Abstract,hl_o,10589810,test,gold,o
229,during supportive periodontal therapy .,3,Abstract,ss_p,10589810,test,gold,p
230,plastic curettes,3,Abstract,ss_i,10589810,test,gold,i
231,conventional steel curettes,3,Abstract,ss_i,10589810,test,gold,i
232,effects,3,Abstract,ss_o,10589810,test,gold,o
233,plastic curettes,3,Abstract,hl_i,10589810,test,gold,i
234,conventional steel curettes,3,Abstract,hl_i,10589810,test,gold,i
235,40 subjects,4,Abstract,ss_p,10589810,test,gold,p
236,40 subjects,4,Abstract,hl_p,10589810,test,gold,p
237,conventional steel curettes,5,Abstract,ss_i,10589810,test,gold,i
238,20,5,Abstract,hl_p,10589810,test,gold,p
239,conventional steel curettes,5,Abstract,hl_i,10589810,test,gold,i
240,plastic curettes,6,Abstract,ss_i,10589810,test,gold,i
241,20,6,Abstract,hl_p,10589810,test,gold,p
242,plastic curettes,6,Abstract,hl_i,10589810,test,gold,i
243,bleeding on probing ( BOP ) and probing pocket depth ( PPD ),7,Abstract,ss_o,10589810,test,gold,o
244,bleeding on probing ( BOP ) and probing pocket depth ( PPD ),7,Abstract,hl_o,10589810,test,gold,o
245,BOP percentage,8,Abstract,ss_o,10589810,test,gold,o
246,BOP percentage,8,Abstract,hl_o,10589810,test,gold,o
247,BOP and PPD,9,Abstract,ss_o,10589810,test,gold,o
248,BOP and PPD,9,Abstract,hl_o,10589810,test,gold,o
249,BOP percentage,10,Abstract,ss_o,10589810,test,gold,o
250,BOP,10,Abstract,ss_o,10589810,test,gold,o
251,BOP,10,Abstract,ss_o,10589810,test,gold,o
252,BOP percentage,10,Abstract,hl_o,10589810,test,gold,o
253,BOP,10,Abstract,hl_o,10589810,test,gold,o
254,BOP,10,Abstract,hl_o,10589810,test,gold,o
255,non-root substance removing curettes,11,Abstract,ss_i,10589810,test,gold,i
256,non-root substance removing curettes,11,Abstract,hl_i,10589810,test,gold,i
257,supportive periodontal therapy ( SPT ) .,0,Title,ss_p,10589810,test,gold,p
258,conventional steel,0,Title,ss_i,10589810,test,gold,i
259,non-tooth substance removing plastic curettes,0,Title,ss_i,10589810,test,gold,i
260,Clinical effects,0,Title,ss_o,10589810,test,gold,o
261,Clinical effects,0,Title,hl_o,10589810,test,gold,o
262,Xylometazoline,0,Abstract,ss_i,10763172,test,gold,i
263,Dexpanthenol ( Nasic ),0,Abstract,ss_i,10763172,test,gold,i
264,Xylometazoline alone .,0,Abstract,ss_i,10763172,test,gold,i
265,efficacy,0,Abstract,ss_o,10763172,test,gold,o
266,tolerability,0,Abstract,ss_o,10763172,test,gold,o
267,Xylometazoline,0,Abstract,hl_i,10763172,test,gold,i
268,Dexpanthenol ( Nasic ),0,Abstract,hl_i,10763172,test,gold,i
269,Xylometazoline,0,Abstract,hl_i,10763172,test,gold,i
270,efficacy,0,Abstract,hl_o,10763172,test,gold,o
271,tolerability,0,Abstract,hl_o,10763172,test,gold,o
273,61 inpatients with the diagnosis Rhinitis following nasal operation,2,Abstract,ss_p,10763172,test,gold,p
274,verum,2,Abstract,ss_i,10763172,test,gold,i
275,placebo,2,Abstract,ss_i,10763172,test,gold,i
276,61 inpatients with the diagnosis Rhinitis following nasal operation,2,Abstract,hl_p,10763172,test,gold,p
277,verum,2,Abstract,hl_i,10763172,test,gold,i
278,placebo,2,Abstract,hl_i,10763172,test,gold,i
279,nasal-breathing-resistance according to scores was defined as target-parameter .,3,Abstract,ss_o,10763172,test,gold,o
280,nasal-breathing-resistance according to scores,3,Abstract,hl_o,10763172,test,gold,o
282,Xylometazoline-Dexpanthenol,5,Abstract,ss_i,10763172,test,gold,i
283,Xylometazoline,5,Abstract,ss_i,10763172,test,gold,i
284,superiority,5,Abstract,ss_o,10763172,test,gold,o
285,target-parameter,5,Abstract,ss_o,10763172,test,gold,o
286,Xylometazoline-Dexpanthenol,5,Abstract,hl_i,10763172,test,gold,i
287,Xylometazoline,5,Abstract,hl_i,10763172,test,gold,i
288,efficacy,6,Abstract,ss_o,10763172,test,gold,o
289,tolerability,6,Abstract,ss_o,10763172,test,gold,o
290,efficacy,6,Abstract,hl_o,10763172,test,gold,o
291,tolerability,6,Abstract,hl_o,10763172,test,gold,o
292,compliance,7,Abstract,ss_o,10763172,test,gold,o
293,compliance,7,Abstract,hl_o,10763172,test,gold,o
294,patients following nasal operations,8,Abstract,ss_p,10763172,test,gold,p
295,improvement,8,Abstract,ss_o,10763172,test,gold,o
296,efficacy,8,Abstract,ss_o,10763172,test,gold,o
297,patients following nasal operations,8,Abstract,hl_p,10763172,test,gold,p
298,improvement,8,Abstract,hl_o,10763172,test,gold,o
299,efficacy,8,Abstract,hl_o,10763172,test,gold,o
300,tolerability,9,Abstract,ss_o,10763172,test,gold,o
301,tolerability,9,Abstract,hl_o,10763172,test,gold,o
302,rhinitis following nasal operation,10,Abstract,ss_p,10763172,test,gold,p
303,Xylometazoline-Dexpanthenol,10,Abstract,ss_i,10763172,test,gold,i
304,Xylometazoline,10,Abstract,ss_i,10763172,test,gold,i
305,rhinitis following nasal operation,10,Abstract,hl_p,10763172,test,gold,p
306,Xylometazoline-Dexpanthenol,10,Abstract,hl_i,10763172,test,gold,i
307,Xylometazoline,10,Abstract,hl_i,10763172,test,gold,i
308,after nose surgery,0,Title,ss_p,10763172,test,gold,p
309,xylometazoline,0,Title,ss_i,10763172,test,gold,i
310,dexpanthenol ],0,Title,ss_i,10763172,test,gold,i
311,[ Improving wound healing,0,Title,ss_o,10763172,test,gold,o
312,after nose surgery,0,Title,hl_p,10763172,test,gold,p
313,xylometazoline,0,Title,hl_i,10763172,test,gold,i
314,dexpanthenol ],0,Title,hl_i,10763172,test,gold,i
315,wound healing,0,Title,hl_o,10763172,test,gold,o
316,patients who underwent hysterectomy .,0,Abstract,ss_p,10764172,test,gold,p
317,morphine,0,Abstract,ss_i,10764172,test,gold,i
318,natural killer ( NK ) cell activity,0,Abstract,ss_o,10764172,test,gold,o
319,underwent hysterectomy,0,Abstract,hl_p,10764172,test,gold,p
320,morphine,0,Abstract,hl_i,10764172,test,gold,i
321,natural killer ( NK ) cell activity,0,Abstract,hl_o,10764172,test,gold,o
322,Forty patients were divided into four groups of ten .,1,Abstract,ss_p,10764172,test,gold,p
323,Forty patients were divided into four groups of ten .,1,Abstract,hl_p,10764172,test,gold,p
324,morphine,2,Abstract,ss_i,10764172,test,gold,i
325,morphine,2,Abstract,ss_i,10764172,test,gold,i
326,morphine,2,Abstract,ss_i,10764172,test,gold,i
327,morphine,2,Abstract,hl_i,10764172,test,gold,i
328,morphine,2,Abstract,hl_i,10764172,test,gold,i
329,morphine,2,Abstract,hl_i,10764172,test,gold,i
332,blood NK cell activity,5,Abstract,ss_o,10764172,test,gold,o
333,"chromium release assay with K562 cells as targets , plasma catecholamines and cortisol levels .",5,Abstract,ss_o,10764172,test,gold,o
334,postoperative pain score and side effects,6,Abstract,ss_o,10764172,test,gold,o
335,postoperative pain score and side effects,6,Abstract,hl_o,10764172,test,gold,o
336,NK cell activity,7,Abstract,ss_o,10764172,test,gold,o
337,NK cell activity,7,Abstract,hl_o,10764172,test,gold,o
338,NK cell activities,8,Abstract,ss_o,10764172,test,gold,o
339,NK cell activities,8,Abstract,hl_o,10764172,test,gold,o
340,plasma adrenaline,9,Abstract,ss_o,10764172,test,gold,o
341,noradrenaline concentrations,9,Abstract,ss_o,10764172,test,gold,o
342,plasma adrenaline,9,Abstract,hl_o,10764172,test,gold,o
343,noradrenaline concentrations,9,Abstract,hl_o,10764172,test,gold,o
344,plasma cortisol levels,10,Abstract,ss_o,10764172,test,gold,o
345,plasma cortisol levels,10,Abstract,hl_o,10764172,test,gold,o
346,pain score,11,Abstract,ss_o,10764172,test,gold,o
347,pain score,11,Abstract,hl_o,10764172,test,gold,o
348,abdominal surgery .,12,Abstract,ss_p,10764172,test,gold,p
349,morphine,12,Abstract,ss_i,10764172,test,gold,i
350,morphine,12,Abstract,hl_i,10764172,test,gold,i
351,abdominal surgery .,0,Title,ss_p,10764172,test,gold,p
352,morphine,0,Title,ss_i,10764172,test,gold,i
353,NK cell activity,0,Title,ss_o,10764172,test,gold,o
354,morphine,0,Title,hl_i,10764172,test,gold,i
355,NK cell activity,0,Title,hl_o,10764172,test,gold,o
357,hypertensive patients receiving drug treatment,1,Abstract,ss_p,10912743,test,gold,p
358,aspirin,1,Abstract,ss_i,10912743,test,gold,i
359,blood pressure ( BP ) control,1,Abstract,ss_o,10912743,test,gold,o
360,hypertensive patients receiving drug treatment,1,Abstract,hl_p,10912743,test,gold,p
361,aspirin,1,Abstract,hl_i,10912743,test,gold,i
362,blood pressure ( BP ) control,1,Abstract,hl_o,10912743,test,gold,o
363,"hypertensives on chronic , stable antihypertensive therapy .",2,Abstract,ss_p,10912743,test,gold,p
364,aspirin,2,Abstract,ss_i,10912743,test,gold,i
365,clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP,2,Abstract,ss_o,10912743,test,gold,o
366,aspirin,2,Abstract,hl_i,10912743,test,gold,i
367,clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP,2,Abstract,hl_o,10912743,test,gold,o
368,people with one or more cardiovascular risk factors .,3,Abstract,ss_p,10912743,test,gold,p
369,aspirin,3,Abstract,ss_i,10912743,test,gold,i
370,vitamin E,3,Abstract,ss_i,10912743,test,gold,i
371,people with one or more cardiovascular risk factors .,3,Abstract,hl_p,10912743,test,gold,p
372,aspirin,3,Abstract,hl_i,10912743,test,gold,i
373,vitamin E,3,Abstract,hl_i,10912743,test,gold,i
374,"Fifteen Italian hypertension units studied 142 hypertensive patients ( 76 men , 66 women ; mean age 59 +/- 5.9 years ) treated with different antihypertensive drugs :",4,Abstract,ss_p,10912743,test,gold,p
375,aspirin,4,Abstract,ss_i,10912743,test,gold,i
376,hypertension,4,Abstract,hl_p,10912743,test,gold,p
377,142 hypertensive,4,Abstract,hl_p,10912743,test,gold,p
378,76 men,4,Abstract,hl_p,10912743,test,gold,p
379,66 women,4,Abstract,hl_p,10912743,test,gold,p
380,mean age 59 +/- 5.9 years,4,Abstract,hl_p,10912743,test,gold,p
381,treated with different antihypertensive drugs,4,Abstract,hl_p,10912743,test,gold,p
382,aspirin,4,Abstract,hl_i,10912743,test,gold,i
383,aspirin,5,Abstract,ss_i,10912743,test,gold,i
384,clinic BP,5,Abstract,ss_o,10912743,test,gold,o
385,24-h ambulatory BP monitoring,5,Abstract,ss_o,10912743,test,gold,o
386,aspirin,5,Abstract,hl_i,10912743,test,gold,i
387,clinic BP,5,Abstract,hl_o,10912743,test,gold,o
388,24-h ambulatory BP monitoring,5,Abstract,hl_o,10912743,test,gold,o
389,clinic SBP and DBP,6,Abstract,ss_o,10912743,test,gold,o
390,clinic SBP and DBP,6,Abstract,hl_o,10912743,test,gold,o
391,aspirin,7,Abstract,ss_i,10912743,test,gold,i
392,Ambulatory SBP and DBP,7,Abstract,ss_o,10912743,test,gold,o
393,aspirin,7,Abstract,hl_i,10912743,test,gold,i
394,Ambulatory SBP and DBP,7,Abstract,hl_o,10912743,test,gold,o
396,aspirin,9,Abstract,ss_i,10912743,test,gold,i
397,aspirin,9,Abstract,hl_i,10912743,test,gold,i
398,hypertensives under treatment .,10,Abstract,ss_p,10912743,test,gold,p
399,aspirin,10,Abstract,ss_i,10912743,test,gold,i
400,BP,10,Abstract,ss_o,10912743,test,gold,o
401,aspirin,10,Abstract,hl_i,10912743,test,gold,i
402,BP,10,Abstract,hl_o,10912743,test,gold,o
403,treated hypertensive patients .,0,Title,ss_p,10912743,test,gold,p
404,aspirin,0,Title,ss_i,10912743,test,gold,i
405,clinic and ambulatory blood pressure,0,Title,ss_o,10912743,test,gold,o
406,treated hypertensive patients .,0,Title,hl_p,10912743,test,gold,p
407,aspirin,0,Title,hl_i,10912743,test,gold,i
408,clinic and ambulatory blood pressure,0,Title,hl_o,10912743,test,gold,o
409,Young children with pervasive developmental disorder,0,Abstract,ss_p,10934569,test,gold,p
410,intensive treatment,0,Abstract,ss_i,10934569,test,gold,i
411,parent training .,0,Abstract,ss_i,10934569,test,gold,i
412,Young children,0,Abstract,hl_p,10934569,test,gold,p
413,pervasive developmental disorder,0,Abstract,hl_p,10934569,test,gold,p
414,intensive treatment,0,Abstract,hl_i,10934569,test,gold,i
415,parent training .,0,Abstract,hl_i,10934569,test,gold,i
416,"( 7 with autism , 8 with pervasive developmental disorder not otherwise specified -- NOS )",1,Abstract,ss_p,10934569,test,gold,p
417,intensive treatment,1,Abstract,ss_i,10934569,test,gold,i
418,7,1,Abstract,hl_p,10934569,test,gold,p
419,autism,1,Abstract,hl_p,10934569,test,gold,p
420,8,1,Abstract,hl_p,10934569,test,gold,p
421,pervasive developmental disorder not otherwise specified -- NOS,1,Abstract,hl_p,10934569,test,gold,p
422,intensive treatment,1,Abstract,hl_i,10934569,test,gold,i
423,"( 7 with autism , 6 with pervasive developmental disorder NOS )",2,Abstract,ss_p,10934569,test,gold,p
424,parent training,2,Abstract,ss_i,10934569,test,gold,i
425,parent training .,2,Abstract,ss_i,10934569,test,gold,i
426,7 with autism,2,Abstract,hl_p,10934569,test,gold,p
427,6 with pervasive developmental disorder NOS,2,Abstract,hl_p,10934569,test,gold,p
428,parent training,2,Abstract,hl_i,10934569,test,gold,i
429,parent training .,2,Abstract,hl_i,10934569,test,gold,i
430,intensive treatment,3,Abstract,ss_i,10934569,test,gold,i
431,parent training,3,Abstract,ss_i,10934569,test,gold,i
432,"intelligence , visual-spatial skills , language , and academics",3,Abstract,ss_o,10934569,test,gold,o
433,adaptive functioning,3,Abstract,ss_o,10934569,test,gold,o
434,behavior problems .,3,Abstract,ss_o,10934569,test,gold,o
435,intensive treatment,3,Abstract,hl_i,10934569,test,gold,i
436,parent training,3,Abstract,hl_i,10934569,test,gold,i
437,intelligence,3,Abstract,hl_o,10934569,test,gold,o
438,visual-spatial skills,3,Abstract,hl_o,10934569,test,gold,o
439,language,3,Abstract,hl_o,10934569,test,gold,o
440,academics,3,Abstract,hl_o,10934569,test,gold,o
441,adaptive functioning,3,Abstract,hl_o,10934569,test,gold,o
442,behavior problems .,3,Abstract,hl_o,10934569,test,gold,o
443,Children with pervasive developmental disorder NOS,4,Abstract,ss_p,10934569,test,gold,p
444,autism .,4,Abstract,ss_p,10934569,test,gold,p
445,Children,4,Abstract,hl_p,10934569,test,gold,p
446,pervasive developmental disorder,4,Abstract,hl_p,10934569,test,gold,p
447,children with pervasive developmental disorder .,0,Title,ss_p,10934569,test,gold,p
448,intensive early intervention,0,Title,ss_i,10934569,test,gold,i
449,children,0,Title,hl_p,10934569,test,gold,p
450,pervasive developmental disorder,0,Title,hl_p,10934569,test,gold,p
451,intensive early intervention,0,Title,hl_i,10934569,test,gold,i
452,on dogs and cats,0,Abstract,ss_p,10940525,test,gold,p
453,selamectin,0,Abstract,ss_i,10940525,test,gold,i
454,efficacy,0,Abstract,ss_o,10940525,test,gold,o
455,safety,0,Abstract,ss_o,10940525,test,gold,o
456,dogs and cats,0,Abstract,hl_p,10940525,test,gold,p
457,selamectin,0,Abstract,hl_i,10940525,test,gold,i
458,efficacy,0,Abstract,hl_o,10940525,test,gold,o
459,safety,0,Abstract,hl_o,10940525,test,gold,o
460,dogs and cats showing signs of flea allergy dermatitis ( FAD ) .,1,Abstract,ss_p,10940525,test,gold,p
461,selamectin,1,Abstract,ss_i,10940525,test,gold,i
462,dogs and cats showing signs of flea allergy dermatitis ( FAD ) .,1,Abstract,hl_p,10940525,test,gold,p
463,selamectin,1,Abstract,hl_i,10940525,test,gold,i
464,selamectin,2,Abstract,ss_i,10940525,test,gold,i
465,selamectin,2,Abstract,hl_i,10940525,test,gold,i
466,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD",3,Abstract,ss_p,10940525,test,gold,p
467,"( 220 dogs , 189 cats )",3,Abstract,ss_p,10940525,test,gold,p
468,selamectin,3,Abstract,ss_i,10940525,test,gold,i
469,fenthion,3,Abstract,ss_i,10940525,test,gold,i
470,pyrethrins,3,Abstract,ss_i,10940525,test,gold,i
471,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD",3,Abstract,hl_p,10940525,test,gold,p
472,"220 dogs , 189 cats",3,Abstract,hl_p,10940525,test,gold,p
473,selamectin,3,Abstract,hl_i,10940525,test,gold,i
474,fenthion,3,Abstract,hl_i,10940525,test,gold,i
475,pyrethrins,3,Abstract,hl_i,10940525,test,gold,i
476,Selamectin,4,Abstract,ss_i,10940525,test,gold,i
477,Selamectin,4,Abstract,hl_i,10940525,test,gold,i
479,flea comb counts and clinical evaluations of FAD,6,Abstract,ss_o,10940525,test,gold,o
480,flea comb counts,6,Abstract,hl_o,10940525,test,gold,o
481,clinical evaluations of FAD,6,Abstract,hl_o,10940525,test,gold,o
482,selamectin-treated,7,Abstract,ss_i,10940525,test,gold,i
483,fenthion-treated,7,Abstract,ss_i,10940525,test,gold,i
484,mean flea counts,7,Abstract,ss_o,10940525,test,gold,o
485,mean flea counts,7,Abstract,ss_o,10940525,test,gold,o
486,selamectin-treated,7,Abstract,hl_i,10940525,test,gold,i
487,mean flea counts,7,Abstract,hl_o,10940525,test,gold,o
488,mean flea counts,7,Abstract,hl_o,10940525,test,gold,o
489,selamectin-treated,8,Abstract,ss_i,10940525,test,gold,i
490,pyrethrin-treated,8,Abstract,ss_i,10940525,test,gold,i
491,mean flea counts,8,Abstract,ss_o,10940525,test,gold,o
492,mean flea counts,8,Abstract,ss_o,10940525,test,gold,o
493,mean flea counts,8,Abstract,hl_o,10940525,test,gold,o
494,mean flea counts,8,Abstract,hl_o,10940525,test,gold,o
495,dogs and cats diagnosed clinically with FAD .,9,Abstract,ss_p,10940525,test,gold,p
496,Selamectin,9,Abstract,ss_i,10940525,test,gold,i
497,signs,9,Abstract,ss_o,10940525,test,gold,o
498,dogs and cats diagnosed clinically with FAD .,9,Abstract,hl_p,10940525,test,gold,p
499,Selamectin,9,Abstract,hl_i,10940525,test,gold,i
500,397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA,10,Abstract,ss_p,10940525,test,gold,p
501,selamectin,10,Abstract,ss_i,10940525,test,gold,i
502,ivermectin,10,Abstract,ss_i,10940525,test,gold,i
503,397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA,10,Abstract,hl_p,10940525,test,gold,p
504,selamectin,10,Abstract,hl_i,10940525,test,gold,i
505,ivermectin,10,Abstract,hl_i,10940525,test,gold,i
506,Selamectin,11,Abstract,ss_i,10940525,test,gold,i
507,heartworm prevention rate,11,Abstract,ss_o,10940525,test,gold,o
508,microfilariae and adult heartworm antigen,11,Abstract,ss_o,10940525,test,gold,o
509,Selamectin,11,Abstract,hl_i,10940525,test,gold,i
510,heartworm prevention rate,11,Abstract,hl_o,10940525,test,gold,o
511,673 dogs and 347 cats having an age range of 6 weeks to 19 years,12,Abstract,ss_p,10940525,test,gold,p
512,Selamectin,12,Abstract,ss_i,10940525,test,gold,i
513,673 dogs and 347 cats,12,Abstract,hl_p,10940525,test,gold,p
514,Selamectin,12,Abstract,hl_i,10940525,test,gold,i
515,"19 purebred or crossbred Collies ( Bearded , Border , and unspecified ) .",13,Abstract,ss_p,10940525,test,gold,p
516,"19 purebred or crossbred Collies ( Bearded , Border , and unspecified ) .",13,Abstract,hl_p,10940525,test,gold,p
517,adverse events .,14,Abstract,ss_o,10940525,test,gold,o
518,adverse events .,14,Abstract,hl_o,10940525,test,gold,o
519,in dogs and cats,15,Abstract,ss_p,10940525,test,gold,p
520,selamectin,15,Abstract,ss_i,10940525,test,gold,i
521,effective,15,Abstract,ss_o,10940525,test,gold,o
522,signs associated with FAD .,15,Abstract,ss_o,10940525,test,gold,o
523,dogs and cats,15,Abstract,hl_p,10940525,test,gold,p
524,selamectin,15,Abstract,hl_i,10940525,test,gold,i
525,effective,15,Abstract,hl_o,10940525,test,gold,o
526,signs associated with FAD .,15,Abstract,hl_o,10940525,test,gold,o
527,dogs and cats .,16,Abstract,ss_p,10940525,test,gold,p
528,Selamectin,16,Abstract,ss_i,10940525,test,gold,i
529,effective,16,Abstract,ss_o,10940525,test,gold,o
530,heartworms,16,Abstract,ss_o,10940525,test,gold,o
531,safe,16,Abstract,ss_o,10940525,test,gold,o
532,dogs and cats .,16,Abstract,hl_p,10940525,test,gold,p
533,Selamectin,16,Abstract,hl_i,10940525,test,gold,i
534,heartworms,16,Abstract,hl_o,10940525,test,gold,o
535,safe,16,Abstract,hl_o,10940525,test,gold,o
536,dogs and cats presented as veterinary patients in North America .,0,Title,ss_p,10940525,test,gold,p
537,selamectin,0,Title,ss_i,10940525,test,gold,i
538,Efficacy,0,Title,ss_o,10940525,test,gold,o
539,safety,0,Title,ss_o,10940525,test,gold,o
540,dogs and cats presented as veterinary patients in North America .,0,Title,hl_p,10940525,test,gold,p
541,selamectin,0,Title,hl_i,10940525,test,gold,i
542,Efficacy,0,Title,hl_o,10940525,test,gold,o
543,safety,0,Title,hl_o,10940525,test,gold,o
544,Acute invasive diarrhea,0,Abstract,ss_p,11099086,test,gold,p
545,in children .,0,Abstract,ss_p,11099086,test,gold,p
546,children .,0,Abstract,hl_p,11099086,test,gold,p
547,acute invasive diarrhea requiring an emergency visit in southern Israel .,1,Abstract,ss_p,11099086,test,gold,p
548,ceftriaxone,1,Abstract,ss_i,11099086,test,gold,i
549,ceftriaxone,1,Abstract,hl_i,11099086,test,gold,i
550,invasive diarrhea .,2,Abstract,ss_p,11099086,test,gold,p
551,acute invasive diarrhea in infants and children .,3,Abstract,ss_p,11099086,test,gold,p
552,ciprofloxacin,3,Abstract,ss_i,11099086,test,gold,i
553,efficacy,3,Abstract,ss_o,11099086,test,gold,o
554,safety,3,Abstract,ss_o,11099086,test,gold,o
555,acute invasive diarrhea,3,Abstract,hl_p,11099086,test,gold,p
556,infants and children,3,Abstract,hl_p,11099086,test,gold,p
557,ciprofloxacin,3,Abstract,hl_i,11099086,test,gold,i
558,efficacy,3,Abstract,hl_o,11099086,test,gold,o
559,safety,3,Abstract,hl_o,11099086,test,gold,o
560,201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room,4,Abstract,ss_p,11099086,test,gold,p
561,ciprofloxacin,4,Abstract,ss_i,11099086,test,gold,i
562,ceftriaxone,4,Abstract,ss_i,11099086,test,gold,i
563,201,4,Abstract,hl_p,11099086,test,gold,p
564,children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room,4,Abstract,hl_p,11099086,test,gold,p
565,ciprofloxacin,4,Abstract,hl_i,11099086,test,gold,i
566,ceftriaxone,4,Abstract,hl_i,11099086,test,gold,i
567,"Stool cultures for Shigella , Salmonella , Campylobacter spp .",5,Abstract,ss_o,11099086,test,gold,o
568,"Stool cultures for Shigella , Salmonella , Campylobacter spp .",5,Abstract,hl_o,11099086,test,gold,o
569,and diarrheagenic Escherichia coli,6,Abstract,ss_o,11099086,test,gold,o
570,and diarrheagenic Escherichia coli,6,Abstract,hl_o,11099086,test,gold,o
571,Clinical response and safety,7,Abstract,ss_o,11099086,test,gold,o
572,Clinical response and safety,7,Abstract,hl_o,11099086,test,gold,o
575,ciprofloxacin,10,Abstract,ss_i,11099086,test,gold,i
576,ceftriaxone,10,Abstract,ss_i,11099086,test,gold,i
577,Clinical cure or improvement,10,Abstract,ss_o,11099086,test,gold,o
578,ciprofloxacin,10,Abstract,hl_i,11099086,test,gold,i
579,ceftriaxone,10,Abstract,hl_i,11099086,test,gold,i
580,Clinical cure or improvement,10,Abstract,hl_o,11099086,test,gold,o
581,ciprofloxacin,11,Abstract,ss_i,11099086,test,gold,i
582,ciprofloxacin,11,Abstract,hl_i,11099086,test,gold,i
584,[ ciprofloxacin,13,Abstract,ss_i,11099086,test,gold,i
585,ceftriaxone,13,Abstract,ss_i,11099086,test,gold,i
586,adverse events,13,Abstract,ss_o,11099086,test,gold,o
587,ciprofloxacin,13,Abstract,hl_i,11099086,test,gold,i
588,ceftriaxone,13,Abstract,hl_i,11099086,test,gold,i
589,adverse events,13,Abstract,hl_o,11099086,test,gold,o
590,Joint examination,14,Abstract,ss_o,11099086,test,gold,o
591,Joint examination,14,Abstract,hl_o,11099086,test,gold,o
592,acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .,15,Abstract,ss_p,11099086,test,gold,p
593,ciprofloxacin,15,Abstract,ss_i,11099086,test,gold,i
594,ceftriaxone,15,Abstract,ss_i,11099086,test,gold,i
595,safe and effective,15,Abstract,ss_o,11099086,test,gold,o
596,ambulatory pediatric patients requiring an emergency room visit .,15,Abstract,hl_p,11099086,test,gold,p
597,ciprofloxacin,15,Abstract,hl_i,11099086,test,gold,i
598,ceftriaxone,15,Abstract,hl_i,11099086,test,gold,i
599,safe,15,Abstract,hl_o,11099086,test,gold,o
600,effective,15,Abstract,hl_o,11099086,test,gold,o
601,acute invasive diarrhea in children .,0,Title,ss_p,11099086,test,gold,p
602,ciprofloxacin,0,Title,ss_i,11099086,test,gold,i
603,ceftriaxone,0,Title,ss_i,11099086,test,gold,i
604,acute invasive diarrhea,0,Title,hl_p,11099086,test,gold,p
605,children,0,Title,hl_p,11099086,test,gold,p
606,ciprofloxacin,0,Title,hl_i,11099086,test,gold,i
607,ceftriaxone,0,Title,hl_i,11099086,test,gold,i
608,children with malaria,0,Abstract,ss_p,11229858,test,gold,p
609,antipyretics,0,Abstract,ss_i,11229858,test,gold,i
610,naproxen,0,Abstract,ss_i,11229858,test,gold,i
611,metamizol,0,Abstract,ss_i,11229858,test,gold,i
612,reduction of fever peaks .,0,Abstract,ss_o,11229858,test,gold,o
613,children,0,Abstract,hl_p,11229858,test,gold,p
614,malaria,0,Abstract,hl_p,11229858,test,gold,p
615,antipyretics,0,Abstract,hl_i,11229858,test,gold,i
616,naproxen,0,Abstract,hl_i,11229858,test,gold,i
617,metamizol,0,Abstract,hl_i,11229858,test,gold,i
618,reduction of fever peaks .,0,Abstract,hl_o,11229858,test,gold,o
619,malaria .,1,Abstract,ss_p,11229858,test,gold,p
620,Antipyretic,1,Abstract,ss_i,11229858,test,gold,i
621,fever clearance,1,Abstract,ss_o,11229858,test,gold,o
622,malaria .,1,Abstract,hl_p,11229858,test,gold,p
623,Antipyretic,1,Abstract,hl_i,11229858,test,gold,i
624,fever clearance,1,Abstract,hl_o,11229858,test,gold,o
625,children with malaria .,0,Title,ss_p,11229858,test,gold,p
626,antipyretic drugs,0,Title,ss_i,11229858,test,gold,i
627,children,0,Title,hl_p,11229858,test,gold,p
628,malaria,0,Title,hl_p,11229858,test,gold,p
629,antipyretic drugs,0,Title,hl_i,11229858,test,gold,i
630,10 healthy subjects .,0,Abstract,ss_p,1131298,test,gold,p
631,garlic and onion,0,Abstract,ss_i,1131298,test,gold,i
632,10 healthy subjects,0,Abstract,hl_p,1131298,test,gold,p
633,garlic and onion,0,Abstract,hl_i,1131298,test,gold,i
634,garlic or onion,1,Abstract,ss_i,1131298,test,gold,i
635,essential oils,1,Abstract,ss_i,1131298,test,gold,i
636,garlic or onion,1,Abstract,hl_i,1131298,test,gold,i
637,essential oils,1,Abstract,hl_i,1131298,test,gold,i
638,Garlic and onion,2,Abstract,ss_i,1131298,test,gold,i
639,serum cholesterol and plasma fibrinogen,2,Abstract,ss_o,1131298,test,gold,o
640,coagulation time,2,Abstract,ss_o,1131298,test,gold,o
641,fibrinolytic activity .,2,Abstract,ss_o,1131298,test,gold,o
642,Garlic and onion,2,Abstract,hl_i,1131298,test,gold,i
643,serum cholesterol and plasma fibrinogen,2,Abstract,hl_o,1131298,test,gold,o
644,coagulation time,2,Abstract,hl_o,1131298,test,gold,o
645,fibrinolytic activity .,2,Abstract,hl_o,1131298,test,gold,o
646,essential oil,3,Abstract,ss_i,1131298,test,gold,i
647,garlic,3,Abstract,ss_i,1131298,test,gold,i
648,onion .,3,Abstract,ss_i,1131298,test,gold,i
649,effects,3,Abstract,ss_o,1131298,test,gold,o
650,garlic,3,Abstract,hl_i,1131298,test,gold,i
651,onion .,3,Abstract,hl_i,1131298,test,gold,i
652,effects,3,Abstract,hl_o,1131298,test,gold,o
653,garlic and onion,4,Abstract,ss_i,1131298,test,gold,i
654,essential oil,4,Abstract,ss_i,1131298,test,gold,i
655,garlic and onion,4,Abstract,hl_i,1131298,test,gold,i
656,essential oils of garlic and onion,0,Title,ss_i,1131298,test,gold,i
657,essential oils of garlic and onion,0,Title,hl_i,1131298,test,gold,i
658,aquatic exercise classes,0,Abstract,ss_i,11317090,test,gold,i
659,cost and outcomes,0,Abstract,ss_o,11317090,test,gold,o
660,aquatic exercise classes,0,Abstract,hl_i,11317090,test,gold,i
661,cost,0,Abstract,hl_o,11317090,test,gold,o
662,outcomes,0,Abstract,hl_o,11317090,test,gold,o
663,aquatic classes .,1,Abstract,ss_i,11317090,test,gold,i
664,aquatic classes .,1,Abstract,hl_i,11317090,test,gold,i
665,Cost per quality-adjusted life year ( QALY ) gained,2,Abstract,ss_o,11317090,test,gold,o
666,Cost per quality-adjusted life year ( QALY ),2,Abstract,hl_o,11317090,test,gold,o
667,cost/QALY gained,3,Abstract,ss_o,11317090,test,gold,o
668,cost/QALY,3,Abstract,hl_o,11317090,test,gold,o
669,249 adults from Washington State aged 55 to 75 with a doctor-confirmed diagnosis of osteoarthritis to participate in aquatic classes .,4,Abstract,ss_p,11317090,test,gold,p
670,aquatic classes .,4,Abstract,ss_i,11317090,test,gold,i
671,249 adults from Washington State aged 55 to 75,4,Abstract,hl_p,11317090,test,gold,p
672,doctor-confirmed diagnosis of osteoarthritis,4,Abstract,hl_p,11317090,test,gold,p
673,aquatic classes .,4,Abstract,hl_i,11317090,test,gold,i
674,Quality of Well-Being Scale ( QWB ),5,Abstract,ss_o,11317090,test,gold,o
675,Current Health Desirability Rating ( CHDR ),5,Abstract,ss_o,11317090,test,gold,o
676,economic evaluation,5,Abstract,ss_o,11317090,test,gold,o
677,"arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D )",5,Abstract,ss_o,11317090,test,gold,o
678,Perceived Quality of Life Scale ( PQOL ),5,Abstract,ss_o,11317090,test,gold,o
679,Quality of Well-Being Scale ( QWB ),5,Abstract,hl_o,11317090,test,gold,o
680,Current Health Desirability Rating ( CHDR ),5,Abstract,hl_o,11317090,test,gold,o
681,"arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D )",5,Abstract,hl_o,11317090,test,gold,o
682,Perceived Quality of Life Scale ( PQOL ),5,Abstract,hl_o,11317090,test,gold,o
683,life expectancy tables,6,Abstract,ss_o,11317090,test,gold,o
684,QALYs .,6,Abstract,ss_o,11317090,test,gold,o
685,QALYs .,6,Abstract,hl_o,11317090,test,gold,o
686,Use of health care facilities,7,Abstract,ss_o,11317090,test,gold,o
687,diaries/questionnaires,7,Abstract,ss_o,11317090,test,gold,o
688,Medicare reimbursement rates,7,Abstract,ss_o,11317090,test,gold,o
689,costs .,7,Abstract,ss_o,11317090,test,gold,o
690,Use of health care facilities,7,Abstract,hl_o,11317090,test,gold,o
691,Medicare reimbursement rates,7,Abstract,hl_o,11317090,test,gold,o
692,Nonparametric bootstrap sampling of costs/QALY ratios,8,Abstract,ss_o,11317090,test,gold,o
693,costs/QALY ratios,8,Abstract,hl_o,11317090,test,gold,o
694,Aquatic exercisers,9,Abstract,ss_i,11317090,test,gold,i
695,( QWB ),9,Abstract,ss_o,11317090,test,gold,o
696,"( CHDR , HAQ , PQOL )",9,Abstract,ss_o,11317090,test,gold,o
697,Aquatic exercisers,9,Abstract,hl_i,11317090,test,gold,i
698,( QWB ),9,Abstract,hl_o,11317090,test,gold,o
699,"( CHDR , HAQ , PQOL )",9,Abstract,hl_o,11317090,test,gold,o
701,Costs/QALY,11,Abstract,ss_o,11317090,test,gold,o
702,QWB,11,Abstract,ss_o,11317090,test,gold,o
703,CHRD .,11,Abstract,ss_o,11317090,test,gold,o
704,Costs/QALY,11,Abstract,hl_o,11317090,test,gold,o
705,QWB,11,Abstract,hl_o,11317090,test,gold,o
706,CHRD .,11,Abstract,hl_o,11317090,test,gold,o
707,Aquatic exercise,12,Abstract,ss_i,11317090,test,gold,i
708,QALY gained,12,Abstract,ss_o,11317090,test,gold,o
709,Aquatic exercise,12,Abstract,hl_i,11317090,test,gold,i
710,QALY,12,Abstract,hl_o,11317090,test,gold,o
711,aquatic exercise .,13,Abstract,ss_i,11317090,test,gold,i
712,aquatic exercise .,13,Abstract,hl_i,11317090,test,gold,i
713,persons with osteoarthritis .,0,Title,ss_p,11317090,test,gold,p
714,aquatic exercise,0,Title,ss_i,11317090,test,gold,i
715,Economic evaluation,0,Title,ss_o,11317090,test,gold,o
716,persons with osteoarthritis .,0,Title,hl_p,11317090,test,gold,p
717,aquatic exercise,0,Title,hl_i,11317090,test,gold,i
718,Economic evaluation,0,Title,hl_o,11317090,test,gold,o
719,patients at high risk for cardiovascular events .,0,Abstract,ss_p,11381289,test,gold,p
720,ramipril,0,Abstract,ss_i,11381289,test,gold,i
721,angiotensin-converting enzyme ( ACE ) inhibitor,0,Abstract,ss_i,11381289,test,gold,i
722,patients at high risk for cardiovascular events .,0,Abstract,hl_p,11381289,test,gold,p
723,ramipril,0,Abstract,hl_i,11381289,test,gold,i
724,angiotensin-converting enzyme ( ACE ) inhibitor,0,Abstract,hl_i,11381289,test,gold,i
725,ramipril,1,Abstract,ss_i,11381289,test,gold,i
726,"rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure",1,Abstract,ss_o,11381289,test,gold,o
727,risk of diabetes-related complications and of diabetes itself .,1,Abstract,ss_o,11381289,test,gold,o
728,ramipril,1,Abstract,hl_i,11381289,test,gold,i
729,"rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure",1,Abstract,hl_o,11381289,test,gold,o
730,risk of diabetes-related complications and of diabetes itself .,1,Abstract,hl_o,11381289,test,gold,o
731,vitamin E,2,Abstract,ss_i,11381289,test,gold,i
732,vitamin E,2,Abstract,hl_i,11381289,test,gold,i
733,ACE inhibitor,3,Abstract,ss_i,11381289,test,gold,i
734,ACE inhibitor,3,Abstract,hl_i,11381289,test,gold,i
736,in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,0,Abstract,ss_p,11401641,test,gold,p
737,timolol,0,Abstract,ss_i,11401641,test,gold,i
738,latanoprost,0,Abstract,ss_i,11401641,test,gold,i
739,latanoprost,0,Abstract,ss_i,11401641,test,gold,i
740,timolol,0,Abstract,ss_i,11401641,test,gold,i
741,intraocular pressure ( IOP ),0,Abstract,ss_o,11401641,test,gold,o
742,patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,0,Abstract,hl_p,11401641,test,gold,p
743,timolol,0,Abstract,hl_i,11401641,test,gold,i
744,latanoprost,0,Abstract,hl_i,11401641,test,gold,i
745,latanoprost,0,Abstract,hl_i,11401641,test,gold,i
746,timolol,0,Abstract,hl_i,11401641,test,gold,i
747,intraocular pressure ( IOP ),0,Abstract,hl_o,11401641,test,gold,o
749,"53 patients with primary open angle glaucoma , capsular glaucoma , or ocular hypertension with an IOP of at least 21 mmHg on current therapy",2,Abstract,ss_p,11401641,test,gold,p
750,"53 patients with primary open angle glaucoma , capsular glaucoma , or ocular hypertension with an IOP of at least 21 mmHg on current therapy",2,Abstract,hl_p,11401641,test,gold,p
751,timolol,3,Abstract,ss_i,11401641,test,gold,i
752,timolol,3,Abstract,hl_i,11401641,test,gold,i
753,timolol,4,Abstract,ss_i,11401641,test,gold,i
754,timolol,4,Abstract,ss_i,11401641,test,gold,i
755,latanoprost,4,Abstract,ss_i,11401641,test,gold,i
756,latanoprost,4,Abstract,ss_i,11401641,test,gold,i
757,timolol .,4,Abstract,ss_i,11401641,test,gold,i
758,timolol,4,Abstract,hl_i,11401641,test,gold,i
759,timolol,4,Abstract,hl_i,11401641,test,gold,i
760,latanoprost,4,Abstract,hl_i,11401641,test,gold,i
761,latanoprost,4,Abstract,hl_i,11401641,test,gold,i
762,timolol .,4,Abstract,hl_i,11401641,test,gold,i
763,efficacy,5,Abstract,ss_o,11401641,test,gold,o
764,IOP,5,Abstract,ss_o,11401641,test,gold,o
765,IOP,5,Abstract,hl_o,11401641,test,gold,o
766,timolol,6,Abstract,ss_i,11401641,test,gold,i
767,latanoprost,6,Abstract,ss_i,11401641,test,gold,i
768,IOP,6,Abstract,ss_o,11401641,test,gold,o
769,IOP,6,Abstract,hl_o,11401641,test,gold,o
770,latanoprost,7,Abstract,ss_i,11401641,test,gold,i
771,timolol,7,Abstract,ss_i,11401641,test,gold,i
772,timolol,7,Abstract,ss_i,11401641,test,gold,i
773,latanoprost,7,Abstract,ss_i,11401641,test,gold,i
774,IOP,7,Abstract,ss_o,11401641,test,gold,o
775,IOP,7,Abstract,ss_o,11401641,test,gold,o
776,IOP,7,Abstract,ss_o,11401641,test,gold,o
777,IOP,7,Abstract,hl_o,11401641,test,gold,o
778,IOP,7,Abstract,hl_o,11401641,test,gold,o
779,IOP,7,Abstract,hl_o,11401641,test,gold,o
780,latanoprost,8,Abstract,ss_i,11401641,test,gold,i
781,timolol,8,Abstract,ss_i,11401641,test,gold,i
782,timolol,8,Abstract,ss_i,11401641,test,gold,i
783,latanoprost,8,Abstract,ss_i,11401641,test,gold,i
784,IOP,8,Abstract,ss_o,11401641,test,gold,o
785,IOP,8,Abstract,hl_o,11401641,test,gold,o
786,patients insufficiently controlled on timolol .,0,Title,ss_p,11401641,test,gold,p
787,latanoprost,0,Title,ss_i,11401641,test,gold,i
788,IOP-reducing,0,Title,ss_o,11401641,test,gold,o
789,patients insufficiently controlled on timolol .,0,Title,hl_p,11401641,test,gold,p
790,IOP-reducing,0,Title,hl_o,11401641,test,gold,o
791,"patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .",0,Abstract,ss_p,11454878,test,gold,p
792,pegylated liposomal doxorubicin ( PLD ),0,Abstract,ss_i,11454878,test,gold,i
793,topotecan,0,Abstract,ss_i,11454878,test,gold,i
794,efficacy,0,Abstract,ss_o,11454878,test,gold,o
795,safety,0,Abstract,ss_o,11454878,test,gold,o
796,"patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .",0,Abstract,hl_p,11454878,test,gold,p
797,pegylated liposomal doxorubicin ( PLD ),0,Abstract,hl_i,11454878,test,gold,i
798,topotecan,0,Abstract,hl_i,11454878,test,gold,i
799,efficacy,0,Abstract,hl_o,11454878,test,gold,o
800,safety,0,Abstract,hl_o,11454878,test,gold,o
801,Patients with measurable and assessable disease,1,Abstract,ss_p,11454878,test,gold,p
802,PLD,1,Abstract,ss_i,11454878,test,gold,i
803,topotecan,1,Abstract,ss_i,11454878,test,gold,i
804,Patients with measurable and assessable disease,1,Abstract,hl_p,11454878,test,gold,p
805,PLD,1,Abstract,hl_i,11454878,test,gold,i
806,topotecan,1,Abstract,hl_i,11454878,test,gold,i
808,A total of 474 patients were treated,3,Abstract,ss_p,11454878,test,gold,p
809,PLD,3,Abstract,ss_i,11454878,test,gold,i
810,topotecan ),3,Abstract,ss_i,11454878,test,gold,i
811,474,3,Abstract,hl_p,11454878,test,gold,p
812,PLD,3,Abstract,hl_i,11454878,test,gold,i
813,topotecan,3,Abstract,hl_i,11454878,test,gold,i
815,overall progression-free survival rates,5,Abstract,ss_o,11454878,test,gold,o
816,overall progression-free survival rates,5,Abstract,hl_o,11454878,test,gold,o
817,PLD,6,Abstract,ss_i,11454878,test,gold,i
818,topotecan,6,Abstract,ss_i,11454878,test,gold,i
819,overall response rates,6,Abstract,ss_o,11454878,test,gold,o
820,PLD,6,Abstract,hl_i,11454878,test,gold,i
821,topotecan,6,Abstract,hl_i,11454878,test,gold,i
822,overall response rates,6,Abstract,hl_o,11454878,test,gold,o
823,PLD,7,Abstract,ss_i,11454878,test,gold,i
824,topotecan .,7,Abstract,ss_i,11454878,test,gold,i
825,Median overall survival times,7,Abstract,ss_o,11454878,test,gold,o
826,PLD,7,Abstract,hl_i,11454878,test,gold,i
827,topotecan,7,Abstract,hl_i,11454878,test,gold,i
828,Median overall survival times,7,Abstract,hl_o,11454878,test,gold,o
829,PLD,8,Abstract,ss_i,11454878,test,gold,i
830,PLD,8,Abstract,ss_i,11454878,test,gold,i
831,topotecan .,8,Abstract,ss_i,11454878,test,gold,i
832,PLD,8,Abstract,hl_i,11454878,test,gold,i
833,PLD,8,Abstract,hl_i,11454878,test,gold,i
834,topotecan .,8,Abstract,hl_i,11454878,test,gold,i
835,PLD,9,Abstract,ss_i,11454878,test,gold,i
836,topotecan,9,Abstract,ss_i,11454878,test,gold,i
837,overall survival,9,Abstract,ss_o,11454878,test,gold,o
838,PLD,9,Abstract,hl_i,11454878,test,gold,i
839,topotecan,9,Abstract,hl_i,11454878,test,gold,i
840,overall survival,9,Abstract,hl_o,11454878,test,gold,o
841,topotecan,10,Abstract,ss_i,11454878,test,gold,i
842,survival,10,Abstract,ss_o,11454878,test,gold,o
843,topotecan,10,Abstract,hl_i,11454878,test,gold,i
844,topotecan,11,Abstract,ss_i,11454878,test,gold,i
845,Severe hematologic toxicity,11,Abstract,ss_o,11454878,test,gold,o
846,topotecan,11,Abstract,hl_i,11454878,test,gold,i
847,Severe hematologic toxicity,11,Abstract,hl_o,11454878,test,gold,o
848,PLD,12,Abstract,ss_i,11454878,test,gold,i
849,"efficacy , favorable safety profile",12,Abstract,ss_o,11454878,test,gold,o
850,convenient dosing,12,Abstract,ss_o,11454878,test,gold,o
851,PLD,12,Abstract,hl_i,11454878,test,gold,i
852,efficacy,12,Abstract,hl_o,11454878,test,gold,o
853,safety,12,Abstract,hl_o,11454878,test,gold,o
854,Recurrent epithelial ovarian carcinoma :,0,Title,ss_p,11454878,test,gold,p
855,pegylated liposomal doxorubicin,0,Title,ss_i,11454878,test,gold,i
856,topotecan .,0,Title,ss_i,11454878,test,gold,i
857,pegylated liposomal doxorubicin,0,Title,hl_i,11454878,test,gold,i
858,topotecan .,0,Title,hl_i,11454878,test,gold,i
859,oral contraceptives ( OCs ),0,Abstract,ss_i,11495215,test,gold,i
860,cardiovascular disease,0,Abstract,ss_o,11495215,test,gold,o
861,oral contraceptives ( OCs ),0,Abstract,hl_i,11495215,test,gold,i
862,OC,1,Abstract,ss_i,11495215,test,gold,i
863,Cardiovascular reactivity,1,Abstract,ss_o,11495215,test,gold,o
864,cigarette smoking,2,Abstract,ss_i,11495215,test,gold,i
865,nicotine,2,Abstract,ss_i,11495215,test,gold,i
866,OC,2,Abstract,ss_i,11495215,test,gold,i
867,cardiovascular and lipid reactivity .,2,Abstract,ss_o,11495215,test,gold,o
868,cardiovascular and lipid reactivity .,2,Abstract,hl_o,11495215,test,gold,o
869,"Sixty healthy women , half of whom had been using OCs for at least the previous 6 months",3,Abstract,ss_p,11495215,test,gold,p
870,OCs,3,Abstract,ss_i,11495215,test,gold,i
871,"Sixty healthy women , half of whom had been using OCs for at least the previous 6 months",3,Abstract,hl_p,11495215,test,gold,p
872,two thirds were smokers,4,Abstract,ss_p,11495215,test,gold,p
873,nicotine deprivation,4,Abstract,ss_i,11495215,test,gold,i
874,nicotine,4,Abstract,ss_i,11495215,test,gold,i
875,two thirds were smokers,4,Abstract,hl_p,11495215,test,gold,p
876,nicotine,4,Abstract,hl_i,11495215,test,gold,i
877,nicotine,4,Abstract,hl_i,11495215,test,gold,i
878,One third were nonsmokers .,5,Abstract,ss_p,11495215,test,gold,p
879,One third were nonsmokers .,5,Abstract,hl_p,11495215,test,gold,p
880,"Heart rate , blood pressure , and lipid measures",6,Abstract,ss_o,11495215,test,gold,o
881,"Heart rate , blood pressure , and lipid measures",6,Abstract,hl_o,11495215,test,gold,o
882,OC,7,Abstract,ss_i,11495215,test,gold,i
883,nicotine,7,Abstract,ss_i,11495215,test,gold,i
884,OC,7,Abstract,hl_i,11495215,test,gold,i
885,nicotine,7,Abstract,hl_i,11495215,test,gold,i
886,OC,8,Abstract,ss_i,11495215,test,gold,i
887,heart rate and diastolic blood pressure reactivity,8,Abstract,ss_o,11495215,test,gold,o
888,OC,8,Abstract,hl_i,11495215,test,gold,i
889,heart rate and diastolic blood pressure reactivity,8,Abstract,hl_o,11495215,test,gold,o
890,women .,9,Abstract,ss_p,11495215,test,gold,p
891,nicotine,9,Abstract,ss_i,11495215,test,gold,i
892,nicotine,9,Abstract,ss_i,11495215,test,gold,i
893,cardiovascular or lipid stress reactivity,9,Abstract,ss_o,11495215,test,gold,o
894,nicotine,9,Abstract,hl_i,11495215,test,gold,i
895,nicotine,9,Abstract,hl_i,11495215,test,gold,i
896,cardiovascular or lipid stress reactivity,9,Abstract,hl_o,11495215,test,gold,o
897,nonsmoking women,10,Abstract,ss_p,11495215,test,gold,p
898,OC,10,Abstract,ss_i,11495215,test,gold,i
899,cardiovascular reactivity,10,Abstract,ss_o,11495215,test,gold,o
900,OC,10,Abstract,hl_i,11495215,test,gold,i
901,cardiovascular reactivity,10,Abstract,hl_o,11495215,test,gold,o
902,nonsmokers .,0,Title,ss_p,11495215,test,gold,p
903,Oral contraceptive,0,Title,ss_i,11495215,test,gold,i
904,cardiovascular reactivity,0,Title,ss_o,11495215,test,gold,o
905,Oral contraceptive,0,Title,hl_i,11495215,test,gold,i
906,cardiovascular reactivity,0,Title,hl_o,11495215,test,gold,o
907,patients on thrombolytic therapy ( TLT ) .,0,Abstract,ss_p,11642083,test,gold,p
908,neoton,0,Abstract,ss_i,11642083,test,gold,i
909,thrombolytic therapy ( TLT ),0,Abstract,ss_i,11642083,test,gold,i
910,"systolic function of the left ventricle , arrhythmia and clinical symptoms",0,Abstract,ss_o,11642083,test,gold,o
911,patients on thrombolytic therapy ( TLT ) .,0,Abstract,hl_p,11642083,test,gold,p
912,neoton,0,Abstract,hl_i,11642083,test,gold,i
913,thrombolytic therapy ( TLT ),0,Abstract,hl_i,11642083,test,gold,i
914,"systolic function of the left ventricle , arrhythmia and clinical symptoms",0,Abstract,hl_o,11642083,test,gold,o
915,106 males with Q-MI entered the study .,1,Abstract,ss_p,11642083,test,gold,p
916,106 males,1,Abstract,hl_p,11642083,test,gold,p
917,Q-MI,1,Abstract,hl_p,11642083,test,gold,p
918,TLT,2,Abstract,ss_i,11642083,test,gold,i
919,neoton,2,Abstract,ss_i,11642083,test,gold,i
920,TLT,2,Abstract,ss_i,11642083,test,gold,i
921,streptokinase,2,Abstract,ss_i,11642083,test,gold,i
922,streptokinase preparations,2,Abstract,ss_i,11642083,test,gold,i
923,neoton .,2,Abstract,ss_i,11642083,test,gold,i
924,TLT,2,Abstract,hl_i,11642083,test,gold,i
925,neoton,2,Abstract,hl_i,11642083,test,gold,i
926,TLT,2,Abstract,hl_i,11642083,test,gold,i
927,streptokinase,2,Abstract,hl_i,11642083,test,gold,i
928,streptokinase preparations,2,Abstract,hl_i,11642083,test,gold,i
929,neoton .,2,Abstract,hl_i,11642083,test,gold,i
930,Left ventricular systolic function was measured by echocardiography,3,Abstract,ss_o,11642083,test,gold,o
931,arrhythmia was analysed at Holter monitoring,3,Abstract,ss_o,11642083,test,gold,o
932,Left ventricular systolic function,3,Abstract,hl_o,11642083,test,gold,o
933,arrhythmia,3,Abstract,hl_o,11642083,test,gold,o
934,TLT,4,Abstract,ss_i,11642083,test,gold,i
935,neoton,5,Abstract,ss_i,11642083,test,gold,i
936,systolic and diastolic volumes,5,Abstract,ss_o,11642083,test,gold,o
937,neoton,5,Abstract,hl_i,11642083,test,gold,i
938,systolic and diastolic volumes,5,Abstract,hl_o,11642083,test,gold,o
939,neoton,6,Abstract,ss_i,11642083,test,gold,i
940,neoton,6,Abstract,hl_i,11642083,test,gold,i
941,MI patients receiving TLT,7,Abstract,ss_p,11642083,test,gold,p
942,Neoton,7,Abstract,ss_i,11642083,test,gold,i
943,TLT,7,Abstract,ss_i,11642083,test,gold,i
944,left ventricular systolic dysfunction,7,Abstract,ss_o,11642083,test,gold,o
945,Neoton,7,Abstract,hl_i,11642083,test,gold,i
946,left ventricular systolic dysfunction,7,Abstract,hl_o,11642083,test,gold,o
947,[ Neoton,0,Title,ss_i,11642083,test,gold,i
948,thrombolytic therapy,0,Title,ss_i,11642083,test,gold,i
949,myocardial infarction,0,Title,hl_p,11642083,test,gold,p
950,Neoton,0,Title,hl_i,11642083,test,gold,i
951,thrombolytic therapy,0,Title,hl_i,11642083,test,gold,i
952,older adults ( 60 ( SE 1 ) years ; BMI 26 ( SE 1 ) kg/m ( 2 ) ) .,0,Abstract,ss_p,11737955,test,gold,p
953,antioxidant supplementation,0,Abstract,ss_i,11737955,test,gold,i
954,exercise-induced oxidative stress,0,Abstract,ss_o,11737955,test,gold,o
955,older adults ( 60 ( SE 1 ) years ; BMI 26 ( SE 1 ) kg/m ( 2 ) ),0,Abstract,hl_p,11737955,test,gold,p
956,antioxidant supplementation,0,Abstract,hl_i,11737955,test,gold,i
957,dl-alpha-tocopheryl acetate,1,Abstract,ss_i,11737955,test,gold,i
958,ascorbic acid,1,Abstract,ss_i,11737955,test,gold,i
959,beta-carotene,1,Abstract,ss_i,11737955,test,gold,i
960,placebo,1,Abstract,ss_i,11737955,test,gold,i
961,dl-alpha-tocopheryl acetate,1,Abstract,hl_i,11737955,test,gold,i
962,ascorbic acid,1,Abstract,hl_i,11737955,test,gold,i
963,beta-carotene,1,Abstract,hl_i,11737955,test,gold,i
964,placebo,1,Abstract,hl_i,11737955,test,gold,i
966,Antipyrine,3,Abstract,ss_i,11737955,test,gold,i
967,Antipyrine,3,Abstract,ss_o,11737955,test,gold,o
968,oxidative stress .,3,Abstract,ss_o,11737955,test,gold,o
969,Antipyrine,3,Abstract,hl_i,11737955,test,gold,i
970,Antipyrine,4,Abstract,ss_i,11737955,test,gold,i
971,Antipyrine,4,Abstract,ss_o,11737955,test,gold,o
972,para- and ortho-hydroxyantipyrine .,4,Abstract,ss_o,11737955,test,gold,o
975,para- and ortho-hydroxyantipyrine to antipyrine .,7,Abstract,ss_o,11737955,test,gold,o
976,para- and ortho-hydroxyantipyrine to antipyrine .,7,Abstract,hl_o,11737955,test,gold,o
977,thiobarbituric acid reactive substances in plasma .,8,Abstract,ss_o,11737955,test,gold,o
978,thiobarbituric acid reactive substances in plasma .,8,Abstract,hl_o,11737955,test,gold,o
979,60-year-old subjects,9,Abstract,ss_p,11737955,test,gold,p
980,antioxidant supplementation,9,Abstract,ss_i,11737955,test,gold,i
981,free radical products of antipyrine .,9,Abstract,ss_o,11737955,test,gold,o
982,60-year-old subjects,9,Abstract,hl_p,11737955,test,gold,p
983,antioxidant supplementation,9,Abstract,hl_i,11737955,test,gold,i
984,free radical products of antipyrine .,9,Abstract,hl_o,11737955,test,gold,o
985,the 60-year-old,0,Title,ss_p,11737955,test,gold,p
986,Antioxidant supplementation,0,Title,ss_i,11737955,test,gold,i
987,antipyrine hydroxylates .,0,Title,ss_i,11737955,test,gold,i
988,exercise-induced oxidative stress,0,Title,ss_o,11737955,test,gold,o
989,the 60-year-old,0,Title,hl_p,11737955,test,gold,p
990,Antioxidant supplementation,0,Title,hl_i,11737955,test,gold,i
991,antipyrine,0,Title,hl_i,11737955,test,gold,i
992,patients with recently diagnosed rheumatoid arthritis ( RA ),0,Abstract,ss_p,11750293,test,gold,p
993,predictors of depression .,0,Abstract,ss_o,11750293,test,gold,o
994,patients with recently diagnosed rheumatoid arthritis ( RA ),0,Abstract,hl_p,11750293,test,gold,p
995,depression .,0,Abstract,hl_o,11750293,test,gold,o
996,Twenty-two patients with a history of recently diagnosed RA of less than 2 years,1,Abstract,ss_p,11750293,test,gold,p
997,clinical outcome and process measures,1,Abstract,ss_o,11750293,test,gold,o
998,Twenty-two patients with a history of recently diagnosed RA of less than 2 years,1,Abstract,hl_p,11750293,test,gold,p
999,clinical outcome and process measures,1,Abstract,hl_o,11750293,test,gold,o
1000,22 patients,2,Abstract,ss_p,11750293,test,gold,p
1001,standard outpatient clinic treatment,2,Abstract,ss_i,11750293,test,gold,i
1002,22 patients,2,Abstract,hl_p,11750293,test,gold,p
1003,standard outpatient clinic treatment,2,Abstract,hl_i,11750293,test,gold,i
1005,predict depression,4,Abstract,ss_o,11750293,test,gold,o
1006,predict depression,4,Abstract,hl_o,11750293,test,gold,o
1007,"initial level of depression , disability , pain , beliefs about the consequences of arthritis and coping strategies .",5,Abstract,ss_o,11750293,test,gold,o
1008,"depression , disability , pain , beliefs about the consequences of arthritis and coping strategies .",5,Abstract,hl_o,11750293,test,gold,o
1010,recent onset RA .,7,Abstract,ss_p,11750293,test,gold,p
1011,recent onset rheumatoid arthritis :,0,Title,ss_p,11750293,test,gold,p
1012,role,0,Title,ss_o,11750293,test,gold,o
1013,"disability , illness perceptions , pain and coping .",0,Title,ss_o,11750293,test,gold,o
1014,recent onset rheumatoid arthritis :,0,Title,hl_p,11750293,test,gold,p
1015,disability,0,Title,hl_o,11750293,test,gold,o
1016,illness perceptions,0,Title,hl_o,11750293,test,gold,o
1017,pain,0,Title,hl_o,11750293,test,gold,o
1018,coping,0,Title,hl_o,11750293,test,gold,o
1019,Eighteen patients who had undergone stoma surgery,0,Abstract,ss_p,11829043,test,gold,p
1020,anxiety level and self-reported quality of life ( QoL ),0,Abstract,ss_o,11829043,test,gold,o
1021,Eighteen patients who had undergone stoma surgery,0,Abstract,hl_p,11829043,test,gold,p
1022,anxiety level and self-reported quality of life ( QoL ),0,Abstract,hl_o,11829043,test,gold,o
1024,progressive muscle relaxation training ( PMRT ),2,Abstract,ss_i,11829043,test,gold,i
1025,progressive muscle relaxation training ( PMRT ),2,Abstract,hl_i,11829043,test,gold,i
1026,"Chinese State-Trait Anxiety Inventory ( C-STAI ) , the Quality of Life Index for Colostomy ( QoL-Colostomy ) and the Hong Kong Chinese version of the World Health Organisation Quality of Life Scale ( WHOQoL ) .",3,Abstract,ss_o,11829043,test,gold,o
1027,"Chinese State-Trait Anxiety Inventory ( C-STAI ) , the Quality of Life Index for Colostomy ( QoL-Colostomy ) and the Hong Kong Chinese version of the World Health Organisation Quality of Life Scale ( WHOQoL ) .",3,Abstract,hl_o,11829043,test,gold,o
1028,C-STAI score,4,Abstract,ss_o,11829043,test,gold,o
1029,WHOQoL score,4,Abstract,ss_o,11829043,test,gold,o
1030,C-STAI score,4,Abstract,hl_o,11829043,test,gold,o
1031,WHOQoL score,4,Abstract,hl_o,11829043,test,gold,o
1032,WHOQoL,5,Abstract,ss_o,11829043,test,gold,o
1033,QoL,5,Abstract,ss_o,11829043,test,gold,o
1034,WHOQoL,5,Abstract,hl_o,11829043,test,gold,o
1035,QoL,5,Abstract,hl_o,11829043,test,gold,o
1036,QoL-Colostomy,6,Abstract,ss_o,11829043,test,gold,o
1037,QoL-Colostomy,6,Abstract,hl_o,11829043,test,gold,o
1038,patients after stoma surgery .,7,Abstract,ss_p,11829043,test,gold,p
1039,PMRT,7,Abstract,ss_i,11829043,test,gold,i
1040,quality of life,7,Abstract,ss_o,11829043,test,gold,o
1041,anxiety,7,Abstract,ss_o,11829043,test,gold,o
1042,patients after stoma surgery .,7,Abstract,hl_p,11829043,test,gold,p
1043,PMRT,7,Abstract,hl_i,11829043,test,gold,i
1044,quality of life,7,Abstract,hl_o,11829043,test,gold,o
1045,anxiety,7,Abstract,hl_o,11829043,test,gold,o
1046,patients after stoma surgery .,0,Title,ss_p,11829043,test,gold,p
1047,progressive muscle relaxation training,0,Title,ss_i,11829043,test,gold,i
1048,patients after stoma surgery .,0,Title,hl_p,11829043,test,gold,p
1049,progressive muscle relaxation training,0,Title,hl_i,11829043,test,gold,i
1050,44 patients with inclusion body myositis,0,Abstract,ss_p,11891832,test,gold,p
1051,methotrexate,0,Abstract,ss_i,11891832,test,gold,i
1052,disease progression,0,Abstract,ss_o,11891832,test,gold,o
1053,44 patients with inclusion body myositis,0,Abstract,hl_p,11891832,test,gold,p
1054,methotrexate,0,Abstract,hl_i,11891832,test,gold,i
1055,disease progression,0,Abstract,hl_o,11891832,test,gold,o
1056,Mean change of quantitative muscle strength testing sum scores,1,Abstract,ss_o,11891832,test,gold,o
1057,Mean change of quantitative muscle strength testing sum scores,1,Abstract,hl_o,11891832,test,gold,o
1058,methotrexate,2,Abstract,ss_i,11891832,test,gold,i
1059,placebo,2,Abstract,ss_i,11891832,test,gold,i
1060,Quantitative muscle strength testing sum scores,2,Abstract,ss_o,11891832,test,gold,o
1061,methotrexate,2,Abstract,hl_i,11891832,test,gold,i
1062,placebo,2,Abstract,hl_i,11891832,test,gold,i
1063,Quantitative muscle strength testing sum scores,2,Abstract,hl_o,11891832,test,gold,o
1064,"manual muscle testing sum scores , activity scale scores and patients ' own assessments",3,Abstract,ss_o,11891832,test,gold,o
1065,"manual muscle testing sum scores , activity scale scores and patients ' own assessments",3,Abstract,hl_o,11891832,test,gold,o
1066,methotrexate,4,Abstract,ss_i,11891832,test,gold,i
1067,Serum creatine kinase activity,4,Abstract,ss_o,11891832,test,gold,o
1068,methotrexate,4,Abstract,hl_i,11891832,test,gold,i
1069,Serum creatine kinase activity,4,Abstract,hl_o,11891832,test,gold,o
1070,methotrexate,5,Abstract,ss_i,11891832,test,gold,i
1071,progression of muscle weakness,5,Abstract,ss_o,11891832,test,gold,o
1072,serum creatine kinase activity .,5,Abstract,ss_o,11891832,test,gold,o
1073,methotrexate,5,Abstract,hl_i,11891832,test,gold,i
1074,progression of muscle weakness,5,Abstract,hl_o,11891832,test,gold,o
1075,serum creatine kinase activity .,5,Abstract,hl_o,11891832,test,gold,o
1076,inclusion body myositis,0,Title,ss_p,11891832,test,gold,p
1077,methotrexate,0,Title,ss_i,11891832,test,gold,i
1078,placebo .,0,Title,ss_i,11891832,test,gold,i
1079,weakness progression,0,Title,ss_o,11891832,test,gold,o
1080,inclusion body myositis,0,Title,hl_p,11891832,test,gold,p
1081,methotrexate,0,Title,hl_i,11891832,test,gold,i
1082,placebo .,0,Title,hl_i,11891832,test,gold,i
1083,weakness progression,0,Title,hl_o,11891832,test,gold,o
1084,pterygium .,0,Abstract,ss_p,12139812,test,gold,p
1085,limbal epithelial autograft transplantation,0,Abstract,ss_i,12139812,test,gold,i
1086,pterygium excision,0,Abstract,ss_i,12139812,test,gold,i
1087,therapeutic effects,0,Abstract,ss_o,12139812,test,gold,o
1088,pterygium .,0,Abstract,hl_p,12139812,test,gold,p
1089,limbal epithelial autograft transplantation,0,Abstract,hl_i,12139812,test,gold,i
1090,pterygium excision,0,Abstract,hl_i,12139812,test,gold,i
1092,208 patients ( 229 eyes ) with initial pterygium,2,Abstract,ss_p,12139812,test,gold,p
1093,excision of pterygium,2,Abstract,ss_i,12139812,test,gold,i
1094,limbal epithelial autograft transplantation surgery,2,Abstract,ss_i,12139812,test,gold,i
1095,simple pterygium excision,2,Abstract,ss_i,12139812,test,gold,i
1096,208 patients,2,Abstract,hl_p,12139812,test,gold,p
1097,initial pterygium,2,Abstract,hl_p,12139812,test,gold,p
1098,excision of pterygium,2,Abstract,hl_i,12139812,test,gold,i
1099,limbal epithelial autograft transplantation surgery,2,Abstract,hl_i,12139812,test,gold,i
1100,simple pterygium excision,2,Abstract,hl_i,12139812,test,gold,i
1101,corneal transparency with stable epithelial healing and no abnormal proliferation of pterygium-like tissue .,3,Abstract,ss_o,12139812,test,gold,o
1102,epithelial healing,3,Abstract,hl_o,12139812,test,gold,o
1103,abnormal proliferation of pterygium-like tissue .,3,Abstract,hl_o,12139812,test,gold,o
1107,pterygium .,7,Abstract,ss_p,12139812,test,gold,p
1108,limbal epithelial autograft transplantation,7,Abstract,ss_i,12139812,test,gold,i
1109,limbal epithelial autograft transplantation,7,Abstract,hl_i,12139812,test,gold,i
1110,pterygium ],0,Title,ss_p,12139812,test,gold,p
1111,[ Limbal epithelial autograft transplantation,0,Title,ss_i,12139812,test,gold,i
1112,pterygium,0,Title,hl_p,12139812,test,gold,p
1113,[ Limbal epithelial autograft transplantation,0,Title,hl_i,12139812,test,gold,i
1114,Reichert AT550 .,0,Abstract,ss_i,12477021,test,gold,i
1115,level of accuracy,0,Abstract,ss_o,12477021,test,gold,o
1116,measurements of intra-ocular pressure ( IOP ),0,Abstract,ss_o,12477021,test,gold,o
1117,Reichert AT550 .,0,Abstract,hl_i,12477021,test,gold,i
1118,level of accuracy,0,Abstract,hl_o,12477021,test,gold,o
1119,measurements,0,Abstract,hl_o,12477021,test,gold,o
1120,"Reichert Xpert Plus , Goldmann applanation tonometer",1,Abstract,ss_i,12477021,test,gold,i
1121,Perkins tonometer .,1,Abstract,ss_i,12477021,test,gold,i
1122,Reichert Xpert Plus,1,Abstract,hl_i,12477021,test,gold,i
1123,Goldmann applanation tonometer,1,Abstract,hl_i,12477021,test,gold,i
1124,Perkins tonometer .,1,Abstract,hl_i,12477021,test,gold,i
1125,Thirty-five university students were assessed,2,Abstract,ss_p,12477021,test,gold,p
1126,Thirty-five university students were assessed,2,Abstract,hl_p,12477021,test,gold,p
1128,IOP,4,Abstract,ss_o,12477021,test,gold,o
1129,AT550 NCT,5,Abstract,ss_i,12477021,test,gold,i
1130,Goldmann tonometer,5,Abstract,ss_i,12477021,test,gold,i
1131,AT550 NCT,5,Abstract,hl_i,12477021,test,gold,i
1132,Goldmann tonometer,5,Abstract,hl_i,12477021,test,gold,i
1133,AT550 NCT,6,Abstract,ss_i,12477021,test,gold,i
1134,Goldmann tonometry,6,Abstract,ss_i,12477021,test,gold,i
1135,IOP,6,Abstract,ss_o,12477021,test,gold,o
1136,IOP,6,Abstract,ss_o,12477021,test,gold,o
1137,AT550 NCT,6,Abstract,hl_i,12477021,test,gold,i
1138,Goldmann tonometry,6,Abstract,hl_i,12477021,test,gold,i
1139,IOP,6,Abstract,hl_o,12477021,test,gold,o
1140,Reichert AT550 :,0,Title,ss_i,12477021,test,gold,i
1141,Clinical performance,0,Title,ss_o,12477021,test,gold,o
1142,Reichert AT550 :,0,Title,hl_i,12477021,test,gold,i
1143,Clinical performance,0,Title,hl_o,12477021,test,gold,o
1144,Internal stenting,0,Abstract,ss_i,12576806,test,gold,i
1145,Internal stenting,0,Abstract,hl_i,12576806,test,gold,i
1147,stent,2,Abstract,ss_i,12576806,test,gold,i
1148,stenting,3,Abstract,ss_i,12576806,test,gold,i
1149,optimum duration of stenting,3,Abstract,ss_o,12576806,test,gold,o
1150,stenting,3,Abstract,hl_i,12576806,test,gold,i
1151,optimum duration of stenting,3,Abstract,hl_o,12576806,test,gold,o
1152,A total of 57 consecutive patients with primary ureteropelvic junction obstruction,4,Abstract,ss_p,12576806,test,gold,p
1153,7/14Fr internal endopyelotomy stent placement,4,Abstract,ss_i,12576806,test,gold,i
1154,57,4,Abstract,hl_p,12576806,test,gold,p
1155,patients with primary ureteropelvic junction obstruction,4,Abstract,hl_p,12576806,test,gold,p
1156,7/14Fr internal endopyelotomy stent placement,4,Abstract,hl_i,12576806,test,gold,i
1157,symptom based questionnaire,5,Abstract,ss_o,12576806,test,gold,o
1158,diuretic scanning,6,Abstract,ss_o,12576806,test,gold,o
1159,diuretic renography .,6,Abstract,ss_o,12576806,test,gold,o
1161,symptoms and ipsilateral glomerular filtration rate .,8,Abstract,ss_o,12576806,test,gold,o
1162,symptoms,8,Abstract,hl_o,12576806,test,gold,o
1163,ipsilateral glomerular filtration rate .,8,Abstract,hl_o,12576806,test,gold,o
1165,drainage pattern .,10,Abstract,ss_o,12576806,test,gold,o
1166,drainage pattern .,10,Abstract,hl_o,12576806,test,gold,o
1168,Stent,12,Abstract,ss_i,12576806,test,gold,i
1169,Stent related symptoms,12,Abstract,ss_o,12576806,test,gold,o
1170,urinary tract infections,12,Abstract,ss_o,12576806,test,gold,o
1171,Stent related symptoms,12,Abstract,hl_o,12576806,test,gold,o
1172,urinary tract infections,12,Abstract,hl_o,12576806,test,gold,o
1174,endopyelotomy,14,Abstract,ss_p,12576806,test,gold,p
1175,duration,14,Abstract,ss_o,12576806,test,gold,o
1176,stent related complications .,14,Abstract,ss_o,12576806,test,gold,o
1177,duration,14,Abstract,hl_o,12576806,test,gold,o
1178,stent related complications .,14,Abstract,hl_o,12576806,test,gold,o
1179,endopyelotomy,0,Title,ss_p,12576806,test,gold,p
1180,stenting,0,Title,ss_i,12576806,test,gold,i
1181,endopyelotomy,0,Title,ss_i,12576806,test,gold,i
1182,duration,0,Title,ss_o,12576806,test,gold,o
1183,stenting,0,Title,hl_i,12576806,test,gold,i
1185,patients with advanced NPC .,1,Abstract,ss_p,12586799,test,gold,p
1186,concurrent chemoradiotherapy ( CCRT ),1,Abstract,ss_i,12586799,test,gold,i
1187,radiotherapy ( RT ),1,Abstract,ss_i,12586799,test,gold,i
1188,patients with advanced NPC .,1,Abstract,hl_p,12586799,test,gold,p
1189,concurrent chemoradiotherapy ( CCRT ),1,Abstract,hl_i,12586799,test,gold,i
1190,radiotherapy ( RT ),1,Abstract,hl_i,12586799,test,gold,i
1191,"From December 1993 to April 1999 , 284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC",2,Abstract,ss_p,12586799,test,gold,p
1192,From December 1993 to April 1999,2,Abstract,hl_p,12586799,test,gold,p
1193,284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC,2,Abstract,hl_p,12586799,test,gold,p
1194,RT,3,Abstract,ss_i,12586799,test,gold,i
1195,chemotherapy,4,Abstract,ss_i,12586799,test,gold,i
1196,cisplatin,4,Abstract,ss_i,12586799,test,gold,i
1197,fluorouracil,4,Abstract,ss_i,12586799,test,gold,i
1198,RT .,4,Abstract,ss_i,12586799,test,gold,i
1199,chemotherapy,4,Abstract,hl_i,12586799,test,gold,i
1200,cisplatin,4,Abstract,hl_i,12586799,test,gold,i
1201,fluorouracil,4,Abstract,hl_i,12586799,test,gold,i
1202,Survival analysis was estimated by the Kaplan-Meier method and compared by the log-rank test .,5,Abstract,ss_o,12586799,test,gold,o
1203,Survival analysis,5,Abstract,hl_o,12586799,test,gold,o
1205,CCRT,7,Abstract,ss_i,12586799,test,gold,i
1206,RT-alone,7,Abstract,ss_i,12586799,test,gold,i
1207,tumor relapse,7,Abstract,ss_o,12586799,test,gold,o
1208,CCRT,7,Abstract,hl_i,12586799,test,gold,i
1209,RT-alone,7,Abstract,hl_i,12586799,test,gold,i
1210,tumor relapse,7,Abstract,hl_o,12586799,test,gold,o
1211,CCRT,8,Abstract,ss_i,12586799,test,gold,i
1212,RT-only,8,Abstract,ss_i,12586799,test,gold,i
1213,5-year overall survival rates,8,Abstract,ss_o,12586799,test,gold,o
1214,CCRT,8,Abstract,hl_i,12586799,test,gold,i
1215,RT-only,8,Abstract,hl_i,12586799,test,gold,i
1216,5-year overall survival rates,8,Abstract,hl_o,12586799,test,gold,o
1217,CCRT,9,Abstract,ss_i,12586799,test,gold,i
1218,RT-only,9,Abstract,ss_i,12586799,test,gold,i
1219,5-year progression-free survival rates,9,Abstract,ss_o,12586799,test,gold,o
1220,CCRT,9,Abstract,hl_i,12586799,test,gold,i
1221,RT-only,9,Abstract,hl_i,12586799,test,gold,i
1222,5-year progression-free survival rates,9,Abstract,hl_o,12586799,test,gold,o
1223,CCRT,10,Abstract,ss_i,12586799,test,gold,i
1224,toxicity,10,Abstract,ss_o,12586799,test,gold,o
1225,leukopenia and emesis,10,Abstract,ss_o,12586799,test,gold,o
1226,CCRT,10,Abstract,hl_i,12586799,test,gold,i
1227,toxicity,10,Abstract,hl_o,12586799,test,gold,o
1228,leukopenia,10,Abstract,hl_o,12586799,test,gold,o
1229,emesis,10,Abstract,hl_o,12586799,test,gold,o
1230,concurrent chemotherapy,11,Abstract,ss_i,12586799,test,gold,i
1231,treatment-related deaths,12,Abstract,ss_o,12586799,test,gold,o
1232,treatment-related deaths,12,Abstract,hl_o,12586799,test,gold,o
1233,patients with advanced NPC in endemic areas .,13,Abstract,ss_p,12586799,test,gold,p
1234,CCRT,13,Abstract,ss_i,12586799,test,gold,i
1235,RT,13,Abstract,ss_i,12586799,test,gold,i
1236,patients with advanced NPC,13,Abstract,hl_p,12586799,test,gold,p
1237,CCRT,13,Abstract,hl_i,12586799,test,gold,i
1238,RT,13,Abstract,hl_i,12586799,test,gold,i
1239,advanced nasopharyngeal carcinoma :,0,Title,ss_p,12586799,test,gold,p
1240,concurrent chemoradiotherapy,0,Title,ss_i,12586799,test,gold,i
1241,radiotherapy,0,Title,ss_i,12586799,test,gold,i
1242,effect,0,Title,ss_o,12586799,test,gold,o
1243,overall and progression-free survival .,0,Title,ss_o,12586799,test,gold,o
1244,advanced nasopharyngeal carcinoma :,0,Title,hl_p,12586799,test,gold,p
1245,concurrent chemoradiotherapy,0,Title,hl_i,12586799,test,gold,i
1246,radiotherapy,0,Title,hl_i,12586799,test,gold,i
1247,overall and progression-free survival .,0,Title,hl_o,12586799,test,gold,o
1248,people with diabetes,0,Abstract,ss_p,12595499,test,gold,p
1249,progress from microalbuminuria,0,Abstract,ss_o,12595499,test,gold,o
1250,clinical proteinuria,0,Abstract,ss_o,12595499,test,gold,o
1251,renal insufficiency .,0,Abstract,ss_o,12595499,test,gold,o
1252,people with diabetes,0,Abstract,hl_p,12595499,test,gold,p
1254,ramipril 's,2,Abstract,ss_i,12595499,test,gold,i
1255,placebo,2,Abstract,ss_i,12595499,test,gold,i
1256,changes of proteinuria,2,Abstract,ss_o,12595499,test,gold,o
1257,ramipril 's,2,Abstract,hl_i,12595499,test,gold,i
1258,placebo,2,Abstract,hl_i,12595499,test,gold,i
1259,7674 participants with albuminuria data at baseline and at follow-up .,3,Abstract,ss_p,12595499,test,gold,p
1260,7674 participants with albuminuria data at baseline and at follow-up,3,Abstract,hl_p,12595499,test,gold,p
1261,"Inclusion criteria were known vascular disease or diabetes plus one other cardiovascular risk factor , exclusion criteria included heart failure or known impaired left ventricular function , dipstick-positive proteinuria ( > 1+ ) , and serum creatinine > 2.3 mg/dl ( 200 microM ) .",4,Abstract,ss_p,12595499,test,gold,p
1262,clinical proteinuria,5,Abstract,ss_o,12595499,test,gold,o
1263,clinical proteinuria,5,Abstract,hl_o,12595499,test,gold,o
1264,progression of albuminuria,6,Abstract,ss_o,12595499,test,gold,o
1265,new microalbuminuria or new clinical proteinuria ),6,Abstract,ss_o,12595499,test,gold,o
1266,new microalbuminuria,6,Abstract,ss_o,12595499,test,gold,o
1267,clinical proteinuria .,6,Abstract,ss_o,12595499,test,gold,o
1268,progression of albuminuria,6,Abstract,hl_o,12595499,test,gold,o
1269,microalbuminuria,6,Abstract,hl_o,12595499,test,gold,o
1270,clinical proteinuria .,6,Abstract,hl_o,12595499,test,gold,o
1271,Ramipril,7,Abstract,ss_i,12595499,test,gold,i
1272,progression,7,Abstract,ss_o,12595499,test,gold,o
1273,Ramipril,7,Abstract,hl_i,12595499,test,gold,i
1274,progression,7,Abstract,hl_o,12595499,test,gold,o
1275,People without and with diabetes who are at high risk for cardiovascular disease,8,Abstract,ss_p,12595499,test,gold,p
1276,albuminuria .,8,Abstract,ss_o,12595499,test,gold,o
1277,albuminuria .,8,Abstract,hl_o,12595499,test,gold,o
1278,nondiabetic and in diabetic people .,9,Abstract,ss_p,12595499,test,gold,p
1279,clinical proteinuria,9,Abstract,ss_o,12595499,test,gold,o
1280,nondiabetic and in diabetic people .,9,Abstract,hl_p,12595499,test,gold,p
1281,Ramipril,10,Abstract,ss_i,12595499,test,gold,i
1282,progression of albuminuria .,10,Abstract,ss_o,12595499,test,gold,o
1283,Ramipril,10,Abstract,hl_i,12595499,test,gold,i
1284,progression of albuminuria .,10,Abstract,hl_o,12595499,test,gold,o
1285,in people at high cardiovascular risk :,0,Title,ss_p,12595499,test,gold,p
1286,Development of renal disease,0,Title,ss_o,12595499,test,gold,o
1287,people at high cardiovascular risk,0,Title,hl_p,12595499,test,gold,p
1288,for colonoscopy,0,Abstract,ss_p,12709693,test,gold,p
1289,remifentanil,0,Abstract,ss_i,12709693,test,gold,i
1290,propofol,0,Abstract,ss_i,12709693,test,gold,i
1291,"midazolam , fentanyl",0,Abstract,ss_i,12709693,test,gold,i
1292,propofol .,0,Abstract,ss_i,12709693,test,gold,i
1293,effective,0,Abstract,ss_o,12709693,test,gold,o
1294,remifentanil,0,Abstract,hl_i,12709693,test,gold,i
1295,propofol,0,Abstract,hl_i,12709693,test,gold,i
1296,midazolam,0,Abstract,hl_i,12709693,test,gold,i
1297,fentanyl,0,Abstract,hl_i,12709693,test,gold,i
1298,propofol,0,Abstract,hl_i,12709693,test,gold,i
1299,100 adult patients,1,Abstract,ss_p,12709693,test,gold,p
1300,100 adult patients,1,Abstract,hl_p,12709693,test,gold,p
1301,remifentanil,2,Abstract,ss_i,12709693,test,gold,i
1302,propofol,2,Abstract,ss_i,12709693,test,gold,i
1303,remifentanil,2,Abstract,hl_i,12709693,test,gold,i
1304,propofol,2,Abstract,hl_i,12709693,test,gold,i
1305,fentanyl,3,Abstract,ss_i,12709693,test,gold,i
1306,midazolam,3,Abstract,ss_i,12709693,test,gold,i
1307,propofol,3,Abstract,ss_i,12709693,test,gold,i
1308,fentanyl,3,Abstract,hl_i,12709693,test,gold,i
1309,midazolam,3,Abstract,hl_i,12709693,test,gold,i
1310,propofol,3,Abstract,hl_i,12709693,test,gold,i
1311,Cardiorespiratory parameters and bispectral index were monitored and recorded .,4,Abstract,ss_o,12709693,test,gold,o
1312,Cardiorespiratory parameters,4,Abstract,hl_o,12709693,test,gold,o
1313,bispectral index,4,Abstract,hl_o,12709693,test,gold,o
1314,"The quality of the analgesia was assessed with a Numerical Pain Rating Scale ( NRS ) ; recovery level and return of psychomotor efficiency were evaluated with , respectively , the Aldrete scale and a Modified Post Anesthesia Discharge Scoring ( MPADS ) system .",5,Abstract,ss_o,12709693,test,gold,o
1315,Numerical Pain Rating Scale ( NRS ),5,Abstract,hl_o,12709693,test,gold,o
1316,recovery level,5,Abstract,hl_o,12709693,test,gold,o
1317,return of psychomotor efficiency,5,Abstract,hl_o,12709693,test,gold,o
1318,Aldrete scale,5,Abstract,hl_o,12709693,test,gold,o
1319,Modified Post Anesthesia Discharge Scoring ( MPADS ) system,5,Abstract,hl_o,12709693,test,gold,o
1321,( NRS,7,Abstract,ss_o,12709693,test,gold,o
1322,pain intensity score,8,Abstract,ss_o,12709693,test,gold,o
1323,pain intensity score,8,Abstract,hl_o,12709693,test,gold,o
1324,maximum MPADS score,9,Abstract,ss_o,12709693,test,gold,o
1325,maximum MPADS score,9,Abstract,hl_o,12709693,test,gold,o
1326,mean arterial pressure and heart rate and signs of respiratory depression,10,Abstract,ss_o,12709693,test,gold,o
1327,mean arterial pressure and heart rate and signs of respiratory depression,10,Abstract,hl_o,12709693,test,gold,o
1328,colonoscopy,11,Abstract,ss_p,12709693,test,gold,p
1329,remifentanil,11,Abstract,ss_i,12709693,test,gold,i
1330,propofol,11,Abstract,ss_i,12709693,test,gold,i
1331,sufficient analgesia,11,Abstract,ss_o,12709693,test,gold,o
1332,hemodynamic stability,11,Abstract,ss_o,12709693,test,gold,o
1333,respiratory depression,11,Abstract,ss_o,12709693,test,gold,o
1334,rapid recovery,11,Abstract,ss_o,12709693,test,gold,o
1335,remifentanil,11,Abstract,hl_i,12709693,test,gold,i
1336,propofol,11,Abstract,hl_i,12709693,test,gold,i
1337,analgesia,11,Abstract,hl_o,12709693,test,gold,o
1338,hemodynamic stability,11,Abstract,hl_o,12709693,test,gold,o
1339,respiratory depression,11,Abstract,hl_o,12709693,test,gold,o
1340,rapid recovery,11,Abstract,hl_o,12709693,test,gold,o
1341,outpatient colonoscopy .,0,Title,ss_p,12709693,test,gold,p
1342,remifentanil,0,Title,ss_i,12709693,test,gold,i
1343,propofol,0,Title,ss_i,12709693,test,gold,i
1344,"fentanyl , midazolam",0,Title,ss_i,12709693,test,gold,i
1345,propofol,0,Title,ss_i,12709693,test,gold,i
1346,outpatient colonoscopy .,0,Title,hl_p,12709693,test,gold,p
1347,remifentanil,0,Title,hl_i,12709693,test,gold,i
1348,propofol,0,Title,hl_i,12709693,test,gold,i
1349,fentanyl,0,Title,hl_i,12709693,test,gold,i
1350,midazolam,0,Title,hl_i,12709693,test,gold,i
1351,propofol,0,Title,hl_i,12709693,test,gold,i
1352,Twenty-nine IDDM patients with borderline hypertension,0,Abstract,ss_p,1286547,test,gold,p
1353,placebo,0,Abstract,ss_i,1286547,test,gold,i
1354,nitrendipine,0,Abstract,ss_i,1286547,test,gold,i
1355,Twenty-nine IDDM patients with borderline hypertension,0,Abstract,hl_p,1286547,test,gold,p
1356,placebo,0,Abstract,hl_i,1286547,test,gold,i
1357,nitrendipine,0,Abstract,hl_i,1286547,test,gold,i
1358,Nitrendipine,1,Abstract,ss_i,1286547,test,gold,i
1359,Nitrendipine,1,Abstract,hl_i,1286547,test,gold,i
1360,Stimulated platelet thromboxane formation,2,Abstract,ss_o,1286547,test,gold,o
1361,non exhausting exercise,2,Abstract,ss_o,1286547,test,gold,o
1362,Stimulated platelet thromboxane formation,2,Abstract,hl_o,1286547,test,gold,o
1363,plasma levels of platelet factor 4 and aggregation responses to collagen and ADP,3,Abstract,ss_o,1286547,test,gold,o
1364,plasma levels of platelet factor 4 and aggregation responses to collagen and ADP,3,Abstract,hl_o,1286547,test,gold,o
1365,thromboxane formation,4,Abstract,ss_o,1286547,test,gold,o
1366,thromboxane formation,4,Abstract,hl_o,1286547,test,gold,o
1367,placebo,5,Abstract,ss_i,1286547,test,gold,i
1368,Exercise induced change of thromboxane synthesis,5,Abstract,ss_o,1286547,test,gold,o
1369,placebo,5,Abstract,hl_i,1286547,test,gold,i
1370,Exercise induced change of thromboxane synthesis,5,Abstract,hl_o,1286547,test,gold,o
1371,PF4 plasma levels,6,Abstract,ss_o,1286547,test,gold,o
1372,PF4 plasma levels,6,Abstract,hl_o,1286547,test,gold,o
1373,nitrendipine,7,Abstract,ss_i,1286547,test,gold,i
1374,Whole blood aggregation after collagen stimulation,7,Abstract,ss_o,1286547,test,gold,o
1375,aggregation,7,Abstract,ss_o,1286547,test,gold,o
1376,nitrendipine,7,Abstract,hl_i,1286547,test,gold,i
1377,Whole blood aggregation after collagen stimulation,7,Abstract,hl_o,1286547,test,gold,o
1378,aggregation,7,Abstract,hl_o,1286547,test,gold,o
1379,nitrendipine,8,Abstract,ss_i,1286547,test,gold,i
1380,nitrendipine,8,Abstract,hl_i,1286547,test,gold,i
1381,diabetic patients with borderline hypertension .,9,Abstract,ss_p,1286547,test,gold,p
1382,nitrendipine,9,Abstract,ss_i,1286547,test,gold,i
1383,collagen dependent platelet activation,9,Abstract,ss_o,1286547,test,gold,o
1384,diabetic patients with borderline hypertension .,9,Abstract,hl_p,1286547,test,gold,p
1385,nitrendipine,9,Abstract,hl_i,1286547,test,gold,i
1386,collagen dependent platelet activation,9,Abstract,hl_o,1286547,test,gold,o
1387,borderline hypertensive patients with IDDM-type diabetes mellitus .,0,Title,ss_p,1286547,test,gold,p
1388,dihydropyridine calcium channel blocker :,0,Title,ss_i,1286547,test,gold,i
1389,nitrendipine,0,Title,ss_i,1286547,test,gold,i
1390,platelet thromboxane formation,0,Title,ss_o,1286547,test,gold,o
1391,borderline hypertensive patients with IDDM-type diabetes mellitus .,0,Title,hl_p,1286547,test,gold,p
1392,dihydropyridine calcium channel blocker,0,Title,hl_i,1286547,test,gold,i
1393,nitrendipine,0,Title,hl_i,1286547,test,gold,i
1394,platelet thromboxane formation,0,Title,hl_o,1286547,test,gold,o
1395,myoelectrical dysrhythmia,0,Abstract,ss_o,12960652,test,gold,o
1396,gastric electrical activity,0,Abstract,ss_o,12960652,test,gold,o
1397,gastric myoelectrical activity and dysrhythmia,1,Abstract,ss_o,12960652,test,gold,o
1398,electrogastrography,1,Abstract,ss_o,12960652,test,gold,o
1399,Epigastric impedance,2,Abstract,ss_i,12960652,test,gold,i
1400,Epigastric impedance,2,Abstract,ss_o,12960652,test,gold,o
1401,gastric emptying time and gastric phasic activity .,2,Abstract,ss_o,12960652,test,gold,o
1402,Epigastric impedance,2,Abstract,hl_i,12960652,test,gold,i
1403,"control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .",3,Abstract,ss_p,12960652,test,gold,p
1404,epigastric impedance,3,Abstract,ss_i,12960652,test,gold,i
1405,gastric dysrhythmia,3,Abstract,ss_o,12960652,test,gold,o
1406,epigastric impedance,3,Abstract,ss_o,12960652,test,gold,o
1407,gastric rhythms,3,Abstract,ss_o,12960652,test,gold,o
1408,impedance gastrography,3,Abstract,ss_o,12960652,test,gold,o
1409,infants with different gastrointestinal diseases,3,Abstract,hl_p,12960652,test,gold,p
1410,epigastric impedance,3,Abstract,hl_i,12960652,test,gold,i
1411,epigastric impedance,3,Abstract,hl_o,12960652,test,gold,o
1412,21 patients ( age 0-2 months ) and 40 healthy infants ( age 0-2 months ),4,Abstract,ss_p,12960652,test,gold,p
1413,21 patients,4,Abstract,hl_p,12960652,test,gold,p
1414,age 0-2 months,4,Abstract,hl_p,12960652,test,gold,p
1415,40 healthy infants,4,Abstract,hl_p,12960652,test,gold,p
1416,age 0-2 months,4,Abstract,hl_p,12960652,test,gold,p
1417,"patients suffered from partial or total intestinal obstruction , necrotizing enterocolitis or pyloric stenosis.All infants were fasting",5,Abstract,ss_p,12960652,test,gold,p
1418,"patients suffered from partial or total intestinal obstruction , necrotizing enterocolitis or pyloric stenosis.All infants were fasting",5,Abstract,hl_p,12960652,test,gold,p
1421,phasic activity,8,Abstract,ss_o,12960652,test,gold,o
1422,frequency phasic activity,8,Abstract,ss_o,12960652,test,gold,o
1423,phasic activity,8,Abstract,hl_o,12960652,test,gold,o
1424,frequency phasic activity,8,Abstract,hl_o,12960652,test,gold,o
1425,phasic activity,9,Abstract,ss_o,12960652,test,gold,o
1426,phasic activity,9,Abstract,hl_o,12960652,test,gold,o
1427,infants with partial or total intestinal obstruction,10,Abstract,ss_p,12960652,test,gold,p
1428,epigastric impedance,10,Abstract,ss_i,12960652,test,gold,i
1429,epigastric impedance,10,Abstract,ss_o,12960652,test,gold,o
1430,epigastric impedance,10,Abstract,hl_i,12960652,test,gold,i
1431,gastric phasic activity patterns,11,Abstract,ss_o,12960652,test,gold,o
1432,infants with gastrointestinal diseases,0,Title,ss_p,12960652,test,gold,p
1433,Gastric dysrhythmia,0,Title,ss_o,12960652,test,gold,o
1434,epigastric impedance .,0,Title,ss_o,12960652,test,gold,o
1435,infants,0,Title,hl_p,12960652,test,gold,p
1436,gastrointestinal diseases,0,Title,hl_p,12960652,test,gold,p
1437,epigastric impedance,0,Title,hl_i,12960652,test,gold,i
1438,in vitro fertilization ( IVF ),0,Abstract,ss_p,1459268,test,gold,p
1439,gonadotropin-releasing hormone agonist ( GnRH-a ),0,Abstract,ss_i,1459268,test,gold,i
1440,usefulness,0,Abstract,ss_o,1459268,test,gold,o
1441,in vitro fertilization ( IVF ),0,Abstract,hl_p,1459268,test,gold,p
1442,gonadotropin-releasing hormone agonist ( GnRH-a ),0,Abstract,hl_i,1459268,test,gold,i
1443,usefulness,0,Abstract,hl_o,1459268,test,gold,o
1444,GnRH-a .,1,Abstract,ss_i,1459268,test,gold,i
1445,GnRH-a .,1,Abstract,hl_i,1459268,test,gold,i
1446,Aberdeen Assisted Reproduction Unit .,2,Abstract,ss_p,1459268,test,gold,p
1447,Forty-eight patients having IVF for the first time,3,Abstract,ss_p,1459268,test,gold,p
1448,Forty-eight patients having IVF for the first time,3,Abstract,hl_p,1459268,test,gold,p
1449,Response to ovarian stimulation and occurrence of spontaneous luteinizing hormone ( LH ) surges .,4,Abstract,ss_o,1459268,test,gold,o
1450,Response to ovarian stimulation and occurrence of spontaneous luteinizing hormone ( LH ) surges .,4,Abstract,hl_o,1459268,test,gold,o
1451,"ovulation induction , fertilization , and pregnancy rates",5,Abstract,ss_o,1459268,test,gold,o
1452,LH surge .,5,Abstract,ss_o,1459268,test,gold,o
1453,"ovulation induction , fertilization , and pregnancy rates",5,Abstract,hl_o,1459268,test,gold,o
1454,LH surge .,5,Abstract,hl_o,1459268,test,gold,o
1455,patients undergoing IVF .,6,Abstract,ss_p,1459268,test,gold,p
1456,ovarian stimulation,6,Abstract,ss_o,1459268,test,gold,o
1457,undergoing IVF,6,Abstract,hl_p,1459268,test,gold,p
1458,in vitro fertilization,0,Title,ss_p,1459268,test,gold,p
1459,gonadotropin-releasing hormone agonist,0,Title,ss_i,1459268,test,gold,i
1460,gonadotropin-releasing hormone agonist,0,Title,hl_i,1459268,test,gold,i
1461,patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .,0,Abstract,ss_p,14679127,test,gold,p
1462,topotecan,0,Abstract,ss_i,14679127,test,gold,i
1463,paclitaxel,0,Abstract,ss_i,14679127,test,gold,i
1464,survival,0,Abstract,ss_o,14679127,test,gold,o
1465,patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .,0,Abstract,hl_p,14679127,test,gold,p
1466,topotecan,0,Abstract,hl_i,14679127,test,gold,i
1467,paclitaxel,0,Abstract,hl_i,14679127,test,gold,i
1468,Patients with bidimensionally measurable disease,1,Abstract,ss_p,14679127,test,gold,p
1469,topotecan,1,Abstract,ss_i,14679127,test,gold,i
1470,paclitaxel,1,Abstract,ss_i,14679127,test,gold,i
1471,Patients with bidimensionally measurable disease,1,Abstract,hl_p,14679127,test,gold,p
1472,topotecan,1,Abstract,hl_i,14679127,test,gold,i
1473,paclitaxel,1,Abstract,hl_i,14679127,test,gold,i
1475,The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire,3,Abstract,ss_o,14679127,test,gold,o
1476,"( pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia )",3,Abstract,ss_o,14679127,test,gold,o
1477,European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire,3,Abstract,hl_o,14679127,test,gold,o
1478,pain,3,Abstract,hl_o,14679127,test,gold,o
1479,anorexia,3,Abstract,hl_o,14679127,test,gold,o
1480,diarrhoea,3,Abstract,hl_o,14679127,test,gold,o
1481,fatigue,3,Abstract,hl_o,14679127,test,gold,o
1482,nausea,3,Abstract,hl_o,14679127,test,gold,o
1483,vomiting,3,Abstract,hl_o,14679127,test,gold,o
1484,dyspnea,3,Abstract,hl_o,14679127,test,gold,o
1485,constipation,3,Abstract,hl_o,14679127,test,gold,o
1486,insomnia,3,Abstract,hl_o,14679127,test,gold,o
1487,A total of 226 patients were evaluable for response .,4,Abstract,ss_p,14679127,test,gold,p
1488,226,4,Abstract,hl_p,14679127,test,gold,p
1489,EORTC QOL-30 questionnaire .,5,Abstract,ss_o,14679127,test,gold,o
1490,topotecan,6,Abstract,ss_i,14679127,test,gold,i
1491,paclitaxel,6,Abstract,ss_i,14679127,test,gold,i
1492,progression,6,Abstract,ss_o,14679127,test,gold,o
1493,topotecan,6,Abstract,hl_i,14679127,test,gold,i
1494,paclitaxel,6,Abstract,hl_i,14679127,test,gold,i
1495,progression,6,Abstract,hl_o,14679127,test,gold,o
1496,topotecan,7,Abstract,ss_i,14679127,test,gold,i
1497,paclitaxel,7,Abstract,ss_i,14679127,test,gold,i
1498,median survival,7,Abstract,ss_o,14679127,test,gold,o
1499,topotecan,7,Abstract,hl_i,14679127,test,gold,i
1500,paclitaxel,7,Abstract,hl_i,14679127,test,gold,i
1501,median survival,7,Abstract,hl_o,14679127,test,gold,o
1502,Topotecan,8,Abstract,ss_i,14679127,test,gold,i
1503,paclitaxel,8,Abstract,ss_i,14679127,test,gold,i
1504,efficacy,8,Abstract,ss_o,14679127,test,gold,o
1505,survival,8,Abstract,ss_o,14679127,test,gold,o
1506,haematological toxicity .,8,Abstract,ss_o,14679127,test,gold,o
1507,Topotecan,8,Abstract,hl_i,14679127,test,gold,i
1508,paclitaxel,8,Abstract,hl_i,14679127,test,gold,i
1509,efficacy,8,Abstract,hl_o,14679127,test,gold,o
1510,survival,8,Abstract,hl_o,14679127,test,gold,o
1511,haematological toxicity .,8,Abstract,hl_o,14679127,test,gold,o
1512,Non-haematological toxicity,9,Abstract,ss_o,14679127,test,gold,o
1513,Non-haematological toxicity,9,Abstract,hl_o,14679127,test,gold,o
1514,ovarian cancer .,10,Abstract,ss_p,14679127,test,gold,p
1515,topotecan,10,Abstract,ss_i,14679127,test,gold,i
1516,long-term survival rate,10,Abstract,ss_o,14679127,test,gold,o
1517,ovarian cancer .,10,Abstract,hl_p,14679127,test,gold,p
1518,topotecan,10,Abstract,hl_i,14679127,test,gold,i
1519,advanced epithelial ovarian carcinoma .,0,Title,ss_p,14679127,test,gold,p
1520,topotecan,0,Title,ss_i,14679127,test,gold,i
1521,paclitaxel,0,Title,ss_i,14679127,test,gold,i
1522,Long-term survival,0,Title,ss_o,14679127,test,gold,o
1523,advanced epithelial ovarian carcinoma .,0,Title,hl_p,14679127,test,gold,p
1524,topotecan,0,Title,hl_i,14679127,test,gold,i
1525,paclitaxel,0,Title,hl_i,14679127,test,gold,i
1526,healthy young subjects,0,Abstract,ss_p,14739125,test,gold,p
1527,"cholesteryl ester transfer protein ( CETP ) inhibitor torcetrapib ( CP-529,414 )",0,Abstract,ss_i,14739125,test,gold,i
1528,high-density lipoprotein cholesterol ( HDL-C ) levels,0,Abstract,ss_o,14739125,test,gold,o
1529,healthy young,0,Abstract,hl_p,14739125,test,gold,p
1530,cholesteryl ester transfer protein ( CETP ) inhibitor torcetrapib,0,Abstract,hl_i,14739125,test,gold,i
1531,Five groups of 8 subjects each,1,Abstract,ss_p,14739125,test,gold,p
1532,placebo,1,Abstract,ss_i,14739125,test,gold,i
1533,torcetrapib,1,Abstract,ss_i,14739125,test,gold,i
1534,Five groups of 8 subjects each,1,Abstract,hl_p,14739125,test,gold,p
1535,placebo,1,Abstract,hl_i,14739125,test,gold,i
1536,torcetrapib,1,Abstract,hl_i,14739125,test,gold,i
1537,Torcetrapib,2,Abstract,ss_i,14739125,test,gold,i
1538,Torcetrapib,2,Abstract,hl_i,14739125,test,gold,i
1539,plasma drug levels,3,Abstract,ss_o,14739125,test,gold,o
1540,plasma drug levels,3,Abstract,hl_o,14739125,test,gold,o
1541,HDL-C,4,Abstract,ss_o,14739125,test,gold,o
1542,Total plasma cholesterol,5,Abstract,ss_o,14739125,test,gold,o
1543,nonHDL-C,5,Abstract,ss_o,14739125,test,gold,o
1544,low-density lipoprotein cholesterol,5,Abstract,ss_o,14739125,test,gold,o
1545,Total plasma cholesterol,5,Abstract,hl_o,14739125,test,gold,o
1546,nonHDL-C,5,Abstract,hl_o,14739125,test,gold,o
1547,low-density lipoprotein cholesterol,5,Abstract,hl_o,14739125,test,gold,o
1548,Apolipoprotein A-I and E,6,Abstract,ss_o,14739125,test,gold,o
1549,apoB,6,Abstract,ss_o,14739125,test,gold,o
1550,Apolipoprotein A-I and E,6,Abstract,hl_o,14739125,test,gold,o
1551,apoB,6,Abstract,hl_o,14739125,test,gold,o
1552,Cholesteryl ester content,7,Abstract,ss_o,14739125,test,gold,o
1553,triglyceride,7,Abstract,ss_o,14739125,test,gold,o
1554,nonHDL,7,Abstract,ss_o,14739125,test,gold,o
1555,HDL .,7,Abstract,ss_o,14739125,test,gold,o
1556,Cholesteryl ester content,7,Abstract,hl_o,14739125,test,gold,o
1557,triglyceride,7,Abstract,hl_o,14739125,test,gold,o
1560,torcetrapib .,0,Title,ss_i,14739125,test,gold,i
1561,high-density lipoprotein,0,Title,ss_o,14739125,test,gold,o
1562,torcetrapib .,0,Title,hl_i,14739125,test,gold,i
1563,patients on continuous ambulatory peritoneal dialysis ( CAPD ) .,0,Abstract,ss_p,14763035,test,gold,p
1564,selective angiotensin II receptor blocker ( ARB ),0,Abstract,ss_i,14763035,test,gold,i
1565,regressive effect on left ventricular hypertrophy ( LVH ),0,Abstract,ss_o,14763035,test,gold,o
1566,patients on continuous ambulatory peritoneal dialysis ( CAPD ) .,0,Abstract,hl_p,14763035,test,gold,p
1567,selective angiotensin II receptor blocker ( ARB ),0,Abstract,hl_i,14763035,test,gold,i
1568,24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and LVMi > 137 g/m2 for men ],1,Abstract,ss_p,14763035,test,gold,p
1569,ARB valsartan,1,Abstract,ss_i,14763035,test,gold,i
1570,placebo,1,Abstract,ss_i,14763035,test,gold,i
1571,[ left ventricular mass index ( LVMi ),1,Abstract,ss_o,14763035,test,gold,o
1572,LVMi,1,Abstract,ss_o,14763035,test,gold,o
1573,24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women,1,Abstract,hl_p,14763035,test,gold,p
1574,LVMi > 137 g/m2 for men,1,Abstract,hl_p,14763035,test,gold,p
1575,ARB valsartan,1,Abstract,hl_i,14763035,test,gold,i
1576,placebo,1,Abstract,hl_i,14763035,test,gold,i
1577,target blood pressure ( BP ),2,Abstract,ss_o,14763035,test,gold,o
1578,blood pressure ( BP ),2,Abstract,hl_o,14763035,test,gold,o
1579,aortic and large-artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI ) application tonometry ] and cardiac echocardiography .,3,Abstract,ss_o,14763035,test,gold,o
1580,aortic and large-artery compliance,3,Abstract,hl_o,14763035,test,gold,o
1581,arterial wave reflections [ pulse wave velocity ( PWV ),3,Abstract,hl_o,14763035,test,gold,o
1582,augmentation index ( AI ) application tonometry ],3,Abstract,hl_o,14763035,test,gold,o
1583,cardiac echocardiography .,3,Abstract,hl_o,14763035,test,gold,o
1584,"body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance .",4,Abstract,ss_o,14763035,test,gold,o
1585,"body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance .",4,Abstract,hl_o,14763035,test,gold,o
1587,ARB .,6,Abstract,ss_i,14763035,test,gold,i
1588,Systolic and diastolic BP,6,Abstract,ss_o,14763035,test,gold,o
1589,ARB .,6,Abstract,hl_i,14763035,test,gold,i
1590,Systolic and diastolic BP,6,Abstract,hl_o,14763035,test,gold,o
1591,ARB,7,Abstract,ss_i,14763035,test,gold,i
1592,placebo,7,Abstract,ss_i,14763035,test,gold,i
1593,LVMi,7,Abstract,ss_o,14763035,test,gold,o
1594,ARB,7,Abstract,hl_i,14763035,test,gold,i
1595,placebo,7,Abstract,hl_i,14763035,test,gold,i
1596,LVMi,7,Abstract,hl_o,14763035,test,gold,o
1597,LVMi,8,Abstract,ss_o,14763035,test,gold,o
1598,PWV,8,Abstract,ss_o,14763035,test,gold,o
1599,AI .,8,Abstract,ss_o,14763035,test,gold,o
1600,LVMi,8,Abstract,hl_o,14763035,test,gold,o
1601,PWV,8,Abstract,hl_o,14763035,test,gold,o
1602,AI,8,Abstract,hl_o,14763035,test,gold,o
1603,CAPD patients with LVH,9,Abstract,ss_p,14763035,test,gold,p
1604,ARB,9,Abstract,ss_i,14763035,test,gold,i
1605,LVMi,9,Abstract,ss_o,14763035,test,gold,o
1606,arterial hemodynamics .,9,Abstract,ss_o,14763035,test,gold,o
1607,ARB,9,Abstract,hl_i,14763035,test,gold,i
1608,LVMi,9,Abstract,hl_o,14763035,test,gold,o
1609,left ventricular hypertrophy,0,Title,ss_p,14763035,test,gold,p
1610,Valsartan,0,Title,ss_i,14763035,test,gold,i
1611,regression of left ventricular hypertrophy,0,Title,ss_o,14763035,test,gold,o
1612,arterial stiffness .,0,Title,ss_o,14763035,test,gold,o
1613,left ventricular hypertrophy,0,Title,hl_p,14763035,test,gold,p
1614,Valsartan,0,Title,hl_i,14763035,test,gold,i
1615,Nearly 2000 patients with stage IIB and III melanoma,0,Abstract,ss_p,15014018,test,gold,p
1616,IFN-alpha 2b,0,Abstract,ss_i,15014018,test,gold,i
1617,Nearly 2000 patients with stage IIB and III melanoma,0,Abstract,hl_p,15014018,test,gold,p
1618,IFN-alpha 2b,0,Abstract,hl_i,15014018,test,gold,i
1619,prognostic factors and treatment effects,1,Abstract,ss_o,15014018,test,gold,o
1621,prognostic factors using optimized statistical models,3,Abstract,ss_o,15014018,test,gold,o
1622,observation ( Obs ),4,Abstract,ss_i,15014018,test,gold,i
1623,IFN-alpha 2b ( HDI ),4,Abstract,ss_i,15014018,test,gold,i
1624,Obs,4,Abstract,ss_i,15014018,test,gold,i
1625,treatment effects versus observation ( Obs ),4,Abstract,ss_o,15014018,test,gold,o
1626,IFN-alpha 2b ( HDI ),4,Abstract,hl_i,15014018,test,gold,i
1627,Obs,4,Abstract,hl_i,15014018,test,gold,i
1629,HDI,6,Abstract,ss_i,15014018,test,gold,i
1630,Obs .,6,Abstract,ss_i,15014018,test,gold,i
1631,relapse-free survival ( RFS ) -but,6,Abstract,ss_o,15014018,test,gold,o
1632,overall survival ( OS ) -was,6,Abstract,ss_o,15014018,test,gold,o
1633,HDI,6,Abstract,hl_i,15014018,test,gold,i
1634,Obs,6,Abstract,hl_i,15014018,test,gold,i
1635,relapse-free survival ( RFS ),6,Abstract,hl_o,15014018,test,gold,o
1636,overall survival ( OS ),6,Abstract,hl_o,15014018,test,gold,o
1637,prognostic factors,7,Abstract,ss_o,15014018,test,gold,o
1638,"ulceration , recurrent disease at entry",7,Abstract,ss_o,15014018,test,gold,o
1639,age,7,Abstract,ss_o,15014018,test,gold,o
1640,HDI,8,Abstract,ss_i,15014018,test,gold,i
1641,Obs,8,Abstract,ss_i,15014018,test,gold,i
1642,RFS,8,Abstract,ss_o,15014018,test,gold,o
1643,OS,8,Abstract,ss_o,15014018,test,gold,o
1644,HDI,8,Abstract,hl_i,15014018,test,gold,i
1645,Obs,8,Abstract,hl_i,15014018,test,gold,i
1646,RFS,8,Abstract,hl_o,15014018,test,gold,o
1647,OS,8,Abstract,hl_o,15014018,test,gold,o
1648,patients with high-risk resected melanoma,9,Abstract,ss_p,15014018,test,gold,p
1649,RFS,9,Abstract,ss_o,15014018,test,gold,o
1650,OS,9,Abstract,ss_o,15014018,test,gold,o
1651,patients with high-risk resected melanoma,9,Abstract,hl_p,15014018,test,gold,p
1652,RFS,9,Abstract,hl_o,15014018,test,gold,o
1653,OS,9,Abstract,hl_o,15014018,test,gold,o
1654,predictors of relapse and response,10,Abstract,ss_o,15014018,test,gold,o
1655,interferon,0,Title,ss_i,15014018,test,gold,i
1656,interferon,0,Title,hl_i,15014018,test,gold,i
1659,catheters ( guiding catheter alone,2,Abstract,ss_i,15133359,test,gold,i
1660,electrophysiology catheter advanced,2,Abstract,ss_i,15133359,test,gold,i
1661,( electrophysiology catheter aided,2,Abstract,ss_i,15133359,test,gold,i
1662,catheters,2,Abstract,hl_i,15133359,test,gold,i
1663,guiding catheter alone,2,Abstract,hl_i,15133359,test,gold,i
1664,GCA,2,Abstract,hl_i,15133359,test,gold,i
1665,electrophysiology catheter advanced,2,Abstract,hl_i,15133359,test,gold,i
1666,electrophysiology catheter aided,2,Abstract,hl_i,15133359,test,gold,i
1667,EPA,3,Abstract,ss_i,15133359,test,gold,i
1668,GCA,3,Abstract,ss_i,15133359,test,gold,i
1669,CS cannulation time,3,Abstract,ss_o,15133359,test,gold,o
1670,EPA,3,Abstract,hl_i,15133359,test,gold,i
1671,GCA,3,Abstract,hl_i,15133359,test,gold,i
1672,CS cannulation time,3,Abstract,hl_o,15133359,test,gold,o
1673,Thirty-four consecutive patients,4,Abstract,ss_p,15133359,test,gold,p
1674,GCA,4,Abstract,ss_i,15133359,test,gold,i
1675,EPA,4,Abstract,ss_i,15133359,test,gold,i
1676,Thirty-four consecutive patients,4,Abstract,hl_p,15133359,test,gold,p
1677,GCA,4,Abstract,hl_i,15133359,test,gold,i
1678,EPA,4,Abstract,hl_i,15133359,test,gold,i
1679,EPA,5,Abstract,ss_i,15133359,test,gold,i
1680,GCA,5,Abstract,ss_i,15133359,test,gold,i
1681,Time to successful catheterization of CS,5,Abstract,ss_o,15133359,test,gold,o
1682,EPA,5,Abstract,hl_i,15133359,test,gold,i
1683,GCA,5,Abstract,hl_i,15133359,test,gold,i
1684,Time to successful catheterization of CS,5,Abstract,hl_o,15133359,test,gold,o
1685,EPA,6,Abstract,ss_i,15133359,test,gold,i
1686,GCA,6,Abstract,ss_i,15133359,test,gold,i
1687,Fluoroscopy time,6,Abstract,ss_o,15133359,test,gold,o
1688,EPA,6,Abstract,hl_i,15133359,test,gold,i
1689,GCA,6,Abstract,hl_i,15133359,test,gold,i
1690,Fluoroscopy time,6,Abstract,hl_o,15133359,test,gold,o
1691,EPA,7,Abstract,ss_i,15133359,test,gold,i
1692,GCA,7,Abstract,ss_i,15133359,test,gold,i
1693,contrast dye volume,7,Abstract,ss_o,15133359,test,gold,o
1694,EPA,7,Abstract,hl_i,15133359,test,gold,i
1695,GCA,7,Abstract,hl_i,15133359,test,gold,i
1696,contrast dye volume,7,Abstract,hl_o,15133359,test,gold,o
1697,"procedural time , fluoroscopy time and contrast dye volume",8,Abstract,ss_o,15133359,test,gold,o
1698,"procedural time , fluoroscopy time",8,Abstract,hl_o,15133359,test,gold,o
1699,contrast dye volume,8,Abstract,hl_o,15133359,test,gold,o
1700,biventricular implantation procedures .,0,Title,ss_p,15133359,test,gold,p
1701,biventricular implantation,0,Title,hl_p,15133359,test,gold,p
1702,peers ',0,Abstract,ss_p,15193668,test,gold,p
1703,child with autism .,0,Abstract,ss_p,15193668,test,gold,p
1704,descriptive and explanatory information,0,Abstract,ss_i,15193668,test,gold,i
1705,peers ' perceptions and behavioral intentions,0,Abstract,ss_o,15193668,test,gold,o
1706,peers,0,Abstract,hl_p,15193668,test,gold,p
1707,child with autism .,0,Abstract,hl_p,15193668,test,gold,p
1708,peers ' perceptions,0,Abstract,hl_o,15193668,test,gold,o
1709,behavioral intentions,0,Abstract,hl_o,15193668,test,gold,o
1710,Children ( N = 576 ; M age = 10.06 ),1,Abstract,ss_p,15193668,test,gold,p
1711,descriptive ( AUT-D ),1,Abstract,ss_i,15193668,test,gold,i
1712,descriptive and explanatory information ( AUT-D + E ) .,1,Abstract,ss_i,15193668,test,gold,i
1713,Children,1,Abstract,hl_p,15193668,test,gold,p
1714,576,1,Abstract,hl_p,15193668,test,gold,p
1715,M age = 10.06,1,Abstract,hl_p,15193668,test,gold,p
1716,descriptive ( AUT-D ),1,Abstract,hl_i,15193668,test,gold,i
1717,descriptive and explanatory information ( AUT-D + E ) .,1,Abstract,hl_i,15193668,test,gold,i
1718,measures of attitudes ( Adjective Checklist ) and behavioral intentions ( Shared Activities Questionnaire ) .,2,Abstract,ss_o,15193668,test,gold,o
1719,( Adjective Checklist ),2,Abstract,hl_o,15193668,test,gold,o
1720,( Shared Activities Questionnaire ),2,Abstract,hl_o,15193668,test,gold,o
1722,descriptive information,4,Abstract,ss_i,15193668,test,gold,i
1723,combination of descriptive and explanatory information,4,Abstract,ss_i,15193668,test,gold,i
1724,behavioral intentions,5,Abstract,ss_o,15193668,test,gold,o
1725,academic intentions .,5,Abstract,ss_o,15193668,test,gold,o
1726,children 's,6,Abstract,ss_p,15193668,test,gold,p
1727,combination of descriptive and explanatory information,6,Abstract,ss_i,15193668,test,gold,i
1728,children 's attitudes and behavioral intentions .,6,Abstract,ss_o,15193668,test,gold,o
1729,children 's,6,Abstract,hl_p,15193668,test,gold,p
1730,descriptive and explanatory information,6,Abstract,hl_i,15193668,test,gold,i
1731,children 's attitudes,6,Abstract,hl_o,15193668,test,gold,o
1732,behavioral intentions,6,Abstract,hl_o,15193668,test,gold,o
1734,peers ',0,Title,ss_p,15193668,test,gold,p
1735,Combined descriptive and explanatory information,0,Title,ss_i,15193668,test,gold,i
1736,peers ' perceptions,0,Title,ss_o,15193668,test,gold,o
1737,peers,0,Title,hl_p,15193668,test,gold,p
1738,peers ' perceptions,0,Title,hl_o,15193668,test,gold,o
1739,visual search,0,Abstract,ss_i,15358868,test,gold,i
1740,visual search tasks,0,Abstract,ss_o,15358868,test,gold,o
1741,adults with autism .,1,Abstract,ss_p,15358868,test,gold,p
1742,adults with autism .,1,Abstract,hl_p,15358868,test,gold,p
1743,adults with autism,2,Abstract,ss_p,15358868,test,gold,p
1744,searching for targets .,2,Abstract,ss_o,15358868,test,gold,o
1745,adults with autism,2,Abstract,hl_p,15358868,test,gold,p
1746,searching for targets .,2,Abstract,hl_o,15358868,test,gold,o
1747,adults with autism,3,Abstract,ss_p,15358868,test,gold,p
1748,visual search performance,3,Abstract,ss_o,15358868,test,gold,o
1749,visual discrimination ability .,3,Abstract,ss_o,15358868,test,gold,o
1750,visual search performance,3,Abstract,hl_o,15358868,test,gold,o
1751,visual discrimination ability .,3,Abstract,hl_o,15358868,test,gold,o
1753,adults with autism,5,Abstract,ss_p,15358868,test,gold,p
1754,unique item detection,5,Abstract,ss_o,15358868,test,gold,o
1755,discrimination,5,Abstract,ss_o,15358868,test,gold,o
1756,unique item detection,5,Abstract,hl_o,15358868,test,gold,o
1757,adults with autism .,0,Title,ss_p,15358868,test,gold,p
1758,visual search,0,Title,ss_i,15358868,test,gold,i
1759,adults with autism .,0,Title,hl_p,15358868,test,gold,p
1760,post-acute hemiparetic patients,0,Abstract,ss_p,15848261,test,gold,p
1761,conventional physical therapy alone,0,Abstract,ss_i,15848261,test,gold,i
1762,with a specialised balance retraining program .,0,Abstract,ss_i,15848261,test,gold,i
1763,gait improvement,0,Abstract,ss_o,15848261,test,gold,o
1764,post-acute hemiparetic patients,0,Abstract,hl_p,15848261,test,gold,p
1765,conventional physical therapy alone,0,Abstract,hl_i,15848261,test,gold,i
1766,specialised balance retraining program,0,Abstract,hl_i,15848261,test,gold,i
1767,gait improvement,0,Abstract,hl_o,15848261,test,gold,o
1768,Twenty-six patients within 3 months of onset of stroke,1,Abstract,ss_p,15848261,test,gold,p
1769,physical therapy,1,Abstract,ss_i,15848261,test,gold,i
1770,therapy and retraining,1,Abstract,ss_i,15848261,test,gold,i
1771,Twenty-six patients within 3 months of onset of stroke,1,Abstract,hl_p,15848261,test,gold,p
1772,physical therapy,1,Abstract,hl_i,15848261,test,gold,i
1773,therapy and retraining,1,Abstract,hl_i,15848261,test,gold,i
1775,conventional therapy,3,Abstract,ss_i,15848261,test,gold,i
1776,therapy combined with standing balance training by biofeedback ( BPM Monitor ) .,3,Abstract,ss_i,15848261,test,gold,i
1777,conventional therapy,3,Abstract,hl_i,15848261,test,gold,i
1778,therapy,3,Abstract,hl_i,15848261,test,gold,i
1779,standing balance training by biofeedback ( BPM Monitor ),3,Abstract,hl_i,15848261,test,gold,i
1780,Clinical measures,4,Abstract,ss_o,15848261,test,gold,o
1781,Gait spatiotemporal parameters,5,Abstract,ss_o,15848261,test,gold,o
1782,Gait spatiotemporal parameters,5,Abstract,hl_o,15848261,test,gold,o
1783,clinical scores,6,Abstract,ss_o,15848261,test,gold,o
1784,clinical scores,6,Abstract,hl_o,15848261,test,gold,o
1785,time between stroke and the beginning of walking,7,Abstract,ss_o,15848261,test,gold,o
1786,time between stroke and the beginning of walking,7,Abstract,hl_o,15848261,test,gold,o
1787,Gait velocity,8,Abstract,ss_o,15848261,test,gold,o
1788,Gait velocity,8,Abstract,hl_o,15848261,test,gold,o
1789,walking pattern,9,Abstract,ss_o,15848261,test,gold,o
1790,duration of the paretic limb single stance .,9,Abstract,ss_o,15848261,test,gold,o
1791,walking pattern,9,Abstract,hl_o,15848261,test,gold,o
1792,duration of the paretic limb single stance .,9,Abstract,hl_o,15848261,test,gold,o
1793,duration of the reception double stance on the paretic limb,10,Abstract,ss_o,15848261,test,gold,o
1794,duration of the reception double stance on the paretic limb,10,Abstract,hl_o,15848261,test,gold,o
1796,conventional therapy .,12,Abstract,ss_i,15848261,test,gold,i
1797,anticipation equilibrium,12,Abstract,ss_o,15848261,test,gold,o
1798,conventional therapy .,12,Abstract,hl_i,15848261,test,gold,i
1799,stroke patients ],0,Title,ss_p,15848261,test,gold,p
1800,stroke patients ],0,Title,hl_p,15848261,test,gold,p
1802,98 patients,1,Abstract,ss_p,15854186,test,gold,p
1803,flexible nasendoscopy .,1,Abstract,ss_p,15854186,test,gold,p
1804,cophenylcaine,1,Abstract,ss_i,15854186,test,gold,i
1805,placebo,1,Abstract,ss_i,15854186,test,gold,i
1806,98 patients,1,Abstract,hl_p,15854186,test,gold,p
1807,flexible nasendoscopy .,1,Abstract,hl_p,15854186,test,gold,p
1808,cophenylcaine,1,Abstract,hl_i,15854186,test,gold,i
1809,placebo,1,Abstract,hl_i,15854186,test,gold,i
1810,"visual analogue scale ( 1-100 ) was used to record pain , unpleasantness of taste and overall discomfort experienced .",2,Abstract,ss_o,15854186,test,gold,o
1811,"pain , unpleasantness of taste and overall discomfort experienced .",2,Abstract,hl_o,15854186,test,gold,o
1812,pain and discomfort,3,Abstract,ss_o,15854186,test,gold,o
1813,pain and discomfort,3,Abstract,hl_o,15854186,test,gold,o
1814,cophenylcaine,4,Abstract,ss_i,15854186,test,gold,i
1815,pain or overall discomfort,4,Abstract,ss_o,15854186,test,gold,o
1816,sensation of bad taste,4,Abstract,ss_o,15854186,test,gold,o
1817,cophenylcaine,4,Abstract,hl_i,15854186,test,gold,i
1818,pain or overall discomfort,4,Abstract,hl_o,15854186,test,gold,o
1819,sensation of bad taste,4,Abstract,hl_o,15854186,test,gold,o
1820,unpleasantness,5,Abstract,ss_o,15854186,test,gold,o
1821,pain,5,Abstract,ss_o,15854186,test,gold,o
1822,unpleasantness of taste .,5,Abstract,ss_o,15854186,test,gold,o
1823,unpleasantness,5,Abstract,hl_o,15854186,test,gold,o
1824,pain,5,Abstract,hl_o,15854186,test,gold,o
1825,unpleasantness of taste .,5,Abstract,hl_o,15854186,test,gold,o
1826,flexible nasendoscopy .,6,Abstract,ss_p,15854186,test,gold,p
1827,cophenylcaine,6,Abstract,ss_i,15854186,test,gold,i
1828,flexible nasendoscopy .,6,Abstract,hl_p,15854186,test,gold,p
1829,cophenylcaine,6,Abstract,hl_i,15854186,test,gold,i
1830,flexible nasendoscopy :,0,Title,ss_p,15854186,test,gold,p
1831,Cophenylcaine spray,0,Title,ss_i,15854186,test,gold,i
1832,placebo,0,Title,ss_i,15854186,test,gold,i
1833,flexible nasendoscopy :,0,Title,hl_p,15854186,test,gold,p
1834,Cophenylcaine,0,Title,hl_i,15854186,test,gold,i
1835,placebo,0,Title,hl_i,15854186,test,gold,i
1837,acute childhood diarrhoea,1,Abstract,ss_p,15858959,test,gold,p
1838,Saccharomyces boulardii .,1,Abstract,ss_i,15858959,test,gold,i
1839,Saccharomyces boulardii .,1,Abstract,hl_i,15858959,test,gold,i
1840,children with acute diarrhoea .,2,Abstract,ss_p,15858959,test,gold,p
1841,S. boulardii,2,Abstract,ss_i,15858959,test,gold,i
1842,effect,2,Abstract,ss_o,15858959,test,gold,o
1843,children with acute diarrhoea .,2,Abstract,hl_p,15858959,test,gold,p
1844,S. boulardii,2,Abstract,hl_i,15858959,test,gold,i
1845,Two hundred children,3,Abstract,ss_p,15858959,test,gold,p
1846,S. boulardii,3,Abstract,ss_i,15858959,test,gold,i
1847,( S. boulardii,3,Abstract,ss_i,15858959,test,gold,i
1848,placebo ( placebo,3,Abstract,ss_i,15858959,test,gold,i
1849,Two hundred children,3,Abstract,hl_p,15858959,test,gold,p
1850,S. boulardii,3,Abstract,hl_i,15858959,test,gold,i
1851,S. boulardii,3,Abstract,hl_i,15858959,test,gold,i
1852,placebo,3,Abstract,hl_i,15858959,test,gold,i
1853,placebo,3,Abstract,hl_i,15858959,test,gold,i
1854,S. boulardii,4,Abstract,ss_i,15858959,test,gold,i
1855,placebo,4,Abstract,ss_i,15858959,test,gold,i
1856,average stool frequency,4,Abstract,ss_o,15858959,test,gold,o
1857,S. boulardii,4,Abstract,hl_i,15858959,test,gold,i
1858,placebo,4,Abstract,hl_i,15858959,test,gold,i
1859,average stool frequency,4,Abstract,hl_o,15858959,test,gold,o
1860,S. boulardii,5,Abstract,ss_i,15858959,test,gold,i
1861,placebo,5,Abstract,ss_i,15858959,test,gold,i
1862,duration of diarrhoea,5,Abstract,ss_o,15858959,test,gold,o
1863,S. boulardii,5,Abstract,hl_i,15858959,test,gold,i
1864,placebo,5,Abstract,hl_i,15858959,test,gold,i
1865,duration of diarrhoea,5,Abstract,hl_o,15858959,test,gold,o
1866,S. boulardii,6,Abstract,ss_i,15858959,test,gold,i
1867,effect,6,Abstract,ss_o,15858959,test,gold,o
1868,S. boulardii,6,Abstract,hl_i,15858959,test,gold,i
1869,S. boulardii,7,Abstract,ss_i,15858959,test,gold,i
1870,placebo,7,Abstract,ss_i,15858959,test,gold,i
1871,duration of hospital stay,7,Abstract,ss_o,15858959,test,gold,o
1872,S. boulardii,7,Abstract,hl_i,15858959,test,gold,i
1873,placebo,7,Abstract,hl_i,15858959,test,gold,i
1874,duration of hospital stay,7,Abstract,hl_o,15858959,test,gold,o
1875,placebo,8,Abstract,ss_i,15858959,test,gold,i
1876,S. boulardii,8,Abstract,ss_i,15858959,test,gold,i
1877,placebo,8,Abstract,hl_i,15858959,test,gold,i
1878,S. boulardii,8,Abstract,hl_i,15858959,test,gold,i
1879,S. boulardii,9,Abstract,ss_i,15858959,test,gold,i
1880,duration of acute diarrhoea and the duration of hospital stay .,9,Abstract,ss_o,15858959,test,gold,o
1881,S. boulardii,9,Abstract,hl_i,15858959,test,gold,i
1882,duration of acute diarrhoea,9,Abstract,hl_o,15858959,test,gold,o
1883,duration of hospital stay,9,Abstract,hl_o,15858959,test,gold,o
1884,acute diarrhoea in children,10,Abstract,ss_p,15858959,test,gold,p
1885,S. boulardii,10,Abstract,ss_i,15858959,test,gold,i
1886,acute diarrhoea in children,10,Abstract,hl_p,15858959,test,gold,p
1887,S. boulardii,10,Abstract,hl_i,15858959,test,gold,i
1888,children with acute diarrhoea .,0,Title,ss_p,15858959,test,gold,p
1889,Saccharomyces boulardii,0,Title,ss_i,15858959,test,gold,i
1890,children,0,Title,hl_p,15858959,test,gold,p
1891,acute diarrhoea,0,Title,hl_p,15858959,test,gold,p
1892,Saccharomyces boulardii,0,Title,hl_i,15858959,test,gold,i
1893,German,0,Abstract,ss_p,16055807,test,gold,p
1894,Schizophrenia,0,Abstract,ss_p,16055807,test,gold,p
1897,"patients in the "" early initial prodromal state "" .",3,Abstract,ss_p,16055807,test,gold,p
1898,Comprehensive cognitive-behavioural therapy,3,Abstract,ss_i,16055807,test,gold,i
1899,""" early initial prodromal state """,3,Abstract,hl_p,16055807,test,gold,p
1900,Comprehensive cognitive-behavioural therapy,3,Abstract,hl_i,16055807,test,gold,i
1901,"patients in the "" late initial prodromal state """,4,Abstract,ss_p,16055807,test,gold,p
1902,atypical neuroleptic amisulpride,4,Abstract,ss_i,16055807,test,gold,i
1903,""" late initial prodromal state """,4,Abstract,hl_p,16055807,test,gold,p
1904,atypical neuroleptic amisulpride,4,Abstract,hl_i,16055807,test,gold,i
1906,1212 individuals seeking help for mental health problems,6,Abstract,ss_p,16055807,test,gold,p
1907,four university centres .,6,Abstract,ss_p,16055807,test,gold,p
1908,1212 individuals seeking help for mental health problems,6,Abstract,hl_p,16055807,test,gold,p
1909,More than 388 individuals fulfilled criteria for both interventions and 188 ( 48.5 % ) gave informed consent to participate in the trials .,7,Abstract,ss_p,16055807,test,gold,p
1910,More than 388 individuals fulfilled criteria for both interventions and 188 ( 48.5 % ) gave informed consent to participate in the trials .,7,Abstract,hl_p,16055807,test,gold,p
1911,people at increased risk of developing psychosis .,8,Abstract,ss_p,16055807,test,gold,p
1912,initial prodromal states of psychosis in Germany :,0,Title,ss_p,16055807,test,gold,p
1913,initial prodromal states of psychosis,0,Title,hl_p,16055807,test,gold,p
1914,Germany,0,Title,hl_p,16055807,test,gold,p
1915,digestive surgery patients .,0,Abstract,ss_p,16167234,test,gold,p
1916,branch chain amino acid ( BCAA ) enriched formula,0,Abstract,ss_i,16167234,test,gold,i
1917,nutritional status,0,Abstract,ss_o,16167234,test,gold,o
1918,postoperative fatigue,0,Abstract,ss_o,16167234,test,gold,o
1919,digestive surgery patients .,0,Abstract,hl_p,16167234,test,gold,p
1920,branch chain amino acid ( BCAA ) enriched formula,0,Abstract,hl_i,16167234,test,gold,i
1921,nutritional status,0,Abstract,hl_o,16167234,test,gold,o
1922,postoperative fatigue,0,Abstract,hl_o,16167234,test,gold,o
1923,Forty patients who underwent digestive surgery,1,Abstract,ss_p,16167234,test,gold,p
1924,BCAA enriched,1,Abstract,ss_i,16167234,test,gold,i
1925,routine amino acid,1,Abstract,ss_i,16167234,test,gold,i
1926,Forty patients who underwent digestive surgery,1,Abstract,hl_p,16167234,test,gold,p
1927,BCAA enriched,1,Abstract,hl_i,16167234,test,gold,i
1928,routine amino acid,1,Abstract,hl_i,16167234,test,gold,i
1929,"Nitrogen balance , serum total protein , albumin , prealbumin , transferrin , retinol binding protein and postoperative fatigue score",2,Abstract,ss_o,16167234,test,gold,o
1930,"Nitrogen balance , serum total protein , albumin , prealbumin , transferrin , retinol binding protein and postoperative fatigue score",2,Abstract,hl_o,16167234,test,gold,o
1931,BCAA,3,Abstract,ss_i,16167234,test,gold,i
1932,cumulative postoperative fatigue scores,3,Abstract,ss_o,16167234,test,gold,o
1933,BCAA,3,Abstract,hl_i,16167234,test,gold,i
1934,cumulative postoperative fatigue scores,3,Abstract,hl_o,16167234,test,gold,o
1935,nitrogen balance,4,Abstract,ss_o,16167234,test,gold,o
1936,cumulative nitrogen balance,4,Abstract,ss_o,16167234,test,gold,o
1937,nitrogen balance,4,Abstract,hl_o,16167234,test,gold,o
1938,cumulative nitrogen balance,4,Abstract,hl_o,16167234,test,gold,o
1939,"serum total protein , albumin , prealbumin , transferrin",5,Abstract,ss_o,16167234,test,gold,o
1940,"serum total protein , albumin , prealbumin , transferrin",5,Abstract,hl_o,16167234,test,gold,o
1941,BCAA-enriched,6,Abstract,ss_i,16167234,test,gold,i
1942,serum level of retinol binding protein,6,Abstract,ss_o,16167234,test,gold,o
1943,BCAA-enriched,6,Abstract,hl_i,16167234,test,gold,i
1944,serum level of retinol binding protein,6,Abstract,hl_o,16167234,test,gold,o
1945,digestive surgery patients .,7,Abstract,ss_p,16167234,test,gold,p
1946,BCAA enriched formula,7,Abstract,ss_i,16167234,test,gold,i
1947,postoperative fatigue score,7,Abstract,ss_o,16167234,test,gold,o
1948,nutritional status,7,Abstract,ss_o,16167234,test,gold,o
1949,digestive surgery patients .,7,Abstract,hl_p,16167234,test,gold,p
1950,BCAA enriched formula,7,Abstract,hl_i,16167234,test,gold,i
1951,postoperative fatigue score,7,Abstract,hl_o,16167234,test,gold,o
1952,nutritional status,7,Abstract,hl_o,16167234,test,gold,o
1953,after digestive surgery ],0,Title,ss_p,16167234,test,gold,p
1954,branch chain amino acid enriched formula,0,Title,ss_i,16167234,test,gold,i
1955,postoperative fatigue and nutritional status,0,Title,ss_o,16167234,test,gold,o
1956,after digestive surgery ],0,Title,hl_p,16167234,test,gold,p
1957,amino acid enriched formula,0,Title,hl_i,16167234,test,gold,i
1958,postoperative fatigue,0,Title,hl_o,16167234,test,gold,o
1959,nutritional status,0,Title,hl_o,16167234,test,gold,o
1960,Parents of children who receive the diagnosis of autistic spectrum disorder ( ASD ),0,Abstract,ss_p,16295154,test,gold,p
1961,Parents of children,0,Abstract,hl_p,16295154,test,gold,p
1962,diagnosis of autistic spectrum disorder ( ASD ),0,Abstract,hl_p,16295154,test,gold,p
1963,parents of children with ASD,1,Abstract,ss_p,16295154,test,gold,p
1964,nursing intervention,1,Abstract,ss_i,16295154,test,gold,i
1965,parents of children with ASD,1,Abstract,hl_p,16295154,test,gold,p
1966,nursing intervention,1,Abstract,hl_i,16295154,test,gold,i
1967,post-diagnosis nursing intervention,2,Abstract,ss_i,16295154,test,gold,i
1968,effects,2,Abstract,ss_o,16295154,test,gold,o
1969,"parents ' reports of stress , impact of event ( diagnosis ) , and use of services",2,Abstract,ss_o,16295154,test,gold,o
1970,post-diagnosis nursing intervention,2,Abstract,hl_i,16295154,test,gold,i
1971,parents ' reports of stress,2,Abstract,hl_o,16295154,test,gold,o
1972,impact of event ( diagnosis ),2,Abstract,hl_o,16295154,test,gold,o
1973,use of services,2,Abstract,hl_o,16295154,test,gold,o
1974,usual care,3,Abstract,ss_i,16295154,test,gold,i
1975,"contact with a pediatric nurse practitioner ( PNP ) for counseling , instruction , and assistance with implementation of the recommended treatment plan .",3,Abstract,ss_i,16295154,test,gold,i
1976,usual care,3,Abstract,hl_i,16295154,test,gold,i
1977,"contact with a pediatric nurse practitioner ( PNP ) for counseling , instruction , and assistance with implementation of the recommended treatment plan",3,Abstract,hl_i,16295154,test,gold,i
1978,usual care,4,Abstract,ss_i,16295154,test,gold,i
1979,consultation session to receive the results of diagnostic tests and a written copy of the recommended treatment plan,4,Abstract,ss_i,16295154,test,gold,i
1980,usual care,4,Abstract,hl_i,16295154,test,gold,i
1981,consultation session to receive the results of diagnostic tests and a written copy of the recommended treatment plan,4,Abstract,hl_i,16295154,test,gold,i
1982,""" impact of event """,5,Abstract,ss_o,16295154,test,gold,o
1983,""" perceived stress """,5,Abstract,ss_o,16295154,test,gold,o
1984,""" impact of event """,5,Abstract,hl_o,16295154,test,gold,o
1985,""" perceived stress """,5,Abstract,hl_o,16295154,test,gold,o
1987,nursing intervention,7,Abstract,ss_i,16295154,test,gold,i
1988,nursing intervention .,8,Abstract,ss_i,16295154,test,gold,i
1989,parents of children with autistic spectrum disorder .,0,Title,ss_p,16295154,test,gold,p
1990,Intervention,0,Title,ss_i,16295154,test,gold,i
1991,parents of children,0,Title,hl_p,16295154,test,gold,p
1992,autistic spectrum disorder,0,Title,hl_p,16295154,test,gold,p
1993,Intervention,0,Title,hl_i,16295154,test,gold,i
1995,melatonin,1,Abstract,ss_i,16427787,test,gold,i
1996,brain activities,1,Abstract,ss_o,16427787,test,gold,o
1997,induction of sleepiness,1,Abstract,ss_o,16427787,test,gold,o
1998,melatonin,1,Abstract,hl_i,16427787,test,gold,i
1999,Melatonin,2,Abstract,ss_i,16427787,test,gold,i
2000,placebo,2,Abstract,ss_i,16427787,test,gold,i
2001,task-related activity,2,Abstract,ss_o,16427787,test,gold,o
2002,Melatonin,2,Abstract,hl_i,16427787,test,gold,i
2003,placebo,2,Abstract,hl_i,16427787,test,gold,i
2004,task-related activity,2,Abstract,hl_o,16427787,test,gold,o
2005,subjective measurements of fatigue .,3,Abstract,ss_o,16427787,test,gold,o
2006,subjective measurements of fatigue .,3,Abstract,hl_o,16427787,test,gold,o
2007,melatonin,4,Abstract,ss_i,16427787,test,gold,i
2008,activation in the left parahippocampus,4,Abstract,ss_o,16427787,test,gold,o
2009,melatonin,4,Abstract,hl_i,16427787,test,gold,i
2010,activation in the left parahippocampus,4,Abstract,hl_o,16427787,test,gold,o
2011,melatonin,5,Abstract,ss_i,16427787,test,gold,i
2012,brain activity,5,Abstract,ss_o,16427787,test,gold,o
2013,melatonin,5,Abstract,hl_i,16427787,test,gold,i
2014,brain activity,5,Abstract,hl_o,16427787,test,gold,o
2015,melatonin,6,Abstract,ss_i,16427787,test,gold,i
2016,fatigue,6,Abstract,ss_o,16427787,test,gold,o
2017,effect,6,Abstract,ss_o,16427787,test,gold,o
2018,brain activity,6,Abstract,ss_o,16427787,test,gold,o
2019,melatonin,6,Abstract,hl_i,16427787,test,gold,i
2020,fatigue,6,Abstract,hl_o,16427787,test,gold,o
2021,melatonin,7,Abstract,ss_i,16427787,test,gold,i
2022,sleep-associated brain activation,7,Abstract,ss_o,16427787,test,gold,o
2023,melatonin,7,Abstract,hl_i,16427787,test,gold,i
2024,human,0,Title,ss_p,16427787,test,gold,p
2025,melatonin,0,Title,ss_i,16427787,test,gold,i
2026,effects,0,Title,ss_o,16427787,test,gold,o
2027,human,0,Title,hl_p,16427787,test,gold,p
2028,melatonin,0,Title,hl_i,16427787,test,gold,i
2029,effects,0,Title,hl_o,16427787,test,gold,o
2030,patients with cancer-associated anemia .,0,Abstract,ss_p,16505427,test,gold,p
2031,epoetin alfa,0,Abstract,ss_i,16505427,test,gold,i
2032,epoetin alfa,0,Abstract,ss_i,16505427,test,gold,i
2033,patients with cancer-associated anemia .,0,Abstract,hl_p,16505427,test,gold,p
2034,epoetin alfa,0,Abstract,hl_i,16505427,test,gold,i
2035,epoetin alfa,0,Abstract,hl_i,16505427,test,gold,i
2036,epoetin alfa,1,Abstract,ss_i,16505427,test,gold,i
2037,epoetin alfa,1,Abstract,ss_i,16505427,test,gold,i
2038,epoetin alfa,1,Abstract,ss_i,16505427,test,gold,i
2039,epoetin alfa,1,Abstract,hl_i,16505427,test,gold,i
2040,epoetin alfa,1,Abstract,hl_i,16505427,test,gold,i
2041,epoetin alfa,1,Abstract,hl_i,16505427,test,gold,i
2042,Three hundred sixty-five patients,2,Abstract,ss_p,16505427,test,gold,p
2043,Three hundred sixty-five patients,2,Abstract,hl_p,16505427,test,gold,p
2045,requiring transfusions,4,Abstract,ss_o,16505427,test,gold,o
2046,requiring transfusions,4,Abstract,hl_o,16505427,test,gold,o
2047,hemoglobin ( Hb ) increment,5,Abstract,ss_o,16505427,test,gold,o
2048,drug dose,5,Abstract,ss_o,16505427,test,gold,o
2049,Hb,5,Abstract,ss_o,16505427,test,gold,o
2050,Hb,5,Abstract,ss_o,16505427,test,gold,o
2051,hemoglobin ( Hb ) increment,5,Abstract,hl_o,16505427,test,gold,o
2052,drug dose,5,Abstract,hl_o,16505427,test,gold,o
2053,Hb,5,Abstract,hl_o,16505427,test,gold,o
2054,Hb,5,Abstract,hl_o,16505427,test,gold,o
2055,"Toxicities , including thromboembolism",6,Abstract,ss_o,16505427,test,gold,o
2056,overall survival,6,Abstract,ss_o,16505427,test,gold,o
2057,Toxicities,6,Abstract,hl_o,16505427,test,gold,o
2058,thromboembolism,6,Abstract,hl_o,16505427,test,gold,o
2059,overall survival,6,Abstract,hl_o,16505427,test,gold,o
2060,global quality of life ( QOL ),7,Abstract,ss_o,16505427,test,gold,o
2061,global QOL,7,Abstract,ss_o,16505427,test,gold,o
2062,QOL,7,Abstract,ss_o,16505427,test,gold,o
2063,global quality of life ( QOL ),7,Abstract,hl_o,16505427,test,gold,o
2064,global QOL,7,Abstract,hl_o,16505427,test,gold,o
2065,QOL,7,Abstract,hl_o,16505427,test,gold,o
2066,epoetin alfa,8,Abstract,ss_i,16505427,test,gold,i
2067,safely,8,Abstract,ss_o,16505427,test,gold,o
2068,transfusion needs,8,Abstract,ss_o,16505427,test,gold,o
2069,QOL .,8,Abstract,ss_o,16505427,test,gold,o
2070,epoetin alfa,8,Abstract,hl_i,16505427,test,gold,i
2071,transfusion needs,8,Abstract,hl_o,16505427,test,gold,o
2072,QOL .,8,Abstract,hl_o,16505427,test,gold,o
2073,epoetin alfa .,9,Abstract,ss_i,16505427,test,gold,i
2074,Hb increment,9,Abstract,ss_o,16505427,test,gold,o
2075,epoetin alfa .,9,Abstract,hl_i,16505427,test,gold,i
2076,Hb increment,9,Abstract,hl_o,16505427,test,gold,o
2078,anemic patients with cancer .,0,Title,ss_p,16505427,test,gold,p
2079,erythropoietin,0,Title,ss_i,16505427,test,gold,i
2080,anemic patients with cancer .,0,Title,hl_p,16505427,test,gold,p
2081,erythropoietin,0,Title,hl_i,16505427,test,gold,i
2082,10 patients with asthma due to HDM,0,Abstract,ss_p,1669598,test,gold,p
2083,local immunotherapy,0,Abstract,ss_i,1669598,test,gold,i
2084,powder extract of house dust mite ( HDM ),0,Abstract,ss_i,1669598,test,gold,i
2085,parenteral immunotherapy ( PI ),0,Abstract,ss_i,1669598,test,gold,i
2086,efficacy,0,Abstract,ss_o,1669598,test,gold,o
2087,tolerability,0,Abstract,ss_o,1669598,test,gold,o
2088,10 patients with asthma due to HDM,0,Abstract,hl_p,1669598,test,gold,p
2089,local immunotherapy,0,Abstract,hl_i,1669598,test,gold,i
2090,powder extract of house dust mite ( HDM ),0,Abstract,hl_i,1669598,test,gold,i
2091,parenteral immunotherapy ( PI ),0,Abstract,hl_i,1669598,test,gold,i
2092,efficacy,0,Abstract,hl_o,1669598,test,gold,o
2093,tolerability,0,Abstract,hl_o,1669598,test,gold,o
2094,placebo,1,Abstract,ss_i,1669598,test,gold,i
2095,lactose,1,Abstract,ss_i,1669598,test,gold,i
2096,placebo,1,Abstract,hl_i,1669598,test,gold,i
2097,lactose,1,Abstract,hl_i,1669598,test,gold,i
2098,disodium cromoglycate ( DSCG ),2,Abstract,ss_i,1669598,test,gold,i
2099,disodium cromoglycate ( DSCG ),2,Abstract,hl_i,1669598,test,gold,i
2100,symptoms score,3,Abstract,ss_o,1669598,test,gold,o
2101,peak expiratory flow ( PEF ) -derived parameters,3,Abstract,ss_o,1669598,test,gold,o
2102,bronchial response,3,Abstract,ss_o,1669598,test,gold,o
2103,symptoms score,3,Abstract,hl_o,1669598,test,gold,o
2104,peak expiratory flow ( PEF ) -derived parameters,3,Abstract,hl_o,1669598,test,gold,o
2105,bronchial response,3,Abstract,hl_o,1669598,test,gold,o
2106,bronchial responsiveness,4,Abstract,ss_o,1669598,test,gold,o
2107,immunologic humoral and cellular parameters in peripheral blood,4,Abstract,ss_o,1669598,test,gold,o
2108,bronchial responsiveness,4,Abstract,hl_o,1669598,test,gold,o
2109,immunologic humoral and cellular parameters in peripheral blood,4,Abstract,hl_o,1669598,test,gold,o
2110,local important adverse reactions,5,Abstract,ss_o,1669598,test,gold,o
2111,systemic side effects,5,Abstract,ss_o,1669598,test,gold,o
2112,local important adverse reactions,5,Abstract,hl_o,1669598,test,gold,o
2113,systemic side effects,5,Abstract,hl_o,1669598,test,gold,o
2114,asthma due to HDM .,6,Abstract,ss_p,1669598,test,gold,p
2115,effective,6,Abstract,ss_o,1669598,test,gold,o
2116,DSCG,7,Abstract,ss_i,1669598,test,gold,i
2117,tolerated,7,Abstract,ss_o,1669598,test,gold,o
2118,systemic side effects .,7,Abstract,ss_o,1669598,test,gold,o
2119,systemic side effects .,7,Abstract,hl_o,1669598,test,gold,o
2120,asthma due to house dust mite Dermatophagoides pteronyssinus :,0,Title,ss_p,1669598,test,gold,p
2121,immunotherapy,0,Title,hl_i,1669598,test,gold,i
2122,immunotherapy,0,Title,hl_i,1669598,test,gold,i
2123,patients with C. difficile-associated diarrhea ( CDAD ),0,Abstract,ss_p,17293018,test,gold,p
2124,whey protein concentrate,0,Abstract,ss_i,17293018,test,gold,i
2125,"immunized against Clostridium difficile ( C. difficile ) and its toxins , toxin A and toxin B",0,Abstract,ss_i,17293018,test,gold,i
2126,patients with C. difficile-associated diarrhea ( CDAD ),0,Abstract,hl_p,17293018,test,gold,p
2127,whey protein concentrate,0,Abstract,hl_i,17293018,test,gold,i
2128,immunized against Clostridium difficile ( C.,0,Abstract,hl_i,17293018,test,gold,i
2129,anti-C. difficile whey protein concentrate ( anti-CD WPC ),1,Abstract,ss_i,17293018,test,gold,i
2130,anti-CD WPC,1,Abstract,ss_i,17293018,test,gold,i
2131,regular whey protein concentrate .,1,Abstract,ss_i,17293018,test,gold,i
2132,safety,1,Abstract,ss_o,17293018,test,gold,o
2133,anti-C. difficile whey protein concentrate ( anti-CD WPC ),1,Abstract,hl_i,17293018,test,gold,i
2134,anti-CD WPC,1,Abstract,hl_i,17293018,test,gold,i
2135,regular whey protein concentrate .,1,Abstract,hl_i,17293018,test,gold,i
2136,77 patients with CDAD,2,Abstract,ss_p,17293018,test,gold,p
2137,anti-CD WPC,2,Abstract,ss_i,17293018,test,gold,i
2138,safety,2,Abstract,ss_o,17293018,test,gold,o
2139,relapse of the infection .,2,Abstract,ss_o,17293018,test,gold,o
2140,77 patients with CDAD,2,Abstract,hl_p,17293018,test,gold,p
2141,anti-CD WPC,2,Abstract,hl_i,17293018,test,gold,i
2142,patients with CDAD .,3,Abstract,ss_p,17293018,test,gold,p
2143,anti-CD WPC,3,Abstract,ss_i,17293018,test,gold,i
2144,"adverse event monitoring , physical examinations , and extensive hematological and biochemical assessments",3,Abstract,ss_o,17293018,test,gold,o
2145,safe,3,Abstract,ss_o,17293018,test,gold,o
2146,patients with CDAD .,3,Abstract,hl_p,17293018,test,gold,p
2147,anti-CD WPC,3,Abstract,hl_i,17293018,test,gold,i
2148,safe,3,Abstract,hl_o,17293018,test,gold,o
2149,individuals with CDAD,4,Abstract,ss_p,17293018,test,gold,p
2150,anti-CD WPC,4,Abstract,ss_i,17293018,test,gold,i
2151,safe,4,Abstract,ss_o,17293018,test,gold,o
2152,individuals with CDAD,4,Abstract,hl_p,17293018,test,gold,p
2153,anti-CD WPC,4,Abstract,hl_i,17293018,test,gold,i
2154,safe,4,Abstract,hl_o,17293018,test,gold,o
2155,whey protein concentrate,0,Title,ss_i,17293018,test,gold,i
2156,safety,0,Title,ss_o,17293018,test,gold,o
2157,whey protein concentrate,0,Title,hl_i,17293018,test,gold,i
2158,patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .,0,Abstract,ss_p,17321989,test,gold,p
2159,fluconazole,0,Abstract,ss_i,17321989,test,gold,i
2160,itraconazole,0,Abstract,ss_i,17321989,test,gold,i
2161,prophylactic effects,0,Abstract,ss_o,17321989,test,gold,o
2162,patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .,0,Abstract,hl_p,17321989,test,gold,p
2163,fluconazole,0,Abstract,hl_i,17321989,test,gold,i
2164,itraconazole,0,Abstract,hl_i,17321989,test,gold,i
2165,itraconazole,1,Abstract,ss_i,17321989,test,gold,i
2166,fluconazole,1,Abstract,ss_i,17321989,test,gold,i
2167,itraconazole,1,Abstract,hl_i,17321989,test,gold,i
2168,fluconazole,1,Abstract,hl_i,17321989,test,gold,i
2169,Adverse events,2,Abstract,ss_o,17321989,test,gold,o
2170,Adverse events,2,Abstract,hl_o,17321989,test,gold,o
2171,itraconazole,3,Abstract,ss_i,17321989,test,gold,i
2172,fluconazole,3,Abstract,ss_i,17321989,test,gold,i
2173,cases with probable or possible infections,3,Abstract,ss_o,17321989,test,gold,o
2174,probable or possible infections,3,Abstract,hl_o,17321989,test,gold,o
2175,fluconazole,4,Abstract,ss_i,17321989,test,gold,i
2176,itraconazole,4,Abstract,ss_i,17321989,test,gold,i
2177,frequency of infection,4,Abstract,ss_o,17321989,test,gold,o
2178,frequency of infection,4,Abstract,hl_o,17321989,test,gold,o
2179,patients with AML or MDS who received chemotherapy,5,Abstract,ss_p,17321989,test,gold,p
2180,itraconazole,5,Abstract,ss_i,17321989,test,gold,i
2181,fluconazole .,5,Abstract,ss_i,17321989,test,gold,i
2182,efficacy,5,Abstract,ss_o,17321989,test,gold,o
2183,patients with AML or MDS who received chemotherapy,5,Abstract,hl_p,17321989,test,gold,p
2184,patients with acute myeloid leukemia and myelodysplastic syndromes :,0,Title,ss_p,17321989,test,gold,p
2185,Japanese,0,Title,ss_p,17321989,test,gold,p
2186,itraconazole,0,Title,ss_i,17321989,test,gold,i
2187,fluconazole,0,Title,ss_i,17321989,test,gold,i
2188,prophylactic effect,0,Title,ss_o,17321989,test,gold,o
2189,patients with acute myeloid leukemia and myelodysplastic syndromes :,0,Title,hl_p,17321989,test,gold,p
2190,Japanese,0,Title,hl_p,17321989,test,gold,p
2191,itraconazole,0,Title,hl_i,17321989,test,gold,i
2192,fluconazole,0,Title,hl_i,17321989,test,gold,i
2193,pospartal anemia,0,Abstract,ss_p,17616069,test,gold,p
2194,trivalent ferrum preparation .,0,Abstract,ss_i,17616069,test,gold,i
2195,effectivity,0,Abstract,ss_o,17616069,test,gold,o
2196,safeness,0,Abstract,ss_o,17616069,test,gold,o
2197,trivalent ferrum preparation .,0,Abstract,hl_i,17616069,test,gold,i
2198,effectivity,0,Abstract,hl_o,17616069,test,gold,o
2199,safeness,0,Abstract,hl_o,17616069,test,gold,o
2201,Prague,2,Abstract,ss_p,17616069,test,gold,p
2202,Prague .,2,Abstract,ss_p,17616069,test,gold,p
2203,Prague,2,Abstract,hl_p,17616069,test,gold,p
2204,Prague,2,Abstract,hl_p,17616069,test,gold,p
2205,50 women with clinical and lab signs of postpartal anemia .,3,Abstract,ss_p,17616069,test,gold,p
2206,sacharose ferric oxide ( Venofer ),3,Abstract,ss_i,17616069,test,gold,i
2207,50 women,3,Abstract,hl_p,17616069,test,gold,p
2208,clinical and lab signs of postpartal anemia,3,Abstract,hl_p,17616069,test,gold,p
2209,sacharose ferric oxide ( Venofer ),3,Abstract,hl_i,17616069,test,gold,i
2210,values of red blood count,4,Abstract,ss_o,17616069,test,gold,o
2211,values of red blood count,4,Abstract,hl_o,17616069,test,gold,o
2212,serum values of soluble transferrin receptors and ferritin,5,Abstract,ss_o,17616069,test,gold,o
2213,iron cell saturation and body iron reserves,5,Abstract,ss_o,17616069,test,gold,o
2214,serum values of soluble transferrin receptors and ferritin,5,Abstract,hl_o,17616069,test,gold,o
2215,iron cell saturation,5,Abstract,hl_o,17616069,test,gold,o
2216,body iron reserves,5,Abstract,hl_o,17616069,test,gold,o
2217,adverse events,6,Abstract,ss_o,17616069,test,gold,o
2218,adverse events,6,Abstract,hl_o,17616069,test,gold,o
2219,pospartal anemia,7,Abstract,ss_p,17616069,test,gold,p
2220,Venofer,7,Abstract,ss_i,17616069,test,gold,i
2221,effective,7,Abstract,ss_o,17616069,test,gold,o
2222,Venofer,7,Abstract,hl_i,17616069,test,gold,i
2223,effective,7,Abstract,hl_o,17616069,test,gold,o
2224,trivalent saccharose ferric oxide,8,Abstract,ss_i,17616069,test,gold,i
2225,serious adverse event,8,Abstract,ss_o,17616069,test,gold,o
2226,trivalent saccharose ferric oxide,8,Abstract,hl_i,17616069,test,gold,i
2227,serious adverse event,8,Abstract,hl_o,17616069,test,gold,o
2228,postpartum anemia,0,Title,ss_p,17616069,test,gold,p
2229,trivalent ferrum preparation ],0,Title,ss_i,17616069,test,gold,i
2230,postpartum,0,Title,hl_p,17616069,test,gold,p
2231,trivalent ferrum preparation ],0,Title,hl_i,17616069,test,gold,i
2232,non-steroid anti-inflammatory drug .,0,Abstract,ss_i,1780092,test,gold,i
2233,efficacy,0,Abstract,ss_o,1780092,test,gold,o
2234,tolerability,0,Abstract,ss_o,1780092,test,gold,o
2235,efficacy,0,Abstract,hl_o,1780092,test,gold,o
2236,tolerability,0,Abstract,hl_o,1780092,test,gold,o
2237,98 patients aged between 18 and 75 suffering from pain-inflammatory pathologies of ENT nature .,1,Abstract,ss_p,1780092,test,gold,p
2238,Nimesulide,1,Abstract,ss_i,1780092,test,gold,i
2239,flurbiprofen,1,Abstract,ss_i,1780092,test,gold,i
2240,98,1,Abstract,hl_p,1780092,test,gold,p
2241,aged between 18 and 75,1,Abstract,hl_p,1780092,test,gold,p
2242,pain-inflammatory pathologies of ENT nature .,1,Abstract,hl_p,1780092,test,gold,p
2243,Nimesulide,1,Abstract,hl_i,1780092,test,gold,i
2244,flurbiprofen,1,Abstract,hl_i,1780092,test,gold,i
2245,"anti-inflammatory , analgesic and antipyretic activity",2,Abstract,ss_o,1780092,test,gold,o
2246,symptoms of the inflammatory state,2,Abstract,ss_o,1780092,test,gold,o
2247,"anti-inflammatory , analgesic and antipyretic activity",2,Abstract,hl_o,1780092,test,gold,o
2248,symptoms of the inflammatory state,2,Abstract,hl_o,1780092,test,gold,o
2249,Nimesulide,3,Abstract,ss_i,1780092,test,gold,i
2250,duration,3,Abstract,ss_o,1780092,test,gold,o
2251,Nimesulide,3,Abstract,hl_i,1780092,test,gold,i
2252,duration,3,Abstract,hl_o,1780092,test,gold,o
2253,effectiveness,4,Abstract,ss_o,1780092,test,gold,o
2254,tolerability,4,Abstract,ss_o,1780092,test,gold,o
2255,effectiveness,4,Abstract,hl_o,1780092,test,gold,o
2256,tolerability,4,Abstract,hl_o,1780092,test,gold,o
2257,"pain-inflammatory pathologies of the ear , nose , and throat ]",0,Title,ss_p,1780092,test,gold,p
2258,nimesulide,0,Title,ss_i,1780092,test,gold,i
2259,efficacy,0,Title,ss_o,1780092,test,gold,o
2260,tolerance,0,Title,ss_o,1780092,test,gold,o
2261,nimesulide,0,Title,hl_i,1780092,test,gold,i
2262,efficacy,0,Title,hl_o,1780092,test,gold,o
2263,tolerance,0,Title,hl_o,1780092,test,gold,o
2264,patients with asthma poorly controlled on low dose inhaled corticosteroids,0,Abstract,ss_p,17897478,test,gold,p
2265,corticosteroids,0,Abstract,ss_i,17897478,test,gold,i
2266,patients with asthma,0,Abstract,hl_p,17897478,test,gold,p
2267,adult asthmatics .,1,Abstract,ss_p,17897478,test,gold,p
2268,salmeterol,1,Abstract,ss_i,17897478,test,gold,i
2269,fluticasone propionate ( FP ) ( Seretide ; SFC ),1,Abstract,ss_i,17897478,test,gold,i
2270,FP,1,Abstract,ss_i,17897478,test,gold,i
2271,montelukast ( FP/M ),1,Abstract,ss_i,17897478,test,gold,i
2272,"sputum inflammatory markers , airway responsiveness , lung function , and symptoms",1,Abstract,ss_o,17897478,test,gold,o
2273,adult asthmatics .,1,Abstract,hl_p,17897478,test,gold,p
2274,salmeterol,1,Abstract,hl_i,17897478,test,gold,i
2275,fluticasone propionate ( FP ) ( Seretide ; SFC ),1,Abstract,hl_i,17897478,test,gold,i
2276,FP,1,Abstract,hl_i,17897478,test,gold,i
2277,montelukast ( FP/M ),1,Abstract,hl_i,17897478,test,gold,i
2278,sputum inflammatory markers,1,Abstract,hl_o,17897478,test,gold,o
2279,"airway responsiveness , lung function",1,Abstract,hl_o,17897478,test,gold,o
2280,symptoms,1,Abstract,hl_o,17897478,test,gold,o
2281,Sixty-six subjects,2,Abstract,ss_p,17897478,test,gold,p
2282,SFC,2,Abstract,ss_i,17897478,test,gold,i
2283,FP/M,2,Abstract,ss_i,17897478,test,gold,i
2284,Sixty-six subjects,2,Abstract,hl_p,17897478,test,gold,p
2285,SFC,2,Abstract,hl_i,17897478,test,gold,i
2286,FP/M,2,Abstract,hl_i,17897478,test,gold,i
2287,"changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum .",3,Abstract,ss_o,17897478,test,gold,o
2288,"changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum .",3,Abstract,hl_o,17897478,test,gold,o
2289,"change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .",4,Abstract,ss_o,17897478,test,gold,o
2290,"change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .",4,Abstract,hl_o,17897478,test,gold,o
2291,induced sputum inflammatory cells,5,Abstract,ss_o,17897478,test,gold,o
2292,sputum eosinophils .,5,Abstract,ss_o,17897478,test,gold,o
2293,sputum inflammatory,5,Abstract,hl_o,17897478,test,gold,o
2294,sputum eosinophils .,5,Abstract,hl_o,17897478,test,gold,o
2295,SFC,6,Abstract,ss_i,17897478,test,gold,i
2296,FP/M .,6,Abstract,ss_i,17897478,test,gold,i
2297,airway responsiveness,6,Abstract,ss_o,17897478,test,gold,o
2298,symptom control and lung function,6,Abstract,ss_o,17897478,test,gold,o
2299,SFC,6,Abstract,hl_i,17897478,test,gold,i
2300,FP/M .,6,Abstract,hl_i,17897478,test,gold,i
2301,airway responsiveness,6,Abstract,hl_o,17897478,test,gold,o
2302,symptom control and lung function,6,Abstract,hl_o,17897478,test,gold,o
2303,FP/M,7,Abstract,ss_i,17897478,test,gold,i
2304,SFC,7,Abstract,ss_i,17897478,test,gold,i
2305,sputum cysteinyl leukotrienes,7,Abstract,ss_o,17897478,test,gold,o
2306,FP/M,7,Abstract,hl_i,17897478,test,gold,i
2307,SFC,7,Abstract,hl_i,17897478,test,gold,i
2308,sputum cysteinyl leukotrienes,7,Abstract,hl_o,17897478,test,gold,o
2309,SFC .,8,Abstract,ss_i,17897478,test,gold,i
2310,eosinophilic airway inflammation,8,Abstract,ss_o,17897478,test,gold,o
2311,symptom control,8,Abstract,ss_o,17897478,test,gold,o
2312,SFC .,8,Abstract,hl_i,17897478,test,gold,i
2313,eosinophilic airway inflammation,8,Abstract,hl_o,17897478,test,gold,o
2315,asthma .,0,Title,ss_p,17897478,test,gold,p
2316,Salmeterol,0,Title,ss_i,17897478,test,gold,i
2317,fluticasone propionate,0,Title,ss_i,17897478,test,gold,i
2318,fluticasone propionate,0,Title,ss_i,17897478,test,gold,i
2319,montelukast :,0,Title,ss_i,17897478,test,gold,i
2320,effects on airway inflammation,0,Title,ss_o,17897478,test,gold,o
2321,Salmeterol,0,Title,hl_i,17897478,test,gold,i
2322,fluticasone propionate,0,Title,hl_i,17897478,test,gold,i
2323,fluticasone propionate,0,Title,hl_i,17897478,test,gold,i
2324,montelukast :,0,Title,hl_i,17897478,test,gold,i
2325,airway inflammation,0,Title,hl_o,17897478,test,gold,o
2326,Zostavax,0,Abstract,ss_i,18077611,test,gold,i
2327,Zostavax,0,Abstract,hl_i,18077611,test,gold,i
2328,subjects > or =50 years of age .,1,Abstract,ss_p,18077611,test,gold,p
2329,( Zostavax,1,Abstract,ss_i,18077611,test,gold,i
2330,( Zostavax,1,Abstract,ss_i,18077611,test,gold,i
2331,safety,1,Abstract,ss_o,18077611,test,gold,o
2332,immunogenicity,1,Abstract,ss_o,18077611,test,gold,o
2333,subjects > or =50 years of age .,1,Abstract,hl_p,18077611,test,gold,p
2334,Zostavax,1,Abstract,hl_i,18077611,test,gold,i
2335,Zostavax,1,Abstract,hl_i,18077611,test,gold,i
2336,safety,1,Abstract,hl_o,18077611,test,gold,o
2337,immunogenicity,1,Abstract,hl_o,18077611,test,gold,o
2338,Subjects with a negative history for HZ,2,Abstract,ss_p,18077611,test,gold,p
2339,Subjects with a negative history for HZ,2,Abstract,hl_p,18077611,test,gold,p
2340,Enrollment was stratified 1:2 by age ( 50 to 59 years and > or =60 years ),3,Abstract,ss_p,18077611,test,gold,p
2341,Enrollment was stratified 1:2 by age ( 50 to 59 years and > or =60 years ),3,Abstract,hl_p,18077611,test,gold,p
2342,Safety,4,Abstract,ss_o,18077611,test,gold,o
2343,Safety,4,Abstract,hl_o,18077611,test,gold,o
2344,Varicella-zoster virus ( VZV ) antibody responses,5,Abstract,ss_o,18077611,test,gold,o
2345,glycoprotein enzyme-linked immunosorbent assay ( gpELISA ) .,5,Abstract,ss_o,18077611,test,gold,o
2346,Varicella-zoster virus ( VZV ) antibody responses,5,Abstract,hl_o,18077611,test,gold,o
2347,VZV antibody geometric mean titer ( GMT ;,6,Abstract,ss_o,18077611,test,gold,o
2348,VZV antibody geometric mean rise ( GMR ;,6,Abstract,ss_o,18077611,test,gold,o
2349,incidence of vaccine-related serious adverse experiences ( AEs ),6,Abstract,ss_o,18077611,test,gold,o
2350,VZV antibody geometric mean titer ( GMT,6,Abstract,hl_o,18077611,test,gold,o
2351,VZV antibody geometric mean rise ( GMR,6,Abstract,hl_o,18077611,test,gold,o
2352,incidence of vaccine-related serious adverse experiences ( AEs ),6,Abstract,hl_o,18077611,test,gold,o
2353,GMTs,7,Abstract,ss_o,18077611,test,gold,o
2354,gpELISA,7,Abstract,ss_o,18077611,test,gold,o
2355,GMT,7,Abstract,ss_o,18077611,test,gold,o
2356,GMTs,7,Abstract,hl_o,18077611,test,gold,o
2357,GMT,7,Abstract,hl_o,18077611,test,gold,o
2358,GMRs,8,Abstract,ss_o,18077611,test,gold,o
2359,GMRs,8,Abstract,hl_o,18077611,test,gold,o
2360,vaccine-related serious AEs,9,Abstract,ss_o,18077611,test,gold,o
2361,safety,9,Abstract,ss_o,18077611,test,gold,o
2362,vaccine-related serious AEs,9,Abstract,hl_o,18077611,test,gold,o
2363,safety,9,Abstract,hl_o,18077611,test,gold,o
2364,injection-site AEs,10,Abstract,ss_o,18077611,test,gold,o
2365,injection-site AEs,10,Abstract,hl_o,18077611,test,gold,o
2366,systemic AEs,11,Abstract,ss_o,18077611,test,gold,o
2367,vaccine-related AEs,11,Abstract,ss_o,18077611,test,gold,o
2368,systemic AEs,11,Abstract,hl_o,18077611,test,gold,o
2369,vaccine-related AEs,11,Abstract,hl_o,18077611,test,gold,o
2370,Zostavax,12,Abstract,ss_i,18077611,test,gold,i
2371,safety,12,Abstract,ss_o,18077611,test,gold,o
2372,immunogenic,12,Abstract,ss_o,18077611,test,gold,o
2373,Zostavax,12,Abstract,hl_i,18077611,test,gold,i
2374,safety,12,Abstract,hl_o,18077611,test,gold,o
2375,immunogenic,12,Abstract,hl_o,18077611,test,gold,o
2376,Zostavax .,0,Title,ss_i,18077611,test,gold,i
2377,safety,0,Title,ss_o,18077611,test,gold,o
2378,immunogenicity,0,Title,ss_o,18077611,test,gold,o
2379,Zostavax .,0,Title,hl_i,18077611,test,gold,i
2380,patients with early breast cancer,0,Abstract,ss_p,18189160,test,gold,p
2381,epirubicin,0,Abstract,ss_i,18189160,test,gold,i
2382,patients with early breast cancer,0,Abstract,hl_p,18189160,test,gold,p
2383,epirubicin,0,Abstract,hl_i,18189160,test,gold,i
2384,fluorouracil/epirubicin/cyclophosphamide ( FEC ),1,Abstract,ss_i,18189160,test,gold,i
2385,FEC ( 60 ),1,Abstract,ss_i,18189160,test,gold,i
2386,FEC ( 100 ),1,Abstract,ss_i,18189160,test,gold,i
2387,fluorouracil/epirubicin/cyclophosphamide ( FEC ),1,Abstract,hl_i,18189160,test,gold,i
2388,FEC ( 100 ),1,Abstract,hl_i,18189160,test,gold,i
2389,FEC,2,Abstract,ss_i,18189160,test,gold,i
2390,feasibility,2,Abstract,ss_o,18189160,test,gold,o
2391,FEC,2,Abstract,hl_i,18189160,test,gold,i
2392,FEC ( 75 ),3,Abstract,ss_i,18189160,test,gold,i
2393,FEC ( 90 ),3,Abstract,ss_i,18189160,test,gold,i
2394,FEC ( 75 ),3,Abstract,hl_i,18189160,test,gold,i
2395,FEC ( 90 ),3,Abstract,hl_i,18189160,test,gold,i
2396,pegfilgrastim,4,Abstract,ss_i,18189160,test,gold,i
2397,pegfilgrastim,4,Abstract,hl_i,18189160,test,gold,i
2398,FEC ( 75 ),5,Abstract,ss_i,18189160,test,gold,i
2399,FEC ( 90 ),5,Abstract,ss_i,18189160,test,gold,i
2400,efficacy,5,Abstract,ss_o,18189160,test,gold,o
2401,proportion of subjects receiving > or =85 % relative dose intensity,5,Abstract,ss_o,18189160,test,gold,o
2402,proportion of subjects receiving > or =85 % relative dose intensity,5,Abstract,hl_o,18189160,test,gold,o
2403,FEC ( 75 ),6,Abstract,ss_i,18189160,test,gold,i
2404,FEC ( 90 ),6,Abstract,ss_i,18189160,test,gold,i
2405,FEC ( 75 ),6,Abstract,hl_i,18189160,test,gold,i
2406,FEC ( 90 ),6,Abstract,hl_i,18189160,test,gold,i
2407,adverse events,7,Abstract,ss_o,18189160,test,gold,o
2408,adverse events,7,Abstract,hl_o,18189160,test,gold,o
2409,( FEC ( 90 ) ),8,Abstract,ss_i,18189160,test,gold,i
2410,diarrhoea .,8,Abstract,ss_o,18189160,test,gold,o
2411,FEC ( 90 ),8,Abstract,hl_i,18189160,test,gold,i
2412,diarrhoea .,8,Abstract,hl_o,18189160,test,gold,o
2413,FEC ( 90 ),9,Abstract,ss_i,18189160,test,gold,i
2414,haematological toxicities,9,Abstract,ss_o,18189160,test,gold,o
2415,FEC ( 90 ),9,Abstract,hl_i,18189160,test,gold,i
2416,haematological toxicities,9,Abstract,hl_o,18189160,test,gold,o
2417,febrile neutropenia,10,Abstract,ss_o,18189160,test,gold,o
2418,febrile neutropenia,10,Abstract,hl_o,18189160,test,gold,o
2419,adverse events,11,Abstract,ss_o,18189160,test,gold,o
2420,increases in liver enzymes and gastrointestinal events ;,11,Abstract,ss_o,18189160,test,gold,o
2421,liver enzymes and gastrointestinal events,11,Abstract,hl_o,18189160,test,gold,o
2422,( FEC ( 90 ) ),12,Abstract,ss_i,18189160,test,gold,i
2423,serious adverse events ( vomiting and throat oedema ) .,12,Abstract,ss_o,18189160,test,gold,o
2424,( FEC ( 90 ) ),12,Abstract,hl_i,18189160,test,gold,i
2425,serious adverse events ( vomiting and throat oedema ) .,12,Abstract,hl_o,18189160,test,gold,o
2426,FEC ( 75,13,Abstract,ss_i,18189160,test,gold,i
2427,FEC ( 90 ),13,Abstract,ss_i,18189160,test,gold,i
2428,pegfilgrastim,13,Abstract,ss_i,18189160,test,gold,i
2429,feasible,13,Abstract,ss_o,18189160,test,gold,o
2430,FEC ( 75,13,Abstract,hl_i,18189160,test,gold,i
2431,FEC ( 90 ),13,Abstract,hl_i,18189160,test,gold,i
2433,patients with early breast cancer :,0,Title,ss_p,18189160,test,gold,p
2434,European,0,Title,ss_p,18189160,test,gold,p
2435,FEC,0,Title,ss_i,18189160,test,gold,i
2436,Feasibility,0,Title,ss_o,18189160,test,gold,o
2437,patients with early breast cancer :,0,Title,hl_p,18189160,test,gold,p
2438,FEC,0,Title,hl_i,18189160,test,gold,i
2439,preschool children with autism,0,Abstract,ss_p,18229990,test,gold,p
2440,joint attention ( JA ),0,Abstract,ss_i,18229990,test,gold,i
2441,symbolic play ( SP ),0,Abstract,ss_i,18229990,test,gold,i
2442,language outcome,0,Abstract,ss_o,18229990,test,gold,o
2443,preschool children with autism,0,Abstract,hl_p,18229990,test,gold,p
2444,joint attention ( JA ),0,Abstract,hl_i,18229990,test,gold,i
2445,symbolic play ( SP ),0,Abstract,hl_i,18229990,test,gold,i
2446,language outcome,0,Abstract,hl_o,18229990,test,gold,o
2447,Participants were 58 children ( 46 boys ) with autism between 3 and 4 years of age .,1,Abstract,ss_p,18229990,test,gold,p
2448,58 children,1,Abstract,hl_p,18229990,test,gold,p
2449,46,1,Abstract,hl_p,18229990,test,gold,p
2450,autism between 3 and 4 years of age,1,Abstract,hl_p,18229990,test,gold,p
2451,JA,2,Abstract,ss_i,18229990,test,gold,i
2452,SP,2,Abstract,ss_i,18229990,test,gold,i
2453,JA,2,Abstract,hl_i,18229990,test,gold,i
2454,SP,2,Abstract,hl_i,18229990,test,gold,i
2456,JA,4,Abstract,ss_i,18229990,test,gold,i
2457,SP,4,Abstract,ss_i,18229990,test,gold,i
2458,"JA skills , SP skills , mother-child interactions , and language development",4,Abstract,ss_o,18229990,test,gold,o
2459,JA,4,Abstract,hl_i,18229990,test,gold,i
2460,SP,4,Abstract,hl_i,18229990,test,gold,i
2461,"JA skills , SP skills , mother-child interactions , and language development",4,Abstract,hl_o,18229990,test,gold,o
2462,expressive language gains,5,Abstract,ss_o,18229990,test,gold,o
2463,expressive language gains,5,Abstract,hl_o,18229990,test,gold,o
2464,JA,6,Abstract,ss_i,18229990,test,gold,i
2465,SP,6,Abstract,ss_i,18229990,test,gold,i
2466,language outcome,6,Abstract,ss_o,18229990,test,gold,o
2467,JA,6,Abstract,hl_i,18229990,test,gold,i
2468,SP,6,Abstract,hl_i,18229990,test,gold,i
2469,language outcome,6,Abstract,hl_o,18229990,test,gold,o
2470,young children with autism .,7,Abstract,ss_p,18229990,test,gold,p
2471,JA,7,Abstract,ss_i,18229990,test,gold,i
2472,SP,7,Abstract,ss_i,18229990,test,gold,i
2473,young children with autism .,7,Abstract,hl_p,18229990,test,gold,p
2474,JA,7,Abstract,hl_i,18229990,test,gold,i
2475,SP,7,Abstract,hl_i,18229990,test,gold,i
2476,autism :,0,Title,ss_p,18229990,test,gold,p
2477,joint attention,0,Title,ss_i,18229990,test,gold,i
2478,play interventions .,0,Title,ss_i,18229990,test,gold,i
2479,Language outcome,0,Title,ss_o,18229990,test,gold,o
2480,autism :,0,Title,hl_p,18229990,test,gold,p
2481,joint attention,0,Title,hl_i,18229990,test,gold,i
2482,play interventions .,0,Title,hl_i,18229990,test,gold,i
2483,Language outcome,0,Title,hl_o,18229990,test,gold,o
2485,GABHS pharyngitis .,1,Abstract,ss_p,18337284,test,gold,p
2486,amoxicillin,1,Abstract,ss_i,18337284,test,gold,i
2487,penicillin V,1,Abstract,ss_i,18337284,test,gold,i
2488,non-inferiority,1,Abstract,ss_o,18337284,test,gold,o
2489,amoxicillin,1,Abstract,hl_i,18337284,test,gold,i
2490,penicillin V,1,Abstract,hl_i,18337284,test,gold,i
2491,non-inferiority,1,Abstract,hl_o,18337284,test,gold,o
2492,school-based clinic in New Zealand .,2,Abstract,ss_p,18337284,test,gold,p
2493,non-inferiority,2,Abstract,ss_o,18337284,test,gold,o
2494,school-based clinic in New Zealand,2,Abstract,hl_p,18337284,test,gold,p
2495,non-inferiority,2,Abstract,hl_o,18337284,test,gold,o
2496,Children presenting with GABHS pharyngitis,3,Abstract,ss_p,18337284,test,gold,p
2497,amoxicillin,3,Abstract,ss_i,18337284,test,gold,i
2498,penicillin,3,Abstract,ss_i,18337284,test,gold,i
2499,Children,3,Abstract,hl_p,18337284,test,gold,p
2500,GABHS pharyngitis,3,Abstract,hl_p,18337284,test,gold,p
2501,amoxicillin,3,Abstract,hl_i,18337284,test,gold,i
2502,penicillin,3,Abstract,hl_i,18337284,test,gold,i
2503,medication and weekend diary cards,4,Abstract,ss_o,18337284,test,gold,o
2504,Eradication of GABHS,5,Abstract,ss_o,18337284,test,gold,o
2505,follow-up throat cultures,5,Abstract,ss_o,18337284,test,gold,o
2506,Eradication of GABHS,5,Abstract,hl_o,18337284,test,gold,o
2507,GABHS isolates were serotyped,6,Abstract,ss_o,18337284,test,gold,o
2508,bacteriological treatment failures,6,Abstract,ss_o,18337284,test,gold,o
2509,relapses ),6,Abstract,ss_o,18337284,test,gold,o
2510,new acquisitions .,6,Abstract,ss_o,18337284,test,gold,o
2511,bacteriological treatment failures,6,Abstract,hl_o,18337284,test,gold,o
2512,relapses,6,Abstract,hl_o,18337284,test,gold,o
2513,amoxicillin,7,Abstract,ss_i,18337284,test,gold,i
2514,penicillin,7,Abstract,ss_i,18337284,test,gold,i
2515,Non-inferiority,7,Abstract,ss_o,18337284,test,gold,o
2516,upper 95 % confidence limit ( CL ) for the difference in success of eradication,7,Abstract,ss_o,18337284,test,gold,o
2517,amoxicillin,7,Abstract,hl_i,18337284,test,gold,i
2518,penicillin,7,Abstract,hl_i,18337284,test,gold,i
2519,Non-inferiority,7,Abstract,hl_o,18337284,test,gold,o
2520,353 children with positive throat swabs for GABHS,8,Abstract,ss_p,18337284,test,gold,p
2521,amoxicillin,8,Abstract,ss_i,18337284,test,gold,i
2522,penicillin,8,Abstract,ss_i,18337284,test,gold,i
2523,353 children with positive throat swabs for GABHS,8,Abstract,hl_p,18337284,test,gold,p
2524,amoxicillin,8,Abstract,hl_i,18337284,test,gold,i
2525,penicillin,8,Abstract,hl_i,18337284,test,gold,i
2526,upper 95 % CL,9,Abstract,ss_o,18337284,test,gold,o
2527,amoxicillin,10,Abstract,ss_i,18337284,test,gold,i
2528,penicillin,10,Abstract,ss_i,18337284,test,gold,i
2529,Treatment failures,10,Abstract,ss_o,18337284,test,gold,o
2530,relapses ),10,Abstract,ss_o,18337284,test,gold,o
2531,amoxicillin,10,Abstract,hl_i,18337284,test,gold,i
2532,penicillin,10,Abstract,hl_i,18337284,test,gold,i
2533,Treatment failures,10,Abstract,hl_o,18337284,test,gold,o
2534,relapses,10,Abstract,hl_o,18337284,test,gold,o
2535,resolution of symptoms,11,Abstract,ss_o,18337284,test,gold,o
2536,resolution of symptoms,11,Abstract,hl_o,18337284,test,gold,o
2537,amoxicillin .,12,Abstract,ss_i,18337284,test,gold,i
2538,amoxicillin .,12,Abstract,hl_i,18337284,test,gold,i
2539,GABHS in children with pharyngitis .,13,Abstract,ss_p,18337284,test,gold,p
2540,amoxicillin,13,Abstract,ss_i,18337284,test,gold,i
2541,penicillin,13,Abstract,ss_i,18337284,test,gold,i
2542,not inferior,13,Abstract,ss_o,18337284,test,gold,o
2543,GABHS in children with pharyngitis .,13,Abstract,hl_p,18337284,test,gold,p
2544,amoxicillin,13,Abstract,hl_i,18337284,test,gold,i
2545,penicillin,13,Abstract,hl_i,18337284,test,gold,i
2546,group A beta-haemolytic streptococcal pharyngitis .,0,Title,ss_p,18337284,test,gold,p
2547,amoxicillin,0,Title,ss_i,18337284,test,gold,i
2548,penicillin V,0,Title,ss_i,18337284,test,gold,i
2549,beta-haemolytic streptococcal pharyngitis .,0,Title,hl_p,18337284,test,gold,p
2550,amoxicillin,0,Title,hl_i,18337284,test,gold,i
2551,penicillin V,0,Title,hl_i,18337284,test,gold,i
2552,children with Asperger syndrome ( AS ) :,0,Abstract,ss_p,18503531,test,gold,p
2553,multi-component social skills intervention,0,Abstract,ss_i,18503531,test,gold,i
2554,effectiveness,0,Abstract,ss_o,18503531,test,gold,o
2555,children,0,Abstract,hl_p,18503531,test,gold,p
2556,Asperger syndrome ( AS ),0,Abstract,hl_p,18503531,test,gold,p
2557,multi-component social skills intervention,0,Abstract,hl_i,18503531,test,gold,i
2558,effectiveness,0,Abstract,hl_o,18503531,test,gold,o
2559,"small group sessions , parent training sessions",1,Abstract,ss_i,18503531,test,gold,i
2560,teacher handouts .,1,Abstract,ss_i,18503531,test,gold,i
2561,Forty-nine children with AS,2,Abstract,ss_p,18503531,test,gold,p
2562,Forty-nine children with AS,2,Abstract,hl_p,18503531,test,gold,p
2563,improvements in social skills,3,Abstract,ss_o,18503531,test,gold,o
2564,parent-report measures .,3,Abstract,ss_o,18503531,test,gold,o
2565,improvements in social skills,3,Abstract,hl_o,18503531,test,gold,o
2566,Teacher-report data,4,Abstract,ss_o,18503531,test,gold,o
2567,social functioning,4,Abstract,ss_o,18503531,test,gold,o
2568,social functioning,4,Abstract,hl_o,18503531,test,gold,o
2569,emotion-management strategies,5,Abstract,ss_o,18503531,test,gold,o
2570,emotion-management strategies,5,Abstract,hl_o,18503531,test,gold,o
2571,facial expression and body-posture recognition measures .,6,Abstract,ss_o,18503531,test,gold,o
2572,facial expression and body-posture recognition measures .,6,Abstract,hl_o,18503531,test,gold,o
2574,children with AS .,8,Abstract,ss_p,18503531,test,gold,p
2575,Junior Detective Training Program,8,Abstract,ss_i,18503531,test,gold,i
2576,effective,8,Abstract,ss_o,18503531,test,gold,o
2577,social skills and emotional understanding,8,Abstract,ss_o,18503531,test,gold,o
2578,children with AS .,8,Abstract,hl_p,18503531,test,gold,p
2579,Junior Detective Training Program,8,Abstract,hl_i,18503531,test,gold,i
2580,social skills and emotional understanding,8,Abstract,hl_o,18503531,test,gold,o
2582,children with Asperger syndrome :,0,Title,ss_p,18503531,test,gold,p
2583,multi-component social skills intervention,0,Title,ss_i,18503531,test,gold,i
2584,Junior Detective Training Program .,0,Title,ss_i,18503531,test,gold,i
2585,children,0,Title,hl_p,18503531,test,gold,p
2586,Asperger syndrome,0,Title,hl_p,18503531,test,gold,p
2587,multi-component social skills intervention,0,Title,hl_i,18503531,test,gold,i
2588,Junior Detective Training Program .,0,Title,hl_i,18503531,test,gold,i
2589,school-aged children .,0,Abstract,ss_p,18544974,test,gold,p
2590,Lactobacillus GG ( LGG ) and galacto-oligosaccharides ( GOS ),0,Abstract,ss_i,18544974,test,gold,i
2591,LGG,0,Abstract,ss_i,18544974,test,gold,i
2592,intestinal microbiota,0,Abstract,ss_o,18544974,test,gold,o
2593,Lactobacillus GG ( LGG ),0,Abstract,hl_i,18544974,test,gold,i
2594,galacto-oligosaccharides ( GOS ),0,Abstract,hl_i,18544974,test,gold,i
2595,LGG,0,Abstract,hl_i,18544974,test,gold,i
2596,30 healthy children .,1,Abstract,ss_p,18544974,test,gold,p
2597,30 healthy,1,Abstract,hl_p,18544974,test,gold,p
2599,LGG,3,Abstract,ss_i,18544974,test,gold,i
2600,LGG,3,Abstract,ss_i,18544974,test,gold,i
2601,GOS .,3,Abstract,ss_i,18544974,test,gold,i
2602,LGG,3,Abstract,hl_i,18544974,test,gold,i
2603,LGG,3,Abstract,hl_i,18544974,test,gold,i
2604,GOS .,3,Abstract,hl_i,18544974,test,gold,i
2605,Symptom,4,Abstract,ss_o,18544974,test,gold,o
2606,Fecal samples,5,Abstract,ss_o,18544974,test,gold,o
2607,LGG + GOS,6,Abstract,ss_i,18544974,test,gold,i
2608,LGG,6,Abstract,ss_i,18544974,test,gold,i
2609,amount of bifidobacteria,6,Abstract,ss_o,18544974,test,gold,o
2610,LGG + GOS,6,Abstract,hl_i,18544974,test,gold,i
2611,LGG,6,Abstract,hl_i,18544974,test,gold,i
2612,amount of bifidobacteria,6,Abstract,hl_o,18544974,test,gold,o
2613,LGG,7,Abstract,ss_i,18544974,test,gold,i
2614,lactobacilli,7,Abstract,ss_o,18544974,test,gold,o
2615,"gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation",7,Abstract,ss_o,18544974,test,gold,o
2616,LGG,7,Abstract,hl_i,18544974,test,gold,i
2617,lactobacilli,7,Abstract,hl_o,18544974,test,gold,o
2618,"gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation",7,Abstract,hl_o,18544974,test,gold,o
2619,LGG,8,Abstract,ss_i,18544974,test,gold,i
2620,GOS,8,Abstract,ss_i,18544974,test,gold,i
2621,LGG,8,Abstract,ss_i,18544974,test,gold,i
2622,GOS,8,Abstract,ss_i,18544974,test,gold,i
2623,bifidobacteria,8,Abstract,ss_o,18544974,test,gold,o
2624,prebiotic effect,8,Abstract,ss_o,18544974,test,gold,o
2625,LGG,8,Abstract,hl_i,18544974,test,gold,i
2626,GOS,8,Abstract,hl_i,18544974,test,gold,i
2627,LGG,8,Abstract,hl_i,18544974,test,gold,i
2628,GOS,8,Abstract,hl_i,18544974,test,gold,i
2629,bifidobacteria,8,Abstract,hl_o,18544974,test,gold,o
2630,GOS .,9,Abstract,ss_i,18544974,test,gold,i
2631,tolerated,9,Abstract,ss_o,18544974,test,gold,o
2632,GOS .,9,Abstract,hl_i,18544974,test,gold,i
2633,school-aged children,0,Title,ss_p,18544974,test,gold,p
2634,galacto-oligosaccharides and Lactobacillus GG,0,Title,ss_i,18544974,test,gold,i
2635,Lactobacillus GG,0,Title,ss_i,18544974,test,gold,i
2636,bifidobacteria,0,Title,ss_o,18544974,test,gold,o
2637,school-aged children,0,Title,hl_p,18544974,test,gold,p
2638,galacto-oligosaccharides,0,Title,hl_i,18544974,test,gold,i
2639,Lactobacillus GG,0,Title,hl_i,18544974,test,gold,i
2640,Lactobacillus GG,0,Title,hl_i,18544974,test,gold,i
2641,Vibrotactile stimuli,0,Abstract,ss_i,18773733,test,gold,i
2642,compelling auditory sensations,0,Abstract,ss_o,18773733,test,gold,o
2643,Vibrotactile stimuli,0,Abstract,hl_i,18773733,test,gold,i
2644,vibrotactile stimulus,1,Abstract,ss_i,18773733,test,gold,i
2645,auditory tones,1,Abstract,ss_o,18773733,test,gold,o
2646,vibrotactile stimulus,1,Abstract,hl_i,18773733,test,gold,i
2647,auditory stimulation,2,Abstract,ss_p,18773733,test,gold,p
2648,"auditory stimulation ( no tone , tone at detection threshold , tone at 5 dB above threshold , and tone at 10 dB above threshold ) .",2,Abstract,ss_o,18773733,test,gold,o
2649,vibrotactile stimulus,3,Abstract,ss_i,18773733,test,gold,i
2650,auditory tones,3,Abstract,ss_o,18773733,test,gold,o
2651,vibrotactile stimulus,3,Abstract,hl_i,18773733,test,gold,i
2652,auditory tones,3,Abstract,hl_o,18773733,test,gold,o
2653,nature of this cross-modal interaction .,4,Abstract,ss_o,18773733,test,gold,o
2654,vibrotaction,5,Abstract,ss_i,18773733,test,gold,i
2655,vibrotaction,5,Abstract,ss_i,18773733,test,gold,i
2656,vibrotactile stimuli .,5,Abstract,ss_i,18773733,test,gold,i
2657,Subjects,5,Abstract,hl_p,18773733,test,gold,p
2658,vibrotaction,5,Abstract,hl_i,18773733,test,gold,i
2659,vibrotaction,5,Abstract,hl_i,18773733,test,gold,i
2660,vibrotactile stimuli .,5,Abstract,hl_i,18773733,test,gold,i
2661,vibrotaction,6,Abstract,ss_i,18773733,test,gold,i
2662,auditory tone .,6,Abstract,ss_o,18773733,test,gold,o
2663,vibrotaction,6,Abstract,hl_i,18773733,test,gold,i
2664,vibrotaction,7,Abstract,ss_i,18773733,test,gold,i
2665,vibrotaction,7,Abstract,hl_i,18773733,test,gold,i
2666,Vibrotactile -- auditory interactions,0,Title,ss_p,18773733,test,gold,p
2667,bupropion sustained-release ( SR ),0,Abstract,ss_i,18783504,test,gold,i
2668,putative mediators,0,Abstract,ss_o,18783504,test,gold,o
2669,"post-quit abstinence , including withdrawal distress , cigarette craving , positive affect and subjective reactions to cigarettes smoked during a lapse .",0,Abstract,ss_o,18783504,test,gold,o
2670,bupropion sustained-release ( SR ),0,Abstract,hl_i,18783504,test,gold,i
2671,bupropion SR,1,Abstract,ss_i,18783504,test,gold,i
2672,specificity,1,Abstract,ss_o,18783504,test,gold,o
2673,bupropion SR,1,Abstract,hl_i,18783504,test,gold,i
2674,bupropion SR,2,Abstract,ss_i,18783504,test,gold,i
2675,bupropion SR,2,Abstract,hl_i,18783504,test,gold,i
2676,"Madison , WI , USA .",3,Abstract,ss_p,18783504,test,gold,p
2677,"Madison , WI , USA",3,Abstract,hl_p,18783504,test,gold,p
2678,"403 adult , daily smokers without contraindications to bupropion SR use .",4,Abstract,ss_p,18783504,test,gold,p
2679,bupropion SR,4,Abstract,ss_i,18783504,test,gold,i
2680,"403 adult , daily smokers without contraindications to bupropion SR use",4,Abstract,hl_p,18783504,test,gold,p
2681,bupropion SR,4,Abstract,hl_i,18783504,test,gold,i
2682,bupropion SR,5,Abstract,ss_i,18783504,test,gold,i
2683,placebo,5,Abstract,ss_i,18783504,test,gold,i
2684,bupropion SR,5,Abstract,hl_i,18783504,test,gold,i
2685,placebo,5,Abstract,hl_i,18783504,test,gold,i
2686,Ecological momentary assessment ratings of smoking behavior and putative mediators,6,Abstract,ss_o,18783504,test,gold,o
2687,Ecological momentary assessment ratings of smoking behavior and putative mediators,6,Abstract,hl_o,18783504,test,gold,o
2688,bupropion SR,7,Abstract,ss_i,18783504,test,gold,i
2689,short-term abstinence,7,Abstract,ss_o,18783504,test,gold,o
2690,withdrawal distress,7,Abstract,ss_o,18783504,test,gold,o
2691,subjective effects of a lapse cigarette,7,Abstract,ss_o,18783504,test,gold,o
2692,cigarette craving reduction,7,Abstract,ss_o,18783504,test,gold,o
2693,positive affect .,7,Abstract,ss_o,18783504,test,gold,o
2694,short-term abstinence,7,Abstract,hl_o,18783504,test,gold,o
2695,cigarette craving reduction,7,Abstract,hl_o,18783504,test,gold,o
2696,positive affect .,7,Abstract,hl_o,18783504,test,gold,o
2697,Bupropion SR,8,Abstract,ss_i,18783504,test,gold,i
2698,point-prevalence abstinence,8,Abstract,ss_o,18783504,test,gold,o
2699,motivation,8,Abstract,ss_o,18783504,test,gold,o
2700,self-efficacy .,8,Abstract,ss_o,18783504,test,gold,o
2701,Bupropion SR,8,Abstract,hl_i,18783504,test,gold,i
2702,abstinence,8,Abstract,hl_o,18783504,test,gold,o
2703,bupropion SR,9,Abstract,ss_i,18783504,test,gold,i
2704,bupropion SR,9,Abstract,ss_i,18783504,test,gold,i
2705,efficacy .,9,Abstract,ss_o,18783504,test,gold,o
2706,bupropion SR,9,Abstract,hl_i,18783504,test,gold,i
2707,smoking cessation .,0,Title,ss_p,18783504,test,gold,p
2708,bupropion sustained-release,0,Title,ss_i,18783504,test,gold,i
2709,Psychological mediators,0,Title,ss_o,18783504,test,gold,o
2710,bupropion sustained-release,0,Title,hl_i,18783504,test,gold,i
2711,patients with metastatic breast cancer ( MBC ) .,0,Abstract,ss_p,18845996,test,gold,p
2712,doxorubicin ( DOX ),0,Abstract,ss_i,18845996,test,gold,i
2713,pegylated liposomal formulation ( PLD ),0,Abstract,ss_i,18845996,test,gold,i
2714,cycle-based risk prediction model for neutropenic complications ( NC ),0,Abstract,ss_o,18845996,test,gold,o
2715,patients with metastatic breast cancer ( MBC ) .,0,Abstract,hl_p,18845996,test,gold,p
2716,doxorubicin ( DOX ),0,Abstract,hl_i,18845996,test,gold,i
2717,pegylated liposomal formulation ( PLD ),0,Abstract,hl_i,18845996,test,gold,i
2718,neutropenic complications ( NC ),0,Abstract,hl_o,18845996,test,gold,o
2719,MBC ( n = 509 ),1,Abstract,ss_p,18845996,test,gold,p
2720,DOX,1,Abstract,ss_i,18845996,test,gold,i
2721,PLD,1,Abstract,ss_i,18845996,test,gold,i
2722,DOX,1,Abstract,hl_i,18845996,test,gold,i
2723,PLD,1,Abstract,hl_i,18845996,test,gold,i
2725,NC,3,Abstract,ss_o,18845996,test,gold,o
2726,"absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L ( ie , > or =grade II ) before the next cycle , febrile neutropenia or neutropenia with a documented infection .",3,Abstract,ss_o,18845996,test,gold,o
2727,NC,3,Abstract,hl_o,18845996,test,gold,o
2728,absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L,3,Abstract,hl_o,18845996,test,gold,o
2729,febrile neutropenia or neutropenia with a documented infection .,3,Abstract,hl_o,18845996,test,gold,o
2730,Patient and hematologic factors potentially associated with NC,4,Abstract,ss_o,18845996,test,gold,o
2732,risk scoring algorithm,6,Abstract,ss_o,18845996,test,gold,o
2733,DOX,7,Abstract,ss_i,18845996,test,gold,i
2734,PLD,7,Abstract,ss_i,18845996,test,gold,i
2735,Risk factors,7,Abstract,ss_o,18845996,test,gold,o
2736,"poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L",7,Abstract,ss_o,18845996,test,gold,o
2737,age .,7,Abstract,ss_o,18845996,test,gold,o
2738,DOX,7,Abstract,hl_i,18845996,test,gold,i
2739,PLD,7,Abstract,hl_i,18845996,test,gold,i
2740,"poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L",7,Abstract,hl_o,18845996,test,gold,o
2741,age,7,Abstract,hl_o,18845996,test,gold,o
2742,precycle risk score,8,Abstract,ss_o,18845996,test,gold,o
2743,precycle risk score,8,Abstract,hl_o,18845996,test,gold,o
2744,risk,9,Abstract,ss_o,18845996,test,gold,o
2745,NC,9,Abstract,ss_o,18845996,test,gold,o
2746,risk,9,Abstract,hl_o,18845996,test,gold,o
2747,MBC patients,10,Abstract,ss_p,18845996,test,gold,p
2748,PLD ),10,Abstract,ss_i,18845996,test,gold,i
2749,NC,10,Abstract,ss_o,18845996,test,gold,o
2750,patients,10,Abstract,hl_p,18845996,test,gold,p
2751,NC,10,Abstract,hl_o,18845996,test,gold,o
2752,metastatic breast cancer,0,Title,ss_p,18845996,test,gold,p
2753,doxorubicin,0,Title,ss_i,18845996,test,gold,i
2754,pegylated liposomal doxorubicin :,0,Title,ss_i,18845996,test,gold,i
2755,Identifying patients at high risk for neutropenic complications,0,Title,ss_o,18845996,test,gold,o
2756,metastatic breast cancer,0,Title,hl_p,18845996,test,gold,p
2757,doxorubicin,0,Title,hl_i,18845996,test,gold,i
2758,pegylated liposomal doxorubicin,0,Title,hl_i,18845996,test,gold,i
2759,neutropenic complications,0,Title,hl_o,18845996,test,gold,o
2761,individuals with autism spectrum disorders ( ASD ) .,1,Abstract,ss_p,18958161,test,gold,p
2762,individuals with autism spectrum disorders ( ASD ) .,1,Abstract,hl_p,18958161,test,gold,p
2763,neural mechanisms,2,Abstract,ss_o,18958161,test,gold,o
2764,images of the subjects ' own face and to faces of others .,3,Abstract,ss_i,18958161,test,gold,i
2765,fMRI,3,Abstract,ss_o,18958161,test,gold,o
2766,brain responsiveness to images of the subjects ' own face and to faces of others .,3,Abstract,ss_o,18958161,test,gold,o
2767,brain responsiveness,3,Abstract,hl_o,18958161,test,gold,o
2768,Children with ASD and typically developing ( TD ) children,4,Abstract,ss_p,18958161,test,gold,p
2769,their own face and a gender-matched other face,4,Abstract,ss_i,18958161,test,gold,i
2770,Children,4,Abstract,hl_p,18958161,test,gold,p
2771,ASD and typically developing ( TD ) children,4,Abstract,hl_p,18958161,test,gold,p
2772,their own face and a gender-matched other face,4,Abstract,hl_i,18958161,test,gold,i
2773,images,5,Abstract,ss_i,18958161,test,gold,i
2774,right premotor/prefrontal system,5,Abstract,ss_o,18958161,test,gold,o
2775,right premotor/prefrontal system,5,Abstract,hl_o,18958161,test,gold,o
2776,self- and other-processing,6,Abstract,ss_i,18958161,test,gold,i
2777,images,6,Abstract,ss_i,18958161,test,gold,i
2778,system,6,Abstract,ss_o,18958161,test,gold,o
2779,neural representations for self and others,7,Abstract,ss_o,18958161,test,gold,o
2780,Neural basis of self and other representation,0,Title,ss_o,18958161,test,gold,o
2781,FMRI,0,Title,ss_o,18958161,test,gold,o
2782,self-face recognition .,0,Title,ss_o,18958161,test,gold,o
2783,autism,0,Title,hl_p,18958161,test,gold,p
2784,self-face recognition,0,Title,hl_o,18958161,test,gold,o
2785,difference,0,Abstract,ss_o,18975051,test,gold,o
2786,difference,0,Abstract,hl_o,18975051,test,gold,o
2787,iopamidol,1,Abstract,ss_i,18975051,test,gold,i
2788,iopamidol,1,Abstract,ss_i,18975051,test,gold,i
2789,iopamidol,1,Abstract,ss_i,18975051,test,gold,i
2790,iopamidol,1,Abstract,hl_i,18975051,test,gold,i
2791,iopamidol,1,Abstract,hl_i,18975051,test,gold,i
2792,iopamidol,1,Abstract,hl_i,18975051,test,gold,i
2793,10 patients in each group .,2,Abstract,ss_p,18975051,test,gold,p
2794,10 patients in each group .,2,Abstract,hl_p,18975051,test,gold,p
2795,"Attenuation values of the bilateral internal carotid arteries ( ICAs ) , basilar artery trunk , bilateral cavernous sinuses ( CSs ) , and Galenic vein",3,Abstract,ss_o,18975051,test,gold,o
2796,four-channel MDCT .,3,Abstract,ss_o,18975051,test,gold,o
2797,"Attenuation values of the bilateral internal carotid arteries ( ICAs ) , basilar artery trunk , bilateral cavernous sinuses ( CSs ) , and Galenic vein",3,Abstract,hl_o,18975051,test,gold,o
2798,arteriovenous contrast at the cavernous portion .,4,Abstract,ss_o,18975051,test,gold,o
2799,arteriovenous contrast,4,Abstract,hl_o,18975051,test,gold,o
2800,CT value,5,Abstract,ss_o,18975051,test,gold,o
2801,CT value,5,Abstract,hl_o,18975051,test,gold,o
2802,ICA attenuation,6,Abstract,ss_o,18975051,test,gold,o
2803,intracavernous attenuation,6,Abstract,ss_o,18975051,test,gold,o
2804,ICA attenuation,6,Abstract,hl_o,18975051,test,gold,o
2805,intracavernous attenuation,6,Abstract,hl_o,18975051,test,gold,o
2806,intracranial arteriovenous contrast,0,Title,ss_o,18975051,test,gold,o
2807,intracranial arteriovenous contrast,0,Title,hl_o,18975051,test,gold,o
2808,risperidone,0,Abstract,ss_i,19096921,test,gold,i
2809,structured parent training,0,Abstract,ss_i,19096921,test,gold,i
2810,risperidone,0,Abstract,ss_i,19096921,test,gold,i
2811,"noncompliance , irritability and adaptive functioning .",0,Abstract,ss_o,19096921,test,gold,o
2812,risperidone,0,Abstract,hl_i,19096921,test,gold,i
2813,structured parent training,0,Abstract,hl_i,19096921,test,gold,i
2814,risperidone,0,Abstract,hl_i,19096921,test,gold,i
2815,noncompliance,0,Abstract,hl_o,19096921,test,gold,o
2816,irritability,0,Abstract,hl_o,19096921,test,gold,o
2817,adaptive functioning,0,Abstract,hl_o,19096921,test,gold,o
2818,"tantrums , aggression and self-injury ;",1,Abstract,ss_o,19096921,test,gold,o
2819,noncompliance and adaptive functioning .,1,Abstract,ss_o,19096921,test,gold,o
2820,tantrums,1,Abstract,hl_o,19096921,test,gold,o
2821,aggression,1,Abstract,hl_o,19096921,test,gold,o
2822,self-injury,1,Abstract,hl_o,19096921,test,gold,o
2823,noncompliance and adaptive functioning .,1,Abstract,hl_o,19096921,test,gold,o
2824,medication,2,Abstract,ss_i,19096921,test,gold,i
2825,parent training,2,Abstract,ss_i,19096921,test,gold,i
2826,medication,3,Abstract,ss_i,19096921,test,gold,i
2827,symptom,4,Abstract,ss_o,19096921,test,gold,o
2828,functional,4,Abstract,ss_o,19096921,test,gold,o
2829,symptom,4,Abstract,hl_o,19096921,test,gold,o
2830,functional,4,Abstract,hl_o,19096921,test,gold,o
2831,effects,5,Abstract,ss_o,19096921,test,gold,o
2832,children with pervasive developmental disorders .,0,Title,ss_p,19096921,test,gold,p
2833,medication,0,Title,ss_i,19096921,test,gold,i
2834,parent training,0,Title,ss_i,19096921,test,gold,i
2835,children,0,Title,hl_p,19096921,test,gold,p
2836,pervasive developmental disorders,0,Title,hl_p,19096921,test,gold,p
2837,medication,0,Title,hl_i,19096921,test,gold,i
2838,parent training,0,Title,hl_i,19096921,test,gold,i
2839,incidence of postoperative nausea and vomiting ( PONV ) .,0,Abstract,ss_o,19108790,test,gold,o
2840,postoperative nausea and vomiting ( PONV ),0,Abstract,hl_o,19108790,test,gold,o
2841,PONV .,1,Abstract,ss_o,19108790,test,gold,o
2842,PONV .,1,Abstract,hl_o,19108790,test,gold,o
2843,propofol,2,Abstract,ss_i,19108790,test,gold,i
2844,placebo,2,Abstract,ss_i,19108790,test,gold,i
2845,PONV,2,Abstract,ss_o,19108790,test,gold,o
2846,propofol,2,Abstract,hl_i,19108790,test,gold,i
2847,placebo,2,Abstract,hl_i,19108790,test,gold,i
2848,PONV,2,Abstract,hl_o,19108790,test,gold,o
2849,breast cancer surgery in Japanese patients .,3,Abstract,ss_p,19108790,test,gold,p
2850,propofol,3,Abstract,ss_i,19108790,test,gold,i
2851,droperidol,3,Abstract,ss_i,19108790,test,gold,i
2852,metoclopramide,3,Abstract,ss_i,19108790,test,gold,i
2853,efficacy,3,Abstract,ss_o,19108790,test,gold,o
2854,prophylaxis of PONV,3,Abstract,ss_o,19108790,test,gold,o
2855,breast cancer surgery in Japanese patients .,3,Abstract,hl_p,19108790,test,gold,p
2856,propofol,3,Abstract,hl_i,19108790,test,gold,i
2857,droperidol,3,Abstract,hl_i,19108790,test,gold,i
2858,metoclopramide,3,Abstract,hl_i,19108790,test,gold,i
2859,efficacy,3,Abstract,hl_o,19108790,test,gold,o
2860,PONV,3,Abstract,hl_o,19108790,test,gold,o
2861,Japanese women,4,Abstract,ss_p,19108790,test,gold,p
2862,propofol,4,Abstract,ss_i,19108790,test,gold,i
2863,droperidol,4,Abstract,ss_i,19108790,test,gold,i
2864,metoclopramide,4,Abstract,ss_i,19108790,test,gold,i
2865,placebo ( isotonic saline ),4,Abstract,ss_i,19108790,test,gold,i
2866,Japanese women,4,Abstract,hl_p,19108790,test,gold,p
2867,propofol,4,Abstract,hl_i,19108790,test,gold,i
2868,droperidol,4,Abstract,hl_i,19108790,test,gold,i
2869,metoclopramide,4,Abstract,hl_i,19108790,test,gold,i
2870,placebo ( isotonic saline ),4,Abstract,hl_i,19108790,test,gold,i
2871,sevoflurane,5,Abstract,ss_i,19108790,test,gold,i
2872,oxygen,5,Abstract,ss_i,19108790,test,gold,i
2873,episodes of PONV during the first 24 hours after anesthesia administration,6,Abstract,ss_o,19108790,test,gold,o
2874,PONV,6,Abstract,hl_o,19108790,test,gold,o
2875,extrapyramidal symptoms .,7,Abstract,ss_o,19108790,test,gold,o
2876,extrapyramidal symptoms .,7,Abstract,hl_o,19108790,test,gold,o
2878,"A total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg )",9,Abstract,ss_p,19108790,test,gold,p
2879,100,9,Abstract,hl_p,19108790,test,gold,p
2880,"mean [ SD ] age , 52 [ 7 ] years",9,Abstract,hl_p,19108790,test,gold,p
2881,"height , 154 [ 6 ] cm",9,Abstract,hl_p,19108790,test,gold,p
2882,"weight , 54 [ 7 ] kg",9,Abstract,hl_p,19108790,test,gold,p
2884,"patient demographics , surgery type , or awakening time .",11,Abstract,ss_o,19108790,test,gold,o
2885,propofol,12,Abstract,ss_i,19108790,test,gold,i
2886,droperidol,12,Abstract,ss_i,19108790,test,gold,i
2887,metoclopramide,12,Abstract,ss_i,19108790,test,gold,i
2888,placebo,12,Abstract,ss_i,19108790,test,gold,i
2889,prevalences of PONV 0 to 24 hours,12,Abstract,ss_o,19108790,test,gold,o
2890,propofol,12,Abstract,hl_i,19108790,test,gold,i
2891,droperidol,12,Abstract,hl_i,19108790,test,gold,i
2892,metoclopramide,12,Abstract,hl_i,19108790,test,gold,i
2893,placebo,12,Abstract,hl_i,19108790,test,gold,i
2894,PONV,12,Abstract,hl_o,19108790,test,gold,o
2895,propofol,13,Abstract,ss_i,19108790,test,gold,i
2896,droperidol,13,Abstract,ss_i,19108790,test,gold,i
2897,propofol,13,Abstract,ss_i,19108790,test,gold,i
2898,droperidol,13,Abstract,ss_i,19108790,test,gold,i
2899,metoclopramide,13,Abstract,ss_i,19108790,test,gold,i
2900,prevalence of PONV,13,Abstract,ss_o,19108790,test,gold,o
2901,prevalences of PONV,13,Abstract,ss_o,19108790,test,gold,o
2902,propofol,13,Abstract,hl_i,19108790,test,gold,i
2903,droperidol,13,Abstract,hl_i,19108790,test,gold,i
2904,propofol,13,Abstract,hl_i,19108790,test,gold,i
2905,droperidol,13,Abstract,hl_i,19108790,test,gold,i
2906,metoclopramide,13,Abstract,hl_i,19108790,test,gold,i
2907,PONV,13,Abstract,hl_o,19108790,test,gold,o
2908,PONV,13,Abstract,hl_o,19108790,test,gold,o
2909,Extrapyramidal symptoms,14,Abstract,ss_o,19108790,test,gold,o
2910,Extrapyramidal symptoms,14,Abstract,hl_o,19108790,test,gold,o
2911,Japanese women who underwent breast cancer surgery .,15,Abstract,ss_p,19108790,test,gold,p
2912,propofol,15,Abstract,ss_i,19108790,test,gold,i
2913,droperidol,15,Abstract,ss_i,19108790,test,gold,i
2914,prevalences of PONV,15,Abstract,ss_o,19108790,test,gold,o
2915,propofol,15,Abstract,hl_i,19108790,test,gold,i
2916,droperidol,15,Abstract,hl_i,19108790,test,gold,i
2917,PONV,15,Abstract,hl_o,19108790,test,gold,o
2918,propofol,16,Abstract,ss_i,19108790,test,gold,i
2919,droperidol,16,Abstract,ss_i,19108790,test,gold,i
2920,metoclopramide,16,Abstract,ss_i,19108790,test,gold,i
2921,placebo .,16,Abstract,ss_i,19108790,test,gold,i
2922,prevalences of PONV,16,Abstract,ss_o,19108790,test,gold,o
2923,propofol,16,Abstract,hl_i,19108790,test,gold,i
2924,droperidol,16,Abstract,hl_i,19108790,test,gold,i
2925,metoclopramide,16,Abstract,hl_i,19108790,test,gold,i
2926,placebo .,16,Abstract,hl_i,19108790,test,gold,i
2927,PONV,16,Abstract,hl_o,19108790,test,gold,o
2928,breast cancer surgery :,0,Title,ss_p,19108790,test,gold,p
2929,Japanese patients .,0,Title,ss_p,19108790,test,gold,p
2930,"propofol , droperidol",0,Title,ss_i,19108790,test,gold,i
2931,metoclopramide,0,Title,ss_i,19108790,test,gold,i
2932,prophylaxis of postoperative nausea and vomiting,0,Title,ss_o,19108790,test,gold,o
2933,breast cancer surgery :,0,Title,hl_p,19108790,test,gold,p
2934,Japanese patients .,0,Title,hl_p,19108790,test,gold,p
2935,propofol,0,Title,hl_i,19108790,test,gold,i
2936,droperidol,0,Title,hl_i,19108790,test,gold,i
2937,metoclopramide,0,Title,hl_i,19108790,test,gold,i
2938,postoperative nausea and vomiting,0,Title,hl_o,19108790,test,gold,o
2939,primary Raynaud 's phenomenon ( RP ) in Korea .,0,Abstract,ss_p,19159999,test,gold,p
2940,nifedipine sustained release ( nifedipine SR ),0,Abstract,ss_i,19159999,test,gold,i
2941,Ginkgo biloba extract,0,Abstract,ss_i,19159999,test,gold,i
2942,efficacy,0,Abstract,ss_o,19159999,test,gold,o
2943,safety,0,Abstract,ss_o,19159999,test,gold,o
2944,nifedipine sustained release ( nifedipine SR ),0,Abstract,hl_i,19159999,test,gold,i
2945,Ginkgo biloba extract,0,Abstract,hl_i,19159999,test,gold,i
2946,efficacy,0,Abstract,hl_o,19159999,test,gold,o
2947,safety,0,Abstract,hl_o,19159999,test,gold,o
2948,nifedipine SR,1,Abstract,ss_i,19159999,test,gold,i
2949,Ginkgo biloba extract,1,Abstract,ss_i,19159999,test,gold,i
2950,nifedipine SR,1,Abstract,hl_i,19159999,test,gold,i
2951,Ginkgo biloba extract,1,Abstract,hl_i,19159999,test,gold,i
2953,percent improvement of the RP attack rate between before and after the 8-week treatment .,3,Abstract,ss_o,19159999,test,gold,o
2954,percent improvement of the RP attack rate,3,Abstract,hl_o,19159999,test,gold,o
2955,Ninety-three subjects,4,Abstract,ss_p,19159999,test,gold,p
2956,Ninety-three subjects,4,Abstract,hl_p,19159999,test,gold,p
2957,percent improvement,5,Abstract,ss_o,19159999,test,gold,o
2958,serious adverse events,6,Abstract,ss_o,19159999,test,gold,o
2959,adverse events,6,Abstract,ss_o,19159999,test,gold,o
2960,serious adverse events,6,Abstract,hl_o,19159999,test,gold,o
2961,adverse events,6,Abstract,hl_o,19159999,test,gold,o
2962,primary RP in Korean patients .,7,Abstract,ss_p,19159999,test,gold,p
2963,nifedipine SR,7,Abstract,ss_i,19159999,test,gold,i
2964,Ginkgo biloba extract,7,Abstract,ss_i,19159999,test,gold,i
2965,effective,7,Abstract,ss_o,19159999,test,gold,o
2966,Korean patients .,7,Abstract,hl_p,19159999,test,gold,p
2967,nifedipine SR,7,Abstract,hl_i,19159999,test,gold,i
2968,Ginkgo biloba extract,7,Abstract,hl_i,19159999,test,gold,i
2969,effective,7,Abstract,hl_o,19159999,test,gold,o
2970,primary RP patients .,8,Abstract,ss_p,19159999,test,gold,p
2971,tolerable,8,Abstract,ss_o,19159999,test,gold,o
2972,RP patients .,8,Abstract,hl_p,19159999,test,gold,p
2973,tolerable,8,Abstract,hl_o,19159999,test,gold,o
2974,patients with primary Raynaud 's phenomenon in South Korea ;,0,Title,ss_p,19159999,test,gold,p
2975,nifedipine sustained release,0,Title,ss_i,19159999,test,gold,i
2976,Ginkgo biloba extract,0,Title,ss_i,19159999,test,gold,i
2977,efficacy,0,Title,ss_o,19159999,test,gold,o
2978,safety,0,Title,ss_o,19159999,test,gold,o
2979,patients with primary Raynaud 's phenomenon in South Korea ;,0,Title,hl_p,19159999,test,gold,p
2980,nifedipine sustained release,0,Title,hl_i,19159999,test,gold,i
2981,Ginkgo biloba extract,0,Title,hl_i,19159999,test,gold,i
2982,efficacy,0,Title,hl_o,19159999,test,gold,o
2983,safety,0,Title,hl_o,19159999,test,gold,o
2984,femoral nerve block ( FNB ),0,Abstract,ss_i,19301724,test,gold,i
2985,pain relief,0,Abstract,ss_o,19301724,test,gold,o
2986,side effects,0,Abstract,ss_o,19301724,test,gold,o
2987,"nausea , vomiting , pruritus , dizziness , and hypotension .",0,Abstract,ss_o,19301724,test,gold,o
2988,femoral nerve block ( FNB ),0,Abstract,hl_i,19301724,test,gold,i
2991,continuous epidural infusion ( CEI ),3,Abstract,ss_i,19301724,test,gold,i
2992,continuous femoral nerve block ( CFNB ),3,Abstract,ss_i,19301724,test,gold,i
2993,"postoperative analgesic efficacy , side effects , postoperative knee rehabilitation , and hospital length of stay ( LOS ) .",3,Abstract,ss_o,19301724,test,gold,o
2994,continuous epidural infusion ( CEI ),3,Abstract,hl_i,19301724,test,gold,i
2995,continuous femoral nerve block ( CFNB ),3,Abstract,hl_i,19301724,test,gold,i
2996,postoperative analgesic efficacy,3,Abstract,hl_o,19301724,test,gold,o
2997,side effects,3,Abstract,hl_o,19301724,test,gold,o
2998,postoperative knee rehabilitation,3,Abstract,hl_o,19301724,test,gold,o
2999,hospital length of stay ( LOS ),3,Abstract,hl_o,19301724,test,gold,o
3000,61 ASA physical status I-III patients scheduled for elective unilateral total knee arthroplasty ( TKA ) under spinal anesthesia ( SA ),4,Abstract,ss_p,19301724,test,gold,p
3001,61 ASA physical status I-III patients scheduled for elective unilateral total knee arthroplasty ( TKA ) under spinal anesthesia ( SA ),4,Abstract,hl_p,19301724,test,gold,p
3003,( CEI ),6,Abstract,ss_i,19301724,test,gold,i
3004,levobupivacaine,6,Abstract,ss_i,19301724,test,gold,i
3005,morphine,6,Abstract,ss_i,19301724,test,gold,i
3006,( CFNB ),6,Abstract,ss_i,19301724,test,gold,i
3007,levobupivacaine,6,Abstract,ss_i,19301724,test,gold,i
3008,( CEI ),6,Abstract,hl_i,19301724,test,gold,i
3009,levobupivacaine,6,Abstract,hl_i,19301724,test,gold,i
3010,morphine,6,Abstract,hl_i,19301724,test,gold,i
3011,( CFNB ),6,Abstract,hl_i,19301724,test,gold,i
3012,levobupivacaine,6,Abstract,hl_i,19301724,test,gold,i
3013,CFNB,7,Abstract,ss_i,19301724,test,gold,i
3014,CEI,7,Abstract,ss_i,19301724,test,gold,i
3015,VAS scores,7,Abstract,ss_o,19301724,test,gold,o
3016,tramadol IV requirement,7,Abstract,ss_o,19301724,test,gold,o
3017,CFNB,7,Abstract,hl_i,19301724,test,gold,i
3018,CEI,7,Abstract,hl_i,19301724,test,gold,i
3019,VAS scores,7,Abstract,hl_o,19301724,test,gold,o
3020,tramadol IV requirement,7,Abstract,hl_o,19301724,test,gold,o
3021,CEI,8,Abstract,ss_i,19301724,test,gold,i
3022,CFNB,8,Abstract,ss_i,19301724,test,gold,i
3023,"dizziness , pruritus , and PONV",8,Abstract,ss_o,19301724,test,gold,o
3024,CEI,8,Abstract,hl_i,19301724,test,gold,i
3025,CFNB,8,Abstract,hl_i,19301724,test,gold,i
3026,dizziness,8,Abstract,hl_o,19301724,test,gold,o
3027,pruritus,8,Abstract,hl_o,19301724,test,gold,o
3028,PONV,8,Abstract,hl_o,19301724,test,gold,o
3029,CFNB,9,Abstract,ss_i,19301724,test,gold,i
3030,Patient satisfaction,9,Abstract,ss_o,19301724,test,gold,o
3031,postoperative knee rehabilitation and the hospital LOS,9,Abstract,ss_o,19301724,test,gold,o
3032,CFNB,9,Abstract,hl_i,19301724,test,gold,i
3033,Patient satisfaction,9,Abstract,hl_o,19301724,test,gold,o
3034,postoperative knee rehabilitation,9,Abstract,hl_o,19301724,test,gold,o
3035,hospital LOS,9,Abstract,hl_o,19301724,test,gold,o
3036,CFNB,10,Abstract,ss_i,19301724,test,gold,i
3037,side effects,10,Abstract,ss_o,19301724,test,gold,o
3038,"patient , satisfaction .",10,Abstract,ss_o,19301724,test,gold,o
3039,CFNB,10,Abstract,hl_i,19301724,test,gold,i
3040,side effects,10,Abstract,hl_o,19301724,test,gold,o
3041,"patient , satisfaction",10,Abstract,hl_o,19301724,test,gold,o
3042,rehabilitation indices and duration of hospital stay,11,Abstract,ss_o,19301724,test,gold,o
3043,rehabilitation indices,11,Abstract,hl_o,19301724,test,gold,o
3044,duration of hospital stay,11,Abstract,hl_o,19301724,test,gold,o
3045,after total knee arthroplasty ( TKA ) .,0,Title,ss_p,19301724,test,gold,p
3046,continuous femoral nerve block ( CFNB ),0,Title,ss_i,19301724,test,gold,i
3047,continuous epidural infusion ( CEI ),0,Title,ss_i,19301724,test,gold,i
3048,total knee arthroplasty ( TKA ) .,0,Title,hl_p,19301724,test,gold,p
3049,continuous femoral nerve block ( CFNB ),0,Title,hl_i,19301724,test,gold,i
3050,continuous epidural infusion ( CEI ),0,Title,hl_i,19301724,test,gold,i
3051,patients with atrial fibrillation ( AF ),0,Abstract,ss_p,19376304,test,gold,p
3052,Vitamin K antagonists,0,Abstract,ss_i,19376304,test,gold,i
3053,stroke prevention,0,Abstract,ss_o,19376304,test,gold,o
3054,atrial fibrillation,0,Abstract,hl_p,19376304,test,gold,p
3055,AF,0,Abstract,hl_p,19376304,test,gold,p
3056,Dabigatran etexilate,1,Abstract,ss_i,19376304,test,gold,i
3057,dabigatran .,1,Abstract,ss_i,19376304,test,gold,i
3058,Dabigatran etexilate,1,Abstract,hl_i,19376304,test,gold,i
3059,dabigatran .,1,Abstract,hl_i,19376304,test,gold,i
3060,warfarin,2,Abstract,ss_i,19376304,test,gold,i
3061,warfarin,2,Abstract,hl_i,19376304,test,gold,i
3062,dabigatran,3,Abstract,ss_i,19376304,test,gold,i
3063,dabigatran,3,Abstract,hl_i,19376304,test,gold,i
3064,patients with nonvalvular AF and at least 1 risk factor for stroke .,4,Abstract,ss_p,19376304,test,gold,p
3065,"Recruitment concluded with a total of 18,113 patients .",5,Abstract,ss_p,19376304,test,gold,p
3066,"18,113",5,Abstract,hl_p,19376304,test,gold,p
3067,Patients who were VKA-naive and experienced are included in balanced proportions .,6,Abstract,ss_p,19376304,test,gold,p
3068,stroke ( including hemorrhagic ) or systemic embolism .,7,Abstract,ss_o,19376304,test,gold,o
3069,stroke ( including hemorrhagic ),7,Abstract,hl_o,19376304,test,gold,o
3070,systemic embolism,7,Abstract,hl_o,19376304,test,gold,o
3071,Safety,8,Abstract,ss_o,19376304,test,gold,o
3072,"bleeding , liver function abnormalities , and other adverse events .",8,Abstract,ss_o,19376304,test,gold,o
3073,bleeding,8,Abstract,hl_o,19376304,test,gold,o
3074,liver function abnormalities,8,Abstract,hl_o,19376304,test,gold,o
3075,other adverse events,8,Abstract,hl_o,19376304,test,gold,o
3078,stroke,11,Abstract,ss_o,19376304,test,gold,o
3079,dabigatran,12,Abstract,ss_i,19376304,test,gold,i
3080,dabigatran,12,Abstract,hl_i,19376304,test,gold,i
3083,warfarin,0,Title,ss_i,19376304,test,gold,i
3084,dabigatran .,0,Title,ss_i,19376304,test,gold,i
3085,warfarin,0,Title,hl_i,19376304,test,gold,i
3086,dabigatran .,0,Title,hl_i,19376304,test,gold,i
3087,ten normotensive and seven hypertensive subjects,0,Abstract,ss_p,1968178,test,gold,p
3088,self-inflation of the cuff,0,Abstract,ss_i,1968178,test,gold,i
3089,just wearing the inflated cuff,0,Abstract,ss_i,1968178,test,gold,i
3090,continuously recorded 'Finapres ' finger blood pressure,0,Abstract,ss_o,1968178,test,gold,o
3091,ten normotensive,0,Abstract,hl_p,1968178,test,gold,p
3092,seven hypertensive,0,Abstract,hl_p,1968178,test,gold,p
3093,self-inflation of the cuff,0,Abstract,hl_i,1968178,test,gold,i
3094,just wearing the inflated cuff,0,Abstract,hl_i,1968178,test,gold,i
3095,'Finapres ' finger blood pressure,0,Abstract,hl_o,1968178,test,gold,o
3096,( hypertensive and normotensive subjects,1,Abstract,ss_p,1968178,test,gold,p
3097,Inflating the cuff,1,Abstract,ss_i,1968178,test,gold,i
3098,systolic blood pressure,1,Abstract,ss_o,1968178,test,gold,o
3099,Inflating the cuff,1,Abstract,hl_i,1968178,test,gold,i
3100,systolic blood pressure,1,Abstract,hl_o,1968178,test,gold,o
3101,inflated cuff,2,Abstract,ss_i,1968178,test,gold,i
3102,blood pressure .,2,Abstract,ss_o,1968178,test,gold,o
3103,inflated cuff,2,Abstract,hl_i,1968178,test,gold,i
3104,blood pressure .,2,Abstract,hl_o,1968178,test,gold,o
3105,cuff inflation .,3,Abstract,ss_i,1968178,test,gold,i
3106,pressure,3,Abstract,ss_o,1968178,test,gold,o
3107,cuff inflation .,3,Abstract,hl_i,1968178,test,gold,i
3108,pressure,3,Abstract,hl_o,1968178,test,gold,o
3109,cuff inflation .,4,Abstract,ss_i,1968178,test,gold,i
3110,Systolic blood pressure,4,Abstract,ss_o,1968178,test,gold,o
3111,Systolic blood pressure,4,Abstract,hl_o,1968178,test,gold,o
3112,inflate their cuff,5,Abstract,ss_i,1968178,test,gold,i
3113,self-recorded systolic blood pressure,5,Abstract,ss_o,1968178,test,gold,o
3114,self-recorded systolic blood pressure,5,Abstract,hl_o,1968178,test,gold,o
3115,self-recorded blood pressure .,0,Title,ss_o,1968178,test,gold,o
3116,cuff inflation,0,Title,hl_i,1968178,test,gold,i
3117,self-recorded blood pressure .,0,Title,hl_o,1968178,test,gold,o
3118,100 patients with gastric ulcer aged from 16 to 60 years .,0,Abstract,ss_p,19708562,test,gold,p
3119,100 patients with gastric ulcer aged from 16 to 60 years,0,Abstract,hl_p,19708562,test,gold,p
3120,traditional treatment,1,Abstract,ss_i,19708562,test,gold,i
3121,transcranial electrotherapy,1,Abstract,ss_i,19708562,test,gold,i
3122,traditional treatment,1,Abstract,hl_i,19708562,test,gold,i
3123,transcranial electrotherapy,1,Abstract,hl_i,19708562,test,gold,i
3124,Laboratory studies,2,Abstract,ss_o,19708562,test,gold,o
3125,"measurements of lactoferrin ( LF ) and tumour necrosis factor-alpha ( TNF-alpha ) , besides standard analyses .",2,Abstract,ss_o,19708562,test,gold,o
3126,lactoferrin ( LF ),2,Abstract,hl_o,19708562,test,gold,o
3127,tumour necrosis factor-alpha ( TNF-alpha ),2,Abstract,hl_o,19708562,test,gold,o
3128,( traditional therapy plus electrostimulation ),3,Abstract,ss_i,19708562,test,gold,i
3129,duration of the main symptoms of the gastric ulcer,3,Abstract,ss_o,19708562,test,gold,o
3130,patients ' age and sex .,3,Abstract,ss_o,19708562,test,gold,o
3131,( traditional therapy,3,Abstract,hl_i,19708562,test,gold,i
3132,electrostimulation,3,Abstract,hl_i,19708562,test,gold,i
3133,duration of the main symptoms,3,Abstract,hl_o,19708562,test,gold,o
3134,ulcer scarring,4,Abstract,ss_o,19708562,test,gold,o
3135,serum LF and TNF-alpha levels .,4,Abstract,ss_o,19708562,test,gold,o
3136,ulcer scarring,4,Abstract,hl_o,19708562,test,gold,o
3137,serum LF and TNF-alpha levels .,4,Abstract,hl_o,19708562,test,gold,o
3138,patients with gastric ulcer ],0,Title,ss_p,19708562,test,gold,p
3139,transcranial electrostimulation,0,Title,ss_i,19708562,test,gold,i
3140,patients with gastric ulcer ],0,Title,hl_p,19708562,test,gold,p
3141,transcranial electrostimulation,0,Title,hl_i,19708562,test,gold,i
3142,autistic children,0,Abstract,ss_p,19727232,test,gold,p
3143,auditory integrative training,0,Abstract,ss_i,19727232,test,gold,i
3144,effect,0,Abstract,ss_o,19727232,test,gold,o
3145,autistic children,0,Abstract,hl_p,19727232,test,gold,p
3146,auditory integrative training,0,Abstract,hl_i,19727232,test,gold,i
3147,81 cases of autistic children were selected,1,Abstract,ss_p,19727232,test,gold,p
3148,81 cases of autistic children,1,Abstract,hl_p,19727232,test,gold,p
3149,auditory integrative training,2,Abstract,ss_i,19727232,test,gold,i
3150,auditory integrative training,2,Abstract,hl_i,19727232,test,gold,i
3151,clinical manifestation and Autism Behavior Checklist ( ABC ) and intelligence quotient ( IQ ),3,Abstract,ss_o,19727232,test,gold,o
3152,clinical manifestation,3,Abstract,hl_o,19727232,test,gold,o
3153,Autism Behavior Checklist ( ABC ),3,Abstract,hl_o,19727232,test,gold,o
3154,intelligence quotient ( IQ ),3,Abstract,hl_o,19727232,test,gold,o
3155,changes of clinical manifestations and scores of ABC and IQ .,4,Abstract,ss_o,19727232,test,gold,o
3156,changes of clinical manifestations,4,Abstract,hl_o,19727232,test,gold,o
3157,ABC,4,Abstract,hl_o,19727232,test,gold,o
3158,IQ .,4,Abstract,hl_o,19727232,test,gold,o
3159,changes of scores of IQ were determined with Gesell and WPPSI or WISC-R .,5,Abstract,ss_o,19727232,test,gold,o
3160,IQ,5,Abstract,hl_o,19727232,test,gold,o
3161,auditory integrative training,6,Abstract,ss_i,19727232,test,gold,i
3162,"disorders of their language , social interactions and typical behavior symptoms",6,Abstract,ss_o,19727232,test,gold,o
3163,abnormal behaviors .,6,Abstract,ss_o,19727232,test,gold,o
3164,auditory integrative training,6,Abstract,hl_i,19727232,test,gold,i
3165,disorders of their language,6,Abstract,hl_o,19727232,test,gold,o
3166,social interactions,6,Abstract,hl_o,19727232,test,gold,o
3167,typical behavior symptoms,6,Abstract,hl_o,19727232,test,gold,o
3168,abnormal behaviors .,6,Abstract,hl_o,19727232,test,gold,o
3169,scores of IQ or DQ,7,Abstract,ss_o,19727232,test,gold,o
3170,scores of ABC,7,Abstract,ss_o,19727232,test,gold,o
3171,scores of IQ or DQ,7,Abstract,hl_o,19727232,test,gold,o
3172,ABC,7,Abstract,hl_o,19727232,test,gold,o
3174,ABC scores,9,Abstract,ss_o,19727232,test,gold,o
3175,IQ scores,9,Abstract,ss_o,19727232,test,gold,o
3176,ABC scores,9,Abstract,ss_o,19727232,test,gold,o
3177,ABC scores,9,Abstract,hl_o,19727232,test,gold,o
3178,IQ scores,9,Abstract,hl_o,19727232,test,gold,o
3179,ABC scores,9,Abstract,hl_o,19727232,test,gold,o
3180,autistic children,10,Abstract,ss_p,19727232,test,gold,p
3181,auditory integrative training ( AIT ),10,Abstract,ss_i,19727232,test,gold,i
3182,"language disorders , the difficulties of social interactions , typical behavior symptoms and developmental levels",10,Abstract,ss_o,19727232,test,gold,o
3183,effect .,10,Abstract,ss_o,19727232,test,gold,o
3184,autistic children,10,Abstract,hl_p,19727232,test,gold,p
3185,auditory integrative training ( AIT ),10,Abstract,hl_i,19727232,test,gold,i
3186,language disorders,10,Abstract,hl_o,19727232,test,gold,o
3187,difficulties of social interactions,10,Abstract,hl_o,19727232,test,gold,o
3188,typical behavior symptoms,10,Abstract,hl_o,19727232,test,gold,o
3189,developmental levels,10,Abstract,hl_o,19727232,test,gold,o
3190,autistic children ],0,Title,ss_p,19727232,test,gold,p
3191,auditory integrative training,0,Title,ss_i,19727232,test,gold,i
3192,autistic children,0,Title,hl_p,19727232,test,gold,p
3193,auditory integrative training,0,Title,hl_i,19727232,test,gold,i
3194,223 postmenopausal breast cancer survivors .,0,Abstract,ss_p,19802506,test,gold,p
3195,weight training exercises,0,Abstract,ss_i,19802506,test,gold,i
3196,effectiveness,0,Abstract,ss_o,19802506,test,gold,o
3197,bone mineral density ( BMD ),0,Abstract,ss_o,19802506,test,gold,o
3198,223 postmenopausal breast cancer survivors,0,Abstract,hl_p,19802506,test,gold,p
3199,weight training exercises,0,Abstract,hl_i,19802506,test,gold,i
3200,bone mineral density ( BMD ),0,Abstract,hl_o,19802506,test,gold,o
3201,BMD,1,Abstract,ss_o,19802506,test,gold,o
3202,BMD .,1,Abstract,ss_o,19802506,test,gold,o
3203,BMD,1,Abstract,hl_o,19802506,test,gold,o
3204,BMD .,1,Abstract,hl_o,19802506,test,gold,o
3205,postmenopausal breast cancer survivors ( BCS ) with bone loss,2,Abstract,ss_p,19802506,test,gold,p
3206,"risedronate , calcium",2,Abstract,ss_i,19802506,test,gold,i
3207,vitamin D,2,Abstract,ss_i,19802506,test,gold,i
3208,strength/weight training ( ST ) exercises,2,Abstract,ss_i,19802506,test,gold,i
3209,"bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius",2,Abstract,ss_o,19802506,test,gold,o
3210,bone turnover ;,2,Abstract,ss_o,19802506,test,gold,o
3211,BMD,2,Abstract,ss_o,19802506,test,gold,o
3212,bone turnover ;,2,Abstract,ss_o,19802506,test,gold,o
3213,BMD .,2,Abstract,ss_o,19802506,test,gold,o
3214,postmenopausal breast cancer survivors ( BCS ) with bone loss,2,Abstract,hl_p,19802506,test,gold,p
3215,risedronate,2,Abstract,hl_i,19802506,test,gold,i
3216,calcium,2,Abstract,hl_i,19802506,test,gold,i
3217,vitamin D,2,Abstract,hl_i,19802506,test,gold,i
3218,strength/weight training ( ST ) exercises,2,Abstract,hl_i,19802506,test,gold,i
3219,bone mineral density ( BMD ),2,Abstract,hl_o,19802506,test,gold,o
3220,bone turnover ;,2,Abstract,hl_o,19802506,test,gold,o
3221,BMD,2,Abstract,hl_o,19802506,test,gold,o
3222,bone turnover ;,2,Abstract,hl_o,19802506,test,gold,o
3223,BMD .,2,Abstract,hl_o,19802506,test,gold,o
3224,Postmenopausal BCS ( 223 ),3,Abstract,ss_p,19802506,test,gold,p
3225,exercise plus medication,3,Abstract,ss_i,19802506,test,gold,i
3226,medication,3,Abstract,ss_i,19802506,test,gold,i
3227,Postmenopausal BCS,3,Abstract,hl_p,19802506,test,gold,p
3228,223,3,Abstract,hl_p,19802506,test,gold,p
3229,exercise,3,Abstract,hl_i,19802506,test,gold,i
3230,medication,3,Abstract,hl_i,19802506,test,gold,i
3231,medication,3,Abstract,hl_i,19802506,test,gold,i
3232,calcium,4,Abstract,ss_i,19802506,test,gold,i
3233,vitamin D,4,Abstract,ss_i,19802506,test,gold,i
3234,risedronate,4,Abstract,ss_i,19802506,test,gold,i
3235,exercise,4,Abstract,ss_i,19802506,test,gold,i
3236,ST exercises,4,Abstract,ss_i,19802506,test,gold,i
3237,calcium,4,Abstract,hl_i,19802506,test,gold,i
3238,vitamin D,4,Abstract,hl_i,19802506,test,gold,i
3239,risedronate,4,Abstract,hl_i,19802506,test,gold,i
3240,exercise,4,Abstract,hl_i,19802506,test,gold,i
3241,ST exercises,4,Abstract,hl_i,19802506,test,gold,i
3242,medications,5,Abstract,ss_i,19802506,test,gold,i
3243,exercising,5,Abstract,ss_i,19802506,test,gold,i
3244,BMD,5,Abstract,ss_o,19802506,test,gold,o
3245,Alkphase B,5,Abstract,ss_o,19802506,test,gold,o
3246,serum NTx,5,Abstract,ss_o,19802506,test,gold,o
3247,medications,5,Abstract,hl_i,19802506,test,gold,i
3248,exercising,5,Abstract,hl_i,19802506,test,gold,i
3249,BMD,5,Abstract,hl_o,19802506,test,gold,o
3250,Alkphase B,5,Abstract,hl_o,19802506,test,gold,o
3251,serum NTx,5,Abstract,hl_o,19802506,test,gold,o
3252,exercised,6,Abstract,ss_i,19802506,test,gold,i
3253,BMD,6,Abstract,ss_o,19802506,test,gold,o
3254,Alkphase B,6,Abstract,ss_o,19802506,test,gold,o
3255,Serum NTx,6,Abstract,ss_o,19802506,test,gold,o
3256,exercised,6,Abstract,hl_i,19802506,test,gold,i
3257,BMD,6,Abstract,hl_o,19802506,test,gold,o
3258,Alkphase B,6,Abstract,hl_o,19802506,test,gold,o
3259,Serum NTx,6,Abstract,hl_o,19802506,test,gold,o
3260,exercise,7,Abstract,ss_i,19802506,test,gold,i
3261,changes in BMD and bone turnover,7,Abstract,ss_o,19802506,test,gold,o
3262,BMD,7,Abstract,hl_o,19802506,test,gold,o
3263,bone turnover,7,Abstract,hl_o,19802506,test,gold,o
3264,exercise,8,Abstract,ss_i,19802506,test,gold,i
3265,BMD,8,Abstract,ss_o,19802506,test,gold,o
3266,exercise,8,Abstract,hl_i,19802506,test,gold,i
3267,BMD,8,Abstract,hl_o,19802506,test,gold,o
3268,postmenopausal BCS at risk for bone loss .,9,Abstract,ss_p,19802506,test,gold,p
3269,Strength/weight training exercises,9,Abstract,ss_i,19802506,test,gold,i
3270,BMD,9,Abstract,ss_o,19802506,test,gold,o
3271,Strength/weight training exercises,9,Abstract,hl_i,19802506,test,gold,i
3272,BMD,9,Abstract,hl_o,19802506,test,gold,o
3273,postmenopausal breast cancer survivors with bone loss :,0,Title,ss_p,19802506,test,gold,p
3274,weight training,0,Title,ss_i,19802506,test,gold,i
3275,bone mineral density and bone turnover,0,Title,ss_o,19802506,test,gold,o
3276,postmenopausal breast cancer survivors with bone loss :,0,Title,hl_p,19802506,test,gold,p
3277,weight training,0,Title,hl_i,19802506,test,gold,i
3278,bone mineral density,0,Title,hl_o,19802506,test,gold,o
3279,bone turnover,0,Title,hl_o,19802506,test,gold,o
3280,in chemo-naïve non-small cell lung cancer patients,0,Abstract,ss_p,20147856,test,gold,p
3281,of gemcitabine,0,Abstract,ss_i,20147856,test,gold,i
3282,with S-1,0,Abstract,ss_i,20147856,test,gold,i
3283,the efficacy and safety,0,Abstract,ss_o,20147856,test,gold,o
3284,to compare dosing schedules,0,Abstract,ss_o,20147856,test,gold,o
3285,chemo-naïve non-small cell lung cancer patients,0,Abstract,hl_p,20147856,test,gold,p
3286,gemcitabine,0,Abstract,hl_i,20147856,test,gold,i
3287,S-1,0,Abstract,hl_i,20147856,test,gold,i
3288,efficacy,0,Abstract,hl_o,20147856,test,gold,o
3289,safety,0,Abstract,hl_o,20147856,test,gold,o
3290,METHODS Patients with chemo-naïve stage IIIB/IV non-small cell lung cancer,1,Abstract,ss_p,20147856,test,gold,p
3291,chemo-naïve stage IIIB/IV non-small cell lung cancer,1,Abstract,hl_p,20147856,test,gold,p
3292,oral S-1,2,Abstract,ss_i,20147856,test,gold,i
3293,with gemcitabine,2,Abstract,ss_i,20147856,test,gold,i
3294,S-1,2,Abstract,hl_i,20147856,test,gold,i
3295,gemcitabine,2,Abstract,hl_i,20147856,test,gold,i
3297,RESULTS A total of 80 patients were entered in this trial,4,Abstract,ss_p,20147856,test,gold,p
3298,80,4,Abstract,hl_p,20147856,test,gold,p
3299,was response rate,5,Abstract,ss_o,20147856,test,gold,o
3300,response rate,5,Abstract,hl_o,20147856,test,gold,o
3301,The response rates,6,Abstract,ss_o,20147856,test,gold,o
3302,0.606 ) .,6,Abstract,ss_o,20147856,test,gold,o
3303,response rates,6,Abstract,hl_o,20147856,test,gold,o
3304,Median time to treatment failure,7,Abstract,ss_o,20147856,test,gold,o
3305,B .,7,Abstract,ss_o,20147856,test,gold,o
3306,Median time to treatment failure,7,Abstract,hl_o,20147856,test,gold,o
3307,Median time to progression,8,Abstract,ss_o,20147856,test,gold,o
3308,B .,8,Abstract,ss_o,20147856,test,gold,o
3309,Median time to progression,8,Abstract,hl_o,20147856,test,gold,o
3310,Median survival time,9,Abstract,ss_o,20147856,test,gold,o
3311,Median survival time,9,Abstract,hl_o,20147856,test,gold,o
3312,The toxicity profile,10,Abstract,ss_o,20147856,test,gold,o
3313,toxicity profile,10,Abstract,hl_o,20147856,test,gold,o
3314,of gemcitabine and S-1,11,Abstract,ss_i,20147856,test,gold,i
3315,be feasible and effective,11,Abstract,ss_o,20147856,test,gold,o
3316,gemcitabine,11,Abstract,hl_i,20147856,test,gold,i
3317,S-1,11,Abstract,hl_i,20147856,test,gold,i
3318,feasible,11,Abstract,hl_o,20147856,test,gold,o
3319,effective,11,Abstract,hl_o,20147856,test,gold,o
3320,higher response rate and survival data,12,Abstract,ss_o,20147856,test,gold,o
3321,response rate,12,Abstract,hl_o,20147856,test,gold,o
3322,survival data,12,Abstract,hl_o,20147856,test,gold,o
3323,chemo-naïve patients with advanced non-small cell lung cancer,0,Title,ss_p,20147856,test,gold,p
3324,gemcitabine,0,Title,ss_i,20147856,test,gold,i
3325,S-1,0,Title,ss_i,20147856,test,gold,i
3326,chemo-naïve,0,Title,hl_p,20147856,test,gold,p
3327,advanced non-small cell lung cancer,0,Title,hl_p,20147856,test,gold,p
3328,gemcitabine,0,Title,hl_i,20147856,test,gold,i
3329,S-1,0,Title,hl_i,20147856,test,gold,i
3330,Remote ischaemic preconditioning,0,Abstract,ss_i,20189026,test,gold,i
3331,Remote ischaemic preconditioning,0,Abstract,hl_i,20189026,test,gold,i
3332,ST-elevation myocardial infarction,1,Abstract,ss_p,20189026,test,gold,p
3333,remote ischaemic conditioning,1,Abstract,ss_i,20189026,test,gold,i
3334,myocardial salvage .,1,Abstract,ss_o,20189026,test,gold,o
3335,remote ischaemic conditioning,1,Abstract,hl_i,20189026,test,gold,i
3336,myocardial salvage .,1,Abstract,hl_o,20189026,test,gold,o
3337,333 consecutive adult patients with a suspected first acute myocardial infarction,2,Abstract,ss_p,20189026,test,gold,p
3338,remote conditioning,2,Abstract,ss_i,20189026,test,gold,i
3339,333 consecutive adult patients with a suspected first acute myocardial infarction,2,Abstract,hl_p,20189026,test,gold,p
3340,remote conditioning,2,Abstract,hl_i,20189026,test,gold,i
3342,remote conditioning,4,Abstract,ss_i,20189026,test,gold,i
3343,remote conditioning,4,Abstract,hl_i,20189026,test,gold,i
3344,"myocardial salvage index at 30 days after primary percutaneous coronary intervention , measured by myocardial perfusion imaging",5,Abstract,ss_o,20189026,test,gold,o
3345,proportion of the area at risk salvaged by treatment ;,5,Abstract,ss_o,20189026,test,gold,o
3346,myocardial salvage index,5,Abstract,hl_o,20189026,test,gold,o
3347,myocardial perfusion imaging,5,Abstract,hl_o,20189026,test,gold,o
3349,"82 patients were excluded on arrival at hospital because they did not meet inclusion criteria , 32 were lost to follow-up , and 77 did not complete the follow-up",7,Abstract,ss_p,20189026,test,gold,p
3350,salvage index .,7,Abstract,ss_o,20189026,test,gold,o
3351,"82 patients were excluded on arrival at hospital because they did not meet inclusion criteria , 32 were lost to follow-up , and 77 did not complete the follow-up",7,Abstract,hl_p,20189026,test,gold,p
3352,remote conditioning,8,Abstract,ss_i,20189026,test,gold,i
3353,Median salvage index,8,Abstract,ss_o,20189026,test,gold,o
3354,median difference,8,Abstract,ss_o,20189026,test,gold,o
3355,mean salvage index,8,Abstract,ss_o,20189026,test,gold,o
3356,mean difference,8,Abstract,ss_o,20189026,test,gold,o
3357,remote conditioning,8,Abstract,hl_i,20189026,test,gold,i
3358,Median salvage index,8,Abstract,hl_o,20189026,test,gold,o
3359,mean salvage index,8,Abstract,hl_o,20189026,test,gold,o
3360,Major adverse coronary events,9,Abstract,ss_o,20189026,test,gold,o
3361,death,9,Abstract,ss_o,20189026,test,gold,o
3362,reinfarction,9,Abstract,ss_o,20189026,test,gold,o
3363,heart failure,9,Abstract,ss_o,20189026,test,gold,o
3364,Major adverse coronary events,9,Abstract,hl_o,20189026,test,gold,o
3365,death,9,Abstract,hl_o,20189026,test,gold,o
3366,reinfarction,9,Abstract,hl_o,20189026,test,gold,o
3367,heart failure,9,Abstract,hl_o,20189026,test,gold,o
3368,Remote ischaemic conditioning,10,Abstract,ss_i,20189026,test,gold,i
3369,myocardial salvage,10,Abstract,ss_o,20189026,test,gold,o
3370,safety profile .,10,Abstract,ss_o,20189026,test,gold,o
3371,Remote ischaemic conditioning,10,Abstract,hl_i,20189026,test,gold,i
3372,myocardial salvage,10,Abstract,hl_o,20189026,test,gold,o
3373,safety,10,Abstract,hl_o,20189026,test,gold,o
3374,remote conditioning,11,Abstract,ss_i,20189026,test,gold,i
3375,remote conditioning,11,Abstract,hl_i,20189026,test,gold,i
3377,patients with acute myocardial infarction :,0,Title,ss_p,20189026,test,gold,p
3378,Remote ischaemic conditioning,0,Title,ss_i,20189026,test,gold,i
3379,myocardial salvage,0,Title,ss_o,20189026,test,gold,o
3380,patients with acute myocardial infarction :,0,Title,hl_p,20189026,test,gold,p
3381,Remote ischaemic conditioning,0,Title,hl_i,20189026,test,gold,i
3382,myocardial salvage,0,Title,hl_o,20189026,test,gold,o
3384,diagnostic yield .,1,Abstract,ss_o,20226474,test,gold,o
3385,cryoprobe,2,Abstract,ss_i,20226474,test,gold,i
3386,""" cryobiopsies",2,Abstract,ss_i,20226474,test,gold,i
3387,cryoprobe,2,Abstract,hl_i,20226474,test,gold,i
3388,cryobiopsy,3,Abstract,ss_i,20226474,test,gold,i
3389,forceps biopsy .,3,Abstract,ss_i,20226474,test,gold,i
3390,diagnostic yield,3,Abstract,ss_o,20226474,test,gold,o
3391,safety,3,Abstract,ss_o,20226474,test,gold,o
3392,cryobiopsy,3,Abstract,hl_i,20226474,test,gold,i
3393,forceps biopsy .,3,Abstract,hl_i,20226474,test,gold,i
3394,296 patients with visible endoluminal tumor lesions were included,4,Abstract,ss_p,20226474,test,gold,p
3395,bronchoscopy unit of a university hospital .,4,Abstract,ss_p,20226474,test,gold,p
3396,296 patients with visible endoluminal tumor lesions were included,4,Abstract,hl_p,20226474,test,gold,p
3397,bronchoscopy unit of a university hospital .,4,Abstract,hl_p,20226474,test,gold,p
3398,forceps biopsy and cryobiopsy,5,Abstract,ss_i,20226474,test,gold,i
3399,forceps biopsy,5,Abstract,hl_i,20226474,test,gold,i
3400,cryobiopsy,5,Abstract,hl_i,20226474,test,gold,i
3401,Pathologic and quantitative image analyses,6,Abstract,ss_o,20226474,test,gold,o
3402,size and quality of the obtained specimens .,6,Abstract,ss_o,20226474,test,gold,o
3403,cryobiopsy .,7,Abstract,ss_i,20226474,test,gold,i
3404,safety,7,Abstract,ss_o,20226474,test,gold,o
3405,diagnostic yield,7,Abstract,ss_o,20226474,test,gold,o
3406,feasibility,7,Abstract,ss_o,20226474,test,gold,o
3407,cryobiopsy .,7,Abstract,hl_i,20226474,test,gold,i
3408,safety,7,Abstract,hl_o,20226474,test,gold,o
3409,diagnostic yield,7,Abstract,hl_o,20226474,test,gold,o
3410,cryobiopsy,8,Abstract,ss_i,20226474,test,gold,i
3411,forceps biopsy,8,Abstract,ss_i,20226474,test,gold,i
3412,diagnostic yield,8,Abstract,ss_o,20226474,test,gold,o
3413,cryobiopsy,8,Abstract,hl_i,20226474,test,gold,i
3414,forceps biopsy,8,Abstract,hl_i,20226474,test,gold,i
3415,diagnostic yield,8,Abstract,hl_o,20226474,test,gold,o
3416,cryobiopsy,9,Abstract,ss_i,20226474,test,gold,i
3417,forceps biopsy,9,Abstract,ss_i,20226474,test,gold,i
3418,quantitative image analysis,9,Abstract,ss_o,20226474,test,gold,o
3419,size,9,Abstract,ss_o,20226474,test,gold,o
3420,cryobiopsy,9,Abstract,hl_i,20226474,test,gold,i
3421,forceps biopsy,9,Abstract,hl_i,20226474,test,gold,i
3422,size,9,Abstract,hl_o,20226474,test,gold,o
3423,cryobiopsy,10,Abstract,ss_i,20226474,test,gold,i
3424,overall diagnostic yield,10,Abstract,ss_o,20226474,test,gold,o
3425,cryobiopsy,10,Abstract,hl_i,20226474,test,gold,i
3426,diagnostic yield,10,Abstract,hl_o,20226474,test,gold,o
3427,bleeding,11,Abstract,ss_o,20226474,test,gold,o
3428,bleeding,11,Abstract,ss_o,20226474,test,gold,o
3429,bleeding,11,Abstract,ss_o,20226474,test,gold,o
3430,bleeding,11,Abstract,hl_o,20226474,test,gold,o
3431,bleeding,11,Abstract,hl_o,20226474,test,gold,o
3432,bleeding,11,Abstract,hl_o,20226474,test,gold,o
3433,Cryobiopsy,12,Abstract,ss_i,20226474,test,gold,i
3434,safe,12,Abstract,ss_o,20226474,test,gold,o
3435,diagnostic yield,12,Abstract,ss_o,20226474,test,gold,o
3436,Cryobiopsy,12,Abstract,hl_i,20226474,test,gold,i
3437,safe,12,Abstract,hl_o,20226474,test,gold,o
3438,diagnostic yield,12,Abstract,hl_o,20226474,test,gold,o
3439,feasible,13,Abstract,ss_o,20226474,test,gold,o
3440,feasible,13,Abstract,hl_o,20226474,test,gold,o
3441,endobronchial tumor lesions .,0,Title,ss_p,20226474,test,gold,p
3442,Cryoprobe biopsy,0,Title,ss_i,20226474,test,gold,i
3443,diagnostic yield,0,Title,ss_o,20226474,test,gold,o
3444,endobronchial tumor lesions .,0,Title,hl_p,20226474,test,gold,p
3445,Cryoprobe biopsy,0,Title,hl_i,20226474,test,gold,i
3448,21 hospitalized trauma patients,2,Abstract,ss_p,20509069,test,gold,p
3449,virtual reality hypnosis ( VRH ) -hypnotic induction,2,Abstract,ss_i,20509069,test,gold,i
3450,analgesic efficacy,2,Abstract,ss_o,20509069,test,gold,o
3451,analgesic suggestion,2,Abstract,ss_o,20509069,test,gold,o
3452,21 hospitalized trauma patients,2,Abstract,hl_p,20509069,test,gold,p
3453,virtual reality hypnosis ( VRH ) -hypnotic induction,2,Abstract,hl_i,20509069,test,gold,i
3454,VRH,3,Abstract,ss_i,20509069,test,gold,i
3455,VR without hypnosis,3,Abstract,ss_i,20509069,test,gold,i
3456,standard care,3,Abstract,ss_i,20509069,test,gold,i
3457,Subjective pain ratings,3,Abstract,ss_o,20509069,test,gold,o
3458,Subjective pain ratings,3,Abstract,hl_o,20509069,test,gold,o
3459,VRH,4,Abstract,ss_i,20509069,test,gold,i
3460,pain intensity,4,Abstract,ss_o,20509069,test,gold,o
3461,pain unpleasantness,4,Abstract,ss_o,20509069,test,gold,o
3462,pain intensity,4,Abstract,hl_o,20509069,test,gold,o
3463,pain unpleasantness,4,Abstract,hl_o,20509069,test,gold,o
3464,VRH,5,Abstract,ss_i,20509069,test,gold,i
3465,pain management,5,Abstract,ss_o,20509069,test,gold,o
3466,VRH,5,Abstract,hl_i,20509069,test,gold,i
3467,pain management,5,Abstract,hl_o,20509069,test,gold,o
3468,physical trauma .,0,Title,ss_p,20509069,test,gold,p
3469,Virtual reality hypnosis,0,Title,ss_i,20509069,test,gold,i
3470,physical trauma .,0,Title,hl_p,20509069,test,gold,p
3471,Virtual reality hypnosis,0,Title,hl_i,20509069,test,gold,i
3472,male adolescents,0,Abstract,ss_p,20560622,test,gold,p
3473,male adolescents,0,Abstract,hl_p,20560622,test,gold,p
3474,adolescents,1,Abstract,ss_p,20560622,test,gold,p
3475,Maillard reaction products ( MRP ),1,Abstract,ss_i,20560622,test,gold,i
3476,calcium availability,1,Abstract,ss_o,20560622,test,gold,o
3477,adolescents,1,Abstract,hl_p,20560622,test,gold,p
3478,Maillard reaction products ( MRP ),1,Abstract,hl_i,20560622,test,gold,i
3479,calcium availability,1,Abstract,hl_o,20560622,test,gold,o
3480,18 male adolescents,2,Abstract,ss_p,20560622,test,gold,p
3481,white diet ( WD ),2,Abstract,ss_i,20560622,test,gold,i
3482,brown diet ( BD ),2,Abstract,ss_i,20560622,test,gold,i
3483,MRP,2,Abstract,ss_i,20560622,test,gold,i
3484,18 male adolescents,2,Abstract,hl_p,20560622,test,gold,p
3485,white diet ( WD ),2,Abstract,hl_i,20560622,test,gold,i
3486,brown diet ( BD ),2,Abstract,hl_i,20560622,test,gold,i
3487,MRP,2,Abstract,hl_i,20560622,test,gold,i
3488,fasting blood samples,3,Abstract,ss_o,20560622,test,gold,o
3489,fasting blood samples,3,Abstract,hl_o,20560622,test,gold,o
3490,Calcium solubility and absorption across Caco-2 cells,4,Abstract,ss_o,20560622,test,gold,o
3491,Calcium solubility,4,Abstract,hl_o,20560622,test,gold,o
3492,absorption across Caco-2 cells,4,Abstract,hl_o,20560622,test,gold,o
3493,solubility,5,Abstract,ss_o,20560622,test,gold,o
3494,solubility,5,Abstract,hl_o,20560622,test,gold,o
3495,calcium bioavailability,6,Abstract,ss_o,20560622,test,gold,o
3496,calcium bioavailability,6,Abstract,hl_o,20560622,test,gold,o
3497,Serum and urine biochemical parameters related to calcium status and bone metabolism,7,Abstract,ss_o,20560622,test,gold,o
3498,Serum and urine biochemical parameters related to calcium status and bone metabolism,7,Abstract,hl_o,20560622,test,gold,o
3499,deoxypyridinoline,8,Abstract,ss_o,20560622,test,gold,o
3500,bone turnover,8,Abstract,ss_o,20560622,test,gold,o
3501,deoxypyridinoline,8,Abstract,hl_o,20560622,test,gold,o
3502,bone turnover,8,Abstract,hl_o,20560622,test,gold,o
3503,MRP,9,Abstract,ss_i,20560622,test,gold,i
3504,MRP,9,Abstract,hl_i,20560622,test,gold,i
3505,Maillard reaction products,0,Title,ss_i,20560622,test,gold,i
3506,calcium bioavailability .,0,Title,ss_o,20560622,test,gold,o
3507,Maillard reaction products,0,Title,hl_i,20560622,test,gold,i
3508,calcium bioavailability .,0,Title,hl_o,20560622,test,gold,o
3509,efficacy,0,Abstract,ss_o,20618920,test,gold,o
3510,Mediterranean diet,0,Abstract,hl_i,20618920,test,gold,i
3513,Eighty depressed patients undergoing standard antidepressant treatment,3,Abstract,ss_p,20618920,test,gold,p
3514,antidepressant,3,Abstract,ss_i,20618920,test,gold,i
3515,hygienic-dietary recommendations,3,Abstract,ss_i,20618920,test,gold,i
3516,Eighty depressed patients undergoing standard antidepressant treatment,3,Abstract,hl_p,20618920,test,gold,p
3517,hygienic-dietary recommendations,3,Abstract,hl_i,20618920,test,gold,i
3518,Outcome measures,4,Abstract,ss_o,20618920,test,gold,o
3519,depressive symptoms .,5,Abstract,ss_o,20618920,test,gold,o
3520,depressive symptoms .,5,Abstract,hl_o,20618920,test,gold,o
3523,patients with depression :,0,Title,ss_p,20618920,test,gold,p
3524,hygienic-dietary recommendations,0,Title,ss_i,20618920,test,gold,i
3525,Effectiveness,0,Title,ss_o,20618920,test,gold,o
3526,patients with depression :,0,Title,hl_p,20618920,test,gold,p
3527,hygienic-dietary recommendations,0,Title,hl_i,20618920,test,gold,i
3528,Effectiveness,0,Title,hl_o,20618920,test,gold,o
3529,46 upper and lower molars with furcation grade II involvement,0,Abstract,ss_p,2066441,test,gold,p
3530,16 patients with periodontal disease .,0,Abstract,ss_p,2066441,test,gold,p
3531,46 upper and lower molars with furcation grade II involvement,0,Abstract,hl_p,2066441,test,gold,p
3532,16 patients with periodontal disease,0,Abstract,hl_p,2066441,test,gold,p
3533,tetracycline-immobilized cross-linked collagen film ( TC film ),1,Abstract,ss_i,2066441,test,gold,i
3534,root planing treatment ( RP,1,Abstract,ss_i,2066441,test,gold,i
3535,( TC + RP,1,Abstract,ss_i,2066441,test,gold,i
3536,tetracycline-immobilized cross-linked collagen film ( TC film ),1,Abstract,hl_i,2066441,test,gold,i
3537,root planing treatment ( RP,1,Abstract,hl_i,2066441,test,gold,i
3538,TC + RP,1,Abstract,hl_i,2066441,test,gold,i
3539,therapeutic effects,2,Abstract,ss_o,2066441,test,gold,o
3540,"plaque index , gingival index , bleeding on probing , probing depth , probing attachment level and microscopic counts",3,Abstract,ss_o,2066441,test,gold,o
3541,"plaque index , gingival index , bleeding on probing , probing depth , probing attachment level and microscopic counts",3,Abstract,hl_o,2066441,test,gold,o
3542,RP,4,Abstract,ss_i,2066441,test,gold,i
3543,TC + RP,4,Abstract,ss_i,2066441,test,gold,i
3544,probing depth and density of micro-organisms,4,Abstract,ss_o,2066441,test,gold,o
3545,RP,4,Abstract,hl_i,2066441,test,gold,i
3546,TC + RP,4,Abstract,hl_i,2066441,test,gold,i
3547,probing depth and density of micro-organisms,4,Abstract,hl_o,2066441,test,gold,o
3548,TC + RP,5,Abstract,ss_i,2066441,test,gold,i
3549,rate of bleeding on pocket probing,5,Abstract,ss_o,2066441,test,gold,o
3550,probing attachment gain .,5,Abstract,ss_o,2066441,test,gold,o
3551,TC + RP,5,Abstract,hl_i,2066441,test,gold,i
3552,rate of bleeding on pocket probing,5,Abstract,hl_o,2066441,test,gold,o
3553,probing attachment gain .,5,Abstract,hl_o,2066441,test,gold,o
3554,root planning,6,Abstract,ss_i,2066441,test,gold,i
3555,TC films .,6,Abstract,ss_i,2066441,test,gold,i
3556,TC,6,Abstract,hl_i,2066441,test,gold,i
3557,periodontal furcation pockets .,0,Title,ss_p,2066441,test,gold,p
3558,tetracycline-immobilized collagen film and root planing,0,Title,ss_i,2066441,test,gold,i
3559,Therapeutic effects,0,Title,ss_o,2066441,test,gold,o
3560,periodontal furcation pockets .,0,Title,hl_p,2066441,test,gold,p
3561,tetracycline-immobilized collagen film,0,Title,hl_i,2066441,test,gold,i
3562,root planing,0,Title,hl_i,2066441,test,gold,i
3563,Eltrombopag,0,Abstract,ss_i,20739054,test,gold,i
3564,Eltrombopag,0,Abstract,hl_i,20739054,test,gold,i
3565,patients with chronic immune thrombocytopenia,1,Abstract,ss_p,20739054,test,gold,p
3566,eltrombopag,1,Abstract,ss_i,20739054,test,gold,i
3567,placebo,1,Abstract,ss_i,20739054,test,gold,i
3568,response,1,Abstract,ss_o,20739054,test,gold,o
3569,patients with chronic immune thrombocytopenia,1,Abstract,hl_p,20739054,test,gold,p
3570,eltrombopag,1,Abstract,hl_i,20739054,test,gold,i
3571,placebo,1,Abstract,hl_i,20739054,test,gold,i
3572,response,1,Abstract,hl_o,20739054,test,gold,o
3573,"adults with previously treated immune thrombocytopenia of more than 6 months ' duration who had baseline platelet counts lower than 30,000 per μL",2,Abstract,ss_p,20739054,test,gold,p
3574,adults,2,Abstract,hl_p,20739054,test,gold,p
3575,previously treated immune thrombocytopenia of more than 6 months ' duration,2,Abstract,hl_p,20739054,test,gold,p
3576,"baseline platelet counts lower than 30,000 per μL",2,Abstract,hl_p,20739054,test,gold,p
3577,placebo-controlled,2,Abstract,hl_i,20739054,test,gold,i
3578,mg eltrombopag,3,Abstract,ss_i,20739054,test,gold,i
3579,matching placebo,3,Abstract,ss_i,20739054,test,gold,i
3580,eltrombopag,3,Abstract,hl_i,20739054,test,gold,i
3581,placebo,3,Abstract,hl_i,20739054,test,gold,i
3585,response to eltrombopag versus placebo,7,Abstract,ss_i,20739054,test,gold,i
3586,"for response to treatment ( defined as a platelet count of 50,000-400,000 per",7,Abstract,ss_o,20739054,test,gold,o
3587,was the odds of response,7,Abstract,ss_o,20739054,test,gold,o
3588,eltrombopag,7,Abstract,hl_i,20739054,test,gold,i
3589,placebo,7,Abstract,hl_i,20739054,test,gold,i
3590,response to treatment,7,Abstract,hl_o,20739054,test,gold,o
3591,platelet count,7,Abstract,hl_o,20739054,test,gold,o
3594,"FINDINGS Between Nov 22 , 2006 , and July 31 , 2007 , 197 patients",10,Abstract,ss_p,20739054,test,gold,p
3595,"( 135 eltrombopag , 62 placebo )",10,Abstract,ss_i,20739054,test,gold,i
3596,197,10,Abstract,hl_p,20739054,test,gold,p
3597,eltrombopag,10,Abstract,hl_i,20739054,test,gold,i
3598,placebo,10,Abstract,hl_i,20739054,test,gold,i
3599,in the eltrombopag,11,Abstract,ss_i,20739054,test,gold,i
3600,in the placebo,11,Abstract,ss_i,20739054,test,gold,i
3601,group responded,11,Abstract,ss_o,20739054,test,gold,o
3602,.,11,Abstract,ss_o,20739054,test,gold,o
3603,eltrombopag,11,Abstract,hl_i,20739054,test,gold,i
3604,responded to treatment,11,Abstract,hl_o,20739054,test,gold,o
3605,in the eltrombopag,12,Abstract,ss_i,20739054,test,gold,i
3606,in the placebo,12,Abstract,ss_i,20739054,test,gold,i
3607,The odds of responding,12,Abstract,ss_o,20739054,test,gold,o
3608,eltrombopag,12,Abstract,hl_i,20739054,test,gold,i
3609,placebo,12,Abstract,hl_i,20739054,test,gold,i
3610,receiving eltrombopag,13,Abstract,ss_i,20739054,test,gold,i
3611,receiving,13,Abstract,ss_i,20739054,test,gold,i
3612,eltrombopag reduced concomitant treatment,13,Abstract,ss_o,20739054,test,gold,o
3613,eltrombopag,13,Abstract,hl_i,20739054,test,gold,i
3614,receiving eltrombopag,14,Abstract,ss_i,20739054,test,gold,i
3615,receiving,14,Abstract,ss_i,20739054,test,gold,i
3616,eltrombopag needed rescue,14,Abstract,ss_o,20739054,test,gold,o
3617,eltrombopag,14,Abstract,hl_i,20739054,test,gold,i
3618,patients receiving eltrombopag,15,Abstract,ss_i,20739054,test,gold,i
3619,patients,15,Abstract,ss_i,20739054,test,gold,i
3620,.,15,Abstract,ss_i,20739054,test,gold,i
3621,eltrombopag had thromboembolic,15,Abstract,ss_o,20739054,test,gold,o
3622,eltrombopag,15,Abstract,hl_i,20739054,test,gold,i
3623,thromboembolic,15,Abstract,hl_o,20739054,test,gold,o
3624,Nine ( 7 % ) eltrombopag-treated,16,Abstract,ss_i,20739054,test,gold,i
3625,( 3 % ) in the,16,Abstract,ss_i,20739054,test,gold,i
3626,and five ( 4 % ) eltrombopag-treated,16,Abstract,ss_i,20739054,test,gold,i
3627,allocated,16,Abstract,ss_i,20739054,test,gold,i
3628,increases in alanine aminotransferase concentration,16,Abstract,ss_o,20739054,test,gold,o
3629,increases in total,16,Abstract,ss_o,20739054,test,gold,o
3630,eltrombopag-treated,16,Abstract,hl_i,20739054,test,gold,i
3631,eltrombopag-treated,16,Abstract,hl_i,20739054,test,gold,i
3632,patients taking,17,Abstract,ss_i,20739054,test,gold,i
3633,treated with eltrombopag,17,Abstract,ss_i,20739054,test,gold,i
3634,placebo had serious bleeding,17,Abstract,ss_o,20739054,test,gold,o
3635,eltrombopag,17,Abstract,hl_i,20739054,test,gold,i
3636,serious bleeding,17,Abstract,hl_o,20739054,test,gold,o
3637,INTERPRETATION Eltrombopag,18,Abstract,ss_i,20739054,test,gold,i
3638,Eltrombopag is,18,Abstract,ss_o,20739054,test,gold,o
3639,Eltrombopag,18,Abstract,hl_i,20739054,test,gold,i
3640,associated with eltrombopag,19,Abstract,ss_i,20739054,test,gold,i
3641,eltrombopag,19,Abstract,hl_i,20739054,test,gold,i
3643,chronic immune thrombocytopenia,0,Title,ss_p,20739054,test,gold,p
3644,Eltrombopag,0,Title,ss_i,20739054,test,gold,i
3645,chronic immune thrombocytopenia,0,Title,hl_p,20739054,test,gold,p
3646,Eltrombopag,0,Title,hl_i,20739054,test,gold,i
3647,children with autism spectrum disorder .,0,Abstract,ss_p,20804366,test,gold,p
3648,acupuncture,0,Abstract,ss_i,20804366,test,gold,i
3649,sham acupuncture,0,Abstract,ss_i,20804366,test,gold,i
3650,efficacy,0,Abstract,ss_o,20804366,test,gold,o
3651,children,0,Abstract,hl_p,20804366,test,gold,p
3652,autism spectrum disorder,0,Abstract,hl_p,20804366,test,gold,p
3653,acupuncture,0,Abstract,hl_i,20804366,test,gold,i
3654,sham acupuncture,0,Abstract,hl_i,20804366,test,gold,i
3655,efficacy,0,Abstract,hl_o,20804366,test,gold,o
3656,50 children .,1,Abstract,ss_p,20804366,test,gold,p
3657,50 children,1,Abstract,hl_p,20804366,test,gold,p
3658,tongue acupuncture,2,Abstract,ss_i,20804366,test,gold,i
3659,( sham tongue acupuncture,2,Abstract,ss_i,20804366,test,gold,i
3660,tongue acupuncture,2,Abstract,hl_i,20804366,test,gold,i
3661,sham tongue acupuncture,2,Abstract,hl_i,20804366,test,gold,i
3662,"eye-hand coordination , performance , and practical reasoning of Griffiths Mental Developmental Scale ; ( 2 ) sensory-motor , social , affectual , language , and total score of Ritvo-Freeman Real Life Scale ; ( 3 ) Comprehension Language age in the Reynell Language Developmental Scale ; and ( 4 ) Total Score and Mental Age in Symbolic Play Test .",3,Abstract,ss_o,20804366,test,gold,o
3663,"eye-hand coordination , performance , and practical reasoning of Griffiths Mental Developmental Scale",3,Abstract,hl_o,20804366,test,gold,o
3664,"sensory-motor , social , affectual , language , and total score of Ritvo-Freeman Real Life Scale",3,Abstract,hl_o,20804366,test,gold,o
3665,Comprehension Language age in the Reynell Language Developmental Scale,3,Abstract,hl_o,20804366,test,gold,o
3666,Total Score and Mental Age in Symbolic Play Test,3,Abstract,hl_o,20804366,test,gold,o
3667,children .,4,Abstract,ss_p,20804366,test,gold,p
3668,self-care and cognition domains of the Functional Independence Measure for children .,4,Abstract,ss_o,20804366,test,gold,o
3669,self-care and cognition domains of the Functional Independence Measure for children .,4,Abstract,hl_o,20804366,test,gold,o
3670,children with autism .,5,Abstract,ss_p,20804366,test,gold,p
3671,acupuncture,5,Abstract,ss_i,20804366,test,gold,i
3672,efficacy,5,Abstract,ss_o,20804366,test,gold,o
3673,children with autism .,5,Abstract,hl_p,20804366,test,gold,p
3674,acupuncture,5,Abstract,hl_i,20804366,test,gold,i
3675,efficacy,6,Abstract,ss_o,20804366,test,gold,o
3676,autism spectrum disorder .,0,Title,ss_p,20804366,test,gold,p
3677,acupuncture,0,Title,ss_i,20804366,test,gold,i
3678,sham acupuncture,0,Title,ss_i,20804366,test,gold,i
3679,autism spectrum disorder .,0,Title,hl_p,20804366,test,gold,p
3680,acupuncture,0,Title,hl_i,20804366,test,gold,i
3681,sham acupuncture,0,Title,hl_i,20804366,test,gold,i
3682,16 patients with localized juvenile periodontitis .,0,Abstract,ss_p,2088233,test,gold,p
3683,doxycycline,0,Abstract,ss_i,2088233,test,gold,i
3684,immediate clinical and microbiological efficacy,0,Abstract,ss_o,2088233,test,gold,o
3685,16 patients with localized juvenile periodontitis,0,Abstract,hl_p,2088233,test,gold,p
3686,doxycycline,0,Abstract,hl_i,2088233,test,gold,i
3687,immediate clinical and microbiological efficacy,0,Abstract,hl_o,2088233,test,gold,o
3688,"gingival fluid flow , probing depths , bleeding on probing and suppuration",1,Abstract,ss_o,2088233,test,gold,o
3689,radiographic attachment loss,1,Abstract,ss_o,2088233,test,gold,o
3690,"gingival fluid flow , probing depths , bleeding on probing and suppuration",1,Abstract,hl_o,2088233,test,gold,o
3691,Subgingival bacterial samples,2,Abstract,ss_o,2088233,test,gold,o
3692,Subgingival bacterial samples,2,Abstract,hl_o,2088233,test,gold,o
3693,Spirochaetes,3,Abstract,ss_o,2088233,test,gold,o
3694,dark-field microscopy .,3,Abstract,ss_o,2088233,test,gold,o
3695,Spirochaetes,3,Abstract,hl_o,2088233,test,gold,o
3696,dark-field microscopy .,3,Abstract,hl_o,2088233,test,gold,o
3697,"Actinobacillus actinomycetemcomitans , pigmented and non-pigmented Bacteroides spp.",4,Abstract,ss_o,2088233,test,gold,o
3698,"Capnocytophaga , Fusobacterium and Actinomyces spp .",4,Abstract,ss_o,2088233,test,gold,o
3700,Bacterial species,6,Abstract,ss_o,2088233,test,gold,o
3701,patients with localized juvenile periodontitis .,7,Abstract,ss_p,2088233,test,gold,p
3702,doxycycline,7,Abstract,ss_i,2088233,test,gold,i
3703,short-term clinical nor microbiological efficacy,7,Abstract,ss_o,2088233,test,gold,o
3704,patients with localized juvenile periodontitis .,7,Abstract,hl_p,2088233,test,gold,p
3705,doxycycline,7,Abstract,hl_i,2088233,test,gold,i
3706,short-term clinical nor microbiological efficacy,7,Abstract,hl_o,2088233,test,gold,o
3707,localized juvenile periodontitis .,0,Title,ss_p,2088233,test,gold,p
3708,doxycycline,0,Title,ss_i,2088233,test,gold,i
3709,immediate efficacy,0,Title,ss_o,2088233,test,gold,o
3710,localized juvenile periodontitis .,0,Title,hl_p,2088233,test,gold,p
3711,doxycycline,0,Title,hl_i,2088233,test,gold,i
3712,immediate efficacy,0,Title,hl_o,2088233,test,gold,o
3713,visual and kinesthetic locomotor imagery training,0,Abstract,ss_i,20943715,test,gold,i
3714,auditory step rhythm,0,Abstract,ss_i,20943715,test,gold,i
3715,walking performance,0,Abstract,ss_o,20943715,test,gold,o
3716,visual and kinesthetic locomotor imagery training,0,Abstract,hl_i,20943715,test,gold,i
3717,auditory step rhythm,0,Abstract,hl_i,20943715,test,gold,i
3718,walking performance,0,Abstract,hl_o,20943715,test,gold,o
3721,Fifteen subjects with post-stroke hemiparesis .,3,Abstract,ss_p,20943715,test,gold,p
3722,Fifteen subjects with post-stroke hemiparesis,3,Abstract,hl_p,20943715,test,gold,p
3723,locomotor imagery trainings,4,Abstract,ss_i,20943715,test,gold,i
3724,"visual locomotor imagery training , kinesthetic locomotor imagery training , visual locomotor imagery training with auditory step rhythm",4,Abstract,ss_i,20943715,test,gold,i
3725,kinesthetic locomotor imagery training with auditory step rhythm .,4,Abstract,ss_i,20943715,test,gold,i
3726,locomotor imagery trainings,4,Abstract,hl_i,20943715,test,gold,i
3727,visual locomotor imagery training,4,Abstract,hl_i,20943715,test,gold,i
3728,kinesthetic locomotor imagery training,4,Abstract,hl_i,20943715,test,gold,i
3729,visual locomotor imagery training with auditory step rhythm,4,Abstract,hl_i,20943715,test,gold,i
3730,kinesthetic locomotor imagery training with auditory step rhythm,4,Abstract,hl_i,20943715,test,gold,i
3731,The timed up-and-go test and electromyographic and kinematic analyses of the affected lower limb,5,Abstract,ss_o,20943715,test,gold,o
3732,The timed up-and-go test and electromyographic and kinematic analyses of the affected lower limb,5,Abstract,hl_o,20943715,test,gold,o
3733,visual locomotor imagery training,6,Abstract,ss_i,20943715,test,gold,i
3734,the kinesthetic locomotor imagery training with auditory step rhythm,6,Abstract,ss_i,20943715,test,gold,i
3735,timed up-and-go test,6,Abstract,ss_o,20943715,test,gold,o
3736,visual locomotor imagery training,6,Abstract,hl_i,20943715,test,gold,i
3737,kinesthetic locomotor imagery training,6,Abstract,hl_i,20943715,test,gold,i
3738,auditory step rhythm,6,Abstract,hl_i,20943715,test,gold,i
3739,timed up-and-go test,6,Abstract,hl_o,20943715,test,gold,o
3740,the kinesthetic locomotor imagery training,7,Abstract,ss_i,20943715,test,gold,i
3741,the visual locomotor imagery training,7,Abstract,ss_i,20943715,test,gold,i
3742,when auditory step rhythm,7,Abstract,ss_i,20943715,test,gold,i
3743,form of locomotor imagery training,7,Abstract,ss_i,20943715,test,gold,i
3744,greater number of muscles,7,Abstract,ss_o,20943715,test,gold,o
3745,increased angular displacement of the knee and ankle joints,7,Abstract,ss_o,20943715,test,gold,o
3746,kinesthetic locomotor imagery,7,Abstract,hl_i,20943715,test,gold,i
3747,visual locomotor imagery training,7,Abstract,hl_i,20943715,test,gold,i
3748,step rhythm,7,Abstract,hl_i,20943715,test,gold,i
3749,the visual locomotor imagery training,8,Abstract,ss_i,20943715,test,gold,i
3750,the kinesthetic locomotor imagery training with auditory step rhythm,8,Abstract,ss_i,20943715,test,gold,i
3751,well as kinematic data of the knee joint,8,Abstract,ss_o,20943715,test,gold,o
3752,visual locomotor imagery training,8,Abstract,hl_i,20943715,test,gold,i
3753,kinesthetic locomotor imagery training,8,Abstract,hl_i,20943715,test,gold,i
3754,auditory step rhythm,8,Abstract,hl_i,20943715,test,gold,i
3755,the kinesthetic locomotor imagery training,9,Abstract,ss_i,20943715,test,gold,i
3756,the visual locomotor imagery training,9,Abstract,ss_i,20943715,test,gold,i
3757,The therapeutic effect,9,Abstract,ss_o,20943715,test,gold,o
3758,kinesthetic locomotor imagery training,9,Abstract,hl_i,20943715,test,gold,i
3759,visual locomotor imagery training,9,Abstract,hl_i,20943715,test,gold,i
3760,performance of patients with post-stroke hemiparesis,10,Abstract,ss_p,20943715,test,gold,p
3761,The auditory step rhythm,10,Abstract,ss_i,20943715,test,gold,i
3762,the locomotor imagery training,10,Abstract,ss_i,20943715,test,gold,i
3763,the walking performance,10,Abstract,ss_o,20943715,test,gold,o
3764,post-stroke hemiparesis,10,Abstract,hl_p,20943715,test,gold,p
3765,auditory step rhythm,10,Abstract,hl_i,20943715,test,gold,i
3766,locomotor imagery training,10,Abstract,hl_i,20943715,test,gold,i
3767,patients with chronic stroke .,0,Title,ss_p,20943715,test,gold,p
3768,Visual and kinesthetic locomotor imagery training integrated with auditory step rhythm,0,Title,ss_i,20943715,test,gold,i
3769,walking performance,0,Title,ss_o,20943715,test,gold,o
3770,patients with chronic stroke .,0,Title,hl_p,20943715,test,gold,p
3771,Visual and kinesthetic locomotor imagery training,0,Title,hl_i,20943715,test,gold,i
3772,auditory step rhythm,0,Title,hl_i,20943715,test,gold,i
3773,schizophrenics .,0,Abstract,ss_p,21029638,test,gold,p
3774,paliperidone,0,Abstract,ss_i,21029638,test,gold,i
3775,efficacy,0,Abstract,ss_o,21029638,test,gold,o
3776,social functions,0,Abstract,ss_o,21029638,test,gold,o
3777,schizophrenics .,0,Abstract,hl_p,21029638,test,gold,p
3778,paliperidone,0,Abstract,hl_i,21029638,test,gold,i
3779,social functions,0,Abstract,hl_o,21029638,test,gold,o
3780,total of 81 schizophrenics,1,Abstract,ss_p,21029638,test,gold,p
3781,paliperidone,1,Abstract,ss_i,21029638,test,gold,i
3782,risperidone,1,Abstract,ss_i,21029638,test,gold,i
3783,81 schizophrenics,1,Abstract,hl_p,21029638,test,gold,p
3784,paliperidone,1,Abstract,hl_i,21029638,test,gold,i
3785,risperidone,1,Abstract,hl_i,21029638,test,gold,i
3786,"positive and negative symptoms scales ( PANSS ) , social disability screening schedule ( SDSS ) and treatment emergent symptom scale ( TESS )",2,Abstract,ss_o,21029638,test,gold,o
3787,positive and negative symptoms scales ( PANSS ),2,Abstract,hl_o,21029638,test,gold,o
3788,social disability screening schedule ( SDSS ),2,Abstract,hl_o,21029638,test,gold,o
3789,treatment emergent symptom scale ( TESS ),2,Abstract,hl_o,21029638,test,gold,o
3790,factors and total scores of PANSS,3,Abstract,ss_o,21029638,test,gold,o
3791,factors and total scores of PANSS,3,Abstract,hl_o,21029638,test,gold,o
3792,"group , the positive factor , negative factor and total scores of",4,Abstract,ss_o,21029638,test,gold,o
3793,"treatment , the factors and total scores",5,Abstract,ss_o,21029638,test,gold,o
3794,"study group , the",6,Abstract,ss_o,21029638,test,gold,o
3795,"In study group , the",7,Abstract,ss_o,21029638,test,gold,o
3797,weekend of treatment,9,Abstract,ss_o,21029638,test,gold,o
3798,"2.9 ) ( t = -4.49 , P < 0.05 )",9,Abstract,ss_o,21029638,test,gold,o
3799,in either group,10,Abstract,ss_i,21029638,test,gold,i
3800,and psychiatric,11,Abstract,ss_p,21029638,test,gold,p
3801,extended-release tablets are effective,11,Abstract,ss_o,21029638,test,gold,o
3802,improve social functions,11,Abstract,ss_o,21029638,test,gold,o
3803,schizophrenics :,0,Title,ss_p,21029638,test,gold,p
3804,paliperidone,0,Title,ss_i,21029638,test,gold,i
3805,[ Efficacy,0,Title,ss_o,21029638,test,gold,o
3806,social functions,0,Title,ss_o,21029638,test,gold,o
3807,schizophrenics,0,Title,hl_p,21029638,test,gold,p
3808,paliperidone,0,Title,hl_i,21029638,test,gold,i
3809,social functions,0,Title,hl_o,21029638,test,gold,o
3810,depressive symptoms,0,Abstract,ss_o,21106663,test,gold,o
3811,depressive symptoms,0,Abstract,hl_o,21106663,test,gold,o
3812,abstinence and depressive symptom,1,Abstract,ss_o,21106663,test,gold,o
3814,time-varying abstinence and depressive symptom,3,Abstract,ss_o,21106663,test,gold,o
3815,depressive symptom,3,Abstract,hl_o,21106663,test,gold,o
3816,Participants were 236 heavy drinking smokers,4,Abstract,ss_p,21106663,test,gold,p
3817,alcohol intervention,4,Abstract,ss_i,21106663,test,gold,i
3818,efficacy,4,Abstract,ss_o,21106663,test,gold,o
3819,236 heavy drinking smokers,4,Abstract,hl_p,21106663,test,gold,p
3820,alcohol intervention,4,Abstract,hl_i,21106663,test,gold,i
3821,Depressive symptoms and biochemically verified abstinence,5,Abstract,ss_o,21106663,test,gold,o
3822,Depressive symptoms,5,Abstract,hl_o,21106663,test,gold,o
3823,biochemically verified abstinence,5,Abstract,hl_o,21106663,test,gold,o
3824,depressive symptoms,6,Abstract,ss_o,21106663,test,gold,o
3825,depressive symptoms,6,Abstract,hl_o,21106663,test,gold,o
3826,time-varying abstinence ( vs. smoking ),7,Abstract,ss_o,21106663,test,gold,o
3827,level of depressive symptoms,7,Abstract,ss_o,21106663,test,gold,o
3828,depressive symptoms .,7,Abstract,ss_o,21106663,test,gold,o
3829,level of depressive symptoms,7,Abstract,hl_o,21106663,test,gold,o
3830,depressive symptoms .,7,Abstract,hl_o,21106663,test,gold,o
3831,depressive symptoms .,8,Abstract,ss_o,21106663,test,gold,o
3832,depressive symptoms .,8,Abstract,hl_o,21106663,test,gold,o
3833,depressive symptoms .,9,Abstract,ss_o,21106663,test,gold,o
3834,depressive symptoms .,9,Abstract,hl_o,21106663,test,gold,o
3836,depressive symptoms,0,Title,ss_o,21106663,test,gold,o
3837,depressive symptoms,0,Title,hl_o,21106663,test,gold,o
3838,"Beluga , Huso huso ( L. )",0,Abstract,ss_p,21170734,test,gold,p
3839,anesthesia,0,Abstract,ss_i,21170734,test,gold,i
3840,anesthesia,0,Abstract,ss_i,21170734,test,gold,i
3841,anesthesia,0,Abstract,ss_i,21170734,test,gold,i
3842,l⁻¹ clove solution,0,Abstract,ss_i,21170734,test,gold,i
3843,serum parameters,0,Abstract,ss_o,21170734,test,gold,o
3844,respectively .,0,Abstract,ss_o,21170734,test,gold,o
3845,"Beluga , Huso huso ( L. )",0,Abstract,hl_p,21170734,test,gold,p
3846,anesthesia,0,Abstract,hl_i,21170734,test,gold,i
3847,anesthesia,0,Abstract,hl_i,21170734,test,gold,i
3848,Blood samples,1,Abstract,ss_o,21170734,test,gold,o
3849,that cortisol and glucose levels,2,Abstract,ss_o,21170734,test,gold,o
3850,control .,2,Abstract,ss_o,21170734,test,gold,o
3851,Serum lactate levels,3,Abstract,ss_o,21170734,test,gold,o
3852,control group .,3,Abstract,ss_o,21170734,test,gold,o
3853,Lactate,4,Abstract,ss_o,21170734,test,gold,o
3854,"differences in serum levels of cholesterol , total protein , lactate dehydrogenase , aspartate aminotransferase , alanine aminotransferase , Na⁺ , Cl⁻",5,Abstract,ss_o,21170734,test,gold,o
3855,for blood,6,Abstract,ss_p,21170734,test,gold,p
3856,Results suggest that,6,Abstract,ss_i,21170734,test,gold,i
3857,dose is better,6,Abstract,ss_i,21170734,test,gold,i
3858,anesthesia with lower dose,6,Abstract,ss_o,21170734,test,gold,o
3859,"Beluga , Huso huso ( L. )",0,Title,ss_p,21170734,test,gold,p
3860,Serum biochemical characteristics,0,Title,ss_o,21170734,test,gold,o
3861,"Beluga , Huso huso ( L. )",0,Title,hl_p,21170734,test,gold,p
3862,pioglitazone,0,Abstract,ss_i,21211686,test,gold,i
3863,effect,0,Abstract,ss_o,21211686,test,gold,o
3864,atheroma progression .,0,Abstract,ss_o,21211686,test,gold,o
3865,pioglitazone,0,Abstract,hl_i,21211686,test,gold,i
3866,coronary atheroma progression .,1,Abstract,ss_o,21211686,test,gold,o
3867,Pioglitazone,2,Abstract,ss_i,21211686,test,gold,i
3868,glimepiride,2,Abstract,ss_i,21211686,test,gold,i
3869,progression,2,Abstract,ss_o,21211686,test,gold,o
3870,Pioglitazone,2,Abstract,hl_i,21211686,test,gold,i
3871,360 diabetic patients with coronary artery disease,3,Abstract,ss_p,21211686,test,gold,p
3872,pioglitazone,3,Abstract,ss_i,21211686,test,gold,i
3873,glimepiride,3,Abstract,ss_i,21211686,test,gold,i
3874,( Pioglitazone,3,Abstract,ss_i,21211686,test,gold,i
3875,360 diabetic patients with coronary artery disease,3,Abstract,hl_p,21211686,test,gold,p
3876,pioglitazone,3,Abstract,hl_i,21211686,test,gold,i
3877,glimepiride,3,Abstract,hl_i,21211686,test,gold,i
3878,Coronary atheroma progression was evaluated by serial intravascular ultrasound .,4,Abstract,ss_o,21211686,test,gold,o
3879,Coronary atheroma progression,4,Abstract,hl_o,21211686,test,gold,o
3880,"changes in biochemical parameters , percent atheroma volume , and total atheroma volume",5,Abstract,ss_o,21211686,test,gold,o
3881,changes in biochemical parameters,5,Abstract,hl_o,21211686,test,gold,o
3882,percent atheroma volume,5,Abstract,hl_o,21211686,test,gold,o
3883,total atheroma volume,5,Abstract,hl_o,21211686,test,gold,o
3884,Pioglitazone-treated,6,Abstract,ss_i,21211686,test,gold,i
3885,high-density lipoprotein cholesterol ( HDL-C ),6,Abstract,ss_o,21211686,test,gold,o
3886,"glycated hemoglobin , triglycerides , and C-reactive protein .",6,Abstract,ss_o,21211686,test,gold,o
3887,Pioglitazone-treated,6,Abstract,hl_i,21211686,test,gold,i
3888,high-density lipoprotein cholesterol ( HDL-C ),6,Abstract,hl_o,21211686,test,gold,o
3889,glycated hemoglobin,6,Abstract,hl_o,21211686,test,gold,o
3890,triglycerides,6,Abstract,hl_o,21211686,test,gold,o
3891,C-reactive protein,6,Abstract,hl_o,21211686,test,gold,o
3892,pioglitazone,7,Abstract,ss_i,21211686,test,gold,i
3893,glimepiride .,7,Abstract,ss_i,21211686,test,gold,i
3894,percent atheroma volume and triglycerides,7,Abstract,ss_o,21211686,test,gold,o
3895,triglyceride/HDL-C ratio,7,Abstract,ss_o,21211686,test,gold,o
3896,glycated hemoglobin,7,Abstract,ss_o,21211686,test,gold,o
3897,low-density lipoprotein cholesterol,7,Abstract,ss_o,21211686,test,gold,o
3898,apolipoprotein B,7,Abstract,ss_o,21211686,test,gold,o
3899,apolipoprotein A-I,7,Abstract,ss_o,21211686,test,gold,o
3900,pioglitazone,7,Abstract,hl_i,21211686,test,gold,i
3901,glimepiride .,7,Abstract,hl_i,21211686,test,gold,i
3902,percent atheroma volume and triglycerides,7,Abstract,hl_o,21211686,test,gold,o
3903,triglyceride/HDL-C ratio,7,Abstract,hl_o,21211686,test,gold,o
3904,glycated hemoglobin,7,Abstract,hl_o,21211686,test,gold,o
3905,low-density lipoprotein cholesterol,7,Abstract,hl_o,21211686,test,gold,o
3906,apolipoprotein B,7,Abstract,hl_o,21211686,test,gold,o
3907,apolipoprotein A-I,7,Abstract,hl_o,21211686,test,gold,o
3908,Substantial atheroma regression,8,Abstract,ss_o,21211686,test,gold,o
3909,progression,8,Abstract,ss_o,21211686,test,gold,o
3910,HDL-C,8,Abstract,ss_o,21211686,test,gold,o
3911,triglycerides,8,Abstract,ss_o,21211686,test,gold,o
3912,triglyceride/HDL-C ratio,8,Abstract,ss_o,21211686,test,gold,o
3913,glycated hemoglobin,8,Abstract,ss_o,21211686,test,gold,o
3914,HDL-C,8,Abstract,hl_o,21211686,test,gold,o
3915,triglycerides,8,Abstract,hl_o,21211686,test,gold,o
3916,triglyceride/HDL-C ratio,8,Abstract,hl_o,21211686,test,gold,o
3917,glycated hemoglobin,8,Abstract,hl_o,21211686,test,gold,o
3918,pioglitazone-induced,9,Abstract,ss_i,21211686,test,gold,i
3919,triglyceride/HDL-C,9,Abstract,ss_o,21211686,test,gold,o
3920,percent atheroma volume,9,Abstract,ss_o,21211686,test,gold,o
3921,total atheroma volume,9,Abstract,ss_o,21211686,test,gold,o
3922,pioglitazone-induced,9,Abstract,hl_i,21211686,test,gold,i
3923,triglyceride/HDL-C,9,Abstract,hl_o,21211686,test,gold,o
3924,percent atheroma volume,9,Abstract,hl_o,21211686,test,gold,o
3925,total atheroma volume,9,Abstract,hl_o,21211686,test,gold,o
3926,diabetic patients .,10,Abstract,ss_p,21211686,test,gold,p
3927,pioglitazone,10,Abstract,ss_i,21211686,test,gold,i
3928,triglyceride/HDL-C ratio,10,Abstract,ss_o,21211686,test,gold,o
3929,atheroma progression,10,Abstract,ss_o,21211686,test,gold,o
3930,diabetic patients .,10,Abstract,hl_p,21211686,test,gold,p
3931,pioglitazone,10,Abstract,hl_i,21211686,test,gold,i
3932,triglyceride/HDL-C ratio,10,Abstract,hl_o,21211686,test,gold,o
3933,atheroma progression,10,Abstract,hl_o,21211686,test,gold,o
3934,diabetic patients with coronary artery disease .,11,Abstract,ss_p,21211686,test,gold,p
3935,diabetic patients with coronary artery disease .,11,Abstract,hl_p,21211686,test,gold,p
3936,diabetic patients :,0,Title,ss_p,21211686,test,gold,p
3937,pioglitazone,0,Title,ss_i,21211686,test,gold,i
3938,( Pioglitazone,0,Title,ss_i,21211686,test,gold,i
3939,triglyceride/high-density lipoprotein cholesterol ratio,0,Title,ss_o,21211686,test,gold,o
3940,progression of coronary atherosclerosis,0,Title,ss_o,21211686,test,gold,o
3941,diabetic patients,0,Title,hl_p,21211686,test,gold,p
3942,pioglitazone,0,Title,hl_i,21211686,test,gold,i
3943,triglyceride/high-density lipoprotein cholesterol ratio,0,Title,hl_o,21211686,test,gold,o
3944,coronary atherosclerosis,0,Title,hl_o,21211686,test,gold,o
3945,step frequency,0,Abstract,ss_o,21393467,test,gold,o
3949,perturbations to treadmill walking,4,Abstract,ss_i,21393467,test,gold,i
3950,perturbations to treadmill walking,4,Abstract,hl_i,21393467,test,gold,i
3951,human step frequency adjustments,5,Abstract,ss_o,21393467,test,gold,o
3952,quite quickly,5,Abstract,ss_o,21393467,test,gold,o
3953,human step frequency adjustments,5,Abstract,hl_o,21393467,test,gold,o
3954,smaller amplitude,6,Abstract,ss_o,21393467,test,gold,o
3955,tens of seconds,6,Abstract,ss_o,21393467,test,gold,o
3959,preferred step frequency,10,Abstract,ss_o,21393467,test,gold,o
3960,human,0,Title,ss_p,21393467,test,gold,p
3961,human,0,Title,hl_p,21393467,test,gold,p
3962,chlorhexidine ( CHX ),0,Abstract,ss_i,21491990,test,gold,i
3963,"clinical , microbiologic , and serologic effects",0,Abstract,ss_o,21491990,test,gold,o
3964,chlorhexidine ( CHX ),0,Abstract,hl_i,21491990,test,gold,i
3965,clinical,0,Abstract,hl_o,21491990,test,gold,o
3966,microbiologic,0,Abstract,hl_o,21491990,test,gold,o
3967,serologic effects,0,Abstract,hl_o,21491990,test,gold,o
3968,Twenty-four patients presenting with ≥12 teeth with probing depth ( PD ) ≥5 mm and bleeding on probing,1,Abstract,ss_p,21491990,test,gold,p
3969,Twenty-four patients,1,Abstract,hl_p,21491990,test,gold,p
3970,"prophylaxis , CHX chips ( test ) or placebo",2,Abstract,ss_i,21491990,test,gold,i
3971,placebo,2,Abstract,hl_i,21491990,test,gold,i
3973,PD ≥5 mm .,4,Abstract,ss_o,21491990,test,gold,o
3974,Parameters,5,Abstract,ss_o,21491990,test,gold,o
3975,treatment .,5,Abstract,ss_o,21491990,test,gold,o
3976,Subgingival,6,Abstract,ss_o,21491990,test,gold,o
3977,treatment .,6,Abstract,ss_o,21491990,test,gold,o
3978,"Periodontal pathogens Aggregatibacter actinomycetemcomitans , Porphyromonas gingivalis , Prevotella intermedia , Tannerella forsythia , and Treponema",7,Abstract,ss_o,21491990,test,gold,o
3979,analyzed .,7,Abstract,ss_o,21491990,test,gold,o
3980,Serum levels of high sensitive C-reactive and lipopolysaccharide-binding,8,Abstract,ss_o,21491990,test,gold,o
3981,changes of the parameters,9,Abstract,ss_o,21491990,test,gold,o
3982,tested by Mann-Whitney,9,Abstract,ss_o,21491990,test,gold,o
3983,RESULTS All clinical and serologic parameters,10,Abstract,ss_o,21491990,test,gold,o
3984,difference in clinical attachment level,11,Abstract,ss_o,21491990,test,gold,o
3985,clinical attachment level ( CAL ),11,Abstract,hl_o,21491990,test,gold,o
3986,treatment with,12,Abstract,ss_i,21491990,test,gold,i
3987,"a greater reduction of the microorganisms of the "" red",12,Abstract,ss_o,21491990,test,gold,o
3988,"reduction of the microorganisms of the "" red",12,Abstract,hl_o,21491990,test,gold,o
3989,treatment of chronic periodontitis,13,Abstract,ss_p,21491990,test,gold,p
3990,The use of,13,Abstract,ss_i,21491990,test,gold,i
3991,SRP improved,13,Abstract,ss_o,21491990,test,gold,o
3992,reduced the subgingival microorganisms of the red,13,Abstract,ss_o,21491990,test,gold,o
3993,subgingival microorganisms of the red,13,Abstract,hl_o,21491990,test,gold,o
3994,chronic periodontitis :,0,Title,ss_p,21491990,test,gold,p
3995,chlorhexidine,0,Title,ss_i,21491990,test,gold,i
3996,chronic periodontitis :,0,Title,hl_p,21491990,test,gold,p
3997,chlorhexidine,0,Title,hl_i,21491990,test,gold,i
3999,chimney woodstove,1,Abstract,ss_i,21669557,test,gold,i
4000,chimney woodstove,1,Abstract,hl_i,21669557,test,gold,i
4001,stove intervention,2,Abstract,ss_i,21669557,test,gold,i
4002,open fire,2,Abstract,ss_i,21669557,test,gold,i
4003,ST-segment depression,2,Abstract,ss_o,21669557,test,gold,o
4004,heart rate variability ( HRV ) .,2,Abstract,ss_o,21669557,test,gold,o
4005,stove intervention,2,Abstract,hl_i,21669557,test,gold,i
4006,open fire,2,Abstract,hl_i,21669557,test,gold,i
4007,ST-segment depression,2,Abstract,hl_o,21669557,test,gold,o
4008,heart rate variability ( HRV ) .,2,Abstract,hl_o,21669557,test,gold,o
4009,stove,3,Abstract,ss_i,21669557,test,gold,i
4010,open fires,3,Abstract,ss_i,21669557,test,gold,i
4011,chimney stoves,3,Abstract,ss_i,21669557,test,gold,i
4012,stove,3,Abstract,hl_i,21669557,test,gold,i
4013,open fires,3,Abstract,hl_i,21669557,test,gold,i
4014,chimney stoves,3,Abstract,hl_i,21669557,test,gold,i
4015,"49 intervention and 70 control women 38-84 years of age , and 55 control subjects were also assessed after receiving stoves .",4,Abstract,ss_p,21669557,test,gold,p
4016,stoves .,4,Abstract,ss_i,21669557,test,gold,i
4017,Electrocardiogram sessions,4,Abstract,ss_o,21669557,test,gold,o
4018,49,4,Abstract,hl_p,21669557,test,gold,p
4019,70,4,Abstract,hl_p,21669557,test,gold,p
4020,38-84 years of age,4,Abstract,hl_p,21669557,test,gold,p
4021,55,4,Abstract,hl_p,21669557,test,gold,p
4022,stoves .,4,Abstract,hl_i,21669557,test,gold,i
4023,HRV and ST-segment values,5,Abstract,ss_o,21669557,test,gold,o
4024,HRV and ST-segment values,5,Abstract,hl_o,21669557,test,gold,o
4025,ST-segment depression was defined as an average value below -1.00 mm .,6,Abstract,ss_o,21669557,test,gold,o
4026,ST-segment depression,6,Abstract,hl_o,21669557,test,gold,o
4027,Personal fine PM [ aerodynamic diameter ≤ 2.5 μm ( PM₂.₅ ] exposures,7,Abstract,ss_o,21669557,test,gold,o
4028,before each electrocardiogram,7,Abstract,ss_o,21669557,test,gold,o
4029,RESULTS PM₂.₅,8,Abstract,ss_o,21669557,test,gold,o
4030,"the trial , the stove",9,Abstract,ss_i,21669557,test,gold,i
4031,0.08-0.90 ) for ST-segment,9,Abstract,ss_o,21669557,test,gold,o
4033,associated,11,Abstract,ss_o,21669557,test,gold,o
4034,CONCLUSIONS The stove,12,Abstract,ss_i,21669557,test,gold,i
4035,of nonspecific ST-segment,12,Abstract,ss_o,21669557,test,gold,o
4036,Guatemala,0,Title,ss_p,21669557,test,gold,p
4037,ST-segment depression,0,Title,ss_o,21669557,test,gold,o
4038,ST-segment depression,0,Title,hl_o,21669557,test,gold,o
4039,with type 1 diabetes ( T1D ),0,Abstract,ss_p,21718094,test,gold,p
4040,starting insulin pump,0,Abstract,ss_i,21718094,test,gold,i
4041,daily insulin,0,Abstract,ss_i,21718094,test,gold,i
4042,the efficacy,0,Abstract,ss_o,21718094,test,gold,o
4043,type 1 diabetes ( T1D ),0,Abstract,hl_p,21718094,test,gold,p
4044,"in 24 patients , 8-18 years old , with newly diagnosed T1D",1,Abstract,ss_p,21718094,test,gold,p
4045,comparing MDI,1,Abstract,ss_i,21718094,test,gold,i
4046,subcutaneous insulin therapy ( pump therapy ),1,Abstract,ss_i,21718094,test,gold,i
4047,24,1,Abstract,hl_p,21718094,test,gold,p
4048,8-18 years old,1,Abstract,hl_p,21718094,test,gold,p
4049,newly diagnosed T1D,1,Abstract,hl_p,21718094,test,gold,p
4050,insulin therapy ( pump therapy ),1,Abstract,hl_i,21718094,test,gold,i
4051,.,2,Abstract,ss_o,21718094,test,gold,o
4052,"Preservation of insulin secretion , measured by mixed-meal-stimulated C-peptide secretion",3,Abstract,ss_o,21718094,test,gold,o
4053,Preservation of insulin secretion,3,Abstract,hl_o,21718094,test,gold,o
4054,by mixed-meal-stimulated C-peptide secretion,3,Abstract,hl_o,21718094,test,gold,o
4055,"in glycosylated hemoglobin ( HbA1c ) , continuous glucose sensor data , insulin utilization , anthropometric measures , and patient satisfaction with therapy",4,Abstract,ss_o,21718094,test,gold,o
4056,"glycosylated hemoglobin ( HbA1c ) , continuous glucose sensor data , insulin utilization , anthropometric measures , and patient satisfaction",4,Abstract,hl_o,21718094,test,gold,o
4057,of pump therapy,5,Abstract,ss_i,21718094,test,gold,i
4058,higher mixed-meal tolerance test-stimulated C-peptide values,5,Abstract,ss_o,21718094,test,gold,o
4059,mixed-meal tolerance,5,Abstract,hl_o,21718094,test,gold,o
4060,C-peptide values,5,Abstract,hl_o,21718094,test,gold,o
4061,in insulin,6,Abstract,ss_i,21718094,test,gold,i
4062,improved glycemic control,6,Abstract,ss_o,21718094,test,gold,o
4063,mean HbA1c ),6,Abstract,ss_o,21718094,test,gold,o
4064,greater satisfaction,6,Abstract,ss_o,21718094,test,gold,o
4065,glycemic control,6,Abstract,hl_o,21718094,test,gold,o
4066,of insulin pump therapy,7,Abstract,ss_i,21718094,test,gold,i
4067,improved glycemic control,7,Abstract,ss_o,21718094,test,gold,o
4068,improved patient satisfaction,7,Abstract,ss_o,21718094,test,gold,o
4069,insulin pump therapy,7,Abstract,hl_i,21718094,test,gold,i
4070,glycemic control,7,Abstract,hl_o,21718094,test,gold,o
4071,preserve residual β-cell function,8,Abstract,ss_o,21718094,test,gold,o
4072,in type 1 diabetes,0,Title,ss_p,21718094,test,gold,p
4073,Insulin pump,0,Title,ss_i,21718094,test,gold,i
4074,glycemic control and pancreatic β-cell function,0,Title,ss_o,21718094,test,gold,o
4075,type 1 diabetes,0,Title,hl_p,21718094,test,gold,p
4076,Insulin pump,0,Title,hl_i,21718094,test,gold,i
4077,glycemic control,0,Title,hl_o,21718094,test,gold,o
4078,pancreatic β-cell function,0,Title,hl_o,21718094,test,gold,o
4079,endometriosis ( EMs ) -related infertility patients .,0,Abstract,ss_p,21866656,test,gold,p
4080,laparoscopic surgery,0,Abstract,ss_i,21866656,test,gold,i
4081,Quyu Jiedu Recipe ( QYJDR ),0,Abstract,ss_i,21866656,test,gold,i
4082,clinical efficacy,0,Abstract,ss_o,21866656,test,gold,o
4083,endometriosis ( EMs ) -related infertility patients .,0,Abstract,hl_p,21866656,test,gold,p
4084,laparoscopic surgery,0,Abstract,hl_i,21866656,test,gold,i
4085,Quyu Jiedu Recipe ( QYJDR ),0,Abstract,hl_i,21866656,test,gold,i
4086,clinical efficacy,0,Abstract,hl_o,21866656,test,gold,o
4087,130 EMs-related infertility patients of blood stasis and toxin accumulation syndrome diagnosed and treated by laparoscopic surgery,1,Abstract,ss_p,21866656,test,gold,p
4088,130 EMs-related infertility patients,1,Abstract,hl_p,21866656,test,gold,p
4089,blood stasis and toxin accumulation syndrome diagnosed and treated by laparoscopic surgery,1,Abstract,hl_p,21866656,test,gold,p
4090,progesterone,2,Abstract,ss_i,21866656,test,gold,i
4091,progesterone,2,Abstract,hl_i,21866656,test,gold,i
4092,QYJDR,3,Abstract,ss_i,21866656,test,gold,i
4093,QYJDR,3,Abstract,hl_i,21866656,test,gold,i
4094,laparoscopic surgery,3,Abstract,hl_i,21866656,test,gold,i
4095,pregnancy rate within one year after laparoscopic surgery,4,Abstract,ss_o,21866656,test,gold,o
4096,pregnancy rate,4,Abstract,hl_o,21866656,test,gold,o
4097,"Chinese medicine syndrome integrals , serum endometrium antibody ( EMAb ) and cancer antigen 125 ( CA125 ) levels",5,Abstract,ss_o,21866656,test,gold,o
4098,"Chinese medicine syndrome integrals , serum endometrium antibody ( EMAb ) and cancer antigen 125 ( CA125 ) levels",5,Abstract,hl_o,21866656,test,gold,o
4099,pregnancy rate,6,Abstract,ss_o,21866656,test,gold,o
4100,pregnancy rate,6,Abstract,hl_o,21866656,test,gold,o
4101,Chinese medicine syndrome integral,7,Abstract,ss_o,21866656,test,gold,o
4102,Chinese medicine syndrome integral,7,Abstract,hl_o,21866656,test,gold,o
4103,Chinese medicine syndrome integral,8,Abstract,ss_o,21866656,test,gold,o
4104,Chinese medicine syndrome integral,8,Abstract,hl_o,21866656,test,gold,o
4105,integral,9,Abstract,ss_o,21866656,test,gold,o
4106,serum EMAb,10,Abstract,ss_o,21866656,test,gold,o
4107,serum EMAb,10,Abstract,hl_o,21866656,test,gold,o
4108,serum CA125 level,11,Abstract,ss_o,21866656,test,gold,o
4109,serum CA125 level,11,Abstract,hl_o,21866656,test,gold,o
4112,EMs patients of blood stasis and toxin accumulation syndrome,14,Abstract,ss_p,21866656,test,gold,p
4113,laparoscopic surgery,14,Abstract,ss_i,21866656,test,gold,i
4114,QYJDR,14,Abstract,ss_i,21866656,test,gold,i
4115,clinical symptoms,14,Abstract,ss_o,21866656,test,gold,o
4116,blood stasis and toxin accumulation syndrome,14,Abstract,ss_o,21866656,test,gold,o
4117,negative conversion of EMAb,14,Abstract,ss_o,21866656,test,gold,o
4118,serum CA125 levels,14,Abstract,ss_o,21866656,test,gold,o
4119,clinical pregnancy rate .,14,Abstract,ss_o,21866656,test,gold,o
4120,laparoscopic surgery,14,Abstract,hl_i,21866656,test,gold,i
4121,QYJDR,14,Abstract,hl_i,21866656,test,gold,i
4122,blood stasis,14,Abstract,hl_o,21866656,test,gold,o
4123,toxin accumulation syndrome,14,Abstract,hl_o,21866656,test,gold,o
4124,negative conversion of EMAb,14,Abstract,hl_o,21866656,test,gold,o
4125,serum CA125 levels,14,Abstract,hl_o,21866656,test,gold,o
4126,clinical pregnancy rate .,14,Abstract,hl_o,21866656,test,gold,o
4127,EMs-related infertility .,15,Abstract,ss_p,21866656,test,gold,p
4128,QYJDR,15,Abstract,ss_i,21866656,test,gold,i
4129,QYJDR,15,Abstract,hl_i,21866656,test,gold,i
4130,endometriosis-related infertility patients,0,Title,ss_p,21866656,test,gold,p
4131,laparoscopic surgery,0,Title,ss_i,21866656,test,gold,i
4132,quyu jiedu recipe ],0,Title,ss_i,21866656,test,gold,i
4133,endometriosis-related infertility patients,0,Title,hl_p,21866656,test,gold,p
4134,laparoscopic surgery,0,Title,hl_i,21866656,test,gold,i
4135,quyu jiedu recipe ],0,Title,hl_i,21866656,test,gold,i
4136,patients with moderate to severe congestive heart failure .,0,Abstract,ss_p,2188766,test,gold,p
4137,flosequinan,0,Abstract,ss_i,2188766,test,gold,i
4138,long-term effect,0,Abstract,ss_o,2188766,test,gold,o
4139,clinical course,0,Abstract,ss_o,2188766,test,gold,o
4140,patients with moderate to severe congestive heart failure .,0,Abstract,hl_p,2188766,test,gold,p
4141,flosequinan,0,Abstract,hl_i,2188766,test,gold,i
4142,long-term effect,0,Abstract,hl_o,2188766,test,gold,o
4143,Seventeen patients on chronic digitalis and diuretic therapy,1,Abstract,ss_p,2188766,test,gold,p
4144,flosequinan,1,Abstract,ss_i,2188766,test,gold,i
4145,placebo,1,Abstract,ss_i,2188766,test,gold,i
4146,Seventeen patients on chronic digitalis and diuretic therapy,1,Abstract,hl_p,2188766,test,gold,p
4147,flosequinan,1,Abstract,hl_i,2188766,test,gold,i
4148,placebo,1,Abstract,hl_i,2188766,test,gold,i
4149,"Changes in symptomatology , exercise performance , and left ventricular function",2,Abstract,ss_o,2188766,test,gold,o
4150,symptomatology,2,Abstract,hl_o,2188766,test,gold,o
4151,exercise performance,2,Abstract,hl_o,2188766,test,gold,o
4152,left ventricular function,2,Abstract,hl_o,2188766,test,gold,o
4153,flosequinan-treated,3,Abstract,ss_i,2188766,test,gold,i
4154,symptom scores and functional classification,3,Abstract,ss_o,2188766,test,gold,o
4155,symptom scores,3,Abstract,hl_o,2188766,test,gold,o
4156,functional classification,3,Abstract,hl_o,2188766,test,gold,o
4157,Flosequinan,4,Abstract,ss_i,2188766,test,gold,i
4158,maximal exercise capacity .,4,Abstract,ss_o,2188766,test,gold,o
4159,Flosequinan,4,Abstract,hl_i,2188766,test,gold,i
4160,maximal exercise capacity .,4,Abstract,hl_o,2188766,test,gold,o
4161,flosequinan,5,Abstract,ss_i,2188766,test,gold,i
4162,resting heart rate,5,Abstract,ss_o,2188766,test,gold,o
4163,left ventricular systolic function .,5,Abstract,ss_o,2188766,test,gold,o
4164,flosequinan,5,Abstract,hl_i,2188766,test,gold,i
4165,resting heart rate,5,Abstract,hl_o,2188766,test,gold,o
4166,left ventricular systolic function .,5,Abstract,hl_o,2188766,test,gold,o
4167,patients with moderate to severe chronic heart failure .,6,Abstract,ss_p,2188766,test,gold,p
4168,flosequinan,6,Abstract,ss_i,2188766,test,gold,i
4169,patients with moderate to severe chronic heart failure .,6,Abstract,hl_p,2188766,test,gold,p
4170,flosequinan,6,Abstract,hl_i,2188766,test,gold,i
4172,congestive heart failure .,0,Title,ss_p,2188766,test,gold,p
4173,flosequinan,0,Title,ss_i,2188766,test,gold,i
4174,congestive heart failure .,0,Title,hl_p,2188766,test,gold,p
4175,flosequinan,0,Title,hl_i,2188766,test,gold,i
4176,physiotherapy,0,Abstract,ss_i,21896676,test,gold,i
4177,physiotherapy,0,Abstract,hl_i,21896676,test,gold,i
4178,physiotherapy service,1,Abstract,ss_i,21896676,test,gold,i
4179,"rate of hospital admission , rate of re-presentation to the ED , visits to community healthcare practitioners , return to usual work/home/leisure activities and patient satisfaction .",1,Abstract,ss_o,21896676,test,gold,o
4180,physiotherapy service,1,Abstract,hl_i,21896676,test,gold,i
4181,rate of hospital admission,1,Abstract,hl_o,21896676,test,gold,o
4182,rate of re-presentation to the ED,1,Abstract,hl_o,21896676,test,gold,o
4183,visits to community healthcare practitioners,1,Abstract,hl_o,21896676,test,gold,o
4184,return to usual work/home/leisure activities,1,Abstract,hl_o,21896676,test,gold,o
4185,patient satisfaction,1,Abstract,hl_o,21896676,test,gold,o
4187,"The sample comprised 186 patients ( mean age 70 years , 123 ( 66 % ) female patients , 130 ( 70 % ) trauma ) who were referred for physiotherapy assessment/intervention .",3,Abstract,ss_p,21896676,test,gold,p
4188,physiotherapy assessment/intervention .,3,Abstract,ss_i,21896676,test,gold,i
4189,186,3,Abstract,hl_p,21896676,test,gold,p
4190,mean age 70 years,3,Abstract,hl_p,21896676,test,gold,p
4191,123,3,Abstract,hl_p,21896676,test,gold,p
4192,female,3,Abstract,hl_p,21896676,test,gold,p
4193,130,3,Abstract,hl_p,21896676,test,gold,p
4194,trauma,3,Abstract,hl_p,21896676,test,gold,p
4195,referred for physiotherapy assessment/intervention,3,Abstract,hl_p,21896676,test,gold,p
4196,physiotherapy assessment/intervention,3,Abstract,hl_i,21896676,test,gold,i
4199,physiotherapy,6,Abstract,ss_i,21896676,test,gold,i
4200,physiotherapy assessment/intervention .,6,Abstract,ss_i,21896676,test,gold,i
4201,physiotherapy,6,Abstract,hl_i,21896676,test,gold,i
4202,physiotherapy assessment/intervention,6,Abstract,hl_i,21896676,test,gold,i
4203,physiotherapy,7,Abstract,ss_i,21896676,test,gold,i
4204,rate of admission to hospital,7,Abstract,ss_o,21896676,test,gold,o
4205,rate of re-presentation to the ED,7,Abstract,ss_o,21896676,test,gold,o
4206,physiotherapy,7,Abstract,hl_i,21896676,test,gold,i
4207,rate of admission to hospital,7,Abstract,hl_o,21896676,test,gold,o
4208,rate of re-presentation to the ED,7,Abstract,hl_o,21896676,test,gold,o
4209,"for use of community healthcare resources , return to usual work/home/leisure activities and satisfaction with their EECU care",8,Abstract,ss_o,21896676,test,gold,o
4210,A physiotherapy service,9,Abstract,ss_i,21896676,test,gold,i
4211,"the rate of hospital admission , rate of re-presentation to the ED , use of community healthcare resources",9,Abstract,ss_o,21896676,test,gold,o
4212,the rate of return to usual work/home/leisure activities or patient satisfaction,9,Abstract,ss_o,21896676,test,gold,o
4213,physiotherapy,9,Abstract,hl_i,21896676,test,gold,i
4215,physiotherapy service,0,Title,ss_i,21896676,test,gold,i
4216,admission rates to hospital :,0,Title,ss_o,21896676,test,gold,o
4217,physiotherapy service,0,Title,hl_i,21896676,test,gold,i
4218,admission rates to hospital :,0,Title,hl_o,21896676,test,gold,o
4219,public education about testicular cancer ( TC ),0,Abstract,ss_i,21914768,test,gold,i
4220,anxiety .,0,Abstract,ss_o,21914768,test,gold,o
4221,"threat control strategies ( eg , testicular self-examination ; TSE )",1,Abstract,ss_i,21914768,test,gold,i
4222,anxiety,1,Abstract,ss_o,21914768,test,gold,o
4223,testicular self-examination ;,1,Abstract,hl_i,21914768,test,gold,i
4224,Male students ( N=443 ),2,Abstract,ss_p,21914768,test,gold,p
4225,TC,2,Abstract,ss_i,21914768,test,gold,i
4226,TC +TSE,2,Abstract,ss_i,21914768,test,gold,i
4227,Male students,2,Abstract,hl_p,21914768,test,gold,p
4228,N=443,2,Abstract,hl_p,21914768,test,gold,p
4229,TC,2,Abstract,hl_i,21914768,test,gold,i
4230,TC +TSE,2,Abstract,hl_i,21914768,test,gold,i
4231,TC+TSE,3,Abstract,ss_i,21914768,test,gold,i
4232,Anxiety levels,3,Abstract,ss_o,21914768,test,gold,o
4233,perceived message benefit,3,Abstract,ss_o,21914768,test,gold,o
4234,intention to self-examine,3,Abstract,ss_o,21914768,test,gold,o
4235,message denigration .,3,Abstract,ss_o,21914768,test,gold,o
4236,Anxiety levels,3,Abstract,hl_o,21914768,test,gold,o
4237,perceived message benefit,3,Abstract,hl_o,21914768,test,gold,o
4238,intention to self-examine,3,Abstract,hl_o,21914768,test,gold,o
4239,message denigration .,3,Abstract,hl_o,21914768,test,gold,o
4240,TC,4,Abstract,ss_i,21914768,test,gold,i
4241,TSE,4,Abstract,ss_i,21914768,test,gold,i
4242,anxiogenic,4,Abstract,ss_o,21914768,test,gold,o
4243,acceptance of disease awareness information .,4,Abstract,ss_o,21914768,test,gold,o
4244,TC,4,Abstract,hl_i,21914768,test,gold,i
4245,Cancer information,0,Title,ss_i,21914768,test,gold,i
4246,anxiety :,0,Title,ss_o,21914768,test,gold,o
4247,anxiety :,0,Title,hl_o,21914768,test,gold,o
4248,Time in therapeutic range ( TTR ),0,Abstract,ss_i,21924760,test,gold,i
4249,Time in therapeutic range ( TTR ),0,Abstract,ss_o,21924760,test,gold,o
4250,stroke and bleeding,0,Abstract,ss_o,21924760,test,gold,o
4251,Time in therapeutic range ( TTR ),0,Abstract,hl_i,21924760,test,gold,i
4252,Time in therapeutic range ( TTR ),0,Abstract,hl_o,21924760,test,gold,o
4253,"ACTIVE W study patients , cases with stroke and cases with bleeding were separately matched with controls .",1,Abstract,ss_p,21924760,test,gold,p
4254,"ACTIVE W study patients , cases with stroke and cases with bleeding were separately matched with controls .",1,Abstract,hl_p,21924760,test,gold,p
4255,anticoagulation quality measures,2,Abstract,ss_o,21924760,test,gold,o
4256,32 cases with ischemic stroke and 234 cases with bleeding in the analysis were matched,3,Abstract,ss_p,21924760,test,gold,p
4257,122 and 865 controls,3,Abstract,ss_p,21924760,test,gold,p
4258,32 cases with ischemic stroke,3,Abstract,hl_p,21924760,test,gold,p
4259,234 cases with bleeding,3,Abstract,hl_p,21924760,test,gold,p
4260,the stroke analysis,4,Abstract,ss_o,21924760,test,gold,o
4261,the bleeding analysis,4,Abstract,ss_o,21924760,test,gold,o
4262,mean TTR,5,Abstract,ss_i,21924760,test,gold,i
4263,mean TTR,5,Abstract,ss_o,21924760,test,gold,o
4264,lower .,5,Abstract,ss_o,21924760,test,gold,o
4265,TTR,5,Abstract,hl_i,21924760,test,gold,i
4266,stroke and,6,Abstract,ss_o,21924760,test,gold,o
4267,Time below range for stroke,6,Abstract,hl_o,21924760,test,gold,o
4268,time above range for bleeding,6,Abstract,hl_o,21924760,test,gold,o
4269,spent more,7,Abstract,ss_o,21924760,test,gold,o
4270,lower in individual AF patients,8,Abstract,ss_p,21924760,test,gold,p
4271,CONCLUSIONS,8,Abstract,ss_i,21924760,test,gold,i
4272,Maintaining a high,8,Abstract,ss_i,21924760,test,gold,i
4273,CONCLUSIONS,8,Abstract,ss_o,21924760,test,gold,o
4274,Maintaining a high,8,Abstract,ss_o,21924760,test,gold,o
4275,treatment to prevent stroke and bleeding,8,Abstract,ss_o,21924760,test,gold,o
4276,atrial fibrillation patients :,0,Title,ss_p,21924760,test,gold,p
4277,risk of stroke and bleeding events,0,Title,ss_o,21924760,test,gold,o
4278,atrial fibrillation patients :,0,Title,hl_p,21924760,test,gold,p
4279,Hormonal contraceptives,0,Abstract,ss_i,21975269,test,gold,i
4280,Hormonal contraceptives,0,Abstract,hl_i,21975269,test,gold,i
4281,hormonal contraceptive,1,Abstract,ss_i,21975269,test,gold,i
4282,risk of HIV-1 acquisition,1,Abstract,ss_o,21975269,test,gold,o
4283,HIV-1 transmission,1,Abstract,ss_o,21975269,test,gold,o
4284,hormonal contraceptive,1,Abstract,hl_i,21975269,test,gold,i
4285,3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries .,2,Abstract,ss_p,21975269,test,gold,p
4286,3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries,2,Abstract,hl_p,21975269,test,gold,p
4287,hormonal contraceptive,3,Abstract,ss_i,21975269,test,gold,i
4288,rates of HIV-1 acquisition,3,Abstract,ss_o,21975269,test,gold,o
4289,HIV-1 transmission,3,Abstract,ss_o,21975269,test,gold,o
4290,hormonal contraceptive,3,Abstract,hl_i,21975269,test,gold,i
4291,HIV-1 seroconversion .,4,Abstract,ss_o,21975269,test,gold,o
4292,HIV-1 risk .,5,Abstract,ss_o,21975269,test,gold,o
4293,Among 1314 couples in which the HIV-1-seronegative partner was female,6,Abstract,ss_p,21975269,test,gold,p
4294,p=0·03 ) .,6,Abstract,ss_p,21975269,test,gold,p
4295,used hormonal contraception,6,Abstract,ss_i,21975269,test,gold,i
4296,of HIV-1 acquisition,6,Abstract,ss_o,21975269,test,gold,o
4297,1314 couples in which the HIV-1-seronegative partner,6,Abstract,hl_p,21975269,test,gold,p
4298,female,6,Abstract,hl_p,21975269,test,gold,p
4299,HIV-1 acquisition,6,Abstract,hl_o,21975269,test,gold,o
4300,Among 2476 couples in which the HIV-1-seronegative partner,7,Abstract,ss_p,21975269,test,gold,p
4301,which women used hormonal contraception,7,Abstract,ss_i,21975269,test,gold,i
4302,women did not use hormonal,7,Abstract,ss_i,21975269,test,gold,i
4303,"months ) , rates of HIV-1 transmission",7,Abstract,ss_o,21975269,test,gold,o
4304,HIV-1 transmission,7,Abstract,hl_o,21975269,test,gold,o
4306,transmission with hormonal,9,Abstract,ss_i,21975269,test,gold,i
4307,potentially increased risk of HIV-1 acquisition,9,Abstract,ss_o,21975269,test,gold,o
4308,risk of HIV-1 acquisition,9,Abstract,hl_o,21975269,test,gold,o
4309,Non-hormonal or low-dose hormonal,10,Abstract,ss_i,21975269,test,gold,i
4311,hormonal contraceptives,0,Title,ss_i,21975269,test,gold,i
4312,risk of HIV-1 transmission :,0,Title,ss_o,21975269,test,gold,o
4313,hormonal contraceptives,0,Title,hl_i,21975269,test,gold,i
4314,patients with heart failure ( HF ) .,0,Abstract,ss_p,21982657,test,gold,p
4315,myoblasts,0,Abstract,ss_i,21982657,test,gold,i
4316,safety,0,Abstract,ss_o,21982657,test,gold,o
4317,preliminary efficacy,0,Abstract,ss_o,21982657,test,gold,o
4318,patients with heart failure ( HF ) .,0,Abstract,hl_p,21982657,test,gold,p
4319,myoblasts,0,Abstract,hl_i,21982657,test,gold,i
4320,safety,0,Abstract,hl_o,21982657,test,gold,o
4321,efficacy,0,Abstract,hl_o,21982657,test,gold,o
4322,patients with class II to IV HF and ejection fraction < 35 % .,1,Abstract,ss_p,21982657,test,gold,p
4323,placebo,1,Abstract,ss_i,21982657,test,gold,i
4324,myoblasts,1,Abstract,ss_i,21982657,test,gold,i
4325,patients with class II to IV HF and ejection fraction < 35 % .,1,Abstract,hl_p,21982657,test,gold,p
4326,placebo,1,Abstract,hl_i,21982657,test,gold,i
4327,myoblasts,1,Abstract,hl_i,21982657,test,gold,i
4328,frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy ) .,2,Abstract,ss_o,21982657,test,gold,o
4329,frequency of serious adverse events ( safety ),2,Abstract,hl_o,21982657,test,gold,o
4330,changes in 6-minute walk test,2,Abstract,hl_o,21982657,test,gold,o
4331,Minnesota Living With HF score ( efficacy ),2,Abstract,hl_o,21982657,test,gold,o
4332,"Of 330 patients intended for enrollment , 23 were randomized ( MARVEL-1 ) before stopping the study for financial reasons .",3,Abstract,ss_p,21982657,test,gold,p
4333,330,3,Abstract,hl_p,21982657,test,gold,p
4334,23,3,Abstract,hl_p,21982657,test,gold,p
4335,( placebo ),4,Abstract,ss_i,21982657,test,gold,i
4336,( placebo ),4,Abstract,hl_i,21982657,test,gold,i
4337,myoblast-treated,5,Abstract,ss_i,21982657,test,gold,i
4338,( placebo ),5,Abstract,ss_i,21982657,test,gold,i
4339,Ventricular tachycardia responsive,5,Abstract,ss_o,21982657,test,gold,o
4340,myoblast-treated,5,Abstract,hl_i,21982657,test,gold,i
4341,( placebo ),5,Abstract,hl_i,21982657,test,gold,i
4342,Ventricular tachycardia responsive,5,Abstract,hl_o,21982657,test,gold,o
4343,myoblast-treated,6,Abstract,ss_i,21982657,test,gold,i
4344,functional capacity,6,Abstract,ss_o,21982657,test,gold,o
4345,in Minnesota Living With HF scores,6,Abstract,ss_o,21982657,test,gold,o
4346,myoblast-treated,6,Abstract,hl_i,21982657,test,gold,i
4347,functional capacity,6,Abstract,hl_o,21982657,test,gold,o
4348,In HF patients with chronic postinfarction cardiomyopathy,7,Abstract,ss_p,21982657,test,gold,p
4349,of myoblasts,7,Abstract,ss_i,21982657,test,gold,i
4350,myoblasts,7,Abstract,hl_i,21982657,test,gold,i
4351,by myoblast,8,Abstract,ss_i,21982657,test,gold,i
4352,in HF patients with postinfarction cardiomyopathy,9,Abstract,ss_p,21982657,test,gold,p
4353,of myoblast,9,Abstract,ss_i,21982657,test,gold,i
4354,patients with chronic heart failure after myocardial infarction .,0,Title,ss_p,21982657,test,gold,p
4355,skeletal myoblast implantation,0,Title,ss_i,21982657,test,gold,i
4356,safety,0,Title,ss_o,21982657,test,gold,o
4357,cardiovascular effects,0,Title,ss_o,21982657,test,gold,o
4358,patients with chronic heart failure after myocardial infarction .,0,Title,hl_p,21982657,test,gold,p
4359,skeletal myoblast implantation,0,Title,hl_i,21982657,test,gold,i
4360,safety,0,Title,hl_o,21982657,test,gold,o
4361,cardiovascular effects,0,Title,hl_o,21982657,test,gold,o
4363,of zoster vaccine ( ZV ),1,Abstract,ss_i,22154769,test,gold,i
4364,of ZV,1,Abstract,ss_i,22154769,test,gold,i
4365,zoster vaccine ( ZV ),1,Abstract,hl_i,22154769,test,gold,i
4366,with 210 subjects ≥60 years,2,Abstract,ss_p,22154769,test,gold,p
4367,doses of,2,Abstract,ss_i,22154769,test,gold,i
4368,vs. placebo,2,Abstract,ss_i,22154769,test,gold,i
4369,compared immunity and safety profiles,2,Abstract,ss_o,22154769,test,gold,o
4370,placebo .,2,Abstract,ss_o,22154769,test,gold,o
4371,210,2,Abstract,hl_p,22154769,test,gold,p
4372,≥60 years,2,Abstract,hl_p,22154769,test,gold,p
4373,placebo,2,Abstract,hl_i,22154769,test,gold,i
4374,immunity,2,Abstract,hl_o,22154769,test,gold,o
4375,safety,2,Abstract,hl_o,22154769,test,gold,o
4376,Immunogenicity was evaluated using VZV interferon-gamma ( IFN-γ ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay .,3,Abstract,ss_o,22154769,test,gold,o
4377,Immunogenicity,3,Abstract,hl_o,22154769,test,gold,o
4378,Adverse experiences ( AEs ),4,Abstract,ss_o,22154769,test,gold,o
4379,on a standardized Vaccination Report,4,Abstract,ss_o,22154769,test,gold,o
4380,Adverse experiences ( AEs ),4,Abstract,hl_o,22154769,test,gold,o
4381,RESULTS No serious vaccine-related,5,Abstract,ss_o,22154769,test,gold,o
4382,occurred .,5,Abstract,ss_o,22154769,test,gold,o
4383,serious vaccine-related,5,Abstract,hl_o,22154769,test,gold,o
4384,in the,6,Abstract,ss_i,22154769,test,gold,i
4385,VZV IFN-γ ELISPOT geometric mean count ( GMC ) of spot-forming cells per 10 ( 6 ) peripheral blood mononuclear,6,Abstract,ss_o,22154769,test,gold,o
4386,respectively,7,Abstract,ss_o,22154769,test,gold,o
4387,in the placebo,8,Abstract,ss_i,22154769,test,gold,i
4388,study .,8,Abstract,ss_o,22154769,test,gold,o
4389,placebo,8,Abstract,hl_i,22154769,test,gold,i
4390,after,9,Abstract,ss_i,22154769,test,gold,i
4391,The peak ELISPOT response,9,Abstract,ss_o,22154769,test,gold,o
4392,dose .,9,Abstract,ss_o,22154769,test,gold,o
4393,( GMTs ) in,10,Abstract,ss_i,22154769,test,gold,i
4394,than in the,10,Abstract,ss_i,22154769,test,gold,i
4395,The gpELISA geometric mean titers,10,Abstract,ss_o,22154769,test,gold,o
4396,between the IFN-γ ELISPOT and gpELISA,11,Abstract,ss_o,22154769,test,gold,o
4397,immunogenic in adults ≥60,12,Abstract,ss_p,22154769,test,gold,p
4398,CONCLUSIONS,12,Abstract,ss_i,22154769,test,gold,i
4399,second,13,Abstract,ss_i,22154769,test,gold,i
4400,was generally,13,Abstract,ss_o,22154769,test,gold,o
4401,VZV-specific,13,Abstract,ss_o,22154769,test,gold,o
4402,healthy adults ≥60 years of age,0,Title,ss_p,22154769,test,gold,p
4403,zoster vaccine,0,Title,ss_i,22154769,test,gold,i
4404,"Safety , tolerability , and immunogenicity",0,Title,ss_o,22154769,test,gold,o
4405,healthy adults ≥60 years of age,0,Title,hl_p,22154769,test,gold,p
4406,zoster vaccine,0,Title,hl_i,22154769,test,gold,i
4407,Safety,0,Title,hl_o,22154769,test,gold,o
4408,tolerability,0,Title,hl_o,22154769,test,gold,o
4409,immunogenicity,0,Title,hl_o,22154769,test,gold,o
4410,60 elderly patients .,0,Abstract,ss_p,2223363,test,gold,p
4411,propofol,0,Abstract,ss_i,2223363,test,gold,i
4412,60 elderly patients,0,Abstract,hl_p,2223363,test,gold,p
4413,propofol,0,Abstract,hl_i,2223363,test,gold,i
4414,Propofol,1,Abstract,ss_i,2223363,test,gold,i
4415,loss of consciousness ( as judged by loss of verbal contact with the patient ),1,Abstract,ss_o,2223363,test,gold,o
4416,Propofol,1,Abstract,hl_i,2223363,test,gold,i
4417,loss of consciousness,1,Abstract,hl_o,2223363,test,gold,o
4418,loss of verbal contact with the patient ),1,Abstract,hl_o,2223363,test,gold,o
4419,duration of induction,2,Abstract,ss_o,2223363,test,gold,o
4420,infusion rates,2,Abstract,ss_o,2223363,test,gold,o
4421,total dose,2,Abstract,ss_o,2223363,test,gold,o
4422,duration of induction,2,Abstract,hl_o,2223363,test,gold,o
4423,systolic and diastolic arterial pressure,3,Abstract,ss_o,2223363,test,gold,o
4424,systolic and diastolic arterial pressure,3,Abstract,hl_o,2223363,test,gold,o
4425,incidence of apnoea,4,Abstract,ss_o,2223363,test,gold,o
4426,incidence of apnoea,4,Abstract,hl_o,2223363,test,gold,o
4427,elderly patients .,0,Title,ss_p,2223363,test,gold,p
4428,propofol,0,Title,ss_i,2223363,test,gold,i
4429,elderly patients .,0,Title,hl_p,2223363,test,gold,p
4430,propofol,0,Title,hl_i,2223363,test,gold,i
4431,bestatin,0,Abstract,ss_i,2224060,test,gold,i
4432,bestatin,0,Abstract,hl_i,2224060,test,gold,i
4433,adult acute nonlymphocytic leukemia ( ANLL ),1,Abstract,ss_p,2224060,test,gold,p
4434,bestatin,1,Abstract,ss_i,2224060,test,gold,i
4435,adult acute nonlymphocytic leukemia ( ANLL ),1,Abstract,hl_p,2224060,test,gold,p
4436,bestatin,1,Abstract,hl_i,2224060,test,gold,i
4437,bestatin,2,Abstract,ss_i,2224060,test,gold,i
4438,bestatin,2,Abstract,hl_i,2224060,test,gold,i
4439,"The 101 eligible cases ( bestatin : 48 , control : 53 )",3,Abstract,ss_p,2224060,test,gold,p
4440,( bestatin :,3,Abstract,ss_i,2224060,test,gold,i
4441,bestatin,3,Abstract,ss_i,2224060,test,gold,i
4442,longer remission,3,Abstract,ss_o,2224060,test,gold,o
4443,longer survival .,3,Abstract,ss_o,2224060,test,gold,o
4444,101,3,Abstract,hl_p,2224060,test,gold,p
4445,48,3,Abstract,hl_p,2224060,test,gold,p
4446,53,3,Abstract,hl_p,2224060,test,gold,p
4447,bestatin,3,Abstract,hl_i,2224060,test,gold,i
4448,bestatin,3,Abstract,hl_i,2224060,test,gold,i
4449,remission,3,Abstract,hl_o,2224060,test,gold,o
4450,survival .,3,Abstract,hl_o,2224060,test,gold,o
4451,bestatin,4,Abstract,ss_i,2224060,test,gold,i
4452,prolongation of remission,4,Abstract,ss_o,2224060,test,gold,o
4453,bestatin,4,Abstract,hl_i,2224060,test,gold,i
4454,prolongation of remission,4,Abstract,hl_o,2224060,test,gold,o
4455,Bestatin,5,Abstract,ss_i,2224060,test,gold,i
4456,prolonged survival and remission,5,Abstract,ss_o,2224060,test,gold,o
4457,side-effects .,5,Abstract,ss_o,2224060,test,gold,o
4458,Bestatin,5,Abstract,hl_i,2224060,test,gold,i
4459,survival,5,Abstract,hl_o,2224060,test,gold,o
4460,remission,5,Abstract,hl_o,2224060,test,gold,o
4461,side-effects .,5,Abstract,hl_o,2224060,test,gold,o
4462,acute nonlymphocytic leukemia in adults .,0,Title,ss_p,2224060,test,gold,p
4463,bestatin,0,Title,ss_i,2224060,test,gold,i
4464,acute nonlymphocytic leukemia,0,Title,hl_p,2224060,test,gold,p
4465,adults,0,Title,hl_p,2224060,test,gold,p
4466,bestatin,0,Title,hl_i,2224060,test,gold,i
4467,psychosocial interventions,0,Abstract,ss_i,22271197,test,gold,i
4468,Goal attainment scaling ( GAS ),0,Abstract,ss_o,22271197,test,gold,o
4469,psychosocial interventions,0,Abstract,hl_i,22271197,test,gold,i
4470,Goal attainment scaling ( GAS ),0,Abstract,hl_o,22271197,test,gold,o
4471,scaling level,1,Abstract,ss_o,22271197,test,gold,o
4472,inter-individual equivalence,1,Abstract,ss_o,22271197,test,gold,o
4473,comparability,1,Abstract,ss_o,22271197,test,gold,o
4474,reliability of coding across different behavioral observation methods .,1,Abstract,ss_o,22271197,test,gold,o
4475,assumptions of equality,2,Abstract,ss_o,22271197,test,gold,o
4476,"measurability , equidistance , level of difficulty , comparability of behavior samples collected from teachers vs. researchers and live vs. videotape )",2,Abstract,ss_o,22271197,test,gold,o
4477,GAS,3,Abstract,ss_o,22271197,test,gold,o
4478,GAS,4,Abstract,ss_o,22271197,test,gold,o
4480,autism .,0,Title,ss_p,22271197,test,gold,p
4481,psychosocial interventions,0,Title,ss_i,22271197,test,gold,i
4482,Goal attainment scaling,0,Title,ss_o,22271197,test,gold,o
4483,autism .,0,Title,hl_p,22271197,test,gold,p
4484,psychosocial interventions,0,Title,hl_i,22271197,test,gold,i
4485,Goal attainment scaling,0,Title,hl_o,22271197,test,gold,o
4486,infants undergoing the Norwood procedure,0,Abstract,ss_p,22341427,test,gold,p
4487,cardiac transplantation,0,Abstract,ss_i,22341427,test,gold,i
4488,factors associated with death and cardiac transplantation,0,Abstract,ss_o,22341427,test,gold,o
4489,infants undergoing the Norwood procedure,0,Abstract,hl_p,22341427,test,gold,p
4490,cardiac transplantation,0,Abstract,hl_i,22341427,test,gold,i
4491,cardiac transplantation,1,Abstract,ss_i,22341427,test,gold,i
4492,"death without transplantation , cardiac transplantation , and survival without transplantation .",1,Abstract,ss_o,22341427,test,gold,o
4493,Parametric time-to-event modeling and bootstrapping were used to identify independent predictors .,2,Abstract,ss_o,22341427,test,gold,o
4494,"549 subjects ( follow-up , 2.7 ± 0.9 years )",3,Abstract,ss_p,22341427,test,gold,p
4495,.,3,Abstract,ss_o,22341427,test,gold,o
4496,549,3,Abstract,hl_p,22341427,test,gold,p
4497,Mortality risk,4,Abstract,ss_o,22341427,test,gold,o
4498,Mortality risk,4,Abstract,hl_o,22341427,test,gold,o
4499,with death,5,Abstract,ss_o,22341427,test,gold,o
4500,lower socioeconomic status,5,Abstract,ss_o,22341427,test,gold,o
4501,obstructed pulmonary venous return,5,Abstract,ss_o,22341427,test,gold,o
4502,smaller ascending aorta,5,Abstract,ss_o,22341427,test,gold,o
4503,and anatomic subtype,5,Abstract,ss_o,22341427,test,gold,o
4504,with death,5,Abstract,hl_o,22341427,test,gold,o
4505,with death included genetic syndrome,6,Abstract,ss_o,22341427,test,gold,o
4506,lower gestational age,6,Abstract,ss_o,22341427,test,gold,o
4507,with death,6,Abstract,hl_o,22341427,test,gold,o
4508,better survival,7,Abstract,ss_o,22341427,test,gold,o
4509,survival,7,Abstract,hl_o,22341427,test,gold,o
4511,"Lower pre-Norwood right ventricular fractional area change , pre-Norwood surgery , and anatomy other than hypoplastic left heart syndrome",9,Abstract,ss_o,22341427,test,gold,o
4512,Independent risk factors for intermediate-term mortality,10,Abstract,ss_o,22341427,test,gold,o
4513,.,11,Abstract,ss_o,22341427,test,gold,o
4514,Right ventricular function and anatomy,12,Abstract,ss_o,22341427,test,gold,o
4515,not shunt type,12,Abstract,ss_o,22341427,test,gold,o
4516,infants with single-ventricle lesions :,0,Title,ss_p,22341427,test,gold,p
4517,cardiac transplantation,0,Title,ss_i,22341427,test,gold,i
4518,Intermediate-term mortality and cardiac transplantation,0,Title,ss_o,22341427,test,gold,o
4519,risk factors,0,Title,ss_o,22341427,test,gold,o
4520,infants,0,Title,hl_p,22341427,test,gold,p
4521,single-ventricle lesions,0,Title,hl_p,22341427,test,gold,p
4522,cardiac transplantation,0,Title,hl_i,22341427,test,gold,i
4523,general knowledge,0,Abstract,ss_o,22416755,test,gold,o
4524,children,1,Abstract,ss_p,22416755,test,gold,p
4525,pretend play .,1,Abstract,ss_i,22416755,test,gold,i
4526,generic knowledge,1,Abstract,ss_o,22416755,test,gold,o
4527,pretend play .,1,Abstract,hl_i,22416755,test,gold,i
4528,twenty-two 3- to 4-year-olds,2,Abstract,ss_p,22416755,test,gold,p
4529,pretense,2,Abstract,ss_i,22416755,test,gold,i
4530,twenty-two 3- to 4-year-olds,2,Abstract,hl_p,22416755,test,gold,p
4531,pretense,2,Abstract,hl_i,22416755,test,gold,i
4533,children 's responses,4,Abstract,ss_o,22416755,test,gold,o
4534,responses,4,Abstract,hl_o,22416755,test,gold,o
4535,thirty-two 4- to 5-year-olds,5,Abstract,ss_p,22416755,test,gold,p
4536,scenarios lacking pretend speech or sound effects .,5,Abstract,ss_i,22416755,test,gold,i
4537,thirty-two 4- to 5-year-olds,5,Abstract,hl_p,22416755,test,gold,p
4538,scenarios lacking pretend speech or sound effects .,5,Abstract,hl_i,22416755,test,gold,i
4539,generic knowledge .,6,Abstract,ss_o,22416755,test,gold,o
4540,Preschoolers,0,Title,ss_p,22416755,test,gold,p
4541,pretense .,0,Title,ss_i,22416755,test,gold,i
4542,general knowledge,0,Title,ss_o,22416755,test,gold,o
4543,Preschoolers,0,Title,hl_p,22416755,test,gold,p
4544,pretense .,0,Title,hl_i,22416755,test,gold,i
4545,individuals formally diagnosed with autism spectrum disorder ( ASD ) .,0,Abstract,ss_p,22420121,test,gold,p
4546,referential communication training,0,Abstract,ss_i,22420121,test,gold,i
4547,individuals formally diagnosed with autism spectrum disorder ( ASD ) .,0,Abstract,hl_p,22420121,test,gold,p
4548,referential communication training,0,Abstract,hl_i,22420121,test,gold,i
4549,20 children with ASD ( M age = 14.3 yr.,1,Abstract,ss_p,22420121,test,gold,p
4550,"SD = 4.2 ; 6 girls , 14 boys ) in the role of speakers and 20 control children , who acted as listeners .",1,Abstract,ss_p,22420121,test,gold,p
4551,20 children,1,Abstract,hl_p,22420121,test,gold,p
4552,ASD,1,Abstract,hl_p,22420121,test,gold,p
4553,M age = 14.3 yr.,1,Abstract,hl_p,22420121,test,gold,p
4554,SD = 4.2,1,Abstract,hl_p,22420121,test,gold,p
4555,6,1,Abstract,hl_p,22420121,test,gold,p
4556,14,1,Abstract,hl_p,22420121,test,gold,p
4557,20,1,Abstract,hl_p,22420121,test,gold,p
4558,children,1,Abstract,hl_p,22420121,test,gold,p
4560,"Inclusion/exclusion criteria were defined according to the clinical diagnosis of ASD , the presence or absence of additional or associated disability , previous training in referential communication , and any drug treatment .",3,Abstract,ss_p,22420121,test,gold,p
4561,referential communication,3,Abstract,ss_i,22420121,test,gold,i
4563,"Linguistic age , cognitive level and autistic symptoms",5,Abstract,ss_o,22420121,test,gold,o
4564,"Peabody Picture Vocabulary Test ( PPVT ) , the Wechsler Intelligence Scale ( WISC-R or WAIS-III ) , and the Autistic Behavior Checklist ( ABC ) .",5,Abstract,ss_o,22420121,test,gold,o
4565,"Linguistic age , cognitive level and autistic symptoms",5,Abstract,hl_o,22420121,test,gold,o
4566,"Peabody Picture Vocabulary Test ( PPVT ) , the Wechsler Intelligence Scale ( WISC-R or WAIS-III ) , and the Autistic Behavior Checklist ( ABC ) .",5,Abstract,hl_o,22420121,test,gold,o
4567,Communicative abilities,6,Abstract,ss_o,22420121,test,gold,o
4568,indexes related to message complexity and self-regulation .,6,Abstract,ss_o,22420121,test,gold,o
4569,Communicative abilities,6,Abstract,hl_o,22420121,test,gold,o
4570,"referential communication tasks ( task analysis , role taking",7,Abstract,ss_i,22420121,test,gold,i
4571,task evaluation ),7,Abstract,ss_i,22420121,test,gold,i
4572,communicative game,7,Abstract,ss_i,22420121,test,gold,i
4573,"referential communication tasks ( task analysis , role taking",7,Abstract,hl_i,22420121,test,gold,i
4574,task evaluation ),7,Abstract,hl_i,22420121,test,gold,i
4575,communicative game,7,Abstract,hl_i,22420121,test,gold,i
4576,complexity of emitted messages,8,Abstract,ss_o,22420121,test,gold,o
4577,complexity of emitted messages,8,Abstract,hl_o,22420121,test,gold,o
4578,individuals with ASD,9,Abstract,ss_p,22420121,test,gold,p
4579,referential communication,9,Abstract,ss_i,22420121,test,gold,i
4580,individuals with ASD,9,Abstract,hl_p,22420121,test,gold,p
4581,referential communication,9,Abstract,hl_i,22420121,test,gold,i
4582,individuals with autism spectrum disorder :,0,Title,ss_p,22420121,test,gold,p
4583,referential communicative skills,0,Title,ss_i,22420121,test,gold,i
4584,individuals with autism spectrum disorder :,0,Title,hl_p,22420121,test,gold,p
4585,referential communicative skills,0,Title,hl_i,22420121,test,gold,i
4588,Cognitive behavioral therapies ( CBT ),2,Abstract,ss_i,22435114,test,gold,i
4589,anxiety symptoms .,2,Abstract,ss_o,22435114,test,gold,o
4590,Cognitive behavioral therapies ( CBT ),2,Abstract,hl_i,22435114,test,gold,i
4591,anxiety symptoms .,2,Abstract,hl_o,22435114,test,gold,o
4592,CBT,3,Abstract,ss_i,22435114,test,gold,i
4593,CBT,3,Abstract,hl_i,22435114,test,gold,i
4594,Fifty children with high-functioning ASD and anxiety,4,Abstract,ss_p,22435114,test,gold,p
4595,CBT,4,Abstract,ss_i,22435114,test,gold,i
4596,treatment-as-usual ( TAU ),4,Abstract,ss_i,22435114,test,gold,i
4597,Fifty children,4,Abstract,hl_p,22435114,test,gold,p
4598,high-functioning ASD and anxiety,4,Abstract,hl_p,22435114,test,gold,p
4599,CBT,4,Abstract,hl_i,22435114,test,gold,i
4600,treatment-as-usual ( TAU ),4,Abstract,hl_i,22435114,test,gold,i
4601,structured interviews ( Anxiety Disorders Interview Schedule – Parent Version ; ADIS-P ),5,Abstract,ss_o,22435114,test,gold,o
4602,RESULTS Forty-seven children completed either the CBT or TAU condition,6,Abstract,ss_p,22435114,test,gold,p
4603,the CBT or TAU,6,Abstract,ss_i,22435114,test,gold,i
4604,Forty-seven children,6,Abstract,hl_p,22435114,test,gold,p
4605,CBT,6,Abstract,hl_i,22435114,test,gold,i
4606,TAU,6,Abstract,hl_i,22435114,test,gold,i
4607,the CBT,7,Abstract,ss_i,22435114,test,gold,i
4608,CBT,7,Abstract,hl_i,22435114,test,gold,i
4609,"in Clinician Severity Ratings , diagnostic status , and clinician ratings of global improvement",8,Abstract,ss_o,22435114,test,gold,o
4610,the CBT,9,Abstract,ss_i,22435114,test,gold,i
4611,the TAU,9,Abstract,ss_i,22435114,test,gold,i
4612,positive treatment response,9,Abstract,ss_o,22435114,test,gold,o
4613,CBT,9,Abstract,hl_i,22435114,test,gold,i
4614,for children with ASD,10,Abstract,ss_p,22435114,test,gold,p
4615,agroup CBT,10,Abstract,ss_i,22435114,test,gold,i
4616,CBT,10,Abstract,hl_i,22435114,test,gold,i
4618,children with high-functioning autism spectrum disorders and anxiety :,0,Title,ss_p,22435114,test,gold,p
4619,Group cognitive behavior therapy,0,Title,ss_i,22435114,test,gold,i
4620,children,0,Title,hl_p,22435114,test,gold,p
4621,high-functioning autism spectrum disorders and anxiety,0,Title,hl_p,22435114,test,gold,p
4622,Group cognitive behavior therapy,0,Title,hl_i,22435114,test,gold,i
4623,patients with spotty calcification .,0,Abstract,ss_p,22538329,test,gold,p
4624,atheroma progression,0,Abstract,ss_o,22538329,test,gold,o
4625,patients with spotty calcification .,0,Abstract,hl_p,22538329,test,gold,p
4626,atheroma progression,0,Abstract,hl_o,22538329,test,gold,o
4628,spotty calcification,2,Abstract,ss_o,22538329,test,gold,o
4629,disease progression,2,Abstract,ss_o,22538329,test,gold,o
4630,disease progression,2,Abstract,hl_o,22538329,test,gold,o
4631,"A total of 1,347 stable patients with angiographic coronary artery disease",3,Abstract,ss_p,22538329,test,gold,p
4632,serial evaluation of atheroma burden with intravascular ultrasound imaging .,3,Abstract,ss_i,22538329,test,gold,i
4633,atheroma burden with intravascular ultrasound imaging .,3,Abstract,ss_o,22538329,test,gold,o
4634,"1,347 stable patients with angiographic coronary artery disease",3,Abstract,hl_p,22538329,test,gold,p
4635,serial evaluation of atheroma burden with intravascular ultrasound imaging .,3,Abstract,hl_i,22538329,test,gold,i
4636,atheroma burden,3,Abstract,hl_o,22538329,test,gold,o
4637,Patients with spotty calcification were identified based on the presence of lesions ( 1 to 4 mm in length ) containing an arc of calcification of < 90°,4,Abstract,ss_p,22538329,test,gold,p
4638,.,4,Abstract,ss_o,22538329,test,gold,o
4639,Clinical characteristics and disease progression,5,Abstract,ss_o,22538329,test,gold,o
4640,"RESULTS Patients with spotty calcification were older ( age 56 years vs. 54 years ; p = 0.001 ) , more likely to be male ( 68 % vs. 54 % ;",6,Abstract,ss_p,22538329,test,gold,p
4641,0.001 ),6,Abstract,ss_p,22538329,test,gold,p
4642,on-treatment high-density lipoprotein cholesterol levels,6,Abstract,ss_o,22538329,test,gold,o
4643,greater percent atheroma volume ( PAV ),7,Abstract,ss_o,22538329,test,gold,o
4644,0.001 ) and total atheroma volume,7,Abstract,ss_o,22538329,test,gold,o
4645,greater progression,8,Abstract,ss_o,22538329,test,gold,o
4646,greater progression,8,Abstract,hl_o,22538329,test,gold,o
4647,attenuated in patients with spotty calcification,9,Abstract,ss_p,22538329,test,gold,p
4648,and diffuse coronary atherosclerosis,10,Abstract,ss_o,22538329,test,gold,o
4649,accelerated disease progression,10,Abstract,ss_o,22538329,test,gold,o
4650,coronary atherosclerosis,10,Abstract,hl_o,22538329,test,gold,o
4651,progression of coronary atherosclerosis :,0,Title,ss_o,22538329,test,gold,o
4652,progression of coronary atherosclerosis :,0,Title,hl_o,22538329,test,gold,o
4653,quality of life ( QoL ) .,0,Abstract,ss_o,22646975,test,gold,o
4654,quality of life ( QoL ) .,0,Abstract,hl_o,22646975,test,gold,o
4657,Fifty-six outpatients,3,Abstract,ss_p,22646975,test,gold,p
4658,Fifty-six outpatients,3,Abstract,hl_p,22646975,test,gold,p
4659,relaxation-training sessions,4,Abstract,ss_i,22646975,test,gold,i
4660,relaxation-training sessions,4,Abstract,hl_i,22646975,test,gold,i
4661,"state anxiety was assessed with the State-Trait Anxiety Inventory , QoL with the IBD Questionnaire .",5,Abstract,ss_o,22646975,test,gold,o
4662,state anxiety,5,Abstract,hl_o,22646975,test,gold,o
4663,"State-Trait Anxiety Inventory , QoL with the IBD Questionnaire .",5,Abstract,hl_o,22646975,test,gold,o
4664,"The Visual Analogue Scale assessed pain , depression , stress and mood .",6,Abstract,ss_o,22646975,test,gold,o
4665,Visual Analogue Scale,6,Abstract,hl_o,22646975,test,gold,o
4666,pain,6,Abstract,hl_o,22646975,test,gold,o
4667,depression,6,Abstract,hl_o,22646975,test,gold,o
4668,stress,6,Abstract,hl_o,22646975,test,gold,o
4669,mood,6,Abstract,hl_o,22646975,test,gold,o
4670,symptom monitoring diary .,7,Abstract,ss_o,22646975,test,gold,o
4672,Thirty-nine subjects completed the study,9,Abstract,ss_p,22646975,test,gold,p
4673,Thirty-nine subjects completed the study,9,Abstract,hl_p,22646975,test,gold,p
4674,relaxation-training,10,Abstract,ss_i,22646975,test,gold,i
4675,interaction ) : anxiety,10,Abstract,ss_o,22646975,test,gold,o
4676,"( p < 0.01 ) , QoL",10,Abstract,ss_o,22646975,test,gold,o
4677,"( p < 0.05 ) , while levels of",10,Abstract,ss_o,22646975,test,gold,o
4678,relaxation-training,10,Abstract,hl_i,22646975,test,gold,i
4679,patients may benefit from,11,Abstract,ss_i,22646975,test,gold,i
4681,patients with inflammatory bowel disease .,0,Title,ss_p,22646975,test,gold,p
4682,relaxation training,0,Title,ss_i,22646975,test,gold,i
4683,anxiety,0,Title,ss_o,22646975,test,gold,o
4684,quality of life,0,Title,ss_o,22646975,test,gold,o
4685,patients with inflammatory bowel disease .,0,Title,hl_p,22646975,test,gold,p
4686,relaxation training,0,Title,hl_i,22646975,test,gold,i
4687,anxiety,0,Title,hl_o,22646975,test,gold,o
4688,quality of life,0,Title,hl_o,22646975,test,gold,o
4689,"preschool children with intellectual disabilities ( IDs ) , including children with Down syndrome and children with autism spectrum disorders .",0,Abstract,ss_p,22744141,test,gold,p
4690,enhanced milieu teaching ( EMT ),0,Abstract,ss_i,22744141,test,gold,i
4691,language skills,0,Abstract,ss_o,22744141,test,gold,o
4692,"preschool children with intellectual disabilities ( IDs ) , including children with Down syndrome and children with autism spectrum disorders .",0,Abstract,hl_p,22744141,test,gold,p
4693,enhanced milieu teaching ( EMT ),0,Abstract,hl_i,22744141,test,gold,i
4694,Seventy-seven children,1,Abstract,ss_p,22744141,test,gold,p
4695,( parent + therapist EMT,1,Abstract,ss_i,22744141,test,gold,i
4696,therapist-only EMT ),1,Abstract,ss_i,22744141,test,gold,i
4697,Seventy-seven children,1,Abstract,hl_p,22744141,test,gold,p
4698,parent + therapist EMT,1,Abstract,hl_i,22744141,test,gold,i
4699,therapist-only EMT,1,Abstract,hl_i,22744141,test,gold,i
4701,standardized and observational measure,3,Abstract,ss_o,22744141,test,gold,o
4702,EMT,4,Abstract,ss_i,22744141,test,gold,i
4703,use of EMT strategies,4,Abstract,ss_o,22744141,test,gold,o
4704,EMT,4,Abstract,hl_i,22744141,test,gold,i
4705,EMT strategies,4,Abstract,hl_o,22744141,test,gold,o
4706,observational measures,5,Abstract,ss_o,22744141,test,gold,o
4707,observational measures,5,Abstract,hl_o,22744141,test,gold,o
4708,preschool children who have ID and significant language impairments .,6,Abstract,ss_p,22744141,test,gold,p
4709,preschool children who have ID and significant language impairments .,6,Abstract,hl_p,22744141,test,gold,p
4710,preschool children who have intellectual disabilities .,0,Title,ss_p,22744141,test,gold,p
4711,enhanced milieu teaching,0,Title,ss_i,22744141,test,gold,i
4712,preschool children who have intellectual disabilities .,0,Title,hl_p,22744141,test,gold,p
4713,enhanced milieu teaching,0,Title,hl_i,22744141,test,gold,i
4714,patients with Posttraumatic stress disorder ( PTSD ) .,0,Abstract,ss_p,22865017,test,gold,p
4715,collaborative care,0,Abstract,ss_i,22865017,test,gold,i
4716,patients with Posttraumatic stress disorder ( PTSD ) .,0,Abstract,hl_p,22865017,test,gold,p
4717,PTSD,1,Abstract,ss_p,22865017,test,gold,p
4718,Three Component Model ( 3CM ),1,Abstract,ss_i,22865017,test,gold,i
4719,usual care,1,Abstract,ss_i,22865017,test,gold,i
4720,Three Component Model ( 3CM ),1,Abstract,hl_i,22865017,test,gold,i
4721,usual care,1,Abstract,hl_i,22865017,test,gold,i
4723,PTSD patients were recruited from five primary care clinics at four Veterans Affairs healthcare facilities,3,Abstract,ss_p,22865017,test,gold,p
4724,usual care,3,Abstract,ss_i,22865017,test,gold,i
4725,usual care plus 3CM .,3,Abstract,ss_i,22865017,test,gold,i
4726,PTSD,3,Abstract,hl_p,22865017,test,gold,p
4727,five primary care clinics at four Veterans Affairs healthcare facilities,3,Abstract,hl_p,22865017,test,gold,p
4728,usual care,3,Abstract,hl_i,22865017,test,gold,i
4729,usual care,3,Abstract,hl_i,22865017,test,gold,i
4730,3CM,3,Abstract,hl_i,22865017,test,gold,i
4732,Participants were 195 Veterans .,5,Abstract,ss_p,22865017,test,gold,p
4733,195 Veterans,5,Abstract,hl_p,22865017,test,gold,p
4734,"Their average age was 45 years , 91 % were male , 58 % were white , 40 % served in Iraq or Afghanistan , and 42 % served in Vietnam .",6,Abstract,ss_p,22865017,test,gold,p
4735,average age was 45 years,6,Abstract,hl_p,22865017,test,gold,p
4736,91 % were male,6,Abstract,hl_p,22865017,test,gold,p
4737,usual care,7,Abstract,hl_i,22865017,test,gold,i
4738,3CM,8,Abstract,ss_i,22865017,test,gold,i
4739,telephone care management .,8,Abstract,ss_i,22865017,test,gold,i
4740,3CM,8,Abstract,hl_i,22865017,test,gold,i
4741,telephone care management .,8,Abstract,hl_i,22865017,test,gold,i
4743,PTSD symptom severity,10,Abstract,ss_o,22865017,test,gold,o
4744,PTSD symptom severity,10,Abstract,hl_o,22865017,test,gold,o
4745,"Depression , functioning , perceived quality of care , utilization , and costs",11,Abstract,ss_o,22865017,test,gold,o
4746,Depression,11,Abstract,hl_o,22865017,test,gold,o
4747,functioning,11,Abstract,hl_o,22865017,test,gold,o
4748,perceived quality of care,11,Abstract,hl_o,22865017,test,gold,o
4749,utilization,11,Abstract,hl_o,22865017,test,gold,o
4750,costs,11,Abstract,hl_o,22865017,test,gold,o
4751,3CM,12,Abstract,ss_i,22865017,test,gold,i
4752,usual care,12,Abstract,ss_i,22865017,test,gold,i
4753,symptoms or functioning .,12,Abstract,ss_o,22865017,test,gold,o
4754,symptoms,12,Abstract,hl_o,22865017,test,gold,o
4755,functioning .,12,Abstract,hl_o,22865017,test,gold,o
4756,3CM,13,Abstract,ss_i,22865017,test,gold,i
4757,"mental health visit , fill an antidepressant prescription",13,Abstract,ss_o,22865017,test,gold,o
4758,adequate antidepressant refills .,13,Abstract,ss_o,22865017,test,gold,o
4759,3CM,13,Abstract,hl_i,22865017,test,gold,i
4760,"mental health visit , fill an antidepressant prescription",13,Abstract,hl_o,22865017,test,gold,o
4761,adequate antidepressant refills .,13,Abstract,hl_o,22865017,test,gold,o
4762,3CM,14,Abstract,ss_i,22865017,test,gold,i
4763,mental health visits,14,Abstract,ss_o,22865017,test,gold,o
4764,outpatient pharmacy costs .,14,Abstract,ss_o,22865017,test,gold,o
4765,3CM,14,Abstract,hl_i,22865017,test,gold,i
4766,mental health visits,14,Abstract,hl_o,22865017,test,gold,o
4767,outpatient pharmacy costs .,14,Abstract,hl_o,22865017,test,gold,o
4768,collaborative care,15,Abstract,ss_i,22865017,test,gold,i
4769,PTSD,0,Title,ss_p,22865017,test,gold,p
4770,PTSD,0,Title,hl_p,22865017,test,gold,p
4772,emotion training,1,Abstract,ss_i,22881991,test,gold,i
4773,emotion training,1,Abstract,hl_i,22881991,test,gold,i
4774,young children with autism with a range of intellectual ability .,2,Abstract,ss_p,22881991,test,gold,p
4775,emotion training programme,2,Abstract,ss_i,22881991,test,gold,i
4776,efficacy,2,Abstract,ss_o,22881991,test,gold,o
4777,young children,2,Abstract,hl_p,22881991,test,gold,p
4778,autism with a range of intellectual ability,2,Abstract,hl_p,22881991,test,gold,p
4779,emotion training programme,2,Abstract,hl_i,22881991,test,gold,i
4780,efficacy,2,Abstract,hl_o,22881991,test,gold,o
4781,"Participants were 55 children with autistic disorder , aged 4-7 years ( FSIQ 42-107 ) .",3,Abstract,ss_p,22881991,test,gold,p
4782,55 children with autistic disorder,3,Abstract,hl_p,22881991,test,gold,p
4783,aged 4-7 years,3,Abstract,hl_p,22881991,test,gold,p
4785,emotion recognition skills,5,Abstract,ss_i,22881991,test,gold,i
4786,( the Transporters ),5,Abstract,ss_i,22881991,test,gold,i
4787,Thomas the Tank Engine .,5,Abstract,ss_i,22881991,test,gold,i
4788,emotion recognition skills,5,Abstract,hl_i,22881991,test,gold,i
4789,the Transporters,5,Abstract,hl_i,22881991,test,gold,i
4790,control,5,Abstract,hl_i,22881991,test,gold,i
4791,Thomas the Tank Engine .,5,Abstract,hl_i,22881991,test,gold,i
4792,"ability to complete basic emotion recognition tasks , mindreading and theory of mind ( TOM ) tasks",6,Abstract,ss_o,22881991,test,gold,o
4793,basic emotion recognition tasks,6,Abstract,hl_o,22881991,test,gold,o
4794,mindreading and theory of mind ( TOM ) tasks,6,Abstract,hl_o,22881991,test,gold,o
4796,recognition of anger,8,Abstract,ss_o,22881991,test,gold,o
4797,recognition of anger,8,Abstract,hl_o,22881991,test,gold,o
4798,TOM or social skills .,9,Abstract,ss_o,22881991,test,gold,o
4799,TOM,9,Abstract,hl_o,22881991,test,gold,o
4800,social skills .,9,Abstract,hl_o,22881991,test,gold,o
4801,young children with autism,10,Abstract,ss_p,22881991,test,gold,p
4802,The Transporters,10,Abstract,ss_i,22881991,test,gold,i
4803,efficacy,10,Abstract,ss_o,22881991,test,gold,o
4804,emotion recognition skills,10,Abstract,ss_o,22881991,test,gold,o
4805,young children with autism,10,Abstract,hl_p,22881991,test,gold,p
4806,The Transporters,10,Abstract,hl_i,22881991,test,gold,i
4807,efficacy,10,Abstract,hl_o,22881991,test,gold,o
4808,recognition of expressions of anger,11,Abstract,ss_o,22881991,test,gold,o
4809,young children with autism,12,Abstract,ss_p,22881991,test,gold,p
4810,the Transporters,12,Abstract,ss_i,22881991,test,gold,i
4811,efficacy,12,Abstract,ss_o,22881991,test,gold,o
4812,young children with autism,12,Abstract,hl_p,22881991,test,gold,p
4813,Transporters,12,Abstract,hl_i,22881991,test,gold,i
4814,young children with autism :,0,Title,ss_p,22881991,test,gold,p
4815,emotion recognition,0,Title,ss_i,22881991,test,gold,i
4816,emotion training programme .,0,Title,ss_i,22881991,test,gold,i
4817,young children with autism :,0,Title,hl_p,22881991,test,gold,p
4818,emotion recognition,0,Title,hl_i,22881991,test,gold,i
4819,emotion training programme .,0,Title,hl_i,22881991,test,gold,i
4821,in patients with mixed dyslipidaemia and MetS,1,Abstract,ss_p,22897461,test,gold,p
4822,high-dose rosuvastatin,1,Abstract,ss_i,22897461,test,gold,i
4823,with fenofibrate or ω-3 fatty acids,1,Abstract,ss_i,22897461,test,gold,i
4824,the lipoprotein subfraction profile,1,Abstract,ss_o,22897461,test,gold,o
4825,patients with mixed dyslipidaemia and MetS,1,Abstract,hl_p,22897461,test,gold,p
4826,rosuvastatin,1,Abstract,hl_i,22897461,test,gold,i
4827,fenofibrate,1,Abstract,hl_i,22897461,test,gold,i
4828,ω-3 fatty acids,1,Abstract,hl_i,22897461,test,gold,i
4829,lipoprotein subfraction profile,1,Abstract,hl_o,22897461,test,gold,o
4830,200 mg/dl to rosuvastatin,2,Abstract,ss_i,22897461,test,gold,i
4831,30 ) or rosuvastatin,2,Abstract,ss_i,22897461,test,gold,i
4832,combined with fenofibrate,2,Abstract,ss_i,22897461,test,gold,i
4833,30 ) or ω-3 fatty,2,Abstract,ss_i,22897461,test,gold,i
4834,patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl,2,Abstract,hl_p,22897461,test,gold,p
4835,rosuvastatin,2,Abstract,hl_i,22897461,test,gold,i
4836,rosuvastatin,2,Abstract,hl_i,22897461,test,gold,i
4837,fenofibrate,2,Abstract,hl_i,22897461,test,gold,i
4838,ω-3 fatty,2,Abstract,hl_i,22897461,test,gold,i
4839,"study , only patients with MetS were included",3,Abstract,ss_p,22897461,test,gold,p
4840,in the,3,Abstract,ss_i,22897461,test,gold,i
4841,RF,3,Abstract,ss_i,22897461,test,gold,i
4842,patients with MetS,3,Abstract,hl_p,22897461,test,gold,p
4843,"treatment , the lipoprotein subfraction profile was determined by polyacrylamide 3 % gel electrophoresis",4,Abstract,ss_o,22897461,test,gold,o
4844,lipoprotein subfraction,4,Abstract,hl_o,22897461,test,gold,o
4845,RESULTS The mean,5,Abstract,ss_o,22897461,test,gold,o
4846,mean,5,Abstract,hl_o,22897461,test,gold,o
4847,prominent,6,Abstract,ss_i,22897461,test,gold,i
4848,compared with,6,Abstract,ss_i,22897461,test,gold,i
4849,its greater hypotriglyceridemic,6,Abstract,ss_o,22897461,test,gold,o
4850,resistance,7,Abstract,ss_i,22897461,test,gold,i
4851,noted,7,Abstract,ss_i,22897461,test,gold,i
4852,decrease in insulin resistance,7,Abstract,ss_o,22897461,test,gold,o
4853,insulin resistance,7,Abstract,hl_o,22897461,test,gold,o
4854,significantly raised HDL-C,8,Abstract,ss_o,22897461,test,gold,o
4855,increasing the cholesterol of small HDL particles .,8,Abstract,ss_o,22897461,test,gold,o
4856,increased by,9,Abstract,ss_i,22897461,test,gold,i
4857,The cholesterol of larger HDL subclasses,9,Abstract,ss_o,22897461,test,gold,o
4858,cholesterol of larger HDL,9,Abstract,hl_o,22897461,test,gold,o
4859,mean LDL,10,Abstract,ss_i,22897461,test,gold,i
4860,regimens increased mean,10,Abstract,ss_o,22897461,test,gold,o
4861,noted on the HDL subfraction,11,Abstract,ss_o,22897461,test,gold,o
4862,in patients with mixed dyslipidaemia and metabolic syndrome,0,Title,ss_p,22897461,test,gold,p
4863,rosuvastatin,0,Title,ss_i,22897461,test,gold,i
4864,fenofibrate,0,Title,ss_i,22897461,test,gold,i
4865,ω-3 fatty acids,0,Title,ss_i,22897461,test,gold,i
4866,on lipoprotein subfraction profile,0,Title,ss_o,22897461,test,gold,o
4867,patients with mixed dyslipidaemia and metabolic syndrome,0,Title,hl_p,22897461,test,gold,p
4868,rosuvastatin,0,Title,hl_i,22897461,test,gold,i
4869,fenofibrate,0,Title,hl_i,22897461,test,gold,i
4870,ω-3 fatty acids,0,Title,hl_i,22897461,test,gold,i
4871,lipoprotein subfraction profile,0,Title,hl_o,22897461,test,gold,o
4872,chemotherapy,0,Abstract,hl_i,22956006,test,gold,i
4873,receive dexamethasone,1,Abstract,ss_i,22956006,test,gold,i
4874,dexamethasone,1,Abstract,hl_i,22956006,test,gold,i
4875,if patients receiving chemotherapy for breast cancer,2,Abstract,ss_p,22956006,test,gold,p
4876,with dexamethasone or placebo,2,Abstract,ss_i,22956006,test,gold,i
4877,cancer prefer,2,Abstract,ss_o,22956006,test,gold,o
4878,compare quality of life ( QOL ),2,Abstract,ss_o,22956006,test,gold,o
4879,breast cancer,2,Abstract,hl_p,22956006,test,gold,p
4880,chemotherapy,2,Abstract,hl_i,22956006,test,gold,i
4881,dexamethasone,2,Abstract,hl_i,22956006,test,gold,i
4882,placebo,2,Abstract,hl_i,22956006,test,gold,i
4883,quality of life ( QOL ),2,Abstract,hl_o,22956006,test,gold,o
4884,for chemotherapy-naïve patients with breast cancer,3,Abstract,ss_p,22956006,test,gold,p
4885,oral dexamethasone,3,Abstract,ss_i,22956006,test,gold,i
4886,versus placebo,3,Abstract,ss_i,22956006,test,gold,i
4887,chemotherapy-naïve patients with breast cancer,3,Abstract,hl_p,22956006,test,gold,p
4888,dexamethasone,3,Abstract,hl_i,22956006,test,gold,i
4889,placebo,3,Abstract,hl_i,22956006,test,gold,i
4890,intravenous granisetron and dexamethasone,4,Abstract,ss_i,22956006,test,gold,i
4891,oral granisetron,4,Abstract,ss_i,22956006,test,gold,i
4892,granisetron,4,Abstract,hl_i,22956006,test,gold,i
4893,dexamethasone pre-chemotherapy,4,Abstract,hl_i,22956006,test,gold,i
4894,granisetron,4,Abstract,hl_i,22956006,test,gold,i
4895,to 8 .,5,Abstract,ss_p,22956006,test,gold,p
4896,( i ) patient preference ;,5,Abstract,ss_o,22956006,test,gold,o
4897,cycles in change of,5,Abstract,ss_o,22956006,test,gold,o
4898,patient preference,5,Abstract,hl_o,22956006,test,gold,o
4899,Median age of the 94 women was 51 years ( range 27-76 ) :,6,Abstract,ss_p,22956006,test,gold,p
4900,received fluorouracil/epirubicin/cyclophosphamide,6,Abstract,ss_i,22956006,test,gold,i
4901,received doxorubicin/cyclophosphamide,6,Abstract,ss_i,22956006,test,gold,i
4902,94 women,6,Abstract,hl_p,22956006,test,gold,p
4903,51 years ( range 27-76 ),6,Abstract,hl_p,22956006,test,gold,p
4904,fluorouracil/epirubicin/cyclophosphamide,6,Abstract,hl_i,22956006,test,gold,i
4905,doxorubicin/cyclophosphamide,6,Abstract,hl_i,22956006,test,gold,i
4907,preferred placebo,8,Abstract,ss_i,22956006,test,gold,i
4908,35-58 % ) preferred dexamethasone ;,8,Abstract,ss_i,22956006,test,gold,i
4909,"stating a preference , 31 preferred",8,Abstract,ss_o,22956006,test,gold,o
4910,CI : 35-58 % ),8,Abstract,ss_o,22956006,test,gold,o
4911,dexamethasone ; 12 had no,8,Abstract,ss_o,22956006,test,gold,o
4912,placebo,8,Abstract,hl_i,22956006,test,gold,i
4913,dexamethasone,8,Abstract,hl_i,22956006,test,gold,i
4914,"differences in intensity of vomiting , nausea , or time to onset of",9,Abstract,ss_o,22956006,test,gold,o
4915,patients received dexamethasone,10,Abstract,ss_i,22956006,test,gold,i
4916,decrease in,10,Abstract,ss_o,22956006,test,gold,o
4917,dexamethasone .,10,Abstract,ss_o,22956006,test,gold,o
4918,dexamethasone,10,Abstract,hl_i,22956006,test,gold,i
4919,No other,11,Abstract,ss_o,22956006,test,gold,o
4920,symptom/QOL,11,Abstract,hl_o,22956006,test,gold,o
4921,regardless of whether dexamethasone,12,Abstract,ss_i,22956006,test,gold,i
4922,"was found in patient preference , QOL",12,Abstract,ss_o,22956006,test,gold,o
4923,dexamethasone,12,Abstract,hl_i,22956006,test,gold,i
4924,patient preference,12,Abstract,hl_o,22956006,test,gold,o
4925,QOL,12,Abstract,hl_o,22956006,test,gold,o
4926,for breast cancer,0,Title,ss_p,22956006,test,gold,p
4927,dexamethasone,0,Title,ss_i,22956006,test,gold,i
4928,quality of life,0,Title,ss_o,22956006,test,gold,o
4929,breast cancer,0,Title,hl_p,22956006,test,gold,p
4930,placebo-controlled,0,Title,hl_i,22956006,test,gold,i
4931,dexamethasone,0,Title,hl_i,22956006,test,gold,i
4932,chemotherapy,0,Title,hl_i,22956006,test,gold,i
4933,quality of life,0,Title,hl_o,22956006,test,gold,o
4934,patients with mild to moderate depression .,0,Abstract,ss_p,23021296,test,gold,p
4935,patients with mild to moderate depression .,0,Abstract,hl_p,23021296,test,gold,p
4936,physical activity,0,Abstract,hl_i,23021296,test,gold,i
4937,patient 's adherence,1,Abstract,ss_o,23021296,test,gold,o
4938,adherence,1,Abstract,hl_o,23021296,test,gold,o
4939,15 depressive patients who had been under antidepressant treatment for at least one month .,2,Abstract,ss_p,23021296,test,gold,p
4940,15 depressive patients who had been under antidepressant treatment for at least one month,2,Abstract,hl_p,23021296,test,gold,p
4941,physical activity,3,Abstract,ss_i,23021296,test,gold,i
4942,sun exposure,3,Abstract,ss_i,23021296,test,gold,i
4943,physical activity and sun exposure,3,Abstract,ss_o,23021296,test,gold,o
4944,physical activity,3,Abstract,hl_o,23021296,test,gold,o
4945,sun exposure,3,Abstract,hl_o,23021296,test,gold,o
4947,physical activity,5,Abstract,ss_i,23021296,test,gold,i
4948,sun exposure,5,Abstract,ss_i,23021296,test,gold,i
4949,control,5,Abstract,ss_i,23021296,test,gold,i
4950,did not receive these explicit recommendations .,5,Abstract,ss_i,23021296,test,gold,i
4951,physical activity level,5,Abstract,ss_o,23021296,test,gold,o
4952,time of sun exposure,5,Abstract,ss_o,23021296,test,gold,o
4953,physical activity,5,Abstract,hl_i,23021296,test,gold,i
4954,sun exposure,5,Abstract,hl_i,23021296,test,gold,i
4955,control,5,Abstract,hl_i,23021296,test,gold,i
4956,not receive these explicit recommendations,5,Abstract,hl_i,23021296,test,gold,i
4957,physical activity level,5,Abstract,hl_o,23021296,test,gold,o
4958,time of sun exposure,5,Abstract,hl_o,23021296,test,gold,o
4959,sun exposure,6,Abstract,ss_i,23021296,test,gold,i
4960,physical activity,6,Abstract,ss_i,23021296,test,gold,i
4961,time of sun exposure and physical activity,6,Abstract,ss_o,23021296,test,gold,o
4962,time of sun exposure,6,Abstract,hl_o,23021296,test,gold,o
4963,physical activity,6,Abstract,hl_o,23021296,test,gold,o
4964,Depressive patients,7,Abstract,ss_p,23021296,test,gold,p
4965,lifestyle recommendations,7,Abstract,ss_i,23021296,test,gold,i
4966,Depressive patients,7,Abstract,hl_p,23021296,test,gold,p
4967,patients with depression .,0,Title,ss_p,23021296,test,gold,p
4968,lifestyle recommendations,0,Title,ss_i,23021296,test,gold,i
4969,Adherence,0,Title,ss_o,23021296,test,gold,o
4970,patients with depression .,0,Title,hl_p,23021296,test,gold,p
4971,lifestyle,0,Title,hl_i,23021296,test,gold,i
4972,Adherence,0,Title,hl_o,23021296,test,gold,o
4973,patients with refractory monosymptomatic nocturnal enuresis .,0,Abstract,ss_p,23103798,test,gold,p
4974,posterior tibial nerve stimulation,0,Abstract,ss_i,23103798,test,gold,i
4975,early clinical and urodynamic results,0,Abstract,ss_o,23103798,test,gold,o
4976,posterior tibial nerve stimulation,0,Abstract,hl_i,23103798,test,gold,i
4977,28 patients with refractory monosymptomatic nocturnal enuresis,1,Abstract,ss_p,23103798,test,gold,p
4978,28,1,Abstract,hl_p,23103798,test,gold,p
4979,posterior tibial nerve stimulation,2,Abstract,ss_i,23103798,test,gold,i
4980,placebo,2,Abstract,ss_i,23103798,test,gold,i
4981,posterior tibial nerve stimulation,2,Abstract,hl_i,23103798,test,gold,i
4982,placebo,2,Abstract,hl_i,23103798,test,gold,i
4983,posterior tibial nerve stimulation,3,Abstract,ss_i,23103798,test,gold,i
4984,clinical and urodynamic findings .,3,Abstract,ss_o,23103798,test,gold,o
4986,baseline clinical and urodynamic data .,5,Abstract,ss_o,23103798,test,gold,o
4987,detrusor overactivity,6,Abstract,ss_o,23103798,test,gold,o
4988,bladder capacity .,6,Abstract,ss_o,23103798,test,gold,o
4989,detrusor overactivity,6,Abstract,hl_o,23103798,test,gold,o
4990,bladder capacity .,6,Abstract,hl_o,23103798,test,gold,o
4991,posterior tibial nerve stimulation,7,Abstract,ss_i,23103798,test,gold,i
4992,response to posterior tibial nerve stimulation,7,Abstract,ss_o,23103798,test,gold,o
4993,response,7,Abstract,ss_o,23103798,test,gold,o
4994,response,7,Abstract,hl_o,23103798,test,gold,o
4995,response,7,Abstract,hl_o,23103798,test,gold,o
4996,number of wet nights,8,Abstract,ss_o,23103798,test,gold,o
4997,number of wet nights,8,Abstract,hl_o,23103798,test,gold,o
4998,urodynamic parameters,9,Abstract,ss_o,23103798,test,gold,o
4999,urodynamic parameters,9,Abstract,hl_o,23103798,test,gold,o
5000,number of wet nights and urodynamic parameters,10,Abstract,ss_o,23103798,test,gold,o
5001,wet nights,10,Abstract,hl_o,23103798,test,gold,o
5002,urodynamic parameters,10,Abstract,hl_o,23103798,test,gold,o
5003,response,11,Abstract,ss_o,23103798,test,gold,o
5004,response,11,Abstract,hl_o,23103798,test,gold,o
5006,patients with refractory monosymptomatic nocturnal enuresis .,13,Abstract,ss_p,23103798,test,gold,p
5007,Posterior tibial nerve stimulation,13,Abstract,ss_i,23103798,test,gold,i
5008,Posterior tibial nerve stimulation,13,Abstract,hl_i,23103798,test,gold,i
5010,refractory monosymptomatic nocturnal enuresis :,0,Title,ss_p,23103798,test,gold,p
5011,posterior tibial nerve stimulation,0,Title,ss_i,23103798,test,gold,i
5012,posterior tibial nerve stimulation,0,Title,hl_i,23103798,test,gold,i
5013,total knee arthroplasty ( TKA ),0,Abstract,ss_i,23114870,test,gold,i
5014,total knee arthroplasty ( TKA ),0,Abstract,hl_i,23114870,test,gold,i
5016,blood loss,2,Abstract,ss_o,23114870,test,gold,o
5017,early outcomes .,2,Abstract,ss_o,23114870,test,gold,o
5018,blood loss,2,Abstract,hl_o,23114870,test,gold,o
5019,early outcomes .,2,Abstract,hl_o,23114870,test,gold,o
5020,patients undergoing minimally invasive TKA,3,Abstract,ss_p,23114870,test,gold,p
5021,custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,3,Abstract,ss_i,23114870,test,gold,i
5022,blood loss and early clinical outcomes,3,Abstract,ss_o,23114870,test,gold,o
5023,patients undergoing minimally invasive TKA,3,Abstract,hl_p,23114870,test,gold,p
5024,minimally invasive TKA,3,Abstract,hl_i,23114870,test,gold,i
5025,custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,3,Abstract,hl_i,23114870,test,gold,i
5026,blood loss,3,Abstract,hl_o,23114870,test,gold,o
5027,early clinical outcomes,3,Abstract,hl_o,23114870,test,gold,o
5028,80 patients,4,Abstract,ss_p,23114870,test,gold,p
5029,80 patients,4,Abstract,hl_p,23114870,test,gold,p
5031,intramedullary alignment jigs,6,Abstract,ss_i,23114870,test,gold,i
5032,intramedullary alignment jigs,6,Abstract,hl_i,23114870,test,gold,i
5033,custom-fit MRI-based pin guides,7,Abstract,ss_i,23114870,test,gold,i
5034,custom-fit MRI-based pin guides,7,Abstract,hl_i,23114870,test,gold,i
5035,cemented posterior-stabilized implant,8,Abstract,ss_i,23114870,test,gold,i
5036,cemented posterior-stabilized implant,8,Abstract,hl_i,23114870,test,gold,i
5037,volume in the drain bottles,9,Abstract,ss_o,23114870,test,gold,o
5038,Hb loss,9,Abstract,ss_o,23114870,test,gold,o
5039,Hb level .,9,Abstract,ss_o,23114870,test,gold,o
5040,Hb loss,9,Abstract,hl_o,23114870,test,gold,o
5041,Transfusion requirements and surgical time,10,Abstract,ss_o,23114870,test,gold,o
5042,Transfusion requirements,10,Abstract,hl_o,23114870,test,gold,o
5043,surgical time,10,Abstract,hl_o,23114870,test,gold,o
5044,"Knee Society Scores ( KSS ) , knee flexion , knee swelling and pain .",11,Abstract,ss_o,23114870,test,gold,o
5045,"Knee Society Scores ( KSS ) , knee flexion , knee swelling and pain .",11,Abstract,hl_o,23114870,test,gold,o
5046,custom-fit,12,Abstract,ss_i,23114870,test,gold,i
5047,drainage of blood,12,Abstract,ss_o,23114870,test,gold,o
5048,custom-fit,12,Abstract,hl_i,23114870,test,gold,i
5049,drainage of blood,12,Abstract,hl_o,23114870,test,gold,o
5050,loss of Hb,13,Abstract,ss_o,23114870,test,gold,o
5051,loss of Hb,13,Abstract,hl_o,23114870,test,gold,o
5053,custom-fit,15,Abstract,ss_i,23114870,test,gold,i
5054,Surgical time,15,Abstract,ss_o,23114870,test,gold,o
5055,custom-fit,15,Abstract,hl_i,23114870,test,gold,i
5056,Surgical time,15,Abstract,hl_o,23114870,test,gold,o
5057,KSS,16,Abstract,ss_o,23114870,test,gold,o
5058,KSS,16,Abstract,hl_o,23114870,test,gold,o
5059,Knee flexion,17,Abstract,ss_o,23114870,test,gold,o
5060,knee swelling,17,Abstract,ss_o,23114870,test,gold,o
5061,pain,17,Abstract,ss_o,23114870,test,gold,o
5062,Knee flexion,17,Abstract,hl_o,23114870,test,gold,o
5063,knee swelling,17,Abstract,hl_o,23114870,test,gold,o
5064,pain,17,Abstract,hl_o,23114870,test,gold,o
5065,custom-fit pin guides,18,Abstract,ss_i,23114870,test,gold,i
5066,blood drainage,18,Abstract,ss_o,23114870,test,gold,o
5067,Hb loss,18,Abstract,ss_o,23114870,test,gold,o
5068,transfusion rate .,18,Abstract,ss_o,23114870,test,gold,o
5069,custom-fit pin guides,18,Abstract,hl_i,23114870,test,gold,i
5070,blood drainage,18,Abstract,hl_o,23114870,test,gold,o
5071,Hb loss,18,Abstract,hl_o,23114870,test,gold,o
5072,transfusion rate .,18,Abstract,hl_o,23114870,test,gold,o
5073,Surgical time,19,Abstract,ss_o,23114870,test,gold,o
5074,Surgical time,19,Abstract,hl_o,23114870,test,gold,o
5075,early clinical outcomes .,20,Abstract,ss_o,23114870,test,gold,o
5076,early clinical outcomes .,20,Abstract,hl_o,23114870,test,gold,o
5078,total knee arthroplasty :,0,Title,ss_i,23114870,test,gold,i
5079,blood loss and early clinical outcomes .,0,Title,ss_o,23114870,test,gold,o
5080,total knee arthroplasty :,0,Title,hl_i,23114870,test,gold,i
5081,blood loss,0,Title,hl_o,23114870,test,gold,o
5082,early clinical outcomes,0,Title,hl_o,23114870,test,gold,o
5083,sickle cell anemia ( SCA ),0,Abstract,ss_p,23356250,test,gold,p
5084,lime juice,1,Abstract,ss_i,23356250,test,gold,i
5085,lime juice,1,Abstract,hl_i,23356250,test,gold,i
5086,lime juice,2,Abstract,ss_i,23356250,test,gold,i
5087,crisis,2,Abstract,ss_o,23356250,test,gold,o
5088,recurrent bone pain .,2,Abstract,ss_o,23356250,test,gold,o
5089,lime juice,2,Abstract,hl_i,23356250,test,gold,i
5090,recurrent bone pain .,2,Abstract,hl_o,23356250,test,gold,o
5091,children with SCA,3,Abstract,ss_p,23356250,test,gold,p
5092,lime juice,3,Abstract,ss_i,23356250,test,gold,i
5093,clinical and some laboratory characteristics,3,Abstract,ss_o,23356250,test,gold,o
5094,children,3,Abstract,hl_p,23356250,test,gold,p
5095,SCA,3,Abstract,hl_p,23356250,test,gold,p
5096,lime juice,3,Abstract,hl_i,23356250,test,gold,i
5097,113 children with SCA studied in two hospitals,4,Abstract,ss_p,23356250,test,gold,p
5098,lime,4,Abstract,ss_i,23356250,test,gold,i
5099,without lime,4,Abstract,ss_i,23356250,test,gold,i
5100,rates of significant painful episodes,4,Abstract,ss_o,23356250,test,gold,o
5101,113 children,4,Abstract,hl_p,23356250,test,gold,p
5102,SCA,4,Abstract,hl_p,23356250,test,gold,p
5103,without lime,4,Abstract,hl_i,23356250,test,gold,i
5104,significant painful episodes,4,Abstract,hl_o,23356250,test,gold,o
5105,had significant painful episodes,5,Abstract,ss_o,23356250,test,gold,o
5106,92.7 % ) ; febrile illness,5,Abstract,ss_o,23356250,test,gold,o
5107,and admission rate,5,Abstract,ss_o,23356250,test,gold,o
5108,The mean hematocrit,6,Abstract,ss_o,23356250,test,gold,o
5109,"However , transfusion rate , presence of hepatomegaly , splenomegaly , and jaundice",7,Abstract,ss_o,23356250,test,gold,o
5110,with lime,8,Abstract,ss_i,23356250,test,gold,i
5111,any significant side-effect,8,Abstract,ss_o,23356250,test,gold,o
5112,in children with SCA,9,Abstract,ss_p,23356250,test,gold,p
5113,of lime juice,9,Abstract,ss_i,23356250,test,gold,i
5114,children,9,Abstract,hl_p,23356250,test,gold,p
5115,SCA,9,Abstract,hl_p,23356250,test,gold,p
5116,lime juice,9,Abstract,hl_i,23356250,test,gold,i
5117,sickle cell anemia .,0,Title,ss_p,23356250,test,gold,p
5118,lime juice,0,Title,ss_i,23356250,test,gold,i
5119,sickle cell anemia .,0,Title,hl_p,23356250,test,gold,p
5120,lime juice,0,Title,hl_i,23356250,test,gold,i
5121,children with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .,0,Abstract,ss_p,23357440,test,gold,p
5122,cognitive-behavioral therapy ( CBT ),0,Abstract,ss_i,23357440,test,gold,i
5123,treatment as usual ( TAU ),0,Abstract,ss_i,23357440,test,gold,i
5124,efficacy,0,Abstract,ss_o,23357440,test,gold,o
5125,children,0,Abstract,hl_p,23357440,test,gold,p
5126,high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety,0,Abstract,hl_p,23357440,test,gold,p
5127,cognitive-behavioral therapy ( CBT ),0,Abstract,hl_i,23357440,test,gold,i
5128,treatment as usual ( TAU ),0,Abstract,hl_i,23357440,test,gold,i
5129,efficacy,0,Abstract,hl_o,23357440,test,gold,o
5130,45 children ( 7-11 years of age ) with high-functioning ASD and clinically significant anxiety,1,Abstract,ss_p,23357440,test,gold,p
5131,CBT,1,Abstract,ss_i,23357440,test,gold,i
5132,TAU,1,Abstract,ss_i,23357440,test,gold,i
5133,45 children ( 7-11 years of age ),1,Abstract,hl_p,23357440,test,gold,p
5134,high-functioning ASD and clinically significant anxiety,1,Abstract,hl_p,23357440,test,gold,p
5135,CBT,1,Abstract,hl_i,23357440,test,gold,i
5136,TAU,1,Abstract,hl_i,23357440,test,gold,i
5139,CBT,4,Abstract,ss_i,23357440,test,gold,i
5140,TAU,4,Abstract,ss_i,23357440,test,gold,i
5141,primary anxiety outcomes .,4,Abstract,ss_o,23357440,test,gold,o
5142,CBT,4,Abstract,hl_i,23357440,test,gold,i
5143,TAU,4,Abstract,hl_i,23357440,test,gold,i
5144,primary anxiety outcomes .,4,Abstract,hl_o,23357440,test,gold,o
5145,CBT,5,Abstract,ss_i,23357440,test,gold,i
5146,TAU,5,Abstract,ss_i,23357440,test,gold,i
5147,treatment responders,5,Abstract,ss_o,23357440,test,gold,o
5148,CBT,5,Abstract,hl_i,23357440,test,gold,i
5149,TAU,5,Abstract,hl_i,23357440,test,gold,i
5150,CBT,6,Abstract,ss_i,23357440,test,gold,i
5151,CBT,6,Abstract,hl_i,23357440,test,gold,i
5152,CBT,7,Abstract,ss_i,23357440,test,gold,i
5153,anxiety symptoms .,7,Abstract,ss_o,23357440,test,gold,o
5154,CBT,7,Abstract,hl_i,23357440,test,gold,i
5155,anxiety symptoms .,7,Abstract,hl_o,23357440,test,gold,o
5156,youth with ASD .,8,Abstract,ss_p,23357440,test,gold,p
5157,CBT,8,Abstract,ss_i,23357440,test,gold,i
5158,CBT,8,Abstract,hl_i,23357440,test,gold,i
5159,children with autism spectrum disorders :,0,Title,ss_p,23357440,test,gold,p
5160,cognitive-behavioral therapy,0,Title,ss_i,23357440,test,gold,i
5161,treatment as usual,0,Title,ss_i,23357440,test,gold,i
5162,children,0,Title,hl_p,23357440,test,gold,p
5163,autism spectrum disorders,0,Title,hl_p,23357440,test,gold,p
5164,cognitive-behavioral therapy,0,Title,hl_i,23357440,test,gold,i
5165,treatment as usual,0,Title,hl_i,23357440,test,gold,i
5166,diabetic nephropathy,0,Abstract,ss_p,23392542,test,gold,p
5167,thiamine ( vitamin B1 ),0,Abstract,ss_i,23392542,test,gold,i
5168,pyridoxine ( vitamin B6 ),0,Abstract,ss_i,23392542,test,gold,i
5169,circulatory AGE-peptide levels,0,Abstract,ss_o,23392542,test,gold,o
5170,thiamine ( vitamin B1 ),0,Abstract,hl_i,23392542,test,gold,i
5171,pyridoxine ( vitamin B6 ),0,Abstract,hl_i,23392542,test,gold,i
5172,circulatory AGE-peptide levels,0,Abstract,hl_o,23392542,test,gold,o
5173,Type 2 diabetic patients ( N.=57 ) were divided,1,Abstract,ss_p,23392542,test,gold,p
5174,Type 2 diabetic patients,1,Abstract,hl_p,23392542,test,gold,p
5175,N.=57,1,Abstract,hl_p,23392542,test,gold,p
5176,Diabetic nephropathy patients,2,Abstract,ss_p,23392542,test,gold,p
5177,B6,2,Abstract,ss_i,23392542,test,gold,i
5178,B1+B6,2,Abstract,ss_i,23392542,test,gold,i
5179,Diabetic nephropathy patients,2,Abstract,hl_p,23392542,test,gold,p
5180,B6,2,Abstract,hl_i,23392542,test,gold,i
5181,B1+B6,2,Abstract,hl_i,23392542,test,gold,i
5182,"glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate and AGE- peptides",3,Abstract,ss_o,23392542,test,gold,o
5183,"glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate and AGE- peptides",3,Abstract,hl_o,23392542,test,gold,o
5184,AGE-peptides,4,Abstract,ss_o,23392542,test,gold,o
5185,AGE-peptides,4,Abstract,hl_o,23392542,test,gold,o
5186,B1+B6,5,Abstract,ss_i,23392542,test,gold,i
5187,B6 .,5,Abstract,ss_i,23392542,test,gold,i
5188,AGE-peptides,5,Abstract,ss_o,23392542,test,gold,o
5189,B1+B6,5,Abstract,hl_i,23392542,test,gold,i
5190,B6 .,5,Abstract,hl_i,23392542,test,gold,i
5191,AGE-peptides,5,Abstract,hl_o,23392542,test,gold,o
5192,B6,6,Abstract,ss_i,23392542,test,gold,i
5193,HbA1c,6,Abstract,ss_o,23392542,test,gold,o
5194,B6,6,Abstract,hl_i,23392542,test,gold,i
5195,HbA1c,6,Abstract,hl_o,23392542,test,gold,o
5196,B1+B6,7,Abstract,ss_i,23392542,test,gold,i
5197,B6,7,Abstract,ss_i,23392542,test,gold,i
5198,C-peptide,7,Abstract,ss_o,23392542,test,gold,o
5199,B1+B6,7,Abstract,hl_i,23392542,test,gold,i
5200,B6,7,Abstract,hl_i,23392542,test,gold,i
5201,C-peptide,7,Abstract,hl_o,23392542,test,gold,o
5202,"type 2 diabetes mellitus patients "" with nephropathy """,8,Abstract,ss_p,23392542,test,gold,p
5203,plasma AGE-peptides,8,Abstract,ss_o,23392542,test,gold,o
5204,type 2 diabetes mellitus patients,8,Abstract,hl_p,23392542,test,gold,p
5205,plasma AGE-peptides,8,Abstract,hl_o,23392542,test,gold,o
5206,patients with nephropathy,9,Abstract,ss_p,23392542,test,gold,p
5207,B1+B6,9,Abstract,ss_i,23392542,test,gold,i
5208,B6,9,Abstract,ss_i,23392542,test,gold,i
5209,AGE-peptides,9,Abstract,ss_o,23392542,test,gold,o
5210,patients,9,Abstract,hl_p,23392542,test,gold,p
5211,B1+B6,9,Abstract,hl_i,23392542,test,gold,i
5212,B6,9,Abstract,hl_i,23392542,test,gold,i
5213,AGE-peptides,9,Abstract,hl_o,23392542,test,gold,o
5214,C-peptide .,10,Abstract,ss_o,23392542,test,gold,o
5215,C-peptide .,10,Abstract,hl_o,23392542,test,gold,o
5216,early-stage diabetic nephropathy patients,0,Title,ss_p,23392542,test,gold,p
5217,thiamine,0,Title,ss_i,23392542,test,gold,i
5218,pyridoxine,0,Title,ss_i,23392542,test,gold,i
5219,Plasma AGE-peptides and C-peptide,0,Title,ss_o,23392542,test,gold,o
5220,early-stage diabetic nephropathy patients,0,Title,hl_p,23392542,test,gold,p
5221,Plasma AGE-peptides and C-peptide,0,Title,hl_o,23392542,test,gold,o
5223,social skills,1,Abstract,ss_o,23417625,test,gold,o
5224,efficacy .,1,Abstract,ss_o,23417625,test,gold,o
5225,young people with HFA .,2,Abstract,ss_p,23417625,test,gold,p
5226,Social Skills Training Group-based Program ( SST-GP ),2,Abstract,ss_i,23417625,test,gold,i
5227,Leisure Activities Group-based Program ( LA-GP ),2,Abstract,ss_i,23417625,test,gold,i
5228,perception of facial emotions and quality of life ( QoL ),2,Abstract,ss_o,23417625,test,gold,o
5229,Social Skills Training Group-based Program ( SST-GP ),2,Abstract,hl_i,23417625,test,gold,i
5230,Leisure Activities Group-based Program ( LA-GP ),2,Abstract,hl_i,23417625,test,gold,i
5231,Eligible patients were children and adolescents with HFA .,3,Abstract,ss_p,23417625,test,gold,p
5232,children and adolescents,3,Abstract,hl_p,23417625,test,gold,p
5233,HFA,3,Abstract,hl_p,23417625,test,gold,p
5234,SST,4,Abstract,ss_i,23417625,test,gold,i
5235,LA,4,Abstract,ss_i,23417625,test,gold,i
5236,SST,4,Abstract,hl_i,23417625,test,gold,i
5237,LA,4,Abstract,hl_i,23417625,test,gold,i
5238,improvement of 2 points in error rates for facial emotion labeling ( DANVA2 ) from baseline .,5,Abstract,ss_o,23417625,test,gold,o
5239,error rates for facial emotion labeling ( DANVA2 ),5,Abstract,hl_o,23417625,test,gold,o
5240,SST,6,Abstract,ss_i,23417625,test,gold,i
5241,LA,6,Abstract,ss_i,23417625,test,gold,i
5242,labeling anger,6,Abstract,ss_o,23417625,test,gold,o
5243,SST,6,Abstract,hl_i,23417625,test,gold,i
5244,LA,6,Abstract,hl_i,23417625,test,gold,i
5245,SST,7,Abstract,ss_i,23417625,test,gold,i
5246,ability to recognize anger,7,Abstract,ss_o,23417625,test,gold,o
5247,SST,7,Abstract,hl_i,23417625,test,gold,i
5248,ability to recognize anger,7,Abstract,hl_o,23417625,test,gold,o
5249,SST,8,Abstract,ss_i,23417625,test,gold,i
5250,QoL,8,Abstract,ss_o,23417625,test,gold,o
5251,SST,8,Abstract,hl_i,23417625,test,gold,i
5252,QoL,8,Abstract,hl_o,23417625,test,gold,o
5253,SST-GP,9,Abstract,ss_i,23417625,test,gold,i
5254,LA-GP .,9,Abstract,ss_i,23417625,test,gold,i
5255,efficacy,9,Abstract,ss_o,23417625,test,gold,o
5256,SST-GP,9,Abstract,hl_i,23417625,test,gold,i
5257,LA-GP .,9,Abstract,hl_i,23417625,test,gold,i
5258,efficacy,9,Abstract,hl_o,23417625,test,gold,o
5260,children with high-functioning autism :,0,Title,ss_p,23417625,test,gold,p
5261,Social skills,0,Title,ss_i,23417625,test,gold,i
5262,Social skills,0,Title,ss_o,23417625,test,gold,o
5263,children,0,Title,hl_p,23417625,test,gold,p
5264,high-functioning autism,0,Title,hl_p,23417625,test,gold,p
5266,duloxetine,1,Abstract,ss_i,23549581,test,gold,i
5267,average pain severity .,1,Abstract,ss_o,23549581,test,gold,o
5268,duloxetine,1,Abstract,hl_i,23549581,test,gold,i
5269,average pain severity .,1,Abstract,hl_o,23549581,test,gold,o
5270,231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011 .,2,Abstract,ss_p,23549581,test,gold,p
5271,231 patients who were 25 years or older,2,Abstract,hl_p,23549581,test,gold,p
5272,treated at community and academic settings between April 2008 and March 2011,2,Abstract,hl_p,23549581,test,gold,p
5274,duloxetine,4,Abstract,ss_i,23549581,test,gold,i
5275,placebo,4,Abstract,ss_i,23549581,test,gold,i
5276,placebo,4,Abstract,ss_i,23549581,test,gold,i
5277,duloxetine .,4,Abstract,ss_i,23549581,test,gold,i
5278,duloxetine,4,Abstract,hl_i,23549581,test,gold,i
5279,placebo,4,Abstract,hl_i,23549581,test,gold,i
5280,placebo,4,Abstract,hl_i,23549581,test,gold,i
5281,duloxetine .,4,Abstract,hl_i,23549581,test,gold,i
5282,"grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after paclitaxel , other taxane , or oxaliplatin treatment .",5,Abstract,ss_p,23549581,test,gold,p
5283,paclitaxel,5,Abstract,ss_i,23549581,test,gold,i
5284,taxane,5,Abstract,ss_i,23549581,test,gold,i
5285,oxaliplatin,5,Abstract,ss_i,23549581,test,gold,i
5286,"grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after paclitaxel , other taxane , or oxaliplatin treatment .",5,Abstract,hl_p,23549581,test,gold,p
5287,duloxetine,6,Abstract,ss_i,23549581,test,gold,i
5288,placebo,6,Abstract,ss_i,23549581,test,gold,i
5289,duloxetine,6,Abstract,ss_i,23549581,test,gold,i
5290,placebo,6,Abstract,ss_i,23549581,test,gold,i
5291,duloxetine,6,Abstract,hl_i,23549581,test,gold,i
5292,placebo,6,Abstract,hl_i,23549581,test,gold,i
5293,duloxetine,6,Abstract,hl_i,23549581,test,gold,i
5294,placebo,6,Abstract,hl_i,23549581,test,gold,i
5295,duloxetine,7,Abstract,ss_i,23549581,test,gold,i
5296,placebo,7,Abstract,ss_i,23549581,test,gold,i
5297,effective,7,Abstract,ss_o,23549581,test,gold,o
5298,chemotherapy-induced peripheral neuropathic pain .,7,Abstract,ss_o,23549581,test,gold,o
5299,duloxetine,7,Abstract,hl_i,23549581,test,gold,i
5300,placebo,7,Abstract,hl_i,23549581,test,gold,i
5301,chemotherapy-induced peripheral neuropathic pain .,7,Abstract,hl_o,23549581,test,gold,o
5302,"Pain severity was assessed using the Brief Pain Inventory-Short Form "" average pain "" item with 0 representing no pain and 10 representing as bad as can be imagined .",8,Abstract,ss_o,23549581,test,gold,o
5303,Pain severity,8,Abstract,hl_o,23549581,test,gold,o
5304,"Brief Pain Inventory-Short Form "" average pain "" item",8,Abstract,hl_o,23549581,test,gold,o
5305,pain,8,Abstract,hl_o,23549581,test,gold,o
5306,duloxetine,9,Abstract,ss_i,23549581,test,gold,i
5307,placebo,9,Abstract,ss_i,23549581,test,gold,i
5308,average pain,9,Abstract,ss_o,23549581,test,gold,o
5309,average pain,9,Abstract,hl_o,23549581,test,gold,o
5310,duloxetine,10,Abstract,ss_i,23549581,test,gold,i
5311,placebo,10,Abstract,ss_i,23549581,test,gold,i
5312,average pain score,10,Abstract,ss_o,23549581,test,gold,o
5313,duloxetine,10,Abstract,hl_i,23549581,test,gold,i
5314,placebo,10,Abstract,hl_i,23549581,test,gold,i
5315,average pain score,10,Abstract,hl_o,23549581,test,gold,o
5316,duloxetine,11,Abstract,ss_i,23549581,test,gold,i
5317,placebo,11,Abstract,ss_i,23549581,test,gold,i
5318,pain,11,Abstract,ss_o,23549581,test,gold,o
5319,duloxetine,11,Abstract,hl_i,23549581,test,gold,i
5320,pain,11,Abstract,hl_o,23549581,test,gold,o
5321,patients with painful chemotherapy-induced peripheral neuropathy,12,Abstract,ss_p,23549581,test,gold,p
5322,duloxetine,12,Abstract,ss_i,23549581,test,gold,i
5323,placebo,12,Abstract,ss_i,23549581,test,gold,i
5324,chemotherapy-induced peripheral neuropathy,12,Abstract,ss_o,23549581,test,gold,o
5325,reduction in pain .,12,Abstract,ss_o,23549581,test,gold,o
5326,patients with painful chemotherapy-induced peripheral neuropathy,12,Abstract,hl_p,23549581,test,gold,p
5327,duloxetine,12,Abstract,hl_i,23549581,test,gold,i
5328,placebo,12,Abstract,hl_i,23549581,test,gold,i
5329,pain .,12,Abstract,hl_o,23549581,test,gold,o
5331,patients with chemotherapy-induced painful peripheral neuropathy :,0,Title,ss_p,23549581,test,gold,p
5332,duloxetine,0,Title,ss_i,23549581,test,gold,i
5333,"pain , function , and quality of life",0,Title,ss_o,23549581,test,gold,o
5334,patients with chemotherapy-induced painful peripheral neuropathy :,0,Title,hl_p,23549581,test,gold,p
5335,duloxetine,0,Title,hl_i,23549581,test,gold,i
5336,pain,0,Title,hl_o,23549581,test,gold,o
5337,function,0,Title,hl_o,23549581,test,gold,o
5338,quality of life,0,Title,hl_o,23549581,test,gold,o
5339,children with autism,0,Abstract,ss_p,23838728,test,gold,p
5340,children with autism,0,Abstract,hl_p,23838728,test,gold,p
5341,47 teachers and children,1,Abstract,ss_p,23838728,test,gold,p
5342,COMPASS intervention,1,Abstract,ss_i,23838728,test,gold,i
5343,Treatment predictor variables,1,Abstract,ss_o,23838728,test,gold,o
5344,47 teachers and children,1,Abstract,hl_p,23838728,test,gold,p
5345,COMPASS intervention,1,Abstract,hl_i,23838728,test,gold,i
5346,The collaborative model for promoting competence and success,2,Abstract,ss_i,23838728,test,gold,i
5348,Predictors,4,Abstract,ss_o,23838728,test,gold,o
5349,"child , teacher , intervention practice , and implementation practice variables based on an implementation science framework",4,Abstract,ss_o,23838728,test,gold,o
5350,intervention quality ( IEP quality for targeted and not targeted elements ),5,Abstract,ss_o,23838728,test,gold,o
5351,implementation quality variables,5,Abstract,ss_o,23838728,test,gold,o
5353,children with autism .,0,Title,ss_p,23838728,test,gold,p
5354,children with autism .,0,Title,hl_p,23838728,test,gold,p
5355,status epilepticus,0,Abstract,ss_p,23849147,test,gold,p
5356,Bayesian adaptive comparative effectiveness trial,0,Abstract,ss_i,23849147,test,gold,i
5357,effectiveness,0,Abstract,ss_o,23849147,test,gold,o
5358,Bayesian adaptive,0,Abstract,hl_i,23849147,test,gold,i
5359,720 unique patients in emergency departments and uses a Bayesian adaptive design .,1,Abstract,ss_p,23849147,test,gold,p
5360,Bayesian adaptive design .,1,Abstract,ss_i,23849147,test,gold,i
5361,720,1,Abstract,hl_p,23849147,test,gold,p
5362,patients in emergency departments and uses a Bayesian adaptive design,1,Abstract,hl_p,23849147,test,gold,p
5363,Bayesian adaptive design .,1,Abstract,hl_i,23849147,test,gold,i
5364,trial without adaptive randomization,2,Abstract,ss_i,23849147,test,gold,i
5365,proportion of patients,2,Abstract,ss_o,23849147,test,gold,o
5366,total patients,2,Abstract,ss_o,23849147,test,gold,o
5367,patient care,3,Abstract,ss_o,23849147,test,gold,o
5368,power,3,Abstract,ss_o,23849147,test,gold,o
5369,expected sample size .,3,Abstract,ss_o,23849147,test,gold,o
5370,patient care,3,Abstract,hl_o,23849147,test,gold,o
5371,power,3,Abstract,hl_o,23849147,test,gold,o
5372,expected sample size .,3,Abstract,hl_o,23849147,test,gold,o
5373,status epilepticus .,0,Title,ss_p,23849147,test,gold,p
5374,Bayesian adaptive trials,0,Title,ss_i,23849147,test,gold,i
5375,effectiveness,0,Title,ss_o,23849147,test,gold,o
5376,status epilepticus .,0,Title,hl_p,23849147,test,gold,p
5377,Bayesian adaptive,0,Title,hl_i,23849147,test,gold,i
5378,postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .,0,Abstract,ss_p,23985254,test,gold,p
5379,capecitabine-based,0,Abstract,ss_i,23985254,test,gold,i
5380,chemoradiotherapy ( CRT ),0,Abstract,ss_i,23985254,test,gold,i
5381,association,0,Abstract,ss_o,23985254,test,gold,o
5382,single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs ),0,Abstract,ss_o,23985254,test,gold,o
5383,postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .,0,Abstract,hl_p,23985254,test,gold,p
5384,capecitabine-based,0,Abstract,hl_i,23985254,test,gold,i
5385,chemoradiotherapy ( CRT ),0,Abstract,hl_i,23985254,test,gold,i
5386,acute adverse events ( AEs ),0,Abstract,hl_o,23985254,test,gold,o
5387,Four hundred patients with stage II and III rectal cancer received postoperative CRT,1,Abstract,ss_p,23985254,test,gold,p
5388,capecitabine,1,Abstract,ss_i,23985254,test,gold,i
5389,oxaliplatin,1,Abstract,ss_i,23985254,test,gold,i
5390,Four hundred patients with stage II and III rectal cancer received postoperative CRT,1,Abstract,hl_p,23985254,test,gold,p
5391,capecitabine,1,Abstract,hl_i,23985254,test,gold,i
5392,oxaliplatin,1,Abstract,hl_i,23985254,test,gold,i
5394,capecitabine and radiotherapy ( Cap-CRT ),3,Abstract,ss_i,23985254,test,gold,i
5395,capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .,3,Abstract,ss_i,23985254,test,gold,i
5396,capecitabine,3,Abstract,hl_i,23985254,test,gold,i
5397,radiotherapy,3,Abstract,hl_i,23985254,test,gold,i
5398,Cap-CRT,3,Abstract,hl_i,23985254,test,gold,i
5399,capecitabine,3,Abstract,hl_i,23985254,test,gold,i
5400,oxaliplatin,3,Abstract,hl_i,23985254,test,gold,i
5401,radiotherapy,3,Abstract,hl_i,23985254,test,gold,i
5402,Cap-Oxa-CRT,3,Abstract,hl_i,23985254,test,gold,i
5403,"Adverse events were graded according to the Common Terminology Criteria for Adverse Events , v. 3.0 ( CTCAE v3.0 ) .",4,Abstract,ss_o,23985254,test,gold,o
5404,Adverse events,4,Abstract,hl_o,23985254,test,gold,o
5405,"Common Terminology Criteria for Adverse Events , v.",4,Abstract,hl_o,23985254,test,gold,o
5406,genotype of CCND1 A870G,5,Abstract,ss_o,23985254,test,gold,o
5407,polymerase chain reaction-based restriction fragment length polymorphism ( PCR-RFLP ) analysis .,5,Abstract,ss_o,23985254,test,gold,o
5408,associations between the SNP and acute AEs,6,Abstract,ss_o,23985254,test,gold,o
5409,odds ratios ( ORs ),6,Abstract,ss_o,23985254,test,gold,o
5410,confidence intervals ( CIs ),6,Abstract,ss_o,23985254,test,gold,o
5411,logistic regression model .,6,Abstract,ss_o,23985254,test,gold,o
5412,acute AEs,6,Abstract,hl_o,23985254,test,gold,o
5413,AEs .,7,Abstract,ss_o,23985254,test,gold,o
5414,AEs .,7,Abstract,hl_o,23985254,test,gold,o
5415,genotypes,8,Abstract,ss_o,23985254,test,gold,o
5416,AEs .,8,Abstract,ss_o,23985254,test,gold,o
5417,AEs .,8,Abstract,hl_o,23985254,test,gold,o
5418,Diarrhea,9,Abstract,ss_o,23985254,test,gold,o
5419,AE,9,Abstract,ss_o,23985254,test,gold,o
5420,severe diarrhea,9,Abstract,ss_o,23985254,test,gold,o
5421,Diarrhea,9,Abstract,hl_o,23985254,test,gold,o
5422,AE,9,Abstract,hl_o,23985254,test,gold,o
5423,severe diarrhea,9,Abstract,hl_o,23985254,test,gold,o
5424,genotypes,10,Abstract,ss_o,23985254,test,gold,o
5425,severe diarrhea .,10,Abstract,ss_o,23985254,test,gold,o
5426,severe diarrhea .,10,Abstract,hl_o,23985254,test,gold,o
5427,severe diarrhea,11,Abstract,ss_o,23985254,test,gold,o
5428,severe diarrhea,11,Abstract,hl_o,23985254,test,gold,o
5429,Cap-Oxa-CRT,12,Abstract,ss_i,23985254,test,gold,i
5430,Cap-CRT,12,Abstract,ss_i,23985254,test,gold,i
5431,severe diarrhea,12,Abstract,ss_o,23985254,test,gold,o
5432,severe diarrhea .,12,Abstract,ss_o,23985254,test,gold,o
5433,Cap-Oxa-CRT,12,Abstract,hl_i,23985254,test,gold,i
5434,Cap-CRT,12,Abstract,hl_i,23985254,test,gold,i
5435,severe diarrhea,12,Abstract,hl_o,23985254,test,gold,o
5436,severe diarrhea .,12,Abstract,hl_o,23985254,test,gold,o
5437,postoperative stage II and III rectal cancer patients,13,Abstract,ss_p,23985254,test,gold,p
5438,chemoradiotherapy,13,Abstract,ss_i,23985254,test,gold,i
5439,capecitabine,13,Abstract,ss_i,23985254,test,gold,i
5440,oxaliplatin .,13,Abstract,ss_i,23985254,test,gold,i
5441,genetic polymorphism of CCND1 A870G,13,Abstract,ss_o,23985254,test,gold,o
5442,acute AEs,13,Abstract,ss_o,23985254,test,gold,o
5443,postoperative stage II and III rectal cancer patients,13,Abstract,hl_p,23985254,test,gold,p
5444,chemoradiotherapy,13,Abstract,hl_i,23985254,test,gold,i
5445,capecitabine,13,Abstract,hl_i,23985254,test,gold,i
5446,oxaliplatin .,13,Abstract,hl_i,23985254,test,gold,i
5447,acute AEs,13,Abstract,hl_o,23985254,test,gold,o
5448,postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ],0,Title,ss_p,23985254,test,gold,p
5449,chemoradiotherapy ],0,Title,ss_i,23985254,test,gold,i
5450,acute adverse events,0,Title,ss_o,23985254,test,gold,o
5451,postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ],0,Title,hl_p,23985254,test,gold,p
5452,chemoradiotherapy,0,Title,hl_i,23985254,test,gold,i
5453,acute adverse events,0,Title,hl_o,23985254,test,gold,o
5454,children diagnosed with an autism spectrum disorder,0,Abstract,ss_p,24075141,test,gold,p
5455,gluten- and casein-free diet,0,Abstract,ss_i,24075141,test,gold,i
5456,children diagnosed with an autism spectrum disorder,0,Abstract,hl_p,24075141,test,gold,p
5457,gluten- and casein-free diet,0,Abstract,hl_i,24075141,test,gold,i
5459,responses to dietary modification,2,Abstract,ss_o,24075141,test,gold,o
5460,dietary intervention .,3,Abstract,ss_i,24075141,test,gold,i
5461,behavioural and psychometric data,3,Abstract,ss_o,24075141,test,gold,o
5462,response to dietary intervention .,3,Abstract,ss_o,24075141,test,gold,o
5463,dietary intervention .,3,Abstract,hl_i,24075141,test,gold,i
5464,dietary intervention .,4,Abstract,ss_i,24075141,test,gold,i
5465,inattention and hyperactivity behaviours,4,Abstract,ss_o,24075141,test,gold,o
5466,responders to the dietary intervention .,4,Abstract,ss_o,24075141,test,gold,o
5467,dietary intervention .,4,Abstract,hl_i,24075141,test,gold,i
5468,inattention and hyperactivity behaviours,4,Abstract,hl_o,24075141,test,gold,o
5469,dietary intervention,5,Abstract,ss_i,24075141,test,gold,i
5470,response to dietary intervention,5,Abstract,ss_o,24075141,test,gold,o
5471,symptom presentation .,5,Abstract,ss_o,24075141,test,gold,o
5472,dietary intervention,5,Abstract,hl_i,24075141,test,gold,i
5473,response,5,Abstract,hl_o,24075141,test,gold,o
5474,dietary intervention .,6,Abstract,ss_i,24075141,test,gold,i
5475,Chronological age,6,Abstract,ss_o,24075141,test,gold,o
5476,dietary intervention .,6,Abstract,ss_o,24075141,test,gold,o
5477,dietary intervention .,6,Abstract,hl_i,24075141,test,gold,i
5478,"urine compound , trans-indolyl-3-acryloylglycine",7,Abstract,ss_o,24075141,test,gold,o
5479,children with autism,8,Abstract,ss_p,24075141,test,gold,p
5480,gluten- and casein-free diet,8,Abstract,ss_i,24075141,test,gold,i
5481,gluten- and casein-free diet,8,Abstract,hl_i,24075141,test,gold,i
5482,children with autism spectrum disorders :,0,Title,ss_p,24075141,test,gold,p
5483,gluten- and casein-free dietary intervention,0,Title,ss_i,24075141,test,gold,i
5484,behavioural and psychometric measures of dietary response .,0,Title,ss_o,24075141,test,gold,o
5485,children,0,Title,hl_p,24075141,test,gold,p
5486,autism spectrum disorders,0,Title,hl_p,24075141,test,gold,p
5487,gluten- and casein-free dietary intervention,0,Title,hl_i,24075141,test,gold,i
5488,behavioural and psychometric measures,0,Title,hl_o,24075141,test,gold,o
5490,patients with isolated hypertriglyceridemia .,1,Abstract,ss_p,24080592,test,gold,p
5491,simvastatin,1,Abstract,ss_i,24080592,test,gold,i
5492,coagulation and fibrinolysis,1,Abstract,ss_o,24080592,test,gold,o
5493,patients with isolated hypertriglyceridemia .,1,Abstract,hl_p,24080592,test,gold,p
5494,simvastatin,1,Abstract,hl_i,24080592,test,gold,i
5495,coagulation and fibrinolysis,1,Abstract,hl_o,24080592,test,gold,o
5496,39 patients with elevated triglyceride levels and peripheral artery sclerosis,2,Abstract,ss_p,24080592,test,gold,p
5497,simvastatin,2,Abstract,ss_i,24080592,test,gold,i
5498,placebo .,2,Abstract,ss_i,24080592,test,gold,i
5499,39 patients with elevated triglyceride levels and peripheral artery sclerosis,2,Abstract,hl_p,24080592,test,gold,p
5500,simvastatin,2,Abstract,hl_i,24080592,test,gold,i
5501,placebo .,2,Abstract,hl_i,24080592,test,gold,i
5502,"Plasma lipids , glucose homeostasis markers and hemostasic variables",3,Abstract,ss_o,24080592,test,gold,o
5503,"Plasma lipids , glucose homeostasis markers",3,Abstract,hl_o,24080592,test,gold,o
5504,hemostasic variables,3,Abstract,hl_o,24080592,test,gold,o
5505,Simvastatin,4,Abstract,ss_i,24080592,test,gold,i
5506,placebo,4,Abstract,ss_i,24080592,test,gold,i
5507,plasma levels/activity of fibrinogen,4,Abstract,ss_o,24080592,test,gold,o
5508,"0.01 ) , factor VII",4,Abstract,ss_o,24080592,test,gold,o
5509,and plasminogen activator inhibitor-1,4,Abstract,ss_o,24080592,test,gold,o
5510,reduction in von Willebrand factor levels,4,Abstract,ss_o,24080592,test,gold,o
5511,prolong the prothrombin and partial thromboplastin,4,Abstract,ss_o,24080592,test,gold,o
5512,Simvastatin,4,Abstract,hl_i,24080592,test,gold,i
5513,placebo,4,Abstract,hl_i,24080592,test,gold,i
5514,plasma levels/activity of fibrinogen,4,Abstract,hl_o,24080592,test,gold,o
5515,fibrinolysis in patients with isolated hypertriglyceridemia,5,Abstract,ss_p,24080592,test,gold,p
5516,benefits to patients with elevated triglyceride levels,5,Abstract,ss_p,24080592,test,gold,p
5517,suggest that statin,5,Abstract,ss_i,24080592,test,gold,i
5518,effect on coagulation and fibrinolysis,5,Abstract,ss_o,24080592,test,gold,o
5519,patients with isolated hypertriglyceridemia .,0,Title,ss_p,24080592,test,gold,p
5520,simvastatin,0,Title,ss_i,24080592,test,gold,i
5521,hemostasis,0,Title,ss_o,24080592,test,gold,o
5522,patients with isolated hypertriglyceridemia .,0,Title,hl_p,24080592,test,gold,p
5523,simvastatin,0,Title,hl_i,24080592,test,gold,i
5524,root canal,0,Abstract,ss_p,24317958,test,gold,p
5525,"sonic , ultrasonic , and hydrodynamic devices",0,Abstract,ss_i,24317958,test,gold,i
5526,efficiency,0,Abstract,ss_o,24317958,test,gold,o
5527,"sonic , ultrasonic , and hydrodynamic devices",0,Abstract,hl_i,24317958,test,gold,i
5528,efficiency,0,Abstract,hl_o,24317958,test,gold,o
5529,Fifty-three root canals with two standardized grooves in the apical and coronal parts of longitudinally split roots,1,Abstract,ss_p,24317958,test,gold,p
5530,Fifty-three root canals with two standardized grooves in the apical and coronal parts of longitudinally split roots,1,Abstract,hl_p,24317958,test,gold,p
5531,syringe irrigation,2,Abstract,ss_i,24317958,test,gold,i
5532,CanalBrush,2,Abstract,ss_i,24317958,test,gold,i
5533,passive ultrasonic irrigation,2,Abstract,ss_i,24317958,test,gold,i
5534,EndoActivator,2,Abstract,ss_i,24317958,test,gold,i
5535,RinsEndo,2,Abstract,ss_i,24317958,test,gold,i
5536,syringe irrigation,2,Abstract,hl_i,24317958,test,gold,i
5537,CanalBrush,2,Abstract,hl_i,24317958,test,gold,i
5538,passive ultrasonic irrigation,2,Abstract,hl_i,24317958,test,gold,i
5539,EndoActivator,2,Abstract,hl_i,24317958,test,gold,i
5540,RinsEndo,2,Abstract,hl_i,24317958,test,gold,i
5541,randomization .,3,Abstract,ss_o,24317958,test,gold,o
5542,The amount of remaining sealer in the root canal irregularities was evaluated under a microscope using a 4-grade scoring,4,Abstract,ss_o,24317958,test,gold,o
5543,whereas the remaining sealer on the root canal surface was evaluated with a 7-grade scoring,4,Abstract,ss_o,24317958,test,gold,o
5544,amount of remaining sealer in the root canal irregularities,4,Abstract,hl_o,24317958,test,gold,o
5545,RESULTS Passive ultrasonic irrigation,5,Abstract,ss_i,24317958,test,gold,i
5546,other tested irrigation systems or syringe irrigation,5,Abstract,ss_i,24317958,test,gold,i
5547,irrigation in removing sealer from root canal,5,Abstract,ss_o,24317958,test,gold,o
5548,Passive ultrasonic irrigation,5,Abstract,hl_i,24317958,test,gold,i
5549,irrigation systems,5,Abstract,hl_i,24317958,test,gold,i
5550,syringe irrigation,5,Abstract,hl_i,24317958,test,gold,i
5551,significant effect on cleaning the lateral,6,Abstract,ss_o,24317958,test,gold,o
5552,study protocol ultrasonic,7,Abstract,ss_i,24317958,test,gold,i
5553,superior effect on sealer removal from the root canal,7,Abstract,ss_o,24317958,test,gold,o
5554,ultrasonic,7,Abstract,hl_i,24317958,test,gold,i
5556,treatment failure .,9,Abstract,ss_i,24317958,test,gold,i
5557,RELEVANCE Incomplete removal of root canal,9,Abstract,ss_o,24317958,test,gold,o
5558,Passive Ultrasonic,10,Abstract,ss_i,24317958,test,gold,i
5559,effective system to remove sealer from a,10,Abstract,ss_o,24317958,test,gold,o
5560,Passive Ultrasonic,10,Abstract,hl_i,24317958,test,gold,i
5562,children and adolescents with autistic disorders .,0,Abstract,ss_p,24350813,test,gold,p
5563,risperidone,0,Abstract,ss_i,24350813,test,gold,i
5564,long-term safety and efficacy,0,Abstract,ss_o,24350813,test,gold,o
5565,children and adolescents,0,Abstract,hl_p,24350813,test,gold,p
5566,autistic disorders,0,Abstract,hl_p,24350813,test,gold,p
5567,risperidone,0,Abstract,hl_i,24350813,test,gold,i
5568,"patients ( 5-17 years of age , who completed the previous fixed-dose , 6 week , double-blind [ DB ] phase )",1,Abstract,ss_p,24350813,test,gold,p
5569,risperidone,1,Abstract,ss_i,24350813,test,gold,i
5570,5-17 years of age,1,Abstract,hl_p,24350813,test,gold,p
5571,risperidone,1,Abstract,hl_i,24350813,test,gold,i
5573,assessed risperidone 's,3,Abstract,ss_i,24350813,test,gold,i
5574,risperidone 's safety ; efficacy,3,Abstract,ss_o,24350813,test,gold,o
5575,risperidone,3,Abstract,hl_i,24350813,test,gold,i
5576,safety,3,Abstract,hl_o,24350813,test,gold,o
5577,efficacy,3,Abstract,hl_o,24350813,test,gold,o
5578,RESULTS Fifty-six ( 71 % ) out of 79 enrolled patients completed the OLE ;,4,Abstract,ss_p,24350813,test,gold,p
5579,or adverse events ( AE ),4,Abstract,ss_o,24350813,test,gold,o
5580,adverse events,4,Abstract,hl_o,24350813,test,gold,o
5581,group ),5,Abstract,ss_o,24350813,test,gold,o
5582,were increased appetite,5,Abstract,ss_o,24350813,test,gold,o
5583,[ n=9 ] ) ; increased weight and vomiting,5,Abstract,ss_o,24350813,test,gold,o
5584,"each ) ; sedation , pyrexia , and upper respiratory tract infection",5,Abstract,ss_o,24350813,test,gold,o
5585,each ) ; nasopharyngitis,5,Abstract,ss_o,24350813,test,gold,o
5586,and somnolence and fatigue,5,Abstract,ss_o,24350813,test,gold,o
5587,each ) .,5,Abstract,ss_o,24350813,test,gold,o
5588,increased appetite,5,Abstract,hl_o,24350813,test,gold,o
5589,increased weight,5,Abstract,hl_o,24350813,test,gold,o
5590,vomiting,5,Abstract,hl_o,24350813,test,gold,o
5591,sedation,5,Abstract,hl_o,24350813,test,gold,o
5592,pyrexia,5,Abstract,hl_o,24350813,test,gold,o
5593,upper respiratory tract infection,5,Abstract,hl_o,24350813,test,gold,o
5594,nasopharyngitis,5,Abstract,hl_o,24350813,test,gold,o
5595,somnolence,5,Abstract,hl_o,24350813,test,gold,o
5596,fatigue,5,Abstract,hl_o,24350813,test,gold,o
5597,Extrapyramidal,6,Abstract,ss_o,24350813,test,gold,o
5598,patients .,6,Abstract,ss_o,24350813,test,gold,o
5599,Extrapyramidal,6,Abstract,hl_o,24350813,test,gold,o
5600,Increase in mean weight,7,Abstract,ss_o,24350813,test,gold,o
5601,and body mass index,7,Abstract,ss_o,24350813,test,gold,o
5602,because of weight increase,7,Abstract,ss_o,24350813,test,gold,o
5603,weight,7,Abstract,hl_o,24350813,test,gold,o
5604,potentially prolactin-related AE ( irregular menstruation ),8,Abstract,ss_o,24350813,test,gold,o
5605,prolactin-related AE,8,Abstract,hl_o,24350813,test,gold,o
5606,irregular menstruation,8,Abstract,hl_o,24350813,test,gold,o
5607,The risperidone,9,Abstract,ss_i,24350813,test,gold,i
5608,greatest mean improvement in sleep visual analog scale,9,Abstract,ss_o,24350813,test,gold,o
5609,risperidone,9,Abstract,hl_i,24350813,test,gold,i
5610,sleep visual analog scale,9,Abstract,hl_o,24350813,test,gold,o
5611,improvement in efficacy scale scores,10,Abstract,ss_o,24350813,test,gold,o
5612,efficacy,10,Abstract,hl_o,24350813,test,gold,o
5613,with risperidone,11,Abstract,ss_i,24350813,test,gold,i
5614,for risperidone,11,Abstract,ss_i,24350813,test,gold,i
5615,"OLE , safety",11,Abstract,ss_o,24350813,test,gold,o
5616,current safety,11,Abstract,ss_o,24350813,test,gold,o
5617,improvement in irritability and related behaviors,12,Abstract,ss_o,24350813,test,gold,o
5619,children and adolescents with autistic disorder .,0,Title,ss_p,24350813,test,gold,p
5620,risperidone,0,Title,ss_i,24350813,test,gold,i
5621,safety,0,Title,ss_o,24350813,test,gold,o
5622,efficacy,0,Title,ss_o,24350813,test,gold,o
5623,children and adolescents,0,Title,hl_p,24350813,test,gold,p
5624,autistic disorder,0,Title,hl_p,24350813,test,gold,p
5625,risperidone,0,Title,hl_i,24350813,test,gold,i
5626,Attention deficit hyperactivity disorder ( ADHD ) and autism spectrum disorder ( ASD ),0,Abstract,ss_p,24451919,test,gold,p
5627,Attention deficit hyperactivity disorder ( ADHD ) and autism spectrum disorder ( ASD ),0,Abstract,hl_p,24451919,test,gold,p
5629,shared and disorder-specific brain dysfunctions,2,Abstract,ss_o,24451919,test,gold,o
5630,"Age-matched boys with ADHD ( 15 ) , ASD ( 18 ) , and controls ( 21 )",3,Abstract,ss_p,24451919,test,gold,p
5631,functional magnetic resonance imaging ( fMRI ),3,Abstract,ss_o,24451919,test,gold,o
5632,15,3,Abstract,hl_p,24451919,test,gold,p
5633,18,3,Abstract,hl_p,24451919,test,gold,p
5634,21,3,Abstract,hl_p,24451919,test,gold,p
5635,Fluoxetine,4,Abstract,ss_i,24451919,test,gold,i
5636,placebo,4,Abstract,ss_i,24451919,test,gold,i
5637,Fluoxetine,4,Abstract,hl_i,24451919,test,gold,i
5638,placebo,4,Abstract,hl_i,24451919,test,gold,i
5641,placebo,7,Abstract,ss_i,24451919,test,gold,i
5642,fMRI,7,Abstract,ss_o,24451919,test,gold,o
5643,medial prefrontal cortex ( mPFC ),7,Abstract,ss_o,24451919,test,gold,o
5644,placebo,7,Abstract,hl_i,24451919,test,gold,i
5645,medial prefrontal cortex ( mPFC ),7,Abstract,hl_o,24451919,test,gold,o
5646,precuneus activation .,8,Abstract,ss_o,24451919,test,gold,o
5647,precuneus activation .,8,Abstract,hl_o,24451919,test,gold,o
5648,Fluoxetine,9,Abstract,ss_i,24451919,test,gold,i
5649,placebo,9,Abstract,ss_i,24451919,test,gold,i
5650,mPFC activation,9,Abstract,ss_o,24451919,test,gold,o
5651,task performance,9,Abstract,ss_o,24451919,test,gold,o
5652,Fluoxetine,9,Abstract,hl_i,24451919,test,gold,i
5653,placebo,9,Abstract,hl_i,24451919,test,gold,i
5654,mPFC activation,9,Abstract,hl_o,24451919,test,gold,o
5655,task performance,9,Abstract,hl_o,24451919,test,gold,o
5656,Fluoxetine,10,Abstract,ss_i,24451919,test,gold,i
5657,effects,10,Abstract,ss_o,24451919,test,gold,o
5658,mPFC activation,10,Abstract,ss_o,24451919,test,gold,o
5659,Fluoxetine,10,Abstract,hl_i,24451919,test,gold,i
5660,mPFC activation,10,Abstract,hl_o,24451919,test,gold,o
5661,ADHD and Autism .,0,Title,ss_p,24451919,test,gold,p
5662,Fluoxetine,0,Title,ss_i,24451919,test,gold,i
5663,Medial Prefrontal Cortex Activation,0,Title,ss_o,24451919,test,gold,o
5664,ADHD and Autism .,0,Title,hl_p,24451919,test,gold,p
5665,Fluoxetine,0,Title,hl_i,24451919,test,gold,i
5666,autism spectrum disorder ( ASD ),0,Abstract,ss_p,24515505,test,gold,p
5667,autism spectrum disorder ( ASD ) diagnoses,0,Abstract,ss_i,24515505,test,gold,i
5668,"service use , caregiver time , and cost outcomes .",0,Abstract,ss_o,24515505,test,gold,o
5669,autism spectrum disorder ( ASD ),0,Abstract,hl_p,24515505,test,gold,p
5670,service use,0,Abstract,hl_o,24515505,test,gold,o
5671,caregiver time,0,Abstract,hl_o,24515505,test,gold,o
5672,cost outcomes,0,Abstract,hl_o,24515505,test,gold,o
5673,"children aged 3 to 17 years , with and without parent-reported ASD .",1,Abstract,ss_p,24515505,test,gold,p
5674,with and without parent-reported ASD .,1,Abstract,ss_i,24515505,test,gold,i
5675,"annual utilization and costs for health care , school , ASD-related therapy , family-coordinated services , as well as caregiver time",1,Abstract,ss_o,24515505,test,gold,o
5676,children aged 3 to 17 years,1,Abstract,hl_p,24515505,test,gold,p
5677,parent-reported ASD,1,Abstract,hl_p,24515505,test,gold,p
5678,annual utilization and costs,1,Abstract,hl_o,24515505,test,gold,o
5679,health care,1,Abstract,hl_o,24515505,test,gold,o
5680,school,1,Abstract,hl_o,24515505,test,gold,o
5681,ASD-related therapy,1,Abstract,hl_o,24515505,test,gold,o
5682,family-coordinated services,1,Abstract,hl_o,24515505,test,gold,o
5683,caregiver time,1,Abstract,hl_o,24515505,test,gold,o
5684,ASD diagnosis,2,Abstract,ss_i,24515505,test,gold,i
5685,Regression analyses,2,Abstract,ss_o,24515505,test,gold,o
5686,"association between ASD diagnosis and cost , controlling for child gender , age , race/ethnicity , insurance status , household income , country region and urban/rural classification , and non-ASD-related illnesses .",2,Abstract,ss_o,24515505,test,gold,o
5687,cost,2,Abstract,hl_o,24515505,test,gold,o
5688,Children with parent-reported ASD,3,Abstract,ss_p,24515505,test,gold,p
5689,Children with parent-reported ASD,3,Abstract,ss_i,24515505,test,gold,i
5690,children without ASD,3,Abstract,ss_i,24515505,test,gold,i
5691,health care office visits and prescription drug use,3,Abstract,ss_o,24515505,test,gold,o
5692,Children with parent-reported ASD,3,Abstract,hl_p,24515505,test,gold,p
5693,health care office visits,3,Abstract,hl_o,24515505,test,gold,o
5694,prescription drug use,3,Abstract,hl_o,24515505,test,gold,o
5695,children in the ASD,4,Abstract,ss_i,24515505,test,gold,i
5696,control,4,Abstract,ss_i,24515505,test,gold,i
5697,special educational services,4,Abstract,ss_o,24515505,test,gold,o
5698,special educational services,4,Abstract,hl_o,24515505,test,gold,o
5699,health care costs,5,Abstract,ss_o,24515505,test,gold,o
5700,non-health care costs,5,Abstract,ss_o,24515505,test,gold,o
5701,higher school costs .,5,Abstract,ss_o,24515505,test,gold,o
5702,health care costs,5,Abstract,hl_o,24515505,test,gold,o
5703,non-health care costs,5,Abstract,hl_o,24515505,test,gold,o
5704,higher school costs .,5,Abstract,hl_o,24515505,test,gold,o
5705,parents who reported that their child had ASD,6,Abstract,ss_i,24515505,test,gold,i
5706,control,6,Abstract,ss_i,24515505,test,gold,i
5707,out-of-pocket costs,6,Abstract,ss_o,24515505,test,gold,o
5708,time on caregiving activities,6,Abstract,ss_o,24515505,test,gold,o
5709,out-of-pocket costs,6,Abstract,hl_o,24515505,test,gold,o
5710,time on caregiving activities,6,Abstract,hl_o,24515505,test,gold,o
5711,economic burden,7,Abstract,ss_o,24515505,test,gold,o
5712,economic burden,8,Abstract,ss_o,24515505,test,gold,o
5713,childhood autism spectrum disorders .,0,Title,ss_p,24515505,test,gold,p
5714,childhood autism spectrum disorders .,0,Title,ss_i,24515505,test,gold,i
5715,Economic burden,0,Title,ss_o,24515505,test,gold,o
5716,childhood autism spectrum disorders,0,Title,hl_p,24515505,test,gold,p
5717,COPD patients,0,Abstract,ss_p,24726342,test,gold,p
5718,forced expiratory volume at 1s ( ΔFEV1 ) and forced vital capacity ( ΔFVC ),0,Abstract,ss_o,24726342,test,gold,o
5719,COPD patients,0,Abstract,hl_p,24726342,test,gold,p
5720,"tone , bronchodilators",1,Abstract,ss_i,24726342,test,gold,i
5721,"decrease dynamic hyperinflation , gas trapping",1,Abstract,ss_o,24726342,test,gold,o
5722,possibly dyspnea at rest,1,Abstract,ss_o,24726342,test,gold,o
5723,to bronchodilators,2,Abstract,ss_i,24726342,test,gold,i
5724,that specific airway resistance changes ( ΔsRAW ),2,Abstract,ss_o,24726342,test,gold,o
5725,specific airway resistance changes ( ΔsRAW ),2,Abstract,hl_o,24726342,test,gold,o
5726,"days , 60 COPD patients",3,Abstract,ss_p,24726342,test,gold,p
5727,after placebo,3,Abstract,ss_i,24726342,test,gold,i
5728,300μg indacaterol,3,Abstract,ss_i,24726342,test,gold,i
5729,underwent dyspnea evaluation ( VAS score ) and pulmonary function testing,3,Abstract,ss_o,24726342,test,gold,o
5730,60 COPD,3,Abstract,hl_p,24726342,test,gold,p
5731,placebo,3,Abstract,hl_i,24726342,test,gold,i
5732,indacaterol,3,Abstract,hl_i,24726342,test,gold,i
5733,dyspnea evaluation ( VAS score ),3,Abstract,hl_o,24726342,test,gold,o
5734,pulmonary function,3,Abstract,hl_o,24726342,test,gold,o
5735,RESULTS Spirographic and ΔsRAW-based criteria,4,Abstract,ss_o,24726342,test,gold,o
5736,Spirographic,4,Abstract,hl_o,24726342,test,gold,o
5737,ΔsRAW-based,4,Abstract,hl_o,24726342,test,gold,o
5738,changes of intrathoracic gas volume ( ΔITGV ),5,Abstract,ss_o,24726342,test,gold,o
5739,"p < 0.001 ) , residual volume",5,Abstract,ss_o,24726342,test,gold,o
5740,p < 0.001 ),5,Abstract,ss_o,24726342,test,gold,o
5741,p=0.001 ),5,Abstract,ss_o,24726342,test,gold,o
5742,"p < 0.001 ) , while",5,Abstract,ss_o,24726342,test,gold,o
5743,correlated only,5,Abstract,ss_o,24726342,test,gold,o
5744,ΔsRAW,5,Abstract,hl_o,24726342,test,gold,o
5745,intrathoracic gas volume ( ΔITGV ),5,Abstract,hl_o,24726342,test,gold,o
5746,residual volume,5,Abstract,hl_o,24726342,test,gold,o
5747,in terms,6,Abstract,ss_o,24726342,test,gold,o
5748,ΔITGV ( p=0.002 ),6,Abstract,ss_o,24726342,test,gold,o
5749,( p=0.023 ),6,Abstract,ss_o,24726342,test,gold,o
5750,stratified according,6,Abstract,ss_o,24726342,test,gold,o
5751,functional effect of,7,Abstract,ss_i,24726342,test,gold,i
5752,closely related to,7,Abstract,ss_i,24726342,test,gold,i
5753,bronchodilator-induced improvements of lung mechanics and,7,Abstract,ss_o,24726342,test,gold,o
5754,ΔsRAW-based,7,Abstract,hl_o,24726342,test,gold,o
5755,FEV1-FVC-based,7,Abstract,hl_o,24726342,test,gold,o
5756,stable COPD patients .,0,Title,ss_p,24726342,test,gold,p
5757,bronchodilator,0,Title,ss_i,24726342,test,gold,i
5758,effects,0,Title,ss_o,24726342,test,gold,o
5759,stable COPD patients .,0,Title,hl_p,24726342,test,gold,p
5760,Individuals with autism spectrum disorder ( ASD ),0,Abstract,ss_p,24803369,test,gold,p
5761,metaphors .,0,Abstract,ss_i,24803369,test,gold,i
5762,comprehending metaphors .,0,Abstract,ss_o,24803369,test,gold,o
5763,Individuals with autism spectrum disorder ( ASD ),0,Abstract,hl_p,24803369,test,gold,p
5764,metaphors .,0,Abstract,hl_i,24803369,test,gold,i
5765,comprehending metaphors,0,Abstract,hl_o,24803369,test,gold,o
5766,conceptual metaphors,1,Abstract,ss_i,24803369,test,gold,i
5767,conceptual metaphors,1,Abstract,ss_o,24803369,test,gold,o
5768,conceptual metaphors,1,Abstract,hl_i,24803369,test,gold,i
5769,conceptual metaphors,1,Abstract,hl_o,24803369,test,gold,o
5771,13 participants with ASD ( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls,3,Abstract,ss_p,24803369,test,gold,p
5772,conceptual metaphors,3,Abstract,ss_i,24803369,test,gold,i
5773,lexicalized conceptual metaphors,3,Abstract,ss_o,24803369,test,gold,o
5774,novel ones,3,Abstract,ss_o,24803369,test,gold,o
5775,13 participants with ASD,3,Abstract,hl_p,24803369,test,gold,p
5776,age 7 ; 03-22 ; 03,3,Abstract,hl_p,24803369,test,gold,p
5777,13 age-matched typically developing ( TD ) controls,3,Abstract,hl_p,24803369,test,gold,p
5778,lexicalized conceptual metaphors,3,Abstract,hl_i,24803369,test,gold,i
5779,lexicalized conceptual metaphors,3,Abstract,hl_o,24803369,test,gold,o
5780,novel ones,3,Abstract,hl_o,24803369,test,gold,o
5781,Individuals with ASD,4,Abstract,ss_p,24803369,test,gold,p
5782,metaphor,4,Abstract,ss_i,24803369,test,gold,i
5783,metaphor,4,Abstract,ss_o,24803369,test,gold,o
5784,Individuals with ASD,4,Abstract,hl_p,24803369,test,gold,p
5785,metaphor,4,Abstract,hl_i,24803369,test,gold,i
5786,metaphor,4,Abstract,hl_o,24803369,test,gold,o
5788,Youth with autism spectrum disorder,0,Title,ss_p,24803369,test,gold,p
5789,lexicalized,0,Title,ss_i,24803369,test,gold,i
5790,primary conceptual metaphors .,0,Title,ss_i,24803369,test,gold,i
5791,Youth,0,Title,hl_p,24803369,test,gold,p
5792,autism spectrum disorder,0,Title,hl_p,24803369,test,gold,p
5793,lexicalized,0,Title,hl_i,24803369,test,gold,i
5794,primary conceptual metaphors .,0,Title,hl_i,24803369,test,gold,i
5795,molecular test,0,Abstract,ss_i,24960665,test,gold,i
5796,paternal RHD zygosity,0,Abstract,ss_o,24960665,test,gold,o
5797,molecular test,0,Abstract,hl_i,24960665,test,gold,i
5798,370 RH:1 Tunisian donors,1,Abstract,ss_p,24960665,test,gold,p
5799,polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ),1,Abstract,ss_i,24960665,test,gold,i
5800,polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ),1,Abstract,ss_i,24960665,test,gold,i
5801,hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ),1,Abstract,ss_i,24960665,test,gold,i
5802,RHD zygosity,1,Abstract,ss_o,24960665,test,gold,o
5803,polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ),1,Abstract,ss_o,24960665,test,gold,o
5804,polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .,1,Abstract,ss_o,24960665,test,gold,o
5805,370 RH:1 Tunisian donors,1,Abstract,hl_p,24960665,test,gold,p
5806,polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ),1,Abstract,hl_i,24960665,test,gold,i
5807,real time quantitative polymerase chain reaction ( RQ-PCR ),1,Abstract,hl_i,24960665,test,gold,i
5808,molecular tests,2,Abstract,ss_i,24960665,test,gold,i
5809,PCR,2,Abstract,ss_i,24960665,test,gold,i
5810,370 donors,3,Abstract,ss_p,24960665,test,gold,p
5811,370 donors,3,Abstract,hl_p,24960665,test,gold,p
5812,RQ-PCR .,4,Abstract,ss_i,24960665,test,gold,i
5813,Positive predictive values,4,Abstract,ss_o,24960665,test,gold,o
5814,Positive predictive values,4,Abstract,hl_o,24960665,test,gold,o
5815,"PCR-SSP , PCR-RFLP and RQ-PCR",5,Abstract,ss_i,24960665,test,gold,i
5816,Negative predictive values,5,Abstract,ss_o,24960665,test,gold,o
5817,Negative predictive values,5,Abstract,hl_o,24960665,test,gold,o
5818,Rhesus box polymorphisms,6,Abstract,ss_o,24960665,test,gold,o
5819,RHD alleles :,6,Abstract,ss_o,24960665,test,gold,o
5820,Rhesus box polymorphisms,6,Abstract,hl_o,24960665,test,gold,o
5821,RHD alleles :,6,Abstract,hl_o,24960665,test,gold,o
5822,Tunisians .,7,Abstract,ss_p,24960665,test,gold,p
5823,RQ-PCR,7,Abstract,ss_i,24960665,test,gold,i
5824,paternal RHD zygosity,7,Abstract,ss_o,24960665,test,gold,o
5825,RQ-PCR,7,Abstract,hl_i,24960665,test,gold,i
5826,PCR-RFLP,8,Abstract,ss_i,24960665,test,gold,i
5827,PCR-RFLP,8,Abstract,ss_o,24960665,test,gold,o
5828,PCR-RFLP,8,Abstract,hl_i,24960665,test,gold,i
5829,Tunisians :,0,Title,ss_p,24960665,test,gold,p
5830,molecular tests .,0,Title,ss_i,24960665,test,gold,i
5831,Paternal RHD zygosity,0,Title,ss_o,24960665,test,gold,o
5832,Tunisians :,0,Title,hl_p,24960665,test,gold,p
5833,children with autism spectrum disorders ( ASDs ),0,Abstract,ss_p,24989854,test,gold,p
5834,Social skills training ( SST ),0,Abstract,ss_i,24989854,test,gold,i
5835,social and communication skills .,0,Abstract,ss_o,24989854,test,gold,o
5836,children with autism spectrum disorders ( ASDs ),0,Abstract,hl_p,24989854,test,gold,p
5837,Social skills training ( SST ),0,Abstract,hl_i,24989854,test,gold,i
5838,children with ASD,1,Abstract,ss_p,24989854,test,gold,p
5839,SSTs,1,Abstract,ss_i,24989854,test,gold,i
5840,effectiveness,1,Abstract,ss_o,24989854,test,gold,o
5841,children with ASD,1,Abstract,hl_p,24989854,test,gold,p
5842,SSTs,1,Abstract,hl_i,24989854,test,gold,i
5843,long term outcome,2,Abstract,ss_o,24989854,test,gold,o
5844,generalization of learned skills,2,Abstract,ss_o,24989854,test,gold,o
5845,SST,3,Abstract,ss_i,24989854,test,gold,i
5846,effectiveness,3,Abstract,ss_o,24989854,test,gold,o
5847,generalization of learned social skills to daily life .,3,Abstract,ss_o,24989854,test,gold,o
5848,SST,3,Abstract,hl_i,24989854,test,gold,i
5849,SST,4,Abstract,ss_i,24989854,test,gold,i
5850,treatment efficacy,4,Abstract,ss_o,24989854,test,gold,o
5851,generalization of learned skills to daily life .,4,Abstract,ss_o,24989854,test,gold,o
5852,SST,4,Abstract,hl_i,24989854,test,gold,i
5853,120 participants with ASD at the end of primary school ( 10-12 years of calendar age ),5,Abstract,ss_p,24989854,test,gold,p
5854,"SST , SST-PTI ( SST with Parent & Teacher Involvement )",5,Abstract,ss_i,24989854,test,gold,i
5855,care-as-usual .,5,Abstract,ss_i,24989854,test,gold,i
5856,120 participants with ASD at the end of primary school,5,Abstract,hl_p,24989854,test,gold,p
5857,10-12 years of calendar age,5,Abstract,hl_p,24989854,test,gold,p
5858,"SST , SST-PTI ( SST with Parent & Teacher Involvement )",5,Abstract,hl_i,24989854,test,gold,i
5859,care-as-usual .,5,Abstract,hl_i,24989854,test,gold,i
5860,SST,6,Abstract,ss_i,24989854,test,gold,i
5861,SST,6,Abstract,hl_i,24989854,test,gold,i
5862,SST-PTI,7,Abstract,ss_i,24989854,test,gold,i
5863,SST-PTI,7,Abstract,hl_i,24989854,test,gold,i
5865,socialization,9,Abstract,ss_o,24989854,test,gold,o
5866,adaptive functioning .,9,Abstract,ss_o,24989854,test,gold,o
5867,socialization,9,Abstract,hl_o,24989854,test,gold,o
5868,SST,10,Abstract,ss_i,24989854,test,gold,i
5869,specific social skills,10,Abstract,ss_o,24989854,test,gold,o
5870,general social skills,10,Abstract,ss_o,24989854,test,gold,o
5871,SST,10,Abstract,hl_i,24989854,test,gold,i
5872,specific social skills,10,Abstract,hl_o,24989854,test,gold,o
5873,general social skills,10,Abstract,hl_o,24989854,test,gold,o
5874,possible predictors of treatment outcome,11,Abstract,ss_o,24989854,test,gold,o
5875,Dutch children with ASD in a specific age range ( 10-12 years ) .,12,Abstract,ss_p,24989854,test,gold,p
5876,SST,12,Abstract,ss_i,24989854,test,gold,i
5877,Dutch children with ASD in a specific age range ( 10-12 years ) .,12,Abstract,hl_p,24989854,test,gold,p
5878,SST,12,Abstract,hl_i,24989854,test,gold,i
5879,generalization,13,Abstract,ss_o,24989854,test,gold,o
5880,efficacy,13,Abstract,ss_o,24989854,test,gold,o
5882,preadolescent children with autism spectrum disorders :,0,Title,ss_p,24989854,test,gold,p
5883,social skills training,0,Title,ss_i,24989854,test,gold,i
5884,preadolescent children,0,Title,hl_p,24989854,test,gold,p
5885,autism spectrum disorders,0,Title,hl_p,24989854,test,gold,p
5886,social skills training,0,Title,hl_i,24989854,test,gold,i
5887,heptavalent conjugate vaccine ( PCV7-TT ),0,Abstract,ss_i,25068497,test,gold,i
5888,heptavalent conjugate vaccine ( PCV7-TT ),0,Abstract,hl_i,25068497,test,gold,i
5889,PCV7-TT,1,Abstract,ss_i,25068497,test,gold,i
5890,PCV7-TT,1,Abstract,hl_i,25068497,test,gold,i
5892,in 4-5-year-old children,3,Abstract,ss_p,25068497,test,gold,p
5893,of PCV7-TT,3,Abstract,ss_i,25068497,test,gold,i
5894,children .,3,Abstract,ss_i,25068497,test,gold,i
5895,the safety,3,Abstract,ss_o,25068497,test,gold,o
5896,the immunogenicity,3,Abstract,ss_o,25068497,test,gold,o
5897,4-5-year-old children,3,Abstract,hl_p,25068497,test,gold,p
5898,PCV7-TT,3,Abstract,hl_i,25068497,test,gold,i
5899,safety,3,Abstract,hl_o,25068497,test,gold,o
5900,immunogenicity,3,Abstract,hl_o,25068497,test,gold,o
5901,PCV7-TT,4,Abstract,ss_i,25068497,test,gold,i
5902,as Synflorix,4,Abstract,ss_i,25068497,test,gold,i
5903,well tolerated,4,Abstract,ss_o,25068497,test,gold,o
5904,as safe,4,Abstract,ss_o,25068497,test,gold,o
5905,PCV7-TT,4,Abstract,hl_i,25068497,test,gold,i
5906,Synflorix,4,Abstract,hl_i,25068497,test,gold,i
5907,in PCV7-TT,5,Abstract,ss_i,25068497,test,gold,i
5908,of IgG GMC and OPA GMT,5,Abstract,ss_o,25068497,test,gold,o
5909,PCV7-TT,5,Abstract,hl_i,25068497,test,gold,i
5910,IgG GMC,5,Abstract,hl_o,25068497,test,gold,o
5911,OPA GMT,5,Abstract,hl_o,25068497,test,gold,o
5912,of PCV7-TT,6,Abstract,ss_i,25068497,test,gold,i
5913,PCV7-TT,6,Abstract,hl_i,25068497,test,gold,i
5915,Cuban pneumococcal conjugate vaccine candidate in healthy children :,0,Title,ss_p,25068497,test,gold,p
5916,Cuban pneumococcal conjugate vaccine,0,Title,ss_i,25068497,test,gold,i
5917,Safety,0,Title,ss_o,25068497,test,gold,o
5918,preliminary immunogenicity,0,Title,ss_o,25068497,test,gold,o
5919,healthy children,0,Title,hl_p,25068497,test,gold,p
5920,Cuban pneumococcal conjugate vaccine,0,Title,hl_i,25068497,test,gold,i
5921,Safety,0,Title,hl_o,25068497,test,gold,o
5922,preliminary immunogenicity,0,Title,hl_o,25068497,test,gold,o
5923,children and adolescents with both ASD and attention-deficit/hyperactivity disorder ( ADHD ) .,0,Abstract,ss_p,25369243,test,gold,p
5924,atomoxetine,0,Abstract,ss_i,25369243,test,gold,i
5925,effects,0,Abstract,ss_o,25369243,test,gold,o
5926,children and adolescents,0,Abstract,hl_p,25369243,test,gold,p
5927,ASD and attention-deficit/hyperactivity disorder ( ADHD ),0,Abstract,hl_p,25369243,test,gold,p
5928,atomoxetine,0,Abstract,hl_i,25369243,test,gold,i
5929,"97 patients 6-17 years of age , with ASD and ADHD",1,Abstract,ss_p,25369243,test,gold,p
5930,of atomoxetine,1,Abstract,ss_i,25369243,test,gold,i
5931,double-blind placebo-controlled,1,Abstract,ss_i,25369243,test,gold,i
5932,97,1,Abstract,hl_p,25369243,test,gold,p
5933,6-17 years of age,1,Abstract,hl_p,25369243,test,gold,p
5934,ASD and ADHD,1,Abstract,hl_p,25369243,test,gold,p
5935,atomoxetine,1,Abstract,hl_i,25369243,test,gold,i
5936,placebo-controlled,1,Abstract,hl_i,25369243,test,gold,i
5937,"measures , the Aberrant Behavior Checklist ( ABC ) and the Children 's Social Behavior Questionnaire ( CSBQ )",2,Abstract,ss_o,25369243,test,gold,o
5938,"treatment , atomoxetine",3,Abstract,ss_i,25369243,test,gold,i
5939,"the ABC subscales Hyperactivity , Inappropriate Speech , and Stereotypic Behavior",3,Abstract,ss_o,25369243,test,gold,o
5940,the CSBQ subscale Fear for Changes,3,Abstract,ss_o,25369243,test,gold,o
5941,atomoxetine,3,Abstract,hl_i,25369243,test,gold,i
5942,ABC subscales Hyperactivity,3,Abstract,hl_o,25369243,test,gold,o
5943,Inappropriate Speech,3,Abstract,hl_o,25369243,test,gold,o
5944,Stereotypic Behavior,3,Abstract,hl_o,25369243,test,gold,o
5945,CSBQ subscale Fear for Changes,3,Abstract,hl_o,25369243,test,gold,o
5946,of atomoxetine,4,Abstract,ss_i,25369243,test,gold,i
5947,"However , atomoxetine",5,Abstract,ss_i,25369243,test,gold,i
5948,ameliorate restricted and stereotyped behaviors and communication,5,Abstract,ss_o,25369243,test,gold,o
5949,atomoxetine,5,Abstract,hl_i,25369243,test,gold,i
5950,stereotyped behaviors,5,Abstract,hl_o,25369243,test,gold,o
5951,communication,5,Abstract,hl_o,25369243,test,gold,o
5953,autism spectrum disorder :,0,Title,ss_p,25369243,test,gold,p
5954,Atomoxetine,0,Title,ss_i,25369243,test,gold,i
5955,social functioning ;,0,Title,ss_o,25369243,test,gold,o
5956,"stereotyped behaviors , inappropriate speech , and fear of change .",0,Title,ss_o,25369243,test,gold,o
5957,autism spectrum disorder :,0,Title,hl_p,25369243,test,gold,p
5958,Atomoxetine,0,Title,hl_i,25369243,test,gold,i
5959,social functioning ;,0,Title,hl_o,25369243,test,gold,o
5960,stereotyped behaviors,0,Title,hl_o,25369243,test,gold,o
5961,inappropriate speech,0,Title,hl_o,25369243,test,gold,o
5962,fear of change,0,Title,hl_o,25369243,test,gold,o
5964,text messaging,1,Abstract,ss_i,25479285,test,gold,i
5965,adherence to cardiovascular disease preventive treatment .,1,Abstract,ss_o,25479285,test,gold,o
5966,text messaging,1,Abstract,hl_i,25479285,test,gold,i
5967,adherence,1,Abstract,hl_o,25479285,test,gold,o
5968,303 patients taking blood pressure and/or lipid-lowering medications,2,Abstract,ss_p,25479285,test,gold,p
5969,text messages ( Text,2,Abstract,ss_i,25479285,test,gold,i
5970,not being sent them ( No text,2,Abstract,ss_i,25479285,test,gold,i
5971,303 patients taking blood pressure and/or lipid-lowering medications,2,Abstract,hl_p,25479285,test,gold,p
5972,text messages ( Text,2,Abstract,hl_i,25479285,test,gold,i
5973,not being sent them,2,Abstract,hl_i,25479285,test,gold,i
5975,text,4,Abstract,ss_i,25479285,test,gold,i
5976,use of medication,5,Abstract,ss_o,25479285,test,gold,o
5978,prescribed regimen,7,Abstract,ss_o,25479285,test,gold,o
5979,Text,8,Abstract,ss_i,25479285,test,gold,i
5980,adherence,8,Abstract,ss_o,25479285,test,gold,o
5981,Text,8,Abstract,hl_i,25479285,test,gold,i
5982,adherence,8,Abstract,hl_o,25479285,test,gold,o
5983,texts,9,Abstract,ss_i,25479285,test,gold,i
5984,stopped taking medication,9,Abstract,ss_o,25479285,test,gold,o
5985,text messaging,10,Abstract,ss_i,25479285,test,gold,i
5986,no text messaging .,10,Abstract,ss_i,25479285,test,gold,i
5987,medication adherence,10,Abstract,ss_o,25479285,test,gold,o
5988,taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease,10,Abstract,hl_p,25479285,test,gold,p
5989,text messaging,10,Abstract,hl_i,25479285,test,gold,i
5990,no text messaging .,10,Abstract,hl_i,25479285,test,gold,i
5991,medication adherence,10,Abstract,hl_o,25479285,test,gold,o
5993,cardiovascular preventive treatment,0,Title,ss_p,25479285,test,gold,p
5994,text messaging,0,Title,ss_i,25479285,test,gold,i
5995,adherence to cardiovascular preventive treatment,0,Title,ss_o,25479285,test,gold,o
5996,adherence,0,Title,hl_o,25479285,test,gold,o
5999,training,2,Abstract,ss_i,25784723,test,gold,i
6000,regional ventricular performance,2,Abstract,ss_o,25784723,test,gold,o
6001,training,2,Abstract,hl_i,25784723,test,gold,i
6002,patients with corrected tetralogy of Fallot .,3,Abstract,ss_p,25784723,test,gold,p
6003,exercise training program,3,Abstract,ss_i,25784723,test,gold,i
6004,adverse changes of regional ventricular performance,3,Abstract,ss_o,25784723,test,gold,o
6005,patients with corrected tetralogy of Fallot .,3,Abstract,hl_p,25784723,test,gold,p
6006,exercise training program,3,Abstract,hl_i,25784723,test,gold,i
6007,patients with tetralogy of Fallot aged 10 to 25 years .,4,Abstract,ss_p,25784723,test,gold,p
6008,patients with tetralogy of Fallot aged 10 to 25 years,4,Abstract,hl_p,25784723,test,gold,p
6009,exercise training program,5,Abstract,ss_i,25784723,test,gold,i
6010,exercise training program,5,Abstract,hl_i,25784723,test,gold,i
6011,"cardiopulmonary exercise tests , MRI , and echocardiography , including tissue-Doppler imaging",6,Abstract,ss_o,25784723,test,gold,o
6012,"cardiopulmonary exercise tests , MRI , and echocardiography , including tissue-Doppler imaging",6,Abstract,hl_o,25784723,test,gold,o
6013,exercise,7,Abstract,ss_i,25784723,test,gold,i
6014,control,7,Abstract,ss_i,25784723,test,gold,i
6015,exercise,7,Abstract,hl_i,25784723,test,gold,i
6016,control,7,Abstract,hl_i,25784723,test,gold,i
6017,exercise,8,Abstract,ss_i,25784723,test,gold,i
6018,exercise,8,Abstract,hl_i,25784723,test,gold,i
6019,exercise,9,Abstract,ss_i,25784723,test,gold,i
6020,control,9,Abstract,ss_i,25784723,test,gold,i
6021,exercise,9,Abstract,ss_i,25784723,test,gold,i
6022,cm/s ; control,9,Abstract,ss_i,25784723,test,gold,i
6023,A ' exercise,9,Abstract,ss_i,25784723,test,gold,i
6024,m/s ; control,9,Abstract,ss_i,25784723,test,gold,i
6025,Change in tissue-Doppler imaging parameters,9,Abstract,ss_o,25784723,test,gold,o
6026,exercise,9,Abstract,hl_i,25784723,test,gold,i
6027,control,9,Abstract,hl_i,25784723,test,gold,i
6028,Change in tissue-Doppler imaging parameters,9,Abstract,hl_o,25784723,test,gold,o
6029,training in children and young adults with repaired tetralogy of Fallot,10,Abstract,ss_p,25784723,test,gold,p
6030,dynamic exercise training,10,Abstract,ss_i,25784723,test,gold,i
6031,that regional ventricular performance,10,Abstract,ss_o,25784723,test,gold,o
6032,exercise training,10,Abstract,hl_i,25784723,test,gold,i
6036,children and young adults after repair of tetralogy of Fallot :,0,Title,ss_p,25784723,test,gold,p
6037,exercise training,0,Title,ss_i,25784723,test,gold,i
6038,children and young adults after repair of tetralogy of Fallot,0,Title,hl_p,25784723,test,gold,p
6039,exercise training,0,Title,hl_i,25784723,test,gold,i
6040,patients with rheumatoid arthritis ( RA ),0,Abstract,ss_p,25885649,test,gold,p
6041,RA patients ',0,Abstract,ss_p,25885649,test,gold,p
6042,physical activity ( PA ),0,Abstract,ss_i,25885649,test,gold,i
6043,PA,0,Abstract,ss_i,25885649,test,gold,i
6044,agreement,0,Abstract,ss_o,25885649,test,gold,o
6045,subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels,0,Abstract,ss_o,25885649,test,gold,o
6046,associations,0,Abstract,ss_o,25885649,test,gold,o
6047,subjective and objective PA,0,Abstract,ss_o,25885649,test,gold,o
6048,scores on the maximal oxygen uptake test ( VO2max ) .,0,Abstract,ss_o,25885649,test,gold,o
6049,patients with rheumatoid arthritis ( RA ),0,Abstract,hl_p,25885649,test,gold,p
6050,International Physical Activity Questionnaire ; IPAQ ),0,Abstract,hl_o,25885649,test,gold,o
6051,GT3X ) physical activity ( PA ),0,Abstract,hl_o,25885649,test,gold,o
6052,maximal oxygen uptake test ( VO2max ),0,Abstract,hl_o,25885649,test,gold,o
6053,IPAQ and VO2max test .,1,Abstract,ss_o,25885649,test,gold,o
6054,IPAQ,1,Abstract,hl_o,25885649,test,gold,o
6055,VO2max,1,Abstract,hl_o,25885649,test,gold,o
6056,PA,2,Abstract,ss_i,25885649,test,gold,i
6057,Bland-Altman plot,2,Abstract,ss_o,25885649,test,gold,o
6058,agreement,2,Abstract,ss_o,25885649,test,gold,o
6059,Wilcoxon test,2,Abstract,ss_o,25885649,test,gold,o
6060,PA,3,Abstract,ss_i,25885649,test,gold,i
6061,association between the PA measurement and VO2max test was examined via the correlations and the magnitude was presented by the Steiger 's Z value .,3,Abstract,ss_o,25885649,test,gold,o
6062,PA,3,Abstract,hl_i,25885649,test,gold,i
6063,PA measurement,3,Abstract,hl_o,25885649,test,gold,o
6064,VO2max,3,Abstract,hl_o,25885649,test,gold,o
6065,"Sixty-eight RA patients ( age=55±13 years , body mass index : 27.8±5.4 kg/m2 , median of disease duration=5 ( 2-8 ) yrs )",4,Abstract,ss_p,25885649,test,gold,p
6066,Sixty-eight RA,4,Abstract,hl_p,25885649,test,gold,p
6067,age=55±13 years,4,Abstract,hl_p,25885649,test,gold,p
6068,when PA,5,Abstract,ss_i,25885649,test,gold,i
6069,the subjective and objective measures,5,Abstract,ss_o,25885649,test,gold,o
6070,level .,5,Abstract,ss_o,25885649,test,gold,o
6071,PA,5,Abstract,hl_o,25885649,test,gold,o
6072,Wilcoxon tests,6,Abstract,ss_o,25885649,test,gold,o
6073,in sedentary behaviours,6,Abstract,ss_o,25885649,test,gold,o
6074,and light PA,6,Abstract,ss_o,25885649,test,gold,o
6075,more moderate PA,6,Abstract,ss_o,25885649,test,gold,o
6076,sedentary behaviours,6,Abstract,hl_o,25885649,test,gold,o
6077,light PA,6,Abstract,hl_o,25885649,test,gold,o
6078,all PA,7,Abstract,ss_i,25885649,test,gold,i
6079,between VO2max,7,Abstract,ss_o,25885649,test,gold,o
6080,from accelerometry,7,Abstract,ss_o,25885649,test,gold,o
6081,to sedentary time ( ST ),7,Abstract,ss_o,25885649,test,gold,o
6082,P=.04 ) .,7,Abstract,ss_o,25885649,test,gold,o
6083,VO2max,7,Abstract,hl_o,25885649,test,gold,o
6084,PA levels,7,Abstract,hl_o,25885649,test,gold,o
6085,sedentary time,7,Abstract,hl_o,25885649,test,gold,o
6086,moderate PA,8,Abstract,ss_i,25885649,test,gold,i
6087,IPAQ-reported moderate PA and MVPA,8,Abstract,ss_o,25885649,test,gold,o
6088,with maxV02,8,Abstract,ss_o,25885649,test,gold,o
6089,IPAQ-reported,8,Abstract,hl_o,25885649,test,gold,o
6090,PA,8,Abstract,hl_o,25885649,test,gold,o
6091,MVPA,8,Abstract,hl_o,25885649,test,gold,o
6092,the IPAQ-VO2 max and GT3X-VO2 max,9,Abstract,ss_o,25885649,test,gold,o
6093,IPAQ-VO2 max,9,Abstract,hl_o,25885649,test,gold,o
6094,GT3X-VO2 max,9,Abstract,hl_o,25885649,test,gold,o
6095,intensity PA,10,Abstract,ss_i,25885649,test,gold,i
6096,the IPAQ,10,Abstract,ss_o,25885649,test,gold,o
6097,less sedentary,10,Abstract,ss_o,25885649,test,gold,o
6098,intensity PA,10,Abstract,ss_o,25885649,test,gold,o
6099,assessed .,10,Abstract,ss_o,25885649,test,gold,o
6100,all PA,11,Abstract,ss_i,25885649,test,gold,i
6101,Accelerometry,11,Abstract,ss_o,25885649,test,gold,o
6102,with VO2max,11,Abstract,ss_o,25885649,test,gold,o
6103,and MPVA,12,Abstract,ss_o,25885649,test,gold,o
6104,with VO2max,12,Abstract,ss_o,25885649,test,gold,o
6105,in people with RA,13,Abstract,ss_p,25885649,test,gold,p
6106,self-reported PA,13,Abstract,ss_i,25885649,test,gold,i
6107,self-reported PA and ST,13,Abstract,ss_o,25885649,test,gold,o
6108,with accelerometry,13,Abstract,ss_o,25885649,test,gold,o
6111,rheumatoid arthritis patients .,0,Title,ss_p,25885649,test,gold,p
6112,physical activity,0,Title,ss_i,25885649,test,gold,i
6113,physical activity,0,Title,ss_o,25885649,test,gold,o
6114,rheumatoid arthritis patients .,0,Title,hl_p,25885649,test,gold,p
6115,faecal occult blood testing ( FOBT ),0,Abstract,ss_o,25886492,test,gold,o
6117,tailored computerised decision support,2,Abstract,ss_i,25886492,test,gold,i
6118,non-tailored computer or paper information .,2,Abstract,ss_i,25886492,test,gold,i
6119,tailored computerised decision support,2,Abstract,hl_i,25886492,test,gold,i
6120,FOBT return,3,Abstract,ss_o,25886492,test,gold,o
6121,FOBT return,3,Abstract,hl_o,25886492,test,gold,o
6122,on movement in decision to screen,4,Abstract,ss_o,25886492,test,gold,o
6123,on psychological variables,4,Abstract,ss_o,25886492,test,gold,o
6124,"trial invited 25,511 people aged 50-74 years",5,Abstract,ss_p,25886492,test,gold,p
6125,"25,511",5,Abstract,hl_p,25886492,test,gold,p
6126,aged 50-74,5,Abstract,hl_p,25886492,test,gold,p
6127,"assigned to Tailored Personalised Decision Support ( TPDS ) , Non-Tailored PDS ( NTPDS ) , or Control",6,Abstract,ss_i,25886492,test,gold,i
6128,sample ) .,6,Abstract,ss_i,25886492,test,gold,i
6129,Tailored Personalised Decision Support ( TPDS ),6,Abstract,hl_i,25886492,test,gold,i
6130,Non-Tailored PDS ( NTPDS ),6,Abstract,hl_i,25886492,test,gold,i
6131,Control,6,Abstract,hl_i,25886492,test,gold,i
6132,TPDS and NTPDS,7,Abstract,ss_i,25886492,test,gold,i
6133,.,7,Abstract,ss_i,25886492,test,gold,i
6134,TPDS,7,Abstract,hl_i,25886492,test,gold,i
6135,NTPDS,7,Abstract,hl_i,25886492,test,gold,i
6136,The,8,Abstract,ss_i,25886492,test,gold,i
6137,intervention,8,Abstract,ss_i,25886492,test,gold,i
6138,tailored intervention,8,Abstract,hl_i,25886492,test,gold,i
6140,.,10,Abstract,ss_o,25886492,test,gold,o
6141,RESULTS FOBT,11,Abstract,ss_o,25886492,test,gold,o
6142,"CG , 74 % )",12,Abstract,ss_i,25886492,test,gold,i
6143,In the PP sample,12,Abstract,ss_o,25886492,test,gold,o
6144,80 % ; NTPDS,12,Abstract,ss_o,25886492,test,gold,o
6145,FOBT completion,13,Abstract,ss_i,25886492,test,gold,i
6148,baseline ( 1083/2227 ),16,Abstract,ss_i,25886492,test,gold,i
6149,those assigned to the,16,Abstract,ss_i,25886492,test,gold,i
6150,more likely to,16,Abstract,ss_o,25886492,test,gold,o
6151,FOBT than those,16,Abstract,ss_o,25886492,test,gold,o
6152,"another ( OR = 1.16 , p = .42 )",17,Abstract,ss_o,25886492,test,gold,o
6153,predictors : Analysis of change indicated that salience and,18,Abstract,ss_o,25886492,test,gold,o
6156,personalised decision support,0,Title,ss_i,25886492,test,gold,i
6157,faecal occult blood test :,0,Title,ss_o,25886492,test,gold,o
6158,personalised decision support,0,Title,hl_i,25886492,test,gold,i
6160,patient-controlled sedation,1,Abstract,ss_i,25898782,test,gold,i
6161,propofol,1,Abstract,ss_i,25898782,test,gold,i
6162,anesthetist-controlled sedation,1,Abstract,ss_i,25898782,test,gold,i
6163,"standard of care , midazolam",1,Abstract,ss_i,25898782,test,gold,i
6164,"safety , ease of treatment , recovery , and patients ' experiences",1,Abstract,ss_o,25898782,test,gold,o
6165,patient-controlled sedation,1,Abstract,hl_i,25898782,test,gold,i
6166,propofol,1,Abstract,hl_i,25898782,test,gold,i
6167,anesthetist-controlled sedation,1,Abstract,hl_i,25898782,test,gold,i
6168,"standard of care , midazolam",1,Abstract,hl_i,25898782,test,gold,i
6169,safety,1,Abstract,hl_o,25898782,test,gold,o
6170,ease of treatment,1,Abstract,hl_o,25898782,test,gold,o
6171,recovery,1,Abstract,hl_o,25898782,test,gold,o
6172,patients ' experiences,1,Abstract,hl_o,25898782,test,gold,o
6173,study included 281 adults in 301 procedures .,2,Abstract,ss_p,25898782,test,gold,p
6174,281 adults,2,Abstract,hl_p,25898782,test,gold,p
6175,propofol,3,Abstract,ss_i,25898782,test,gold,i
6176,propofol,3,Abstract,hl_i,25898782,test,gold,i
6177,propofol,4,Abstract,ss_i,25898782,test,gold,i
6178,Observer 's Assessment of Alertness/Sedation ( OAA/S ) scale .,4,Abstract,ss_o,25898782,test,gold,o
6179,propofol,4,Abstract,hl_i,25898782,test,gold,i
6180,midazolam,5,Abstract,ss_i,25898782,test,gold,i
6181,midazolam,5,Abstract,hl_i,25898782,test,gold,i
6182,midazolam,6,Abstract,ss_i,25898782,test,gold,i
6183,midazolam,6,Abstract,ss_i,25898782,test,gold,i
6184,ease of the procedure,6,Abstract,ss_o,25898782,test,gold,o
6185,number of sedation failures,6,Abstract,ss_o,25898782,test,gold,o
6186,midazolam,6,Abstract,hl_i,25898782,test,gold,i
6187,midazolam,6,Abstract,hl_i,25898782,test,gold,i
6188,ease of the procedure,6,Abstract,hl_o,25898782,test,gold,o
6189,number of sedation failures,6,Abstract,hl_o,25898782,test,gold,o
6190,midazolam,7,Abstract,ss_i,25898782,test,gold,i
6191,midazolam,7,Abstract,hl_i,25898782,test,gold,i
6192,Time to full recovery ( Aldrete score,8,Abstract,ss_o,25898782,test,gold,o
6193,Time to full recovery ( Aldrete score,8,Abstract,hl_o,25898782,test,gold,o
6194,least fatigue and pain,9,Abstract,ss_o,25898782,test,gold,o
6195,procedure .,9,Abstract,ss_o,25898782,test,gold,o
6196,Patients ' preference,10,Abstract,ss_o,25898782,test,gold,o
6197,with propofol,11,Abstract,ss_i,25898782,test,gold,i
6198,to midazolam,11,Abstract,ss_i,25898782,test,gold,i
6199,propofol,11,Abstract,hl_i,25898782,test,gold,i
6200,midazolam,11,Abstract,hl_i,25898782,test,gold,i
6201,"a rapid recovery , fewer respiratory events",12,Abstract,ss_o,25898782,test,gold,o
6202,as effective,12,Abstract,ss_o,25898782,test,gold,o
6203,retrograde cholangiopancreatography :,0,Title,ss_p,25898782,test,gold,p
6204,propofol,0,Title,ss_i,25898782,test,gold,i
6205,retrograde cholangiopancreatography :,0,Title,hl_p,25898782,test,gold,p
6206,propofol,0,Title,hl_i,25898782,test,gold,i
6207,children with autism spectrum disorder ( ASD ) .,0,Abstract,ss_p,25931290,test,gold,p
6208,sensory adapted dental environment ( SADE ),0,Abstract,ss_i,25931290,test,gold,i
6209,"distress , sensory discomfort , and perception of pain",0,Abstract,ss_o,25931290,test,gold,o
6210,children,0,Abstract,hl_p,25931290,test,gold,p
6211,autism spectrum disorder ( ASD ),0,Abstract,hl_p,25931290,test,gold,p
6212,sensory adapted dental environment ( SADE ),0,Abstract,hl_i,25931290,test,gold,i
6213,distress,0,Abstract,hl_o,25931290,test,gold,o
6214,sensory discomfort,0,Abstract,hl_o,25931290,test,gold,o
6215,perception of pain,0,Abstract,hl_o,25931290,test,gold,o
6216,"Participants were 44 children ages 6-12 ( n = 22 typical , n = 22 ASD ) .",1,Abstract,ss_p,25931290,test,gold,p
6217,44 children ages 6-12,1,Abstract,hl_p,25931290,test,gold,p
6218,"n = 22 typical , n = 22 ASD",1,Abstract,hl_p,25931290,test,gold,p
6219,regular dental environment ( RDE ),2,Abstract,ss_i,25931290,test,gold,i
6220,SADE,2,Abstract,ss_i,25931290,test,gold,i
6221,regular dental environment ( RDE ),2,Abstract,hl_i,25931290,test,gold,i
6222,SADE,2,Abstract,hl_i,25931290,test,gold,i
6223,"physiological anxiety , behavioral distress , pain intensity , and sensory discomfort .",3,Abstract,ss_o,25931290,test,gold,o
6224,physiological anxiety,3,Abstract,hl_o,25931290,test,gold,o
6225,behavioral distress,3,Abstract,hl_o,25931290,test,gold,o
6226,pain intensity,3,Abstract,hl_o,25931290,test,gold,o
6227,sensory discomfort,3,Abstract,hl_o,25931290,test,gold,o
6228,SADE,4,Abstract,ss_i,25931290,test,gold,i
6229,RDE,4,Abstract,ss_i,25931290,test,gold,i
6230,SADE .,4,Abstract,ss_i,25931290,test,gold,i
6231,physiological anxiety,4,Abstract,ss_o,25931290,test,gold,o
6232,pain and sensory discomfort,4,Abstract,ss_o,25931290,test,gold,o
6233,SADE,4,Abstract,hl_i,25931290,test,gold,i
6234,RDE,4,Abstract,hl_i,25931290,test,gold,i
6235,SADE .,4,Abstract,hl_i,25931290,test,gold,i
6236,physiological anxiety,4,Abstract,hl_o,25931290,test,gold,o
6237,pain,4,Abstract,hl_o,25931290,test,gold,o
6238,sensory discomfort,4,Abstract,hl_o,25931290,test,gold,o
6239,Children with Autism Spectrum Disorders :,0,Title,ss_p,25931290,test,gold,p
6240,Sensory Adapted Dental Environments,0,Title,ss_i,25931290,test,gold,i
6241,Children,0,Title,hl_p,25931290,test,gold,p
6242,Autism Spectrum Disorders,0,Title,hl_p,25931290,test,gold,p
6243,Sensory Adapted Dental Environments,0,Title,hl_i,25931290,test,gold,i
6244,patients undergoing laparotomy .,0,Abstract,ss_p,25950425,test,gold,p
6245,pregabalin,0,Abstract,ss_i,25950425,test,gold,i
6246,lidocaine,0,Abstract,ss_i,25950425,test,gold,i
6247,"postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization , time to first defecation and time to discharge",0,Abstract,ss_o,25950425,test,gold,o
6248,pregabalin,0,Abstract,hl_i,25950425,test,gold,i
6249,lidocaine,0,Abstract,hl_i,25950425,test,gold,i
6250,postoperative morphine requirement,0,Abstract,hl_o,25950425,test,gold,o
6251,adverse effects,0,Abstract,hl_o,25950425,test,gold,o
6252,patients ' satisfaction,0,Abstract,hl_o,25950425,test,gold,o
6253,mobilization,0,Abstract,hl_o,25950425,test,gold,o
6254,time to first defecation,0,Abstract,hl_o,25950425,test,gold,o
6255,time to discharge,0,Abstract,hl_o,25950425,test,gold,o
6256,Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy,1,Abstract,ss_p,25950425,test,gold,p
6257,placebo,1,Abstract,ss_i,25950425,test,gold,i
6258,normal saline infusion,1,Abstract,ss_i,25950425,test,gold,i
6259,placebo,1,Abstract,ss_i,25950425,test,gold,i
6260,lidocaine,1,Abstract,ss_i,25950425,test,gold,i
6261,mg oral pregabalin and normal saline infusion,1,Abstract,ss_i,25950425,test,gold,i
6262,150 & nbsp ; mg oral pregabalin and lidocaine,1,Abstract,ss_i,25950425,test,gold,i
6263,skin closure .,1,Abstract,ss_o,25950425,test,gold,o
6264,Eighty,1,Abstract,hl_p,25950425,test,gold,p
6265,18 to 65 years of age,1,Abstract,hl_p,25950425,test,gold,p
6266,undergoing elective laparotomy,1,Abstract,hl_p,25950425,test,gold,p
6267,placebo,1,Abstract,hl_i,25950425,test,gold,i
6268,normal saline infusion,1,Abstract,hl_i,25950425,test,gold,i
6269,placebo,1,Abstract,hl_i,25950425,test,gold,i
6270,lidocaine,1,Abstract,hl_i,25950425,test,gold,i
6271,pregabalin,1,Abstract,hl_i,25950425,test,gold,i
6272,normal saline infusion,1,Abstract,hl_i,25950425,test,gold,i
6273,pregabalin,1,Abstract,hl_i,25950425,test,gold,i
6274,lidocaine,1,Abstract,hl_i,25950425,test,gold,i
6275,"Hemodynamic parameters , visual analogue scale ( VAS ) scores , analgesic consumption , side effects , time to mobilization , time to first defecation , time to discharge and patients ' satisfaction",2,Abstract,ss_o,25950425,test,gold,o
6276,recorded .,2,Abstract,ss_o,25950425,test,gold,o
6277,RESULTS VAS,3,Abstract,ss_o,25950425,test,gold,o
6278,( P < 0.05 ) .,3,Abstract,ss_o,25950425,test,gold,o
6279,Morphine consumption,4,Abstract,ss_o,25950425,test,gold,o
6280,( P < 0.05 ) .,4,Abstract,ss_o,25950425,test,gold,o
6281,Morphine consumption,4,Abstract,hl_o,25950425,test,gold,o
6282,Incidence,5,Abstract,ss_o,25950425,test,gold,o
6283,group PL .,5,Abstract,ss_o,25950425,test,gold,o
6284,Time to first defecation and mobilization,6,Abstract,ss_o,25950425,test,gold,o
6285,Time to first defecation,6,Abstract,hl_o,25950425,test,gold,o
6286,mobilization,6,Abstract,hl_o,25950425,test,gold,o
6287,Preoperative oral pregabalin,7,Abstract,ss_i,25950425,test,gold,i
6288,intravenous,7,Abstract,ss_i,25950425,test,gold,i
6289,decreased postoperative VAS,7,Abstract,ss_o,25950425,test,gold,o
6290,pregabalin,7,Abstract,hl_i,25950425,test,gold,i
6291,lidocaine,7,Abstract,hl_i,25950425,test,gold,i
6292,nausea in patients undergoing laparotomy,8,Abstract,ss_p,25950425,test,gold,p
6293,Preoperative oral pregabalin,8,Abstract,ss_i,25950425,test,gold,i
6294,intravenous,8,Abstract,ss_i,25950425,test,gold,i
6295,decreased morphine requirement,8,Abstract,ss_o,25950425,test,gold,o
6296,decreased the incidence,8,Abstract,ss_o,25950425,test,gold,o
6297,pregabalin,8,Abstract,hl_i,25950425,test,gold,i
6298,lidocaine,8,Abstract,hl_i,25950425,test,gold,i
6299,morphine requirement,8,Abstract,hl_o,25950425,test,gold,o
6300,relief in patients undergoing laparatomy,9,Abstract,ss_p,25950425,test,gold,p
6301,preoperative pregabalin,9,Abstract,ss_i,25950425,test,gold,i
6302,or without,9,Abstract,ss_i,25950425,test,gold,i
6303,provides superior pain,9,Abstract,ss_o,25950425,test,gold,o
6304,pregabalin,9,Abstract,hl_i,25950425,test,gold,i
6305,patients undergoing laparatomy .,0,Title,ss_p,25950425,test,gold,p
6306,pregabalin,0,Title,ss_i,25950425,test,gold,i
6307,lidocaine,0,Title,ss_i,25950425,test,gold,i
6308,postoperative morphine requirement,0,Title,ss_o,25950425,test,gold,o
6309,patients undergoing laparatomy .,0,Title,hl_p,25950425,test,gold,p
6310,pregabalin,0,Title,hl_i,25950425,test,gold,i
6311,lidocaine,0,Title,hl_i,25950425,test,gold,i
6312,postoperative morphine requirement,0,Title,hl_o,25950425,test,gold,o
6313,autism spectrum disorders ( ASD ) in toddlers,0,Abstract,ss_p,26210844,test,gold,p
6314,autism spectrum disorders ( ASD ),0,Abstract,hl_p,26210844,test,gold,p
6315,toddlers,0,Abstract,hl_p,26210844,test,gold,p
6316,Rapid Interactive Screening Test,1,Abstract,ss_i,26210844,test,gold,i
6317,Rapid Interactive Screening Test for Autism in Toddlers ( RITA-T ),1,Abstract,ss_o,26210844,test,gold,o
6318,Rapid Interactive Screening Test,1,Abstract,hl_i,26210844,test,gold,i
6319,RITA-T,2,Abstract,ss_i,26210844,test,gold,i
6320,RITA-T,2,Abstract,ss_o,26210844,test,gold,o
6321,RITA-T,2,Abstract,hl_i,26210844,test,gold,i
6322,toddlers with ASD from toddlers with developmental delay ( DD ) /non-ASD in an early childhood clinic .,3,Abstract,ss_p,26210844,test,gold,p
6323,RITA-T,3,Abstract,ss_i,26210844,test,gold,i
6324,RITA-T,3,Abstract,ss_o,26210844,test,gold,o
6325,toddlers with ASD from toddlers with developmental delay ( DD ) /non-ASD in an early childhood clinic .,3,Abstract,hl_p,26210844,test,gold,p
6326,RITA-T,3,Abstract,hl_i,26210844,test,gold,i
6327,toddlers with no developmental concerns .,4,Abstract,ss_p,26210844,test,gold,p
6328,test 's performance,4,Abstract,ss_o,26210844,test,gold,o
6329,toddlers with no developmental concerns .,4,Abstract,hl_p,26210844,test,gold,p
6330,RITA-T,5,Abstract,ss_i,26210844,test,gold,i
6331,cutoff score,5,Abstract,ss_o,26210844,test,gold,o
6332,"sensitivity , specificity , and positive predictive value of the RITA-T",5,Abstract,ss_o,26210844,test,gold,o
6333,RITA-T,5,Abstract,hl_i,26210844,test,gold,i
6334,cutoff score,5,Abstract,hl_o,26210844,test,gold,o
6335,"sensitivity , specificity , and positive predictive value",5,Abstract,hl_o,26210844,test,gold,o
6336,RITA-T,5,Abstract,hl_o,26210844,test,gold,o
6337,A total of 61 toddlers were enrolled .,6,Abstract,ss_p,26210844,test,gold,p
6338,A total of 61 toddlers,6,Abstract,hl_p,26210844,test,gold,p
6339,RITA-T scores,7,Abstract,ss_o,26210844,test,gold,o
6340,RITA-T scores,7,Abstract,hl_o,26210844,test,gold,o
6341,scores,8,Abstract,ss_o,26210844,test,gold,o
6342,scores,8,Abstract,hl_o,26210844,test,gold,o
6343,RITA-T,9,Abstract,ss_i,26210844,test,gold,i
6344,RITA-T,9,Abstract,ss_o,26210844,test,gold,o
6345,sensitivity,9,Abstract,ss_o,26210844,test,gold,o
6346,specificity,9,Abstract,ss_o,26210844,test,gold,o
6347,positive predictive value,9,Abstract,ss_o,26210844,test,gold,o
6348,RITA-T,9,Abstract,hl_i,26210844,test,gold,i
6349,ASD in toddlers,10,Abstract,ss_p,26210844,test,gold,p
6350,RITA-T,10,Abstract,ss_i,26210844,test,gold,i
6351,RITA-T,10,Abstract,ss_o,26210844,test,gold,o
6352,ASD in toddlers,10,Abstract,hl_p,26210844,test,gold,p
6353,RITA-T,10,Abstract,hl_i,26210844,test,gold,i
6354,Autism Spectrum Disorders in Toddlers .,0,Title,ss_p,26210844,test,gold,p
6355,Interactive Screening Test,0,Title,ss_i,26210844,test,gold,i
6356,Autism Spectrum Disorders,0,Title,hl_p,26210844,test,gold,p
6357,Toddlers,0,Title,hl_p,26210844,test,gold,p
6358,Interactive Screening Test,0,Title,hl_i,26210844,test,gold,i
6359,poor-insight OCD .,0,Abstract,ss_p,26278470,test,gold,p
6360,effectiveness,0,Abstract,ss_o,26278470,test,gold,o
6361,inference-based approach ( IBA ),1,Abstract,ss_i,26278470,test,gold,i
6362,inference-based approach ( IBA ),1,Abstract,hl_i,26278470,test,gold,i
6363,patients with OCD with poor insight .,2,Abstract,ss_p,26278470,test,gold,p
6364,cognitive behavior therapy ( CBT ),2,Abstract,ss_i,26278470,test,gold,i
6365,effectiveness,2,Abstract,ss_o,26278470,test,gold,o
6366,effectiveness,2,Abstract,ss_o,26278470,test,gold,o
6367,patients with OCD with poor insight .,2,Abstract,hl_p,26278470,test,gold,p
6368,cognitive behavior therapy ( CBT ),2,Abstract,hl_i,26278470,test,gold,i
6369,90 patients with OCD with poor insight,3,Abstract,ss_p,26278470,test,gold,p
6370,CBT,3,Abstract,ss_i,26278470,test,gold,i
6371,IBA,3,Abstract,ss_i,26278470,test,gold,i
6372,90 patients with OCD with poor insight,3,Abstract,hl_p,26278470,test,gold,p
6373,CBT,3,Abstract,hl_i,26278470,test,gold,i
6374,IBA,3,Abstract,hl_i,26278470,test,gold,i
6375,Yale-Brown Obsessive Compulsive Scale ( YBOCS ) .,4,Abstract,ss_o,26278470,test,gold,o
6376,Yale-Brown Obsessive Compulsive Scale ( YBOCS ) .,4,Abstract,hl_o,26278470,test,gold,o
6377,"level of insight , anxiety and depressive symptoms , and quality of life .",5,Abstract,ss_o,26278470,test,gold,o
6378,"level of insight , anxiety and depressive symptoms , and quality of life .",5,Abstract,hl_o,26278470,test,gold,o
6379,Mixed-effects models,6,Abstract,ss_o,26278470,test,gold,o
6380,OCD symptom reduction,7,Abstract,ss_o,26278470,test,gold,o
6381,condition effects,7,Abstract,ss_o,26278470,test,gold,o
6382,OCD symptom reduction,7,Abstract,hl_o,26278470,test,gold,o
6383,IBA,8,Abstract,ss_i,26278470,test,gold,i
6384,CBT,8,Abstract,ss_i,26278470,test,gold,i
6385,OCD symptom reduction,8,Abstract,ss_o,26278470,test,gold,o
6386,IBA,8,Abstract,hl_i,26278470,test,gold,i
6387,CBT,8,Abstract,hl_i,26278470,test,gold,i
6388,OCD symptom reduction,8,Abstract,hl_o,26278470,test,gold,o
6389,Patients with OCD with poor insight,9,Abstract,ss_p,26278470,test,gold,p
6390,Patients with OCD with poor insight,9,Abstract,hl_p,26278470,test,gold,p
6391,CBT,10,Abstract,ss_i,26278470,test,gold,i
6392,IBA,10,Abstract,ss_i,26278470,test,gold,i
6393,effective,10,Abstract,ss_o,26278470,test,gold,o
6394,CBT,10,Abstract,hl_i,26278470,test,gold,i
6395,IBA,10,Abstract,hl_i,26278470,test,gold,i
6396,patients with more extreme poor insight .,11,Abstract,ss_p,26278470,test,gold,p
6397,IBA,11,Abstract,ss_i,26278470,test,gold,i
6398,CBT,11,Abstract,ss_i,26278470,test,gold,i
6399,IBA,11,Abstract,hl_i,26278470,test,gold,i
6400,CBT,11,Abstract,hl_i,26278470,test,gold,i
6401,Obsessive-Compulsive Disorder with Poor Insight :,0,Title,ss_p,26278470,test,gold,p
6402,Inference-Based Approach,0,Title,ss_i,26278470,test,gold,i
6403,Cognitive Behavioral Therapy,0,Title,ss_i,26278470,test,gold,i
6404,Obsessive-Compulsive Disorder with Poor Insight :,0,Title,hl_p,26278470,test,gold,p
6405,Inference-Based Approach,0,Title,hl_i,26278470,test,gold,i
6406,Cognitive Behavioral Therapy,0,Title,hl_i,26278470,test,gold,i
6407,16 patients with ischaemic heart disease .,0,Abstract,ss_p,2678230,test,gold,p
6408,Amidotrizoate,0,Abstract,ss_i,2678230,test,gold,i
6409,Iopromide,0,Abstract,ss_i,2678230,test,gold,i
6410,"global myocardial perfusion and function ( pressures in the left ventricle , heart rate )",0,Abstract,ss_o,2678230,test,gold,o
6411,excitation formation and transmission,0,Abstract,ss_o,2678230,test,gold,o
6412,16 patients with ischaemic heart disease,0,Abstract,hl_p,2678230,test,gold,p
6413,Amidotrizoate,0,Abstract,hl_i,2678230,test,gold,i
6414,Iopromide,0,Abstract,hl_i,2678230,test,gold,i
6415,global myocardial perfusion and function,0,Abstract,hl_o,2678230,test,gold,o
6416,dipyridamole,1,Abstract,ss_i,2678230,test,gold,i
6417,myocardial perfusion,1,Abstract,ss_o,2678230,test,gold,o
6418,myocardial perfusion,1,Abstract,hl_o,2678230,test,gold,o
6419,ionic,0,Title,ss_i,2678230,test,gold,i
6420,nonionic x-ray contrast,0,Title,ss_i,2678230,test,gold,i
6421,myocardial perfusion and myocardial function ],0,Title,ss_o,2678230,test,gold,o
6422,ionic,0,Title,hl_i,2678230,test,gold,i
6423,nonionic x-ray contrast,0,Title,hl_i,2678230,test,gold,i
6424,myocardial,0,Title,hl_o,2678230,test,gold,o
6425,ear microsurgical operations .,0,Abstract,ss_p,2803397,test,gold,p
6426,endocrine stress responses,0,Abstract,ss_o,2803397,test,gold,o
6427,ear microsurgical operations .,0,Abstract,hl_p,2803397,test,gold,p
6428,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients",1,Abstract,ss_p,2803397,test,gold,p
6429,halothane,1,Abstract,ss_i,2803397,test,gold,i
6430,lidocaine,1,Abstract,ss_i,2803397,test,gold,i
6431,ornipressin,1,Abstract,ss_i,2803397,test,gold,i
6432,fentanyl,1,Abstract,ss_i,2803397,test,gold,i
6433,lidocaine,1,Abstract,ss_i,2803397,test,gold,i
6434,ornipressin,1,Abstract,ss_i,2803397,test,gold,i
6435,fentanyl,1,Abstract,ss_i,2803397,test,gold,i
6436,lidocaine,1,Abstract,ss_i,2803397,test,gold,i
6437,epinephrine,1,Abstract,ss_i,2803397,test,gold,i
6438,prilocaine,1,Abstract,ss_i,2803397,test,gold,i
6439,epinephrine,1,Abstract,ss_i,2803397,test,gold,i
6440,"Simple mastoidectomies , radical mastoidectomies and tympano plastics",1,Abstract,hl_p,2803397,test,gold,p
6441,49,1,Abstract,hl_p,2803397,test,gold,p
6442,halothane,1,Abstract,hl_i,2803397,test,gold,i
6443,lidocaine,1,Abstract,hl_i,2803397,test,gold,i
6444,ornipressin,1,Abstract,hl_i,2803397,test,gold,i
6445,fentanyl,1,Abstract,hl_i,2803397,test,gold,i
6446,lidocaine,1,Abstract,hl_i,2803397,test,gold,i
6447,ornipressin,1,Abstract,hl_i,2803397,test,gold,i
6448,fentanyl,1,Abstract,hl_i,2803397,test,gold,i
6449,lidocaine,1,Abstract,hl_i,2803397,test,gold,i
6450,epinephrine,1,Abstract,hl_i,2803397,test,gold,i
6451,prilocaine,1,Abstract,hl_i,2803397,test,gold,i
6452,epinephrine,1,Abstract,hl_i,2803397,test,gold,i
6453,"plasma levels of epinephrine , norepinephrine , glucose , lactate and free glycerol",2,Abstract,ss_o,2803397,test,gold,o
6454,mean arterial pressure ( MAP ) and heart rate ( HR ),2,Abstract,ss_o,2803397,test,gold,o
6455,"plasma levels of epinephrine , norepinephrine , glucose , lactate",2,Abstract,hl_o,2803397,test,gold,o
6457,Plasma catecholamine concentrations,4,Abstract,ss_o,2803397,test,gold,o
6458,Plasma catecholamine concentrations,4,Abstract,hl_o,2803397,test,gold,o
6459,Plasma catecholamines ( epinephrine and norepinephrine ),5,Abstract,ss_o,2803397,test,gold,o
6460,Plasma catecholamines ( epinephrine and norepinephrine ),5,Abstract,hl_o,2803397,test,gold,o
6461,MAP,6,Abstract,ss_o,2803397,test,gold,o
6462,HR .,6,Abstract,ss_o,2803397,test,gold,o
6463,MAP,6,Abstract,hl_o,2803397,test,gold,o
6464,HR .,6,Abstract,hl_o,2803397,test,gold,o
6465,plasma levels of epinephrine and norepinephrine,7,Abstract,ss_o,2803397,test,gold,o
6466,"glucose , lactate and free glycerol .",7,Abstract,ss_o,2803397,test,gold,o
6467,plasma levels of epinephrine and norepinephrine,7,Abstract,hl_o,2803397,test,gold,o
6468,"glucose , lactate and free glycerol .",7,Abstract,hl_o,2803397,test,gold,o
6471,ear surgery,0,Title,ss_p,2803397,test,gold,p
6472,[ The sympatho-adrenergic stress reaction,0,Title,ss_o,2803397,test,gold,o
6473,ear surgery,0,Title,hl_p,2803397,test,gold,p
6474,92 outpatients affected by generalized anxiety disorders,0,Abstract,ss_p,2908133,test,gold,p
6475,ketazolam,0,Abstract,ss_i,2908133,test,gold,i
6476,placebo,0,Abstract,ss_i,2908133,test,gold,i
6477,92 outpatients affected by generalized anxiety disorders,0,Abstract,hl_p,2908133,test,gold,p
6478,ketazolam,0,Abstract,hl_i,2908133,test,gold,i
6479,placebo,0,Abstract,hl_i,2908133,test,gold,i
6480,ketazolam,1,Abstract,ss_i,2908133,test,gold,i
6481,placebo,1,Abstract,ss_i,2908133,test,gold,i
6482,ketazolam,1,Abstract,hl_i,2908133,test,gold,i
6483,placebo,1,Abstract,hl_i,2908133,test,gold,i
6484,ketazolam,2,Abstract,ss_i,2908133,test,gold,i
6485,total Hamilton Anxiety Rating Scale ( HAM-A ),2,Abstract,ss_o,2908133,test,gold,o
6486,ketazolam,2,Abstract,hl_i,2908133,test,gold,i
6487,total Hamilton Anxiety Rating Scale ( HAM-A ),2,Abstract,hl_o,2908133,test,gold,o
6488,Anxiety,3,Abstract,ss_o,2908133,test,gold,o
6489,Italian HAM-A scale and with a 4-point scale ( patient 's assessment ) .,3,Abstract,ss_o,2908133,test,gold,o
6490,Italian HAM-A scale,3,Abstract,hl_o,2908133,test,gold,o
6491,4-point scale ( patient 's assessment ) .,3,Abstract,hl_o,2908133,test,gold,o
6492,Seventy-eight patients completed the first period and 75 the whole study .,4,Abstract,ss_p,2908133,test,gold,p
6493,Seventy-eight,4,Abstract,hl_p,2908133,test,gold,p
6494,75,4,Abstract,hl_p,2908133,test,gold,p
6495,placebo,5,Abstract,ss_i,2908133,test,gold,i
6496,ketazolam,5,Abstract,ss_i,2908133,test,gold,i
6497,HAM-A score,5,Abstract,ss_o,2908133,test,gold,o
6498,placebo,5,Abstract,hl_i,2908133,test,gold,i
6499,ketazolam,5,Abstract,hl_i,2908133,test,gold,i
6500,HAM-A score,5,Abstract,hl_o,2908133,test,gold,o
6501,4-point scale,6,Abstract,ss_o,2908133,test,gold,o
6502,4-point scale,6,Abstract,hl_o,2908133,test,gold,o
6503,placebo,7,Abstract,ss_i,2908133,test,gold,i
6504,severe headache .,7,Abstract,ss_o,2908133,test,gold,o
6505,placebo,7,Abstract,hl_i,2908133,test,gold,i
6506,severe headache .,7,Abstract,hl_o,2908133,test,gold,o
6507,anxiety :,0,Title,ss_p,2908133,test,gold,p
6508,ketazolam,0,Title,ss_i,2908133,test,gold,i
6509,anxiety :,0,Title,hl_p,2908133,test,gold,p
6510,ketazolam,0,Title,hl_i,2908133,test,gold,i
6511,Fifty-one patients with raised intraocular pressure ( IOP ),0,Abstract,ss_p,3067745,test,gold,p
6512,levobunolol,0,Abstract,ss_i,3067745,test,gold,i
6513,levobunolol,0,Abstract,ss_i,3067745,test,gold,i
6514,timolol .,0,Abstract,ss_i,3067745,test,gold,i
6515,intraocular pressure ( IOP ),0,Abstract,ss_o,3067745,test,gold,o
6516,Fifty-one patients,0,Abstract,hl_p,3067745,test,gold,p
6517,raised intraocular pressure ( IOP ),0,Abstract,hl_p,3067745,test,gold,p
6518,levobunolol,0,Abstract,hl_i,3067745,test,gold,i
6519,levobunolol,0,Abstract,hl_i,3067745,test,gold,i
6520,timolol .,0,Abstract,hl_i,3067745,test,gold,i
6522,Levobunolol,2,Abstract,ss_i,3067745,test,gold,i
6523,timolol,2,Abstract,ss_i,3067745,test,gold,i
6524,effective,2,Abstract,ss_o,3067745,test,gold,o
6525,overall mean IOP ;,2,Abstract,ss_o,3067745,test,gold,o
6526,Levobunolol,2,Abstract,hl_i,3067745,test,gold,i
6527,timolol,2,Abstract,hl_i,3067745,test,gold,i
6528,overall mean IOP ;,2,Abstract,hl_o,3067745,test,gold,o
6529,levobunolol,3,Abstract,ss_i,3067745,test,gold,i
6530,timolol,3,Abstract,ss_i,3067745,test,gold,i
6531,effective,3,Abstract,ss_o,3067745,test,gold,o
6532,levobunolol,3,Abstract,hl_i,3067745,test,gold,i
6533,timolol,3,Abstract,hl_i,3067745,test,gold,i
6534,Levobunolol,0,Title,ss_i,3067745,test,gold,i
6535,timolol :,0,Title,ss_i,3067745,test,gold,i
6536,Levobunolol,0,Title,hl_i,3067745,test,gold,i
6537,timolol :,0,Title,hl_i,3067745,test,gold,i
6538,30 non-insulin dependent ( Type II ) diabetic subjects,0,Abstract,ss_p,3074300,test,gold,p
6539,captopril,0,Abstract,ss_i,3074300,test,gold,i
6540,placebo-controlled,0,Abstract,ss_i,3074300,test,gold,i
6541,placebo/wash-out ),0,Abstract,ss_i,3074300,test,gold,i
6542,blood pressure and metabolism,0,Abstract,ss_o,3074300,test,gold,o
6543,30 non-insulin dependent ( Type II ) diabetic subjects,0,Abstract,hl_p,3074300,test,gold,p
6544,captopril,0,Abstract,hl_i,3074300,test,gold,i
6545,placebo-controlled,0,Abstract,hl_i,3074300,test,gold,i
6546,blood pressure,0,Abstract,hl_o,3074300,test,gold,o
6547,metabolism,0,Abstract,hl_o,3074300,test,gold,o
6548,Captopril,1,Abstract,ss_i,3074300,test,gold,i
6549,systolic and diastolic blood pressure,1,Abstract,ss_o,3074300,test,gold,o
6550,Captopril,1,Abstract,hl_i,3074300,test,gold,i
6551,systolic and diastolic blood pressure,1,Abstract,hl_o,3074300,test,gold,o
6552,postprandial blood glucose concentrations,2,Abstract,ss_o,3074300,test,gold,o
6553,blood kinin concentrations,2,Abstract,ss_o,3074300,test,gold,o
6554,postprandial blood glucose concentrations,2,Abstract,hl_o,3074300,test,gold,o
6555,blood kinin concentrations,2,Abstract,hl_o,3074300,test,gold,o
6556,"Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile as well as hepatic and renal function",3,Abstract,ss_o,3074300,test,gold,o
6557,"Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile",3,Abstract,hl_o,3074300,test,gold,o
6558,hepatic and renal function,3,Abstract,hl_o,3074300,test,gold,o
6559,Type II diabetes .,4,Abstract,ss_p,3074300,test,gold,p
6560,captopril,4,Abstract,ss_i,3074300,test,gold,i
6561,metabolic effect,4,Abstract,ss_o,3074300,test,gold,o
6562,captopril,4,Abstract,hl_i,3074300,test,gold,i
6563,Type II diabetic patients .,5,Abstract,ss_p,3074300,test,gold,p
6564,ACE inhibitors,5,Abstract,ss_i,3074300,test,gold,i
6565,Type II diabetic,5,Abstract,hl_p,3074300,test,gold,p
6566,ACE inhibitors,5,Abstract,hl_i,3074300,test,gold,i
6567,non-insulin dependent diabetes mellitus .,0,Title,ss_p,3074300,test,gold,p
6568,angiotensin-converting enzyme inhibitors,0,Title,ss_i,3074300,test,gold,i
6569,non-insulin dependent diabetes mellitus .,0,Title,hl_p,3074300,test,gold,p
6570,angiotensin-converting enzyme inhibitors,0,Title,hl_i,3074300,test,gold,i
6571,outpatients with primary depression,0,Abstract,ss_p,3081600,test,gold,p
6572,bupropion,0,Abstract,ss_i,3081600,test,gold,i
6573,doxepin,0,Abstract,ss_i,3081600,test,gold,i
6574,efficacy,0,Abstract,ss_o,3081600,test,gold,o
6575,safety differences,0,Abstract,ss_o,3081600,test,gold,o
6576,outpatients with primary depression,0,Abstract,hl_p,3081600,test,gold,p
6577,bupropion,0,Abstract,hl_i,3081600,test,gold,i
6578,doxepin,0,Abstract,hl_i,3081600,test,gold,i
6579,efficacy,0,Abstract,hl_o,3081600,test,gold,o
6580,safety,0,Abstract,hl_o,3081600,test,gold,o
6581,placebo,1,Abstract,ss_i,3081600,test,gold,i
6582,placebo,1,Abstract,hl_i,3081600,test,gold,i
6583,Antidepressant response,2,Abstract,ss_o,3081600,test,gold,o
6584,"Hamilton Depression and Anxiety Scales , Clinical Global Severity and Improvement Ratings , and the Zung Self-Rating Depression Scale .",2,Abstract,ss_o,3081600,test,gold,o
6585,Antidepressant response,2,Abstract,hl_o,3081600,test,gold,o
6586,Hamilton Depression and Anxiety Scales,2,Abstract,hl_o,3081600,test,gold,o
6587,Clinical Global Severity and Improvement Ratings,2,Abstract,hl_o,3081600,test,gold,o
6588,Zung Self-Rating Depression Scale,2,Abstract,hl_o,3081600,test,gold,o
6589,efficacy,3,Abstract,ss_o,3081600,test,gold,o
6590,efficacy,3,Abstract,hl_o,3081600,test,gold,o
6591,Doxepin,4,Abstract,ss_i,3081600,test,gold,i
6592,bupropion,4,Abstract,ss_i,3081600,test,gold,i
6593,doxepin,4,Abstract,ss_i,3081600,test,gold,i
6594,bupropion .,4,Abstract,ss_i,3081600,test,gold,i
6595,sleep,4,Abstract,ss_o,3081600,test,gold,o
6596,Hamilton Depression Scale,4,Abstract,ss_o,3081600,test,gold,o
6597,sleep,4,Abstract,ss_o,3081600,test,gold,o
6598,Doxepin,4,Abstract,hl_i,3081600,test,gold,i
6599,bupropion,4,Abstract,hl_i,3081600,test,gold,i
6600,doxepin,4,Abstract,hl_i,3081600,test,gold,i
6601,bupropion .,4,Abstract,hl_i,3081600,test,gold,i
6602,sleep,4,Abstract,hl_o,3081600,test,gold,o
6603,Hamilton Depression Scale,4,Abstract,hl_o,3081600,test,gold,o
6604,sleep,4,Abstract,hl_o,3081600,test,gold,o
6605,Doxepin,5,Abstract,ss_i,3081600,test,gold,i
6606,bupropion .,5,Abstract,ss_i,3081600,test,gold,i
6607,anticholinergic side effects,5,Abstract,ss_o,3081600,test,gold,o
6608,"dry mouth , constipation , sleepiness , and tiredness",5,Abstract,ss_o,3081600,test,gold,o
6609,Doxepin,5,Abstract,hl_i,3081600,test,gold,i
6610,bupropion .,5,Abstract,hl_i,3081600,test,gold,i
6611,anticholinergic side effects,5,Abstract,hl_o,3081600,test,gold,o
6612,"dry mouth , constipation , sleepiness , and tiredness",5,Abstract,hl_o,3081600,test,gold,o
6613,doxepin,6,Abstract,ss_i,3081600,test,gold,i
6614,bupropion .,6,Abstract,ss_i,3081600,test,gold,i
6615,increased appetite and weight gain,6,Abstract,ss_o,3081600,test,gold,o
6616,side effects,6,Abstract,ss_o,3081600,test,gold,o
6617,doxepin,6,Abstract,hl_i,3081600,test,gold,i
6618,bupropion .,6,Abstract,hl_i,3081600,test,gold,i
6619,appetite and weight gain,6,Abstract,hl_o,3081600,test,gold,o
6620,outpatients with a major depressive disorder .,0,Title,ss_p,3081600,test,gold,p
6621,doxepin,0,Title,ss_i,3081600,test,gold,i
6622,bupropion,0,Title,ss_i,3081600,test,gold,i
6623,outpatients with a major depressive disorder .,0,Title,hl_p,3081600,test,gold,p
6624,doxepin,0,Title,hl_i,3081600,test,gold,i
6625,bupropion,0,Title,hl_i,3081600,test,gold,i
6626,"stasis , a hypercoagulable state and venous endothelial damage .",0,Abstract,ss_o,3534803,test,gold,o
6629,dihydroergotamine ( DHE ),3,Abstract,ss_i,3534803,test,gold,i
6630,heparin,3,Abstract,ss_i,3534803,test,gold,i
6631,stasis and the hypercoagulable state,3,Abstract,ss_o,3534803,test,gold,o
6632,dihydroergotamine ( DHE ),3,Abstract,hl_i,3534803,test,gold,i
6633,heparin,3,Abstract,hl_i,3534803,test,gold,i
6635,United States,5,Abstract,ss_p,3534803,test,gold,p
6636,DHE,5,Abstract,ss_i,3534803,test,gold,i
6637,heparin,5,Abstract,ss_i,3534803,test,gold,i
6638,DHE,5,Abstract,ss_i,3534803,test,gold,i
6639,heparin,5,Abstract,ss_i,3534803,test,gold,i
6640,heparin,5,Abstract,ss_i,3534803,test,gold,i
6641,DHE,5,Abstract,ss_i,3534803,test,gold,i
6642,placebo .,5,Abstract,ss_i,3534803,test,gold,i
6643,prophylactic efficacy,5,Abstract,ss_o,3534803,test,gold,o
6644,United States,5,Abstract,hl_p,3534803,test,gold,p
6645,DHE,5,Abstract,hl_i,3534803,test,gold,i
6646,heparin,5,Abstract,hl_i,3534803,test,gold,i
6647,DHE,5,Abstract,hl_i,3534803,test,gold,i
6648,heparin,5,Abstract,hl_i,3534803,test,gold,i
6649,heparin,5,Abstract,hl_i,3534803,test,gold,i
6650,DHE,5,Abstract,hl_i,3534803,test,gold,i
6651,placebo .,5,Abstract,hl_i,3534803,test,gold,i
6652,General surgical patients including those undergoing noncardiac thoracic and pelvic operations who were identified at moderate to high risk for postop DVT were included .,6,Abstract,ss_p,3534803,test,gold,p
6653,General surgical patients including those undergoing noncardiac thoracic and pelvic operations who were identified at moderate to high risk for postop DVT were included .,6,Abstract,hl_p,3534803,test,gold,p
6655,Eight hundred and eighty eight patients were entered into this trial and 744 ( 85 % ) completed the study .,8,Abstract,ss_p,3534803,test,gold,p
6656,Eight hundred and eighty eight,8,Abstract,hl_p,3534803,test,gold,p
6657,744,8,Abstract,hl_p,3534803,test,gold,p
6658,DHE/Hep,9,Abstract,ss_i,3534803,test,gold,i
6659,placebo,9,Abstract,ss_i,3534803,test,gold,i
6660,DHE/Hep,9,Abstract,hl_i,3534803,test,gold,i
6661,placebo,9,Abstract,hl_i,3534803,test,gold,i
6664,prophylaxis,0,Title,ss_o,3534803,test,gold,o
6665,600 cases,0,Abstract,ss_p,361799,test,gold,p
6666,600 cases,0,Abstract,hl_p,361799,test,gold,p
6667,advanced breast cancers,1,Abstract,ss_p,361799,test,gold,p
6668,in eight French anticancer centres .,1,Abstract,ss_p,361799,test,gold,p
6669,advanced breast cancers,1,Abstract,hl_p,361799,test,gold,p
6670,in eight French anticancer centres,1,Abstract,hl_p,361799,test,gold,p
6672,603 patients,3,Abstract,ss_p,361799,test,gold,p
6673,603 patients,3,Abstract,hl_p,361799,test,gold,p
6674,chemotherapy,4,Abstract,ss_i,361799,test,gold,i
6675,vincristine,4,Abstract,ss_i,361799,test,gold,i
6676,cyclophosphamide,4,Abstract,ss_i,361799,test,gold,i
6677,5-fluoro-uracil,4,Abstract,ss_i,361799,test,gold,i
6678,doxorubicine,4,Abstract,ss_i,361799,test,gold,i
6679,methotrexate .,4,Abstract,ss_i,361799,test,gold,i
6680,chemotherapy,4,Abstract,hl_i,361799,test,gold,i
6681,vincristine,4,Abstract,hl_i,361799,test,gold,i
6682,cyclophosphamide,4,Abstract,hl_i,361799,test,gold,i
6683,5-fluoro-uracil,4,Abstract,hl_i,361799,test,gold,i
6684,doxorubicine,4,Abstract,hl_i,361799,test,gold,i
6685,methotrexate .,4,Abstract,hl_i,361799,test,gold,i
6686,doxorubicine,5,Abstract,ss_i,361799,test,gold,i
6687,results,5,Abstract,ss_o,361799,test,gold,o
6688,quality,5,Abstract,ss_o,361799,test,gold,o
6689,doxorubicine,5,Abstract,hl_i,361799,test,gold,i
6690,quality,5,Abstract,hl_o,361799,test,gold,o
6691,chemotherapy,6,Abstract,ss_i,361799,test,gold,i
6692,chemotherapy,6,Abstract,hl_i,361799,test,gold,i
6693,advanced breast cancer .,0,Title,ss_p,361799,test,gold,p
6694,chemotherapy,0,Title,ss_i,361799,test,gold,i
6695,advanced breast cancer .,0,Title,hl_p,361799,test,gold,p
6696,chemotherapy,0,Title,hl_i,361799,test,gold,i
6697,Three hundred forty-one Tanzanian preschool children,0,Abstract,ss_p,384815,test,gold,p
6698,levamisole,0,Abstract,ss_i,384815,test,gold,i
6699,placebo,0,Abstract,ss_i,384815,test,gold,i
6700,Three hundred forty-one Tanzanian preschool children,0,Abstract,hl_p,384815,test,gold,p
6701,levamisole,0,Abstract,hl_i,384815,test,gold,i
6702,placebo,0,Abstract,hl_i,384815,test,gold,i
6703,Weights and heights,1,Abstract,ss_o,384815,test,gold,o
6704,Weights and heights,1,Abstract,hl_o,384815,test,gold,o
6705,levamisole,2,Abstract,ss_i,384815,test,gold,i
6706,placebo-treated,2,Abstract,ss_i,384815,test,gold,i
6707,rate of weight gain,2,Abstract,ss_o,384815,test,gold,o
6708,levamisole,2,Abstract,hl_i,384815,test,gold,i
6709,placebo-treated,2,Abstract,hl_i,384815,test,gold,i
6710,rate of weight gain,2,Abstract,hl_o,384815,test,gold,o
6711,levamisole,3,Abstract,ss_i,384815,test,gold,i
6712,placebo,3,Abstract,ss_i,384815,test,gold,i
6713,rate of weight gain,3,Abstract,ss_o,384815,test,gold,o
6714,children,3,Abstract,hl_p,384815,test,gold,p
6715,levamisole,3,Abstract,hl_i,384815,test,gold,i
6716,placebo,3,Abstract,hl_i,384815,test,gold,i
6717,rate of weight gain,3,Abstract,hl_o,384815,test,gold,o
6718,placebo,4,Abstract,ss_i,384815,test,gold,i
6719,rate of height gain,4,Abstract,ss_o,384815,test,gold,o
6720,placebo,4,Abstract,hl_i,384815,test,gold,i
6721,rate of height gain,4,Abstract,hl_o,384815,test,gold,o
6722,growth rates :,0,Title,ss_o,384815,test,gold,o
6723,45 type I ( insulin dependent ) diabetics without proliferative retinopathy,0,Abstract,ss_p,3919804,test,gold,p
6724,insulin infusion,0,Abstract,ss_i,3919804,test,gold,i
6725,insulin injections,0,Abstract,ss_i,3919804,test,gold,i
6726,insulin treatment,0,Abstract,ss_i,3919804,test,gold,i
6727,blood glucose,0,Abstract,ss_o,3919804,test,gold,o
6728,45 type I ( insulin dependent ) diabetics without proliferative retinopathy,0,Abstract,hl_p,3919804,test,gold,p
6729,insulin infusion,0,Abstract,hl_i,3919804,test,gold,i
6730,insulin injections,0,Abstract,hl_i,3919804,test,gold,i
6731,insulin treatment,0,Abstract,hl_i,3919804,test,gold,i
6733,fluorescein angiograms,2,Abstract,ss_o,3919804,test,gold,o
6734,progression of retinopathy,2,Abstract,ss_o,3919804,test,gold,o
6735,fluorescein angiograms,2,Abstract,hl_o,3919804,test,gold,o
6736,progression of retinopathy,2,Abstract,hl_o,3919804,test,gold,o
6739,cotton wool spots .,5,Abstract,ss_o,3919804,test,gold,o
6740,cotton wool spots .,5,Abstract,hl_o,3919804,test,gold,o
6741,glycosylated haemoglobin and blood glucose values,6,Abstract,ss_o,3919804,test,gold,o
6742,frequent episodes of hypoglycaemia,6,Abstract,ss_o,3919804,test,gold,o
6743,duration of diabetes,6,Abstract,ss_o,3919804,test,gold,o
6744,retinopathy at onset .,6,Abstract,ss_o,3919804,test,gold,o
6745,glycosylated haemoglobin,6,Abstract,hl_o,3919804,test,gold,o
6746,blood glucose values,6,Abstract,hl_o,3919804,test,gold,o
6747,episodes of hypoglycaemia,6,Abstract,hl_o,3919804,test,gold,o
6748,duration of diabetes,6,Abstract,hl_o,3919804,test,gold,o
6749,retinopathy,6,Abstract,hl_o,3919804,test,gold,o
6750,blood glucose concentration,7,Abstract,ss_o,3919804,test,gold,o
6751,retinopathy .,7,Abstract,ss_o,3919804,test,gold,o
6752,blood glucose concentration,7,Abstract,hl_o,3919804,test,gold,o
6753,insulin dependent diabetes mellitus :,0,Title,ss_p,3919804,test,gold,p
6754,blood glucose,0,Title,ss_o,3919804,test,gold,o
6755,transient deterioration of retinopathy,0,Title,ss_o,3919804,test,gold,o
6756,insulin dependent diabetes mellitus :,0,Title,hl_p,3919804,test,gold,p
6757,retinopathy,0,Title,hl_o,3919804,test,gold,o
6758,391 medical student volunteers during the influenza A2 Hong Kong epidemic in Helsinki in the winter of 1969 .,0,Abstract,ss_p,4919024,test,gold,p
6759,amantadine,0,Abstract,ss_i,4919024,test,gold,i
6760,391 medical student volunteers during the influenza A2 Hong Kong epidemic in Helsinki in the winter of 1969,0,Abstract,hl_p,4919024,test,gold,p
6761,amantadine,0,Abstract,hl_i,4919024,test,gold,i
6762,amantadine,1,Abstract,ss_i,4919024,test,gold,i
6763,placebo,1,Abstract,ss_i,4919024,test,gold,i
6764,Serologically verified influenza,1,Abstract,ss_o,4919024,test,gold,o
6765,complement fixation and/or haemagglutination inhibition,1,Abstract,ss_o,4919024,test,gold,o
6766,amantadine,1,Abstract,hl_i,4919024,test,gold,i
6767,placebo,1,Abstract,hl_i,4919024,test,gold,i
6768,Serologically verified influenza,1,Abstract,hl_o,4919024,test,gold,o
6769,complement fixation and/or haemagglutination inhibition,1,Abstract,hl_o,4919024,test,gold,o
6770,amantadine :,0,Title,ss_i,4919024,test,gold,i
6771,amantadine,0,Title,hl_i,4919024,test,gold,i
6772,31 adult asthmatic patients,0,Abstract,ss_p,6418441,test,gold,p
6773,Sodium cromoglycate,0,Abstract,ss_i,6418441,test,gold,i
6774,placebo,0,Abstract,ss_i,6418441,test,gold,i
6775,31 adult asthmatic,0,Abstract,hl_p,6418441,test,gold,p
6776,Sodium cromoglycate,0,Abstract,hl_i,6418441,test,gold,i
6777,placebo,0,Abstract,hl_i,6418441,test,gold,i
6778,Sodium cromoglycate,1,Abstract,ss_i,6418441,test,gold,i
6779,placebo,1,Abstract,ss_i,6418441,test,gold,i
6780,breathlessness at rest,1,Abstract,ss_o,6418441,test,gold,o
6781,breathlessness on exertion,1,Abstract,ss_o,6418441,test,gold,o
6782,quality of sleep,1,Abstract,ss_o,6418441,test,gold,o
6783,morning peak expiratory flow rate value,1,Abstract,ss_o,6418441,test,gold,o
6784,Sodium cromoglycate,1,Abstract,hl_i,6418441,test,gold,i
6785,placebo,1,Abstract,hl_i,6418441,test,gold,i
6786,breathlessness at rest,1,Abstract,hl_o,6418441,test,gold,o
6787,breathlessness on exertion,1,Abstract,hl_o,6418441,test,gold,o
6788,quality of sleep,1,Abstract,hl_o,6418441,test,gold,o
6789,morning peak expiratory flow rate value,1,Abstract,hl_o,6418441,test,gold,o
6790,sodium cromoglycate .,2,Abstract,ss_i,6418441,test,gold,i
6791,treatment opinions,2,Abstract,ss_o,6418441,test,gold,o
6792,treatment preferences,2,Abstract,ss_o,6418441,test,gold,o
6793,sodium cromoglycate .,2,Abstract,hl_i,6418441,test,gold,i
6794,treatment preferences,2,Abstract,hl_o,6418441,test,gold,o
6795,sodium cromoglycate,3,Abstract,ss_i,6418441,test,gold,i
6796,placebo .,3,Abstract,ss_i,6418441,test,gold,i
6797,sodium cromoglycate,3,Abstract,hl_i,6418441,test,gold,i
6798,placebo .,3,Abstract,hl_i,6418441,test,gold,i
6799,side-effects,4,Abstract,ss_o,6418441,test,gold,o
6800,side-effects,4,Abstract,hl_o,6418441,test,gold,o
6801,sodium cromoglycate,5,Abstract,ss_i,6418441,test,gold,i
6802,placebo,5,Abstract,ss_i,6418441,test,gold,i
6803,superior,5,Abstract,ss_o,6418441,test,gold,o
6804,asthmatic symptoms,5,Abstract,ss_o,6418441,test,gold,o
6805,bronchodilator therapy required .,5,Abstract,ss_o,6418441,test,gold,o
6806,sodium cromoglycate,5,Abstract,hl_i,6418441,test,gold,i
6807,placebo,5,Abstract,hl_i,6418441,test,gold,i
6808,asthmatic symptoms,5,Abstract,hl_o,6418441,test,gold,o
6809,asthma in adults,0,Title,ss_p,6418441,test,gold,p
6810,sodium cromoglycate,0,Title,ss_i,6418441,test,gold,i
6811,asthma,0,Title,hl_p,6418441,test,gold,p
6812,adults,0,Title,hl_p,6418441,test,gold,p
6813,sodium cromoglycate,0,Title,hl_i,6418441,test,gold,i
6814,31 healthy middle aged men,0,Abstract,ss_p,6421395,test,gold,p
6815,physical exercise,0,Abstract,ss_i,6421395,test,gold,i
6816,regular physical exercise,0,Abstract,ss_i,6421395,test,gold,i
6817,biochemical risk factors for ischaemic heart disease,0,Abstract,ss_o,6421395,test,gold,o
6818,31 healthy middle aged men,0,Abstract,hl_p,6421395,test,gold,p
6819,physical exercise,0,Abstract,hl_i,6421395,test,gold,i
6820,regular physical exercise,0,Abstract,hl_i,6421395,test,gold,i
6821,biochemical risk factors for ischaemic heart disease,0,Abstract,hl_o,6421395,test,gold,o
6822,regular exercise,1,Abstract,ss_i,6421395,test,gold,i
6823,serum cholesterol concentrations,1,Abstract,ss_o,6421395,test,gold,o
6824,high density lipoprotein subfraction two ( HDL2 ),1,Abstract,ss_o,6421395,test,gold,o
6825,subfraction three ( HDL3 ),1,Abstract,ss_o,6421395,test,gold,o
6826,low density lipoprotein fraction,1,Abstract,ss_o,6421395,test,gold,o
6827,serum cholesterol concentrations,1,Abstract,hl_o,6421395,test,gold,o
6828,high density lipoprotein subfraction two ( HDL2 ),1,Abstract,hl_o,6421395,test,gold,o
6829,subfraction three ( HDL3 ),1,Abstract,hl_o,6421395,test,gold,o
6830,low density lipoprotein fraction,1,Abstract,hl_o,6421395,test,gold,o
6831,regular exercise,2,Abstract,ss_i,6421395,test,gold,i
6832,plasma 6-keto-prostaglandin F1 alpha concentration,2,Abstract,ss_o,6421395,test,gold,o
6833,serum thromboxane B2 concentration,2,Abstract,ss_o,6421395,test,gold,o
6834,prostaglandin E2 concentrations,2,Abstract,ss_o,6421395,test,gold,o
6835,exercise,2,Abstract,hl_i,6421395,test,gold,i
6836,plasma 6-keto-prostaglandin F1 alpha concentration,2,Abstract,hl_o,6421395,test,gold,o
6837,serum thromboxane B2 concentration,2,Abstract,hl_o,6421395,test,gold,o
6838,prostaglandin E2 concentrations,2,Abstract,hl_o,6421395,test,gold,o
6839,regular exercise .,3,Abstract,ss_i,6421395,test,gold,i
6840,plasma 6-keto-prostaglandin F1 alpha concentration,3,Abstract,ss_o,6421395,test,gold,o
6841,serum HDL2 cholesterol concentration,3,Abstract,ss_o,6421395,test,gold,o
6842,exercise .,3,Abstract,hl_i,6421395,test,gold,i
6843,plasma 6-keto-prostaglandin F1 alpha concentration,3,Abstract,hl_o,6421395,test,gold,o
6844,serum HDL2 cholesterol concentration,3,Abstract,hl_o,6421395,test,gold,o
6845,healthy middle aged men,4,Abstract,ss_p,6421395,test,gold,p
6846,mild regular physical exercise,4,Abstract,ss_i,6421395,test,gold,i
6847,serum lipoproteins,4,Abstract,ss_o,6421395,test,gold,o
6848,circulating metabolites of arachidonic acid .,4,Abstract,ss_o,6421395,test,gold,o
6849,healthy middle aged men,4,Abstract,hl_p,6421395,test,gold,p
6850,mild regular physical exercise,4,Abstract,hl_i,6421395,test,gold,i
6851,serum lipoproteins,4,Abstract,hl_o,6421395,test,gold,o
6852,circulating metabolites of arachidonic acid .,4,Abstract,hl_o,6421395,test,gold,o
6853,middle aged men .,0,Title,ss_p,6421395,test,gold,p
6854,mild physical exercise,0,Title,ss_i,6421395,test,gold,i
6855,serum lipoproteins and metabolites of arachidonic acid :,0,Title,ss_o,6421395,test,gold,o
6856,middle aged men .,0,Title,hl_p,6421395,test,gold,p
6857,mild physical exercise,0,Title,hl_i,6421395,test,gold,i
6858,serum lipoproteins,0,Title,hl_o,6421395,test,gold,o
6859,metabolites of arachidonic acid :,0,Title,hl_o,6421395,test,gold,o
6860,premature monkey ( Macaca nemestrina ) model of hyaline membrane disease ( HMD ) .,0,Abstract,ss_p,6920252,test,gold,p
6861,glucocorticoid,0,Abstract,ss_i,6920252,test,gold,i
6862,premature monkey ( Macaca nemestrina ) model of hyaline membrane disease ( HMD ) .,0,Abstract,hl_p,6920252,test,gold,p
6863,glucocorticoid,0,Abstract,hl_i,6920252,test,gold,i
6864,Twelve dams,1,Abstract,ss_p,6920252,test,gold,p
6865,dexamethasone,1,Abstract,ss_i,6920252,test,gold,i
6866,Twelve dams,1,Abstract,hl_p,6920252,test,gold,p
6867,dexamethasone,1,Abstract,hl_i,6920252,test,gold,i
6868,Twelve control animals,2,Abstract,ss_p,6920252,test,gold,p
6869,saline .,2,Abstract,ss_i,6920252,test,gold,i
6870,Twelve control animals,2,Abstract,hl_p,6920252,test,gold,p
6871,saline .,2,Abstract,hl_i,6920252,test,gold,i
6872,dexamethasone-treated,3,Abstract,ss_i,6920252,test,gold,i
6873,incidence and severity of HMD,3,Abstract,ss_o,6920252,test,gold,o
6874,dexamethasone-treated,3,Abstract,hl_i,6920252,test,gold,i
6875,incidence and severity of HMD,3,Abstract,hl_o,6920252,test,gold,o
6877,dexamethasone-treated,5,Abstract,ss_i,6920252,test,gold,i
6878,volume-pressure behavior,5,Abstract,ss_o,6920252,test,gold,o
6879,distensibility,5,Abstract,ss_o,6920252,test,gold,o
6880,deflation stability,5,Abstract,ss_o,6920252,test,gold,o
6881,dexamethasone-treated,5,Abstract,hl_i,6920252,test,gold,i
6882,volume-pressure behavior,5,Abstract,hl_o,6920252,test,gold,o
6883,distensibility,5,Abstract,hl_o,6920252,test,gold,o
6884,deflation stability,5,Abstract,hl_o,6920252,test,gold,o
6885,dexamethasone-treated,6,Abstract,ss_i,6920252,test,gold,i
6886,production of surface active material ( SAM ) phospholipids,6,Abstract,ss_o,6920252,test,gold,o
6887,total lung phospholipid,6,Abstract,ss_o,6920252,test,gold,o
6888,alveolar lavage fluid phospholipid,6,Abstract,ss_o,6920252,test,gold,o
6889,alveolar lavage fluid disaturated phosphatidylcholine,6,Abstract,ss_o,6920252,test,gold,o
6890,dexamethasone-treated,6,Abstract,hl_i,6920252,test,gold,i
6891,production of surface active material ( SAM ) phospholipids,6,Abstract,hl_o,6920252,test,gold,o
6892,total lung phospholipid,6,Abstract,hl_o,6920252,test,gold,o
6893,alveolar lavage fluid phospholipid,6,Abstract,hl_o,6920252,test,gold,o
6894,alveolar lavage fluid disaturated phosphatidylcholine,6,Abstract,hl_o,6920252,test,gold,o
6895,dexamethasone,7,Abstract,ss_i,6920252,test,gold,i
6896,14C-palmitate,7,Abstract,ss_o,6920252,test,gold,o
6897,lung lipid,7,Abstract,ss_o,6920252,test,gold,o
6898,DPC fraction,7,Abstract,ss_o,6920252,test,gold,o
6899,dexamethasone,7,Abstract,hl_i,6920252,test,gold,i
6900,14C-palmitate,7,Abstract,hl_o,6920252,test,gold,o
6901,lung lipid,7,Abstract,hl_o,6920252,test,gold,o
6902,in this animal model ;,8,Abstract,ss_p,6920252,test,gold,p
6903,dexamethasone,8,Abstract,ss_i,6920252,test,gold,i
6904,incidence and severity of experimental HMD,8,Abstract,ss_o,6920252,test,gold,o
6905,effects,8,Abstract,ss_o,6920252,test,gold,o
6906,fetal pulmonary functions,8,Abstract,ss_o,6920252,test,gold,o
6907,dexamethasone,8,Abstract,hl_i,6920252,test,gold,i
6908,incidence and severity of experimental HMD,8,Abstract,hl_o,6920252,test,gold,o
6909,fetal pulmonary functions,8,Abstract,hl_o,6920252,test,gold,o
6910,the premature monkey :,0,Title,ss_p,6920252,test,gold,p
6911,dexamethasone .,0,Title,ss_i,6920252,test,gold,i
6912,the premature monkey :,0,Title,hl_p,6920252,test,gold,p
6913,dexamethasone .,0,Title,hl_i,6920252,test,gold,i
6915,previously untreated patients with prostatic cancer,1,Abstract,ss_p,6938020,test,gold,p
6916,Stilboestrol,1,Abstract,ss_i,6938020,test,gold,i
6917,Cyproterone acetate,1,Abstract,ss_i,6938020,test,gold,i
6918,Medroxyprogesterone acetate,1,Abstract,ss_i,6938020,test,gold,i
6919,Stilboestrol,1,Abstract,ss_i,6938020,test,gold,i
6920,Estracyt,1,Abstract,ss_i,6938020,test,gold,i
6921,previously untreated patients with prostatic cancer,1,Abstract,hl_p,6938020,test,gold,p
6922,Stilboestrol,1,Abstract,hl_i,6938020,test,gold,i
6923,Cyproterone acetate,1,Abstract,hl_i,6938020,test,gold,i
6924,Medroxyprogesterone acetate,1,Abstract,hl_i,6938020,test,gold,i
6925,Stilboestrol,1,Abstract,hl_i,6938020,test,gold,i
6926,Estracyt,1,Abstract,hl_i,6938020,test,gold,i
6927,Stilboestrol,2,Abstract,ss_i,6938020,test,gold,i
6928,side effects,2,Abstract,ss_o,6938020,test,gold,o
6929,gynaecomastia .,2,Abstract,ss_o,6938020,test,gold,o
6930,Stilboestrol,2,Abstract,hl_i,6938020,test,gold,i
6931,side effects,2,Abstract,hl_o,6938020,test,gold,o
6932,gynaecomastia .,2,Abstract,hl_o,6938020,test,gold,o
6933,patients with advanced disease no longer responsive to hormonal treatment,3,Abstract,ss_p,6938020,test,gold,p
6934,Adriamycin,3,Abstract,ss_i,6938020,test,gold,i
6935,Procarbazine .,3,Abstract,ss_i,6938020,test,gold,i
6936,patients with advanced disease no longer responsive to hormonal treatment,3,Abstract,hl_p,6938020,test,gold,p
6937,Adriamycin,3,Abstract,hl_i,6938020,test,gold,i
6938,Procarbazine .,3,Abstract,hl_i,6938020,test,gold,i
6939,Procarbazine,4,Abstract,ss_i,6938020,test,gold,i
6940,Toxicity and early death,4,Abstract,ss_o,6938020,test,gold,o
6941,Procarbazine,4,Abstract,hl_i,6938020,test,gold,i
6942,Toxicity and early death,4,Abstract,hl_o,6938020,test,gold,o
6943,prostatic cancer .,0,Title,ss_p,6938020,test,gold,p
6944,prostatic cancer .,0,Title,hl_p,6938020,test,gold,p
6945,One hundred and twenty patients presenting at Macquarie Hospital for admission,0,Abstract,ss_p,6951573,test,gold,p
6946,One hundred and twenty patients presenting at Macquarie Hospital for admission,0,Abstract,hl_p,6951573,test,gold,p
6947,standard hospital care and follow-up .,1,Abstract,ss_i,6951573,test,gold,i
6948,standard hospital care and follow-up .,1,Abstract,hl_i,6951573,test,gold,i
6949,taken back to the community,2,Abstract,ss_i,6951573,test,gold,i
6950,follow-up treatment,2,Abstract,ss_i,6951573,test,gold,i
6951,back to the community,2,Abstract,hl_i,6951573,test,gold,i
6952,follow-up treatment,2,Abstract,hl_i,6951573,test,gold,i
6953,admission,3,Abstract,ss_o,6951573,test,gold,o
6954,burden on the relatives,4,Abstract,ss_o,6951573,test,gold,o
6955,burden on the control group relatives .,4,Abstract,ss_o,6951573,test,gold,o
6956,burden on the relatives,4,Abstract,hl_o,6951573,test,gold,o
6957,satisfied,5,Abstract,ss_o,6951573,test,gold,o
6958,satisfied,5,Abstract,hl_o,6951573,test,gold,o
6959,psychiatric patients,6,Abstract,ss_p,6951573,test,gold,p
6960,burden on their relatives .,6,Abstract,ss_o,6951573,test,gold,o
6961,psychiatric patients,6,Abstract,hl_p,6951573,test,gold,p
6962,burden on their relatives .,6,Abstract,hl_o,6951573,test,gold,o
6963,psychiatric hospital,0,Title,ss_i,6951573,test,gold,i
6964,community treatment,0,Title,ss_i,6951573,test,gold,i
6965,effect on relatives .,0,Title,ss_o,6951573,test,gold,o
6966,psychiatric hospital,0,Title,hl_i,6951573,test,gold,i
6967,community treatment,0,Title,hl_i,6951573,test,gold,i
6968,effect on relatives .,0,Title,hl_o,6951573,test,gold,o
6969,clofibrate,0,Abstract,ss_i,6989377,test,gold,i
6970,niceritrol .,0,Abstract,ss_i,6989377,test,gold,i
6971,proportion of linoleate,0,Abstract,ss_o,6989377,test,gold,o
6972,linoleate,0,Abstract,hl_o,6989377,test,gold,o
6973,95 patients with atherosclerotic disease .,1,Abstract,ss_p,6989377,test,gold,p
6974,fatty acid composition of the plasma lipid esters,1,Abstract,ss_o,6989377,test,gold,o
6975,95 patients with atherosclerotic disease,1,Abstract,hl_p,6989377,test,gold,p
6976,fatty acid composition of the plasma lipid esters,1,Abstract,hl_o,6989377,test,gold,o
6978,clofibrate,3,Abstract,ss_i,6989377,test,gold,i
6979,niceritrol,3,Abstract,ss_i,6989377,test,gold,i
6980,clofibrate,3,Abstract,hl_i,6989377,test,gold,i
6981,niceritrol,3,Abstract,hl_i,6989377,test,gold,i
6983,"diet , clofibrate",5,Abstract,ss_i,6989377,test,gold,i
6984,niceritrol,5,Abstract,ss_i,6989377,test,gold,i
6985,serum lipid reductions .,5,Abstract,ss_o,6989377,test,gold,o
6986,diet,5,Abstract,hl_i,6989377,test,gold,i
6987,clofibrate,5,Abstract,hl_i,6989377,test,gold,i
6988,niceritrol,5,Abstract,hl_i,6989377,test,gold,i
6989,serum lipid,5,Abstract,hl_o,6989377,test,gold,o
6990,fatty acid composition in the plasma lipid esters,6,Abstract,ss_o,6989377,test,gold,o
6991,degree of dietary adherence .,6,Abstract,ss_o,6989377,test,gold,o
6992,fatty acid composition in the plasma lipid esters,6,Abstract,hl_o,6989377,test,gold,o
6993,dietary treatment,7,Abstract,ss_i,6989377,test,gold,i
6994,content of saturated and monounsaturated fatty acids,7,Abstract,ss_o,6989377,test,gold,o
6995,polyunsaturated fatty acids,7,Abstract,ss_o,6989377,test,gold,o
6996,ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ) in the cholesterol esters and triglycerides .,7,Abstract,ss_o,6989377,test,gold,o
6997,content of saturated and monounsaturated fatty acids,7,Abstract,hl_o,6989377,test,gold,o
6998,polyunsaturated fatty acids,7,Abstract,hl_o,6989377,test,gold,o
6999,ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ),7,Abstract,hl_o,6989377,test,gold,o
7000,phospholipids .,8,Abstract,ss_o,6989377,test,gold,o
7001,phospholipids .,8,Abstract,hl_o,6989377,test,gold,o
7002,diet,9,Abstract,ss_i,6989377,test,gold,i
7003,clofibrate,9,Abstract,ss_i,6989377,test,gold,i
7004,niceritrol,9,Abstract,ss_i,6989377,test,gold,i
7005,changes of the fatty acid composition .,9,Abstract,ss_o,6989377,test,gold,o
7006,diet,9,Abstract,hl_i,6989377,test,gold,i
7007,clofibrate,9,Abstract,hl_i,6989377,test,gold,i
7008,niceritrol,9,Abstract,hl_i,6989377,test,gold,i
7009,fatty acid composition .,9,Abstract,hl_o,6989377,test,gold,o
7010,Clofibrate,10,Abstract,ss_i,6989377,test,gold,i
7011,"amounts of monounsaturated fatty acids , especially oleate ( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids",10,Abstract,ss_o,6989377,test,gold,o
7012,content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides .,10,Abstract,ss_o,6989377,test,gold,o
7013,Clofibrate,10,Abstract,hl_i,6989377,test,gold,i
7014,monounsaturated fatty acids,10,Abstract,hl_o,6989377,test,gold,o
7015,oleate,10,Abstract,hl_o,6989377,test,gold,o
7016,triglycerides and phospholipids,10,Abstract,hl_o,6989377,test,gold,o
7017,content of linoleic ( 18 : 2 ) acid,10,Abstract,hl_o,6989377,test,gold,o
7019,clofibrate,12,Abstract,ss_i,6989377,test,gold,i
7020,P/S ratio,12,Abstract,ss_o,6989377,test,gold,o
7021,relative content of saturated fatty acids,12,Abstract,ss_o,6989377,test,gold,o
7022,P/S ratio,12,Abstract,hl_o,6989377,test,gold,o
7023,saturated fatty acids,12,Abstract,hl_o,6989377,test,gold,o
7024,clofibrate,13,Abstract,ss_i,6989377,test,gold,i
7025,diet,13,Abstract,ss_i,6989377,test,gold,i
7026,change from polyunsaturated to monounsaturated fatty acids in the plasma lipid esters,13,Abstract,ss_o,6989377,test,gold,o
7027,ratio between polyunsaturated and saturated fatty acids .,13,Abstract,ss_o,6989377,test,gold,o
7028,polyunsaturated to monounsaturated fatty acids in the plasma lipid esters,13,Abstract,hl_o,6989377,test,gold,o
7029,ratio between polyunsaturated and saturated fatty acids .,13,Abstract,hl_o,6989377,test,gold,o
7030,clofibrate,14,Abstract,ss_i,6989377,test,gold,i
7031,diet .,14,Abstract,ss_i,6989377,test,gold,i
7032,The fatty acid changes,14,Abstract,ss_o,6989377,test,gold,o
7033,clofibrate,14,Abstract,hl_i,6989377,test,gold,i
7034,diet .,14,Abstract,hl_i,6989377,test,gold,i
7035,acid changes,14,Abstract,hl_o,6989377,test,gold,o
7036,"diet , clofibrate",0,Title,ss_i,6989377,test,gold,i
7037,niceritrol .,0,Title,ss_i,6989377,test,gold,i
7038,Changes in the fatty acid composition of the plasma lipid esters,0,Title,ss_o,6989377,test,gold,o
7039,diet,0,Title,hl_i,6989377,test,gold,i
7040,clofibrate,0,Title,hl_i,6989377,test,gold,i
7041,niceritrol .,0,Title,hl_i,6989377,test,gold,i
7042,fatty acid composition of the plasma lipid esters,0,Title,hl_o,6989377,test,gold,o
7043,efficacy,0,Abstract,ss_o,7598243,test,gold,o
7044,360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .,1,Abstract,ss_p,7598243,test,gold,p
7045,"ondansetron , droperidol , perphenazine",1,Abstract,ss_i,7598243,test,gold,i
7046,metoclopramide,1,Abstract,ss_i,7598243,test,gold,i
7047,360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ),1,Abstract,hl_p,7598243,test,gold,p
7048,ondansetron,1,Abstract,hl_i,7598243,test,gold,i
7049,droperidol,1,Abstract,hl_i,7598243,test,gold,i
7050,perphenazine,1,Abstract,hl_i,7598243,test,gold,i
7051,metoclopramide,1,Abstract,hl_i,7598243,test,gold,i
7052,ondansetron,2,Abstract,ss_i,7598243,test,gold,i
7053,droperidol,2,Abstract,ss_i,7598243,test,gold,i
7054,perphenazine,2,Abstract,ss_i,7598243,test,gold,i
7055,metoclopramide,2,Abstract,ss_i,7598243,test,gold,i
7056,placebo,2,Abstract,ss_i,7598243,test,gold,i
7057,ondansetron,2,Abstract,hl_i,7598243,test,gold,i
7058,droperidol,2,Abstract,hl_i,7598243,test,gold,i
7059,perphenazine,2,Abstract,hl_i,7598243,test,gold,i
7060,metoclopramide,2,Abstract,hl_i,7598243,test,gold,i
7061,placebo,2,Abstract,hl_i,7598243,test,gold,i
7062,metoclopramide,3,Abstract,ss_i,7598243,test,gold,i
7063,ondansetron,3,Abstract,ss_i,7598243,test,gold,i
7064,Hypotension,3,Abstract,ss_o,7598243,test,gold,o
7065,systolic hypotension,3,Abstract,ss_o,7598243,test,gold,o
7066,metoclopramide,3,Abstract,hl_i,7598243,test,gold,i
7067,Hypotension,3,Abstract,hl_o,7598243,test,gold,o
7068,droperidol,4,Abstract,ss_i,7598243,test,gold,i
7069,"severe nausea , retching , or vomiting , defined as severe emetic sequelae ( SES )",5,Abstract,ss_o,7598243,test,gold,o
7070,"severe nausea , retching , or vomiting",5,Abstract,hl_o,7598243,test,gold,o
7071,severe emetic sequelae ( SES ),5,Abstract,hl_o,7598243,test,gold,o
7073,ondansetron,7,Abstract,ss_i,7598243,test,gold,i
7074,droperidol,7,Abstract,ss_i,7598243,test,gold,i
7075,perphenazine,7,Abstract,ss_i,7598243,test,gold,i
7076,placebo,7,Abstract,ss_i,7598243,test,gold,i
7077,SES,7,Abstract,ss_o,7598243,test,gold,o
7078,SES,7,Abstract,hl_o,7598243,test,gold,o
7079,Metoclopramide,8,Abstract,ss_i,7598243,test,gold,i
7080,"ondansetron , droperidol",9,Abstract,ss_i,7598243,test,gold,i
7081,perphenazine,9,Abstract,ss_i,7598243,test,gold,i
7082,effective,9,Abstract,ss_o,7598243,test,gold,o
7083,effective,9,Abstract,hl_o,7598243,test,gold,o
7084,perphenazine,10,Abstract,ss_i,7598243,test,gold,i
7085,side effects .,10,Abstract,ss_o,7598243,test,gold,o
7086,side effects .,10,Abstract,hl_o,7598243,test,gold,o
7087,perphenazine,11,Abstract,ss_i,7598243,test,gold,i
7088,major gynecologic surgery .,0,Title,ss_p,7598243,test,gold,p
7089,"ondansetron , droperidol , perphenazine",0,Title,ss_i,7598243,test,gold,i
7090,metoclopramide,0,Title,ss_i,7598243,test,gold,i
7091,efficacy,0,Title,ss_o,7598243,test,gold,o
7092,ondansetron,0,Title,hl_i,7598243,test,gold,i
7093,droperidol,0,Title,hl_i,7598243,test,gold,i
7094,perphenazine,0,Title,hl_i,7598243,test,gold,i
7095,metoclopramide,0,Title,hl_i,7598243,test,gold,i
7096,risk,0,Abstract,ss_o,7707420,test,gold,o
7097,risk,1,Abstract,ss_o,7707420,test,gold,o
7098,first-degree relatives of index breast cancer patients,2,Abstract,ss_p,7707420,test,gold,p
7099,individualized breast cancer risk counseling,2,Abstract,ss_i,7707420,test,gold,i
7100,counseling .,2,Abstract,ss_i,7707420,test,gold,i
7101,risk,2,Abstract,ss_o,7707420,test,gold,o
7102,benefit,2,Abstract,ss_o,7707420,test,gold,o
7103,first-degree relatives of index breast cancer patients,2,Abstract,hl_p,7707420,test,gold,p
7104,individualized breast cancer risk counseling,2,Abstract,hl_i,7707420,test,gold,i
7105,comprehension of personal risk,2,Abstract,hl_o,7707420,test,gold,o
7106,individualized breast cancer risk counseling,3,Abstract,ss_i,7707420,test,gold,i
7107,general health counseling ( control ) .,3,Abstract,ss_i,7707420,test,gold,i
7108,risk,3,Abstract,ss_o,7707420,test,gold,o
7109,individualized breast cancer risk counseling,3,Abstract,hl_i,7707420,test,gold,i
7110,general health counseling ( control ) .,3,Abstract,hl_i,7707420,test,gold,i
7111,200 women aged 35 years and older who had a family history of breast cancer in a first-degree relative .,4,Abstract,ss_p,7707420,test,gold,p
7112,200 women aged 35 years and older,4,Abstract,hl_p,7707420,test,gold,p
7113,family history of breast cancer in a first-degree relative,4,Abstract,hl_p,7707420,test,gold,p
7114,Women with a personal history of cancer were excluded .,5,Abstract,ss_p,7707420,test,gold,p
7115,Women,5,Abstract,hl_p,7707420,test,gold,p
7116,personal history of cancer,5,Abstract,hl_p,7707420,test,gold,p
7117,Risk comprehension,6,Abstract,ss_o,7707420,test,gold,o
7118,"concordance between perceived "" subjective "" lifetime breast cancer risk and estimated "" objective "" lifetime risk .",6,Abstract,ss_o,7707420,test,gold,o
7119,Risk comprehension,6,Abstract,hl_o,7707420,test,gold,o
7120,risk counseling,7,Abstract,ss_i,7707420,test,gold,i
7121,risk,7,Abstract,ss_o,7707420,test,gold,o
7122,risk comprehension,7,Abstract,ss_o,7707420,test,gold,o
7123,risk counseling,7,Abstract,hl_i,7707420,test,gold,i
7124,risk comprehension,7,Abstract,hl_o,7707420,test,gold,o
7125,counseling .,8,Abstract,ss_i,7707420,test,gold,i
7126,lifetime risks,8,Abstract,ss_o,7707420,test,gold,o
7127,lifetime risks,8,Abstract,hl_o,7707420,test,gold,o
7128,risk counseling,9,Abstract,ss_i,7707420,test,gold,i
7129,risk,9,Abstract,ss_o,7707420,test,gold,o
7130,comprehension,9,Abstract,ss_o,7707420,test,gold,o
7131,risk counseling,9,Abstract,hl_i,7707420,test,gold,i
7132,comprehension,9,Abstract,hl_o,7707420,test,gold,o
7134,risks,11,Abstract,ss_o,7707420,test,gold,o
7135,effective,11,Abstract,ss_o,7707420,test,gold,o
7136,risk-counseling programs,12,Abstract,ss_i,7707420,test,gold,i
7137,risk,12,Abstract,ss_o,7707420,test,gold,o
7138,risk-counseling,12,Abstract,ss_o,7707420,test,gold,o
7139,risk-counseling programs,12,Abstract,hl_i,7707420,test,gold,i
7140,individualized breast cancer risk counseling :,0,Title,ss_i,7707420,test,gold,i
7141,risk counseling :,0,Title,ss_o,7707420,test,gold,o
7142,individualized breast cancer risk counseling :,0,Title,hl_i,7707420,test,gold,i
7143,patients suffering from post-operative pain after cholecystectomy .,0,Abstract,ss_p,7808649,test,gold,p
7144,ketorolac tromethamine,0,Abstract,ss_i,7808649,test,gold,i
7145,placebo,0,Abstract,ss_i,7808649,test,gold,i
7146,efficacy,0,Abstract,ss_o,7808649,test,gold,o
7147,tolerability,0,Abstract,ss_o,7808649,test,gold,o
7148,patients suffering from post-operative pain after cholecystectomy .,0,Abstract,hl_p,7808649,test,gold,p
7149,ketorolac tromethamine,0,Abstract,hl_i,7808649,test,gold,i
7150,placebo,0,Abstract,hl_i,7808649,test,gold,i
7151,efficacy,0,Abstract,hl_o,7808649,test,gold,o
7152,tolerability,0,Abstract,hl_o,7808649,test,gold,o
7155,99 patients with severe pain following surgery .,3,Abstract,ss_p,7808649,test,gold,p
7156,99 patients with severe pain following surgery,3,Abstract,hl_p,7808649,test,gold,p
7158,ketorolac tromethamine,5,Abstract,ss_i,7808649,test,gold,i
7159,analgesia activity,5,Abstract,ss_o,7808649,test,gold,o
7160,assessing pain intensity and pain relief,5,Abstract,ss_o,7808649,test,gold,o
7161,4 point scale ( VRS ),5,Abstract,ss_o,7808649,test,gold,o
7162,ketorolac tromethamine,5,Abstract,hl_i,7808649,test,gold,i
7163,pain intensity and pain relief,5,Abstract,hl_o,7808649,test,gold,o
7164,4 point scale ( VRS ),5,Abstract,hl_o,7808649,test,gold,o
7165,safety,6,Abstract,ss_o,7808649,test,gold,o
7166,efficacy,6,Abstract,ss_o,7808649,test,gold,o
7167,safety,6,Abstract,hl_o,7808649,test,gold,o
7168,efficacy,6,Abstract,hl_o,7808649,test,gold,o
7169,pain intensity,7,Abstract,ss_o,7808649,test,gold,o
7170,pain intensity,7,Abstract,hl_o,7808649,test,gold,o
7172,placebo,9,Abstract,ss_i,7808649,test,gold,i
7173,rescue analgesic drug,9,Abstract,ss_o,7808649,test,gold,o
7174,placebo,9,Abstract,hl_i,7808649,test,gold,i
7175,rescue analgesic drug,9,Abstract,hl_o,7808649,test,gold,o
7176,placebo,10,Abstract,ss_i,7808649,test,gold,i
7177,ketorolac,10,Abstract,ss_i,7808649,test,gold,i
7178,adverse events,10,Abstract,ss_o,7808649,test,gold,o
7179,adverse events,10,Abstract,hl_o,7808649,test,gold,o
7180,systemic and local tolerability,11,Abstract,ss_o,7808649,test,gold,o
7181,systemic and local tolerability,11,Abstract,hl_o,7808649,test,gold,o
7182,ketorolac,12,Abstract,ss_i,7808649,test,gold,i
7183,effective,12,Abstract,ss_o,7808649,test,gold,o
7184,ketorolac,12,Abstract,hl_i,7808649,test,gold,i
7185,placebo-controlled,0,Title,ss_i,7808649,test,gold,i
7186,ketorolac tromethamine,0,Title,ss_i,7808649,test,gold,i
7187,effectiveness,0,Title,ss_o,7808649,test,gold,o
7188,tolerability,0,Title,ss_o,7808649,test,gold,o
7189,ketorolac tromethamine,0,Title,hl_i,7808649,test,gold,i
7190,effectiveness,0,Title,hl_o,7808649,test,gold,o
7191,tolerability,0,Title,hl_o,7808649,test,gold,o
7192,"Staphylococcus aureus mastitis , 37 Holstein cows",0,Abstract,ss_p,7814711,test,gold,p
7193,oxytetracycline,0,Abstract,ss_i,7814711,test,gold,i
7194,cephapirin benzathine,0,Abstract,ss_i,7814711,test,gold,i
7195,cephapirin benzathine,0,Abstract,ss_i,7814711,test,gold,i
7196,oxytetracycline,0,Abstract,ss_i,7814711,test,gold,i
7197,efficacy,0,Abstract,ss_o,7814711,test,gold,o
7198,37 Holstein cows,0,Abstract,hl_p,7814711,test,gold,p
7199,oxytetracycline,0,Abstract,hl_i,7814711,test,gold,i
7200,cephapirin benzathine,0,Abstract,hl_i,7814711,test,gold,i
7201,cephapirin benzathine,0,Abstract,hl_i,7814711,test,gold,i
7202,oxytetracycline,0,Abstract,hl_i,7814711,test,gold,i
7203,Milk samples,1,Abstract,ss_o,7814711,test,gold,o
7204,infected,1,Abstract,ss_o,7814711,test,gold,o
7206,oxytetracycline,3,Abstract,ss_i,7814711,test,gold,i
7207,cephapirin,3,Abstract,ss_i,7814711,test,gold,i
7208,cephapirin,3,Abstract,ss_i,7814711,test,gold,i
7209,rate of cure,3,Abstract,ss_o,7814711,test,gold,o
7210,oxytetracycline,3,Abstract,hl_i,7814711,test,gold,i
7211,cephapirin,3,Abstract,hl_i,7814711,test,gold,i
7212,cephapirin,3,Abstract,hl_i,7814711,test,gold,i
7213,rate of cure,3,Abstract,hl_o,7814711,test,gold,o
7214,cephapirin,4,Abstract,ss_i,7814711,test,gold,i
7215,culture,4,Abstract,ss_o,7814711,test,gold,o
7216,cephapirin,4,Abstract,hl_i,7814711,test,gold,i
7217,oxytetracycline,5,Abstract,ss_i,7814711,test,gold,i
7218,rate of cure,5,Abstract,ss_o,7814711,test,gold,o
7219,oxytetracycline,5,Abstract,hl_i,7814711,test,gold,i
7220,rate of cure,5,Abstract,hl_o,7814711,test,gold,o
7221,Staphylococcus aureus mastitis .,0,Title,ss_p,7814711,test,gold,p
7222,oxytetracycline,0,Title,ss_i,7814711,test,gold,i
7223,Efficacy,0,Title,ss_o,7814711,test,gold,o
7224,oxytetracycline,0,Title,hl_i,7814711,test,gold,i
7225,elderly patients,0,Abstract,ss_p,7827398,test,gold,p
7226,preventive pharmacological strategies in elderly patients,0,Abstract,ss_i,7827398,test,gold,i
7227,preventive pharmacological strategies,0,Abstract,ss_o,7827398,test,gold,o
7228,elderly patients,0,Abstract,hl_p,7827398,test,gold,p
7229,preventive pharmacological strategies,0,Abstract,hl_i,7827398,test,gold,i
7231,in older patients .,2,Abstract,ss_p,7827398,test,gold,p
7232,incidence of stroke,2,Abstract,ss_o,7827398,test,gold,o
7233,older patients,2,Abstract,hl_p,7827398,test,gold,p
7234,Old Patients with Hypertension,3,Abstract,ss_p,7827398,test,gold,p
7235,older patients ( > 60 years ) with both diastolic and isolated systolic hypertension .,3,Abstract,ss_p,7827398,test,gold,p
7236,treating older patients,3,Abstract,ss_i,7827398,test,gold,i
7237,Old Patients with Hypertension,3,Abstract,hl_p,7827398,test,gold,p
7238,older patients ( > 60 years ) with both diastolic and isolated systolic hypertension .,3,Abstract,hl_p,7827398,test,gold,p
7239,older patients .,4,Abstract,ss_p,7827398,test,gold,p
7240,treating older patients .,4,Abstract,ss_i,7827398,test,gold,i
7241,older individuals with hypertension .,5,Abstract,ss_p,7827398,test,gold,p
7242,treatment of older individuals,5,Abstract,ss_i,7827398,test,gold,i
7243,Cost-effectiveness data,5,Abstract,ss_o,7827398,test,gold,o
7244,older individuals with hypertension .,5,Abstract,hl_p,7827398,test,gold,p
7245,Cost-effectiveness data,5,Abstract,hl_o,7827398,test,gold,o
7247,Transfer factor of the lung for carbon monoxide,0,Abstract,ss_i,7831628,test,gold,i
7248,Transfer factor of the lung for carbon monoxide ( TLCO ),0,Abstract,ss_o,7831628,test,gold,o
7249,ratio of the concentrations of carbon monoxide,0,Abstract,ss_o,7831628,test,gold,o
7250,Transfer factor of the lung for carbon monoxide ( TLCO ),0,Abstract,hl_o,7831628,test,gold,o
7252,dyspnoeic patients .,2,Abstract,ss_p,7831628,test,gold,p
7253,100 consecutive patients .,3,Abstract,ss_p,7831628,test,gold,p
7254,TLCO ( TLCO,3,Abstract,ss_i,7831628,test,gold,i
7255,standard ( Jones and Meade ),3,Abstract,ss_i,7831628,test,gold,i
7256,TLCO ( TLCO,3,Abstract,ss_i,7831628,test,gold,i
7257,"Exhalation TLCO ( TLCO , ex )",3,Abstract,ss_o,7831628,test,gold,o
7258,"standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh )",3,Abstract,ss_o,7831628,test,gold,o
7259,TLCO ( TLCO,3,Abstract,hl_i,7831628,test,gold,i
7260,standard ( Jones and Meade ),3,Abstract,hl_i,7831628,test,gold,i
7261,TLCO ( TLCO,3,Abstract,hl_i,7831628,test,gold,i
7262,"Exhalation TLCO ( TLCO , ex )",3,Abstract,hl_o,7831628,test,gold,o
7263,"standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh )",3,Abstract,hl_o,7831628,test,gold,o
7266,patients with severe pulmonary disease ;,6,Abstract,ss_p,7831628,test,gold,p
7267,relation,6,Abstract,ss_o,7831628,test,gold,o
7268,FEV1,6,Abstract,ss_o,7831628,test,gold,o
7269,relation,6,Abstract,hl_o,7831628,test,gold,o
7270,TLCO,7,Abstract,ss_i,7831628,test,gold,i
7271,TLCO .,8,Abstract,ss_i,7831628,test,gold,i
7272,clinical measurement of TLCO .,8,Abstract,ss_o,7831628,test,gold,o
7274,effectiveness,0,Abstract,ss_o,7844976,test,gold,o
7275,diffusion of Smart Choices,0,Abstract,ss_o,7844976,test,gold,o
7276,effectiveness,0,Abstract,hl_o,7844976,test,gold,o
7277,diffusion of Smart Choices,0,Abstract,hl_o,7844976,test,gold,o
7278,teacher training,1,Abstract,ss_i,7844976,test,gold,i
7279,impact,1,Abstract,ss_o,7844976,test,gold,o
7280,School districts,2,Abstract,ss_p,7844976,test,gold,p
7281,live workshop training,2,Abstract,ss_i,7844976,test,gold,i
7282,video training condition .,2,Abstract,ss_i,7844976,test,gold,i
7283,School districts,2,Abstract,hl_p,7844976,test,gold,p
7284,live workshop training,2,Abstract,hl_i,7844976,test,gold,i
7285,video training condition .,2,Abstract,hl_i,7844976,test,gold,i
7286,teachers ' implementation of Smart Choices .,3,Abstract,ss_o,7844976,test,gold,o
7287,teachers ' implementation of Smart Choices .,3,Abstract,hl_o,7844976,test,gold,o
7288,video-trained teachers,4,Abstract,ss_i,7844976,test,gold,i
7289,completeness and fidelity of implementation,4,Abstract,ss_o,7844976,test,gold,o
7290,video-trained,4,Abstract,hl_i,7844976,test,gold,i
7291,completeness and fidelity of implementation,4,Abstract,hl_o,7844976,test,gold,o
7292,Video-trained teachers,5,Abstract,ss_i,7844976,test,gold,i
7293,Video-trained,5,Abstract,hl_i,7844976,test,gold,i
7294,teacher training,6,Abstract,ss_i,7844976,test,gold,i
7295,teacher training,0,Title,ss_i,7844976,test,gold,i
7296,implementation of Smart Choices :,0,Title,ss_o,7844976,test,gold,o
7297,teacher training,0,Title,hl_i,7844976,test,gold,i
7298,patients with previously undetected anxiety,0,Abstract,ss_p,7853069,test,gold,p
7299,screener,0,Abstract,ss_i,7853069,test,gold,i
7300,physician intervention,0,Abstract,ss_i,7853069,test,gold,i
7301,elevated anxiety levels,0,Abstract,ss_o,7853069,test,gold,o
7302,patients with previously undetected anxiety,0,Abstract,hl_p,7853069,test,gold,p
7303,demonstration,1,Abstract,ss_i,7853069,test,gold,i
7304,demonstration,1,Abstract,hl_i,7853069,test,gold,i
7307,"573 patients who had unrecognized and untreated anxiety identified from the approximately 8,000 patients who completed the waiting room screening questionnaire .",4,Abstract,ss_p,7853069,test,gold,p
7308,573 patients who had unrecognized and untreated anxiety,4,Abstract,hl_p,7853069,test,gold,p
7309,physician intervention,5,Abstract,ss_i,7853069,test,gold,i
7310,anxiety symptom levels,5,Abstract,ss_o,7853069,test,gold,o
7311,functioning status,5,Abstract,ss_o,7853069,test,gold,o
7312,physician intervention,5,Abstract,hl_i,7853069,test,gold,i
7313,Patient outcomes,6,Abstract,ss_o,7853069,test,gold,o
7314,"global anxiety scores , functioning and well-being",6,Abstract,ss_o,7853069,test,gold,o
7315,patients ' reports of global improvements .,6,Abstract,ss_o,7853069,test,gold,o
7316,global anxiety scores,6,Abstract,hl_o,7853069,test,gold,o
7317,functioning and well-being,6,Abstract,hl_o,7853069,test,gold,o
7318,patients ' reports of global improvements .,6,Abstract,hl_o,7853069,test,gold,o
7321,primary care patients with untreated anxiety .,0,Title,ss_p,7853069,test,gold,p
7322,outcomes,0,Title,ss_o,7853069,test,gold,o
7323,primary care patients with untreated anxiety .,0,Title,hl_p,7853069,test,gold,p
7324,screening,0,Title,hl_i,7853069,test,gold,i
7325,feedback,0,Title,hl_i,7853069,test,gold,i
7326,pain,0,Abstract,ss_o,8519720,test,gold,o
7327,pulmonary function .,0,Abstract,ss_o,8519720,test,gold,o
7328,Intercostal nerve blocks ( INB ),1,Abstract,ss_i,8519720,test,gold,i
7329,subarachnoid morphine ( SM ),1,Abstract,ss_i,8519720,test,gold,i
7330,Intercostal nerve blocks ( INB ),1,Abstract,hl_i,8519720,test,gold,i
7331,subarachnoid morphine ( SM ),1,Abstract,hl_i,8519720,test,gold,i
7332,pain,2,Abstract,ss_o,8519720,test,gold,o
7333,pain,2,Abstract,hl_o,8519720,test,gold,o
7334,post-thoracotomy pain,3,Abstract,ss_o,8519720,test,gold,o
7335,postoperative pulmonary function,3,Abstract,ss_o,8519720,test,gold,o
7336,post-thoracotomy pain,3,Abstract,hl_o,8519720,test,gold,o
7337,postoperative pulmonary function,3,Abstract,hl_o,8519720,test,gold,o
7338,20 patients undergoing lateral thoracotomy for lung resection,4,Abstract,ss_p,8519720,test,gold,p
7339,SM,4,Abstract,ss_i,8519720,test,gold,i
7340,INB,4,Abstract,ss_i,8519720,test,gold,i
7341,bupivacaine,4,Abstract,ss_i,8519720,test,gold,i
7342,SM,4,Abstract,ss_i,8519720,test,gold,i
7343,INB,4,Abstract,ss_i,8519720,test,gold,i
7344,saline ( INB- ),4,Abstract,ss_i,8519720,test,gold,i
7345,SM,4,Abstract,hl_i,8519720,test,gold,i
7346,INB with bupivacaine ( INB+ ),4,Abstract,hl_i,8519720,test,gold,i
7347,SM,4,Abstract,hl_i,8519720,test,gold,i
7348,INB using saline ( INB- ),4,Abstract,hl_i,8519720,test,gold,i
7349,"Visual analog scale pain scores at rest , with cough , and with movement of the ipsilateral arm , forced expiratory volume in 1 second ( FEV1 ) , and forced vital capacity ( FVC )",5,Abstract,ss_o,8519720,test,gold,o
7350,Visual analog scale pain scores,5,Abstract,hl_o,8519720,test,gold,o
7351,"with cough , and with movement of the ipsilateral arm , forced expiratory volume in 1 second ( FEV1 )",5,Abstract,hl_o,8519720,test,gold,o
7352,forced vital capacity ( FVC ),5,Abstract,hl_o,8519720,test,gold,o
7353,Opioid use,6,Abstract,ss_o,8519720,test,gold,o
7354,Opioid use,6,Abstract,hl_o,8519720,test,gold,o
7355,INB+,7,Abstract,ss_i,8519720,test,gold,i
7356,FEV1,7,Abstract,ss_o,8519720,test,gold,o
7357,FVC,7,Abstract,ss_o,8519720,test,gold,o
7358,resting and cough pain,7,Abstract,ss_o,8519720,test,gold,o
7359,INB+,7,Abstract,hl_i,8519720,test,gold,i
7360,FEV1,7,Abstract,hl_o,8519720,test,gold,o
7361,FVC,7,Abstract,hl_o,8519720,test,gold,o
7362,INB+,8,Abstract,ss_i,8519720,test,gold,i
7363,INB-,8,Abstract,ss_i,8519720,test,gold,i
7364,FEV1,8,Abstract,ss_o,8519720,test,gold,o
7365,pain scores,8,Abstract,ss_o,8519720,test,gold,o
7366,INB+,8,Abstract,hl_i,8519720,test,gold,i
7367,INB-,8,Abstract,hl_i,8519720,test,gold,i
7368,FEV1,8,Abstract,hl_o,8519720,test,gold,o
7369,pain scores,8,Abstract,hl_o,8519720,test,gold,o
7370,( INB-,9,Abstract,ss_i,8519720,test,gold,i
7371,INB+,9,Abstract,ss_i,8519720,test,gold,i
7372,Opioid usage,9,Abstract,ss_o,8519720,test,gold,o
7373,INB-,9,Abstract,hl_i,8519720,test,gold,i
7374,INB+,9,Abstract,hl_i,8519720,test,gold,i
7375,Opioid usage,9,Abstract,hl_o,8519720,test,gold,o
7376,INB,10,Abstract,ss_i,8519720,test,gold,i
7377,SM,10,Abstract,ss_i,8519720,test,gold,i
7378,pain and pulmonary function,10,Abstract,ss_o,8519720,test,gold,o
7379,INB,10,Abstract,hl_i,8519720,test,gold,i
7380,SM,10,Abstract,hl_i,8519720,test,gold,i
7381,patients undergoing lateral thoracotomy,11,Abstract,ss_p,8519720,test,gold,p
7382,INB,11,Abstract,ss_i,8519720,test,gold,i
7383,SM .,11,Abstract,ss_i,8519720,test,gold,i
7384,INB,11,Abstract,hl_i,8519720,test,gold,i
7385,SM,11,Abstract,hl_i,8519720,test,gold,i
7386,post-thoracotomy,0,Title,ss_p,8519720,test,gold,p
7387,intercostal nerve blocks,0,Title,ss_i,8519720,test,gold,i
7388,morphine,0,Title,ss_i,8519720,test,gold,i
7389,intercostal nerve blocks,0,Title,hl_i,8519720,test,gold,i
7390,morphine,0,Title,hl_i,8519720,test,gold,i
7391,47 healthy women undergoing elective ambulatory surgery .,0,Abstract,ss_p,8726604,test,gold,p
7392,sevoflurane,0,Abstract,ss_i,8726604,test,gold,i
7393,isoflurane,0,Abstract,ss_i,8726604,test,gold,i
7394,47 healthy women undergoing elective ambulatory surgery,0,Abstract,hl_p,8726604,test,gold,p
7395,sevoflurane,0,Abstract,hl_i,8726604,test,gold,i
7396,isoflurane,0,Abstract,hl_i,8726604,test,gold,i
7397,women,1,Abstract,ss_p,8726604,test,gold,p
7398,sevoflurane,1,Abstract,ss_i,8726604,test,gold,i
7399,isoflurane,1,Abstract,ss_i,8726604,test,gold,i
7400,women,1,Abstract,hl_p,8726604,test,gold,p
7401,sevoflurane,1,Abstract,hl_i,8726604,test,gold,i
7402,isoflurane,1,Abstract,hl_i,8726604,test,gold,i
7403,thiopental,2,Abstract,ss_i,8726604,test,gold,i
7404,vecuronium,2,Abstract,ss_i,8726604,test,gold,i
7405,fentanyl,2,Abstract,ss_i,8726604,test,gold,i
7406,thiopental,2,Abstract,hl_i,8726604,test,gold,i
7407,vecuronium,2,Abstract,hl_i,8726604,test,gold,i
7408,fentanyl,2,Abstract,hl_i,8726604,test,gold,i
7409,"Duration of anesthesia , time to emergence , orientation , length of stay in the surgical unit , and hospital discharge",3,Abstract,ss_o,8726604,test,gold,o
7410,Duration of anesthesia,3,Abstract,hl_o,8726604,test,gold,o
7411,time to emergence,3,Abstract,hl_o,8726604,test,gold,o
7412,orientation,3,Abstract,hl_o,8726604,test,gold,o
7413,length of stay in the surgical unit,3,Abstract,hl_o,8726604,test,gold,o
7414,sevoflurane,4,Abstract,ss_i,8726604,test,gold,i
7415,isoflurane,4,Abstract,ss_i,8726604,test,gold,i
7416,"The emergence , length of stay , and discharge times after discontinuation",4,Abstract,ss_o,8726604,test,gold,o
7417,sevoflurane,4,Abstract,hl_i,8726604,test,gold,i
7418,isoflurane,4,Abstract,hl_i,8726604,test,gold,i
7419,"emergence , length of stay , and discharge times",4,Abstract,hl_o,8726604,test,gold,o
7420,isoflurane,5,Abstract,ss_i,8726604,test,gold,i
7421,postoperative cough .,5,Abstract,ss_o,8726604,test,gold,o
7422,postoperative cough .,5,Abstract,hl_o,8726604,test,gold,o
7423,sevoflurane,6,Abstract,ss_i,8726604,test,gold,i
7424,isoflurane ;,6,Abstract,ss_i,8726604,test,gold,i
7425,level of anesthesia,6,Abstract,ss_o,8726604,test,gold,o
7426,anesthesia,6,Abstract,hl_o,8726604,test,gold,o
7427,outpatient surgery .,0,Title,ss_p,8726604,test,gold,p
7428,sevoflurane,0,Title,ss_i,8726604,test,gold,i
7429,isoflurane,0,Title,ss_i,8726604,test,gold,i
7430,outpatient surgery .,0,Title,hl_p,8726604,test,gold,p
7431,sevoflurane,0,Title,hl_i,8726604,test,gold,i
7432,isoflurane,0,Title,hl_i,8726604,test,gold,i
7434,prosthesis,1,Abstract,ss_i,8771302,test,gold,i
7435,bileaflet prostheses .,2,Abstract,ss_i,8771302,test,gold,i
7436,feasibility,2,Abstract,ss_o,8771302,test,gold,o
7437,accuracy,2,Abstract,ss_o,8771302,test,gold,o
7438,postoperative fluoroscopic evaluation,2,Abstract,ss_o,8771302,test,gold,o
7439,bileaflet prostheses .,2,Abstract,hl_i,8771302,test,gold,i
7440,feasibility,2,Abstract,hl_o,8771302,test,gold,o
7441,accuracy,2,Abstract,hl_o,8771302,test,gold,o
7442,"90 patients who had aortic , mitral , and/or tricuspid valve replacement with Sorin Bicarbon or CarboMedics bileaflet prostheses .",3,Abstract,ss_p,8771302,test,gold,p
7443,Sorin Bicarbon or CarboMedics bileaflet prostheses .,3,Abstract,ss_i,8771302,test,gold,i
7444,"90 patients who had aortic , mitral , and/or tricuspid valve replacement with Sorin Bicarbon or CarboMedics bileaflet prostheses",3,Abstract,hl_p,8771302,test,gold,p
7445,Sorin Bicarbon or CarboMedics bileaflet prostheses .,3,Abstract,hl_i,8771302,test,gold,i
7446,prostheses,4,Abstract,ss_i,8771302,test,gold,i
7447,prostheses,4,Abstract,hl_i,8771302,test,gold,i
7448,prosthesis ',5,Abstract,ss_i,8771302,test,gold,i
7449,Fluoroscopic evaluation,5,Abstract,ss_o,8771302,test,gold,o
7450,valve 's hemodynamic performance was investigated through Doppler study .,6,Abstract,ss_o,8771302,test,gold,o
7451,hemodynamic performance,6,Abstract,hl_o,8771302,test,gold,o
7452,fluoroscopic evaluation,7,Abstract,ss_o,8771302,test,gold,o
7453,fluoroscopic evaluation,7,Abstract,hl_o,8771302,test,gold,o
7455,hemodynamic performance,9,Abstract,ss_o,8771302,test,gold,o
7456,hemodynamic performance,9,Abstract,hl_o,8771302,test,gold,o
7457,Prosthesis,10,Abstract,ss_i,8771302,test,gold,i
7458,rate of success of the fluoroscopic evaluation .,10,Abstract,ss_o,8771302,test,gold,o
7459,Prosthesis,10,Abstract,hl_i,8771302,test,gold,i
7460,rate of success of the fluoroscopic evaluation .,10,Abstract,hl_o,8771302,test,gold,o
7461,feasibility and accuracy of fluoroscopy,11,Abstract,ss_o,8771302,test,gold,o
7462,valve 's hemodynamic performance .,11,Abstract,ss_o,8771302,test,gold,o
7463,feasibility,11,Abstract,hl_o,8771302,test,gold,o
7464,accuracy of fluoroscopy,11,Abstract,hl_o,8771302,test,gold,o
7465,valve 's hemodynamic performance .,11,Abstract,hl_o,8771302,test,gold,o
7466,fluoroscopic,12,Abstract,ss_o,8771302,test,gold,o
7467,fluoroscopic,12,Abstract,hl_o,8771302,test,gold,o
7468,bileaflet prostheses :,0,Title,ss_i,8771302,test,gold,i
7469,Fluoroscopic functional evaluation,0,Title,ss_o,8771302,test,gold,o
7470,bileaflet prostheses :,0,Title,hl_i,8771302,test,gold,i
7471,82 patients having postoperative epidural analgesia,0,Abstract,ss_p,8779382,test,gold,p
7472,tunnelling,0,Abstract,ss_i,8779382,test,gold,i
7473,migration .,0,Abstract,ss_o,8779382,test,gold,o
7474,82 patients having postoperative epidural analgesia,0,Abstract,hl_p,8779382,test,gold,p
7475,tunnelling,0,Abstract,hl_i,8779382,test,gold,i
7476,migration .,0,Abstract,hl_o,8779382,test,gold,o
7477,Tunnelling,1,Abstract,ss_i,8779382,test,gold,i
7478,incidence of inward migration,1,Abstract,ss_o,8779382,test,gold,o
7479,Tunnelling,1,Abstract,hl_i,8779382,test,gold,i
7480,incidence of inward migration,1,Abstract,hl_o,8779382,test,gold,o
7482,tunnelled catheters,3,Abstract,ss_i,8779382,test,gold,i
7483,non-tunnelled catheters,3,Abstract,ss_i,8779382,test,gold,i
7484,position,3,Abstract,ss_o,8779382,test,gold,o
7485,tunnelled catheters,3,Abstract,hl_i,8779382,test,gold,i
7486,non-tunnelled catheters,3,Abstract,hl_i,8779382,test,gold,i
7487,tunnelling .,4,Abstract,ss_i,8779382,test,gold,i
7488,catheter migration,4,Abstract,ss_o,8779382,test,gold,o
7489,tunnelling .,4,Abstract,hl_i,8779382,test,gold,i
7490,catheter migration,4,Abstract,hl_o,8779382,test,gold,o
7491,tunnelling,0,Title,ss_i,8779382,test,gold,i
7492,effect,0,Title,ss_o,8779382,test,gold,o
7493,tunnelling,0,Title,hl_i,8779382,test,gold,i
7494,drug-free adult patients with autistic disorder .,0,Abstract,ss_p,8911222,test,gold,p
7495,tryptophan depletion,0,Abstract,ss_i,8911222,test,gold,i
7496,behavioral and biochemical responses,0,Abstract,ss_o,8911222,test,gold,o
7497,drug-free adult patients with autistic disorder .,0,Abstract,hl_p,8911222,test,gold,p
7498,"Twenty drug-free adults with autistic disorder ( 16 men and 4 women ) ( mean [ +/- SD ] age , 30.5 +/- 8.5 years )",1,Abstract,ss_p,8911222,test,gold,p
7499,tryptophan depletion,1,Abstract,ss_i,8911222,test,gold,i
7500,Twenty drug-free adults with autistic disorder,1,Abstract,hl_p,8911222,test,gold,p
7501,16 men and 4 women,1,Abstract,hl_p,8911222,test,gold,p
7502,"mean [ +/- SD ] age , 30.5 +/- 8.5 years",1,Abstract,hl_p,8911222,test,gold,p
7503,tryptophan depletion,1,Abstract,hl_i,8911222,test,gold,i
7504,low-tryptophan diet,2,Abstract,ss_i,8911222,test,gold,i
7505,amino acid drink .,2,Abstract,ss_i,8911222,test,gold,i
7506,low-tryptophan diet,2,Abstract,hl_i,8911222,test,gold,i
7507,amino acid drink .,2,Abstract,hl_i,8911222,test,gold,i
7508,amino acid drink,3,Abstract,ss_i,8911222,test,gold,i
7509,Behavioral ratings,3,Abstract,ss_o,8911222,test,gold,o
7510,amino acid drink,3,Abstract,hl_i,8911222,test,gold,i
7511,Plasma free and total tryptophan levels,4,Abstract,ss_o,8911222,test,gold,o
7512,Plasma free and total tryptophan levels,4,Abstract,hl_o,8911222,test,gold,o
7514,tryptophan depletion,6,Abstract,ss_i,8911222,test,gold,i
7515,sham depletion,6,Abstract,ss_i,8911222,test,gold,i
7516,behavioral symptoms,6,Abstract,ss_o,8911222,test,gold,o
7517,Tryptophan depletion,7,Abstract,ss_i,8911222,test,gold,i
7518,"behaviors such as whirling , flapping , pacing , banging and hitting self , rocking , and toe walking",7,Abstract,ss_o,8911222,test,gold,o
7519,"whirling , flapping , pacing , banging and hitting self , rocking , and toe walking",7,Abstract,hl_o,8911222,test,gold,o
7520,calm and happy,8,Abstract,ss_o,8911222,test,gold,o
7521,anxious .,8,Abstract,ss_o,8911222,test,gold,o
7522,calm and happy,8,Abstract,hl_o,8911222,test,gold,o
7523,anxious .,8,Abstract,hl_o,8911222,test,gold,o
7524,social relatedness or repetitive thoughts and behavior .,9,Abstract,ss_o,8911222,test,gold,o
7525,social relatedness or repetitive thoughts and behavior .,9,Abstract,hl_o,8911222,test,gold,o
7526,tryptophan-deficient amino acid drink .,10,Abstract,ss_i,8911222,test,gold,i
7527,Plasma total and free tryptophan levels,10,Abstract,ss_o,8911222,test,gold,o
7528,Plasma total and free tryptophan levels,10,Abstract,hl_o,8911222,test,gold,o
7529,tryptophan depletion .,11,Abstract,ss_i,8911222,test,gold,i
7530,symptoms,11,Abstract,ss_o,8911222,test,gold,o
7531,plasma total tryptophan levels,11,Abstract,ss_o,8911222,test,gold,o
7532,Autism Behavior Checklist scores,11,Abstract,ss_o,8911222,test,gold,o
7533,symptoms,11,Abstract,ss_o,8911222,test,gold,o
7534,plasma total tryptophan levels,11,Abstract,hl_o,8911222,test,gold,o
7535,Autism Behavior Checklist scores,11,Abstract,hl_o,8911222,test,gold,o
7536,patients with autism .,12,Abstract,ss_p,8911222,test,gold,p
7537,patients with autism .,12,Abstract,hl_p,8911222,test,gold,p
7538,symptoms,13,Abstract,ss_o,8911222,test,gold,o
7539,symptoms,13,Abstract,hl_o,8911222,test,gold,o
7541,drug-free adults with autistic disorder .,0,Title,ss_p,8911222,test,gold,p
7542,tryptophan depletion,0,Title,ss_i,8911222,test,gold,i
7543,drug-free adults,0,Title,hl_p,8911222,test,gold,p
7544,autistic disorder,0,Title,hl_p,8911222,test,gold,p
7545,"social interaction , impairments in communication",0,Abstract,ss_o,8911223,test,gold,o
7546,restricted repertoire of activities and interests .,0,Abstract,ss_o,8911223,test,gold,o
7548,symptoms,2,Abstract,ss_o,8911223,test,gold,o
7549,Thirty adults with autistic disorder,3,Abstract,ss_p,8911223,test,gold,p
7550,placebo-controlled,3,Abstract,ss_i,8911223,test,gold,i
7551,fluvoxamine maleate .,3,Abstract,ss_i,8911223,test,gold,i
7552,Thirty adults,3,Abstract,hl_p,8911223,test,gold,p
7553,autistic disorder,3,Abstract,hl_p,8911223,test,gold,p
7554,placebo-controlled,3,Abstract,hl_i,8911223,test,gold,i
7555,fluvoxamine maleate .,3,Abstract,hl_i,8911223,test,gold,i
7556,Behavioral ratings,4,Abstract,ss_o,8911223,test,gold,o
7557,Behavioral ratings,4,Abstract,hl_o,8911223,test,gold,o
7558,fluvoxamine-treated,5,Abstract,ss_i,8911223,test,gold,i
7559,placebo,5,Abstract,ss_i,8911223,test,gold,i
7560,fluvoxamine-treated,5,Abstract,hl_i,8911223,test,gold,i
7561,placebo,5,Abstract,hl_i,8911223,test,gold,i
7562,Fluvoxamine,6,Abstract,ss_i,8911223,test,gold,i
7563,placebo,6,Abstract,ss_i,8911223,test,gold,i
7564,repetitive thoughts and behavior,6,Abstract,ss_o,8911223,test,gold,o
7565,maladaptive behavior,6,Abstract,ss_o,8911223,test,gold,o
7566,aggression,6,Abstract,ss_o,8911223,test,gold,o
7567,social relatedness,6,Abstract,ss_o,8911223,test,gold,o
7568,language usage,6,Abstract,ss_o,8911223,test,gold,o
7569,Fluvoxamine,6,Abstract,hl_i,8911223,test,gold,i
7570,placebo,6,Abstract,hl_i,8911223,test,gold,i
7571,repetitive thoughts and behavior,6,Abstract,hl_o,8911223,test,gold,o
7572,maladaptive behavior,6,Abstract,hl_o,8911223,test,gold,o
7573,aggression,6,Abstract,hl_o,8911223,test,gold,o
7574,social relatedness,6,Abstract,hl_o,8911223,test,gold,o
7575,language usage,6,Abstract,hl_o,8911223,test,gold,o
7576,Treatment response,7,Abstract,ss_o,8911223,test,gold,o
7577,age level of autistic behavior,7,Abstract,ss_o,8911223,test,gold,o
7578,full-scale IQ .,7,Abstract,ss_o,8911223,test,gold,o
7579,fluvoxamine,8,Abstract,ss_i,8911223,test,gold,i
7580,mild sedation and nausea,8,Abstract,ss_o,8911223,test,gold,o
7581,fluvoxamine,8,Abstract,hl_i,8911223,test,gold,i
7582,mild sedation and nausea,8,Abstract,hl_o,8911223,test,gold,o
7583,"dyskinesias , adverse cardiovascular events , or seizures",9,Abstract,ss_o,8911223,test,gold,o
7584,"dyskinesias , adverse cardiovascular events , or seizures",9,Abstract,hl_o,8911223,test,gold,o
7585,autistic disorder in adults .,10,Abstract,ss_p,8911223,test,gold,p
7586,Fluvoxamine,10,Abstract,ss_i,8911223,test,gold,i
7587,placebo,10,Abstract,ss_i,8911223,test,gold,i
7588,effective,10,Abstract,ss_o,8911223,test,gold,o
7589,symptoms,10,Abstract,ss_o,8911223,test,gold,o
7590,Fluvoxamine,10,Abstract,hl_i,8911223,test,gold,i
7591,placebo,10,Abstract,hl_i,8911223,test,gold,i
7592,fluvoxamine,11,Abstract,ss_i,8911223,test,gold,i
7593,fluvoxamine,11,Abstract,hl_i,8911223,test,gold,i
7594,adults with autistic disorder .,0,Title,ss_p,8911223,test,gold,p
7595,fluvoxamine,0,Title,ss_i,8911223,test,gold,i
7596,adults with autistic disorder .,0,Title,hl_p,8911223,test,gold,p
7597,placebo-controlled,0,Title,hl_i,8911223,test,gold,i
7598,fluvoxamine,0,Title,hl_i,8911223,test,gold,i
7600,patients with multivessel coronary artery disease,1,Abstract,ss_p,8913901,test,gold,p
7601,coronary artery bypass grafting,1,Abstract,ss_i,8913901,test,gold,i
7602,percutaneous transluminal coronary angioplasty .,1,Abstract,ss_i,8913901,test,gold,i
7603,patients with multivessel coronary artery disease,1,Abstract,hl_p,8913901,test,gold,p
7604,coronary artery bypass grafting,1,Abstract,hl_i,8913901,test,gold,i
7605,percutaneous transluminal coronary angioplasty .,1,Abstract,hl_i,8913901,test,gold,i
7606,"serial changes in Q , ST , and T wave items according to Minnesota code ( MC ) criteria",2,Abstract,ss_o,8913901,test,gold,o
7607,"serial changes in Q , ST , and T wave items",2,Abstract,hl_o,8913901,test,gold,o
7609,changes,4,Abstract,ss_o,8913901,test,gold,o
7611,"4,244 BARI randomized and registry study participants with follow-up ECGs received at the Core ECG Laboratory as of March 1995",6,Abstract,ss_p,8913901,test,gold,p
7612,MC Q wave progression,6,Abstract,ss_o,8913901,test,gold,o
7613,"4,244",6,Abstract,hl_p,8913901,test,gold,p
7614,registry study participants with follow-up ECGs received at the Core ECG Laboratory as of March 1995,6,Abstract,hl_p,8913901,test,gold,p
7615,MC Q wave progressions,7,Abstract,ss_o,8913901,test,gold,o
7616,Q wave progression codes,8,Abstract,ss_o,8913901,test,gold,o
7618,prevention programs,0,Abstract,ss_i,8916620,test,gold,i
7620,generalized estimating equations ( GEE ),2,Abstract,ss_i,8916620,test,gold,i
7621,GEE-independent,2,Abstract,ss_i,8916620,test,gold,i
7622,generalized estimating equations ( GEE ),2,Abstract,hl_i,8916620,test,gold,i
7623,GEE-independent,2,Abstract,hl_i,8916620,test,gold,i
7624,GEE-independent,3,Abstract,ss_i,8916620,test,gold,i
7625,GEE-independent,3,Abstract,hl_i,8916620,test,gold,i
7626,youth substance abuse prevention program,4,Abstract,hl_p,8916620,test,gold,p
7627,prevention program,0,Title,ss_i,8916620,test,gold,i
7628,effectiveness,0,Title,ss_o,8916620,test,gold,o
7629,prevention program,0,Title,hl_p,8916620,test,gold,p
7630,crystalloid,0,Abstract,ss_i,8989009,test,gold,i
7631,colloid solution,0,Abstract,ss_i,8989009,test,gold,i
7632,efficacy,0,Abstract,ss_o,8989009,test,gold,o
7633,crystalloid,0,Abstract,hl_i,8989009,test,gold,i
7634,colloid solution,0,Abstract,hl_i,8989009,test,gold,i
7635,in elderly patients .,1,Abstract,ss_p,8989009,test,gold,p
7636,no prehydration,1,Abstract,ss_i,8989009,test,gold,i
7637,crystalloid,1,Abstract,ss_i,8989009,test,gold,i
7638,colloid prehydration,1,Abstract,ss_i,8989009,test,gold,i
7639,incidence and frequency of hypotension and vasopressor therapy,1,Abstract,ss_o,8989009,test,gold,o
7640,elderly patients,1,Abstract,hl_p,8989009,test,gold,p
7641,no prehydration,1,Abstract,hl_i,8989009,test,gold,i
7642,crystalloid,1,Abstract,hl_i,8989009,test,gold,i
7643,colloid prehydration,1,Abstract,hl_i,8989009,test,gold,i
7644,incidence and frequency of hypotension and vasopressor therapy,1,Abstract,hl_o,8989009,test,gold,o
7645,Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement,2,Abstract,ss_p,8989009,test,gold,p
7646,crystalloid solution ( Hartmanns,2,Abstract,ss_i,8989009,test,gold,i
7647,colloid ( Haemaccel,2,Abstract,ss_i,8989009,test,gold,i
7648,no prehydration,2,Abstract,ss_i,8989009,test,gold,i
7649,Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement,2,Abstract,hl_p,8989009,test,gold,p
7650,crystalloid solution,2,Abstract,hl_i,8989009,test,gold,i
7651,colloid ( Haemaccel,2,Abstract,hl_i,8989009,test,gold,i
7652,no prehydration,2,Abstract,hl_i,8989009,test,gold,i
7653,Hypotension,3,Abstract,ss_o,8989009,test,gold,o
7654,30 % decrease from baseline systolic blood pressure ( BP ),3,Abstract,ss_o,8989009,test,gold,o
7655,systolic < 90 mm Hg,3,Abstract,ss_o,8989009,test,gold,o
7656,Hypotension,3,Abstract,hl_o,8989009,test,gold,o
7657,systolic blood pressure,3,Abstract,hl_o,8989009,test,gold,o
7658,colloid,4,Abstract,ss_i,8989009,test,gold,i
7659,absolute systolic BP readings,4,Abstract,ss_o,8989009,test,gold,o
7660,incidence of hypotension,4,Abstract,ss_o,8989009,test,gold,o
7661,colloid,4,Abstract,hl_i,8989009,test,gold,i
7662,absolute systolic BP readings,4,Abstract,hl_o,8989009,test,gold,o
7663,incidence of hypotension,4,Abstract,hl_o,8989009,test,gold,o
7664,ephedrine,5,Abstract,ss_i,8989009,test,gold,i
7665,ephedrine,5,Abstract,ss_i,8989009,test,gold,i
7666,"incidence of ephedrine use , incidence of nausea/vomiting , and median total dose of ephedrine",5,Abstract,ss_o,8989009,test,gold,o
7667,incidence of ephedrine use,5,Abstract,hl_o,8989009,test,gold,o
7668,incidence of nausea/vomiting,5,Abstract,hl_o,8989009,test,gold,o
7669,median total dose of ephedrine,5,Abstract,hl_o,8989009,test,gold,o
7670,elderly patients undergoing elective procedures,6,Abstract,ss_p,8989009,test,gold,p
7671,prehydration,6,Abstract,ss_i,8989009,test,gold,i
7672,crystalloid,6,Abstract,ss_i,8989009,test,gold,i
7673,colloid prehydration .,6,Abstract,ss_i,8989009,test,gold,i
7674,degree of hypotension or need for vasopressor therapy,6,Abstract,ss_o,8989009,test,gold,o
7675,elderly patients undergoing elective procedures,6,Abstract,hl_p,8989009,test,gold,p
7676,crystalloid,6,Abstract,hl_i,8989009,test,gold,i
7677,colloid prehydration .,6,Abstract,hl_i,8989009,test,gold,i
7678,hypotension,6,Abstract,hl_o,8989009,test,gold,o
7679,need for vasopressor therapy,6,Abstract,hl_o,8989009,test,gold,o
7680,in the elderly :,0,Title,ss_p,8989009,test,gold,p
7681,"crystalloids , colloids",0,Title,ss_i,8989009,test,gold,i
7682,no prehydration .,0,Title,ss_i,8989009,test,gold,i
7683,the elderly,0,Title,hl_p,8989009,test,gold,p
7684,crystalloids,0,Title,hl_i,8989009,test,gold,i
7685,colloids,0,Title,hl_i,8989009,test,gold,i
7686,no prehydration .,0,Title,hl_i,8989009,test,gold,i
7688,Antazolin/Tetryzolin,1,Abstract,ss_i,9229602,test,gold,i
7689,Levocabastine,1,Abstract,ss_i,9229602,test,gold,i
7690,"efficacy , local tolerance and safety",1,Abstract,ss_o,9229602,test,gold,o
7691,Antazolin/Tetryzolin,1,Abstract,hl_i,9229602,test,gold,i
7692,Levocabastine,1,Abstract,hl_i,9229602,test,gold,i
7693,69 patients,2,Abstract,ss_p,9229602,test,gold,p
7694,69 patients,2,Abstract,hl_p,9229602,test,gold,p
7695,subjective and objective ocular symptoms,3,Abstract,ss_o,9229602,test,gold,o
7696,subjective and objective ocular symptoms,3,Abstract,hl_o,9229602,test,gold,o
7697,subjective and objective ocular symptoms,4,Abstract,ss_o,9229602,test,gold,o
7698,subjective and objective ocular symptoms,4,Abstract,hl_o,9229602,test,gold,o
7699,Antazolin/Tetryzolin,5,Abstract,ss_i,9229602,test,gold,i
7700,onset of action,5,Abstract,ss_o,9229602,test,gold,o
7701,Antazolin/Tetryzolin,5,Abstract,hl_i,9229602,test,gold,i
7702,onset of action,5,Abstract,hl_o,9229602,test,gold,o
7703,effective onset of action,6,Abstract,ss_o,9229602,test,gold,o
7704,Antazolin/Tetryzolin,7,Abstract,ss_i,9229602,test,gold,i
7705,Antazolin/Tetryzolin,7,Abstract,hl_i,9229602,test,gold,i
7706,acute allergic conjunctivitis ],0,Title,ss_p,9229602,test,gold,p
7707,[ Antazoline/tetryzoline,0,Title,ss_i,9229602,test,gold,i
7708,levocabastine,0,Title,ss_i,9229602,test,gold,i
7709,acute allergic conjunctivitis ],0,Title,hl_p,9229602,test,gold,p
7710,Antazoline/tetryzoline,0,Title,hl_i,9229602,test,gold,i
7711,levocabastine,0,Title,hl_i,9229602,test,gold,i
7713,patients with alcoholic liver disease .,1,Abstract,ss_p,9394106,test,gold,p
7714,antibiotic,1,Abstract,ss_i,9394106,test,gold,i
7715,endotoxemia,1,Abstract,ss_o,9394106,test,gold,o
7716,patients with alcoholic liver disease .,1,Abstract,hl_p,9394106,test,gold,p
7717,endotoxemia,1,Abstract,hl_o,9394106,test,gold,o
7718,"Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis )",2,Abstract,ss_p,9394106,test,gold,p
7719,paromomycin sulfate,2,Abstract,ss_i,9394106,test,gold,i
7720,placebo,2,Abstract,ss_i,9394106,test,gold,i
7721,"Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis )",2,Abstract,hl_p,9394106,test,gold,p
7722,paromomycin sulfate,2,Abstract,hl_i,9394106,test,gold,i
7723,placebo,2,Abstract,hl_i,9394106,test,gold,i
7724,"Endotoxin concentration , liver function tests , and other laboratory parameters",3,Abstract,ss_o,9394106,test,gold,o
7725,Endotoxin concentration,3,Abstract,hl_o,9394106,test,gold,o
7726,liver function tests,3,Abstract,hl_o,9394106,test,gold,o
7727,15 healthy controls .,4,Abstract,ss_p,9394106,test,gold,p
7728,Endotoxin concentration,4,Abstract,ss_o,9394106,test,gold,o
7729,15 healthy controls,4,Abstract,hl_p,9394106,test,gold,p
7730,Endotoxin concentration,4,Abstract,hl_o,9394106,test,gold,o
7731,paromomycin,5,Abstract,ss_i,9394106,test,gold,i
7732,placebo,5,Abstract,ss_i,9394106,test,gold,i
7733,paromomycin,5,Abstract,hl_i,9394106,test,gold,i
7734,placebo,5,Abstract,hl_i,9394106,test,gold,i
7735,paromomycin,6,Abstract,ss_i,9394106,test,gold,i
7736,placebo,6,Abstract,ss_i,9394106,test,gold,i
7737,endotoxin concentrations,6,Abstract,ss_o,9394106,test,gold,o
7738,paromomycin,6,Abstract,hl_i,9394106,test,gold,i
7739,placebo,6,Abstract,hl_i,9394106,test,gold,i
7740,endotoxin concentrations,6,Abstract,hl_o,9394106,test,gold,o
7741,( paromomycin,7,Abstract,ss_i,9394106,test,gold,i
7742,placebo,7,Abstract,ss_i,9394106,test,gold,i
7743,paromomycin,7,Abstract,ss_i,9394106,test,gold,i
7744,endotoxin concentration,7,Abstract,ss_o,9394106,test,gold,o
7745,endotoxin concentration or liver function tests,7,Abstract,ss_o,9394106,test,gold,o
7746,paromomycin,7,Abstract,hl_i,9394106,test,gold,i
7747,placebo,7,Abstract,hl_i,9394106,test,gold,i
7748,paromomycin,7,Abstract,hl_i,9394106,test,gold,i
7749,endotoxin concentration,7,Abstract,hl_o,9394106,test,gold,o
7750,endotoxin concentration,7,Abstract,hl_o,9394106,test,gold,o
7751,liver function tests,7,Abstract,hl_o,9394106,test,gold,o
7752,patients with alcoholic liver disease .,8,Abstract,ss_p,9394106,test,gold,p
7753,paromomycin,8,Abstract,ss_i,9394106,test,gold,i
7754,patients with alcoholic liver disease .,8,Abstract,hl_p,9394106,test,gold,p
7755,paromomycin,8,Abstract,hl_i,9394106,test,gold,i
7756,patients with alcoholic liver disease -- a,0,Title,ss_p,9394106,test,gold,p
7757,paromomycin,0,Title,ss_i,9394106,test,gold,i
7758,placebo-controlled,0,Title,ss_i,9394106,test,gold,i
7759,endotoxemia,0,Title,ss_o,9394106,test,gold,o
7760,patients with alcoholic liver disease,0,Title,hl_p,9394106,test,gold,p
7761,paromomycin,0,Title,hl_i,9394106,test,gold,i
7762,placebo-controlled,0,Title,hl_i,9394106,test,gold,i
7763,endotoxemia,0,Title,hl_o,9394106,test,gold,o
7764,temporomandibular ( TMJ ) joint pain,0,Abstract,ss_p,9481998,test,gold,p
7765,indomethacin phonophoresis,0,Abstract,ss_i,9481998,test,gold,i
7766,placebo-controlled,0,Abstract,ss_i,9481998,test,gold,i
7767,pain-relieving,0,Abstract,ss_o,9481998,test,gold,o
7768,indomethacin phonophoresis,0,Abstract,hl_i,9481998,test,gold,i
7769,placebo-controlled,0,Abstract,hl_i,9481998,test,gold,i
7770,pain-relieving,0,Abstract,hl_o,9481998,test,gold,o
7771,"Twenty subjects , who have TMJ pain , were included for this study",1,Abstract,ss_p,9481998,test,gold,p
7772,"Twenty subjects , who have TMJ pain",1,Abstract,hl_p,9481998,test,gold,p
7774,indomethacin,3,Abstract,ss_i,9481998,test,gold,i
7775,placebo,3,Abstract,ss_i,9481998,test,gold,i
7776,indomethacin,3,Abstract,hl_i,9481998,test,gold,i
7777,placebo,3,Abstract,hl_i,9481998,test,gold,i
7778,Pre- and post-treatment pain levels and pain sensitivity,4,Abstract,ss_o,9481998,test,gold,o
7779,visual analogue scales ( VAS ) and pressure pain threshold ( PPT ) .,4,Abstract,ss_o,9481998,test,gold,o
7780,pain levels,4,Abstract,hl_o,9481998,test,gold,o
7781,pain sensitivity,4,Abstract,hl_o,9481998,test,gold,o
7782,visual analogue scales ( VAS ),4,Abstract,hl_o,9481998,test,gold,o
7783,pressure pain threshold ( PPT ),4,Abstract,hl_o,9481998,test,gold,o
7784,post-treatment VAS,5,Abstract,ss_o,9481998,test,gold,o
7785,post-treatment PPT,5,Abstract,ss_o,9481998,test,gold,o
7786,post-treatment VAS,5,Abstract,hl_o,9481998,test,gold,o
7787,post-treatment PPT,5,Abstract,hl_o,9481998,test,gold,o
7788,indomethacin phonophoresis,6,Abstract,ss_i,9481998,test,gold,i
7789,pain,6,Abstract,ss_o,9481998,test,gold,o
7790,indomethacin phonophoresis,6,Abstract,hl_i,9481998,test,gold,i
7791,pain,6,Abstract,hl_o,9481998,test,gold,o
7792,temporomandibular joint pain .,0,Title,ss_p,9481998,test,gold,p
7793,indomethacin phonophoresis,0,Title,ss_i,9481998,test,gold,i
7794,pain .,0,Title,ss_o,9481998,test,gold,o
7795,temporomandibular joint pain .,0,Title,hl_p,9481998,test,gold,p
7796,indomethacin phonophoresis,0,Title,hl_i,9481998,test,gold,i
7797,Human brain natriuretic peptide ( hBNP ),0,Abstract,ss_i,9573502,test,gold,i
7798,Human brain natriuretic peptide ( hBNP ),0,Abstract,hl_i,9573502,test,gold,i
7799,hBNP,1,Abstract,ss_i,9573502,test,gold,i
7800,"systemic hemodynamic , neurohormonal , and renal effects",1,Abstract,ss_o,9573502,test,gold,o
7801,hBNP,1,Abstract,hl_i,9573502,test,gold,i
7802,systemic hemodynamic,1,Abstract,hl_o,9573502,test,gold,o
7803,neurohormonal,1,Abstract,hl_o,9573502,test,gold,o
7804,renal effects,1,Abstract,hl_o,9573502,test,gold,o
7805,16 decompensated heart failure patients,2,Abstract,ss_p,9573502,test,gold,p
7806,hBNP,2,Abstract,ss_i,9573502,test,gold,i
7807,placebo-controlled,2,Abstract,ss_i,9573502,test,gold,i
7808,16 decompensated heart failure patients,2,Abstract,hl_p,9573502,test,gold,p
7809,hBNP,2,Abstract,hl_i,9573502,test,gold,i
7810,placebo-controlled,2,Abstract,hl_i,9573502,test,gold,i
7811,( placebo,3,Abstract,ss_i,9573502,test,gold,i
7812,hBNP,3,Abstract,ss_i,9573502,test,gold,i
7813,placebo,3,Abstract,hl_i,9573502,test,gold,i
7814,hBNP,3,Abstract,hl_i,9573502,test,gold,i
7815,hBNP .,4,Abstract,ss_i,9573502,test,gold,i
7816,Urinary volume losses,4,Abstract,ss_o,9573502,test,gold,o
7817,hBNP .,4,Abstract,hl_i,9573502,test,gold,i
7818,hBNP,5,Abstract,ss_i,9573502,test,gold,i
7819,adverse events .,5,Abstract,ss_o,9573502,test,gold,o
7820,hBNP,5,Abstract,hl_i,9573502,test,gold,i
7821,adverse events .,5,Abstract,hl_o,9573502,test,gold,o
7822,hBNP,6,Abstract,ss_i,9573502,test,gold,i
7823,right atrial pressure and pulmonary capillary wedge pressure,6,Abstract,ss_o,9573502,test,gold,o
7824,hBNP,6,Abstract,hl_i,9573502,test,gold,i
7825,right atrial pressure and pulmonary capillary wedge pressure,6,Abstract,hl_o,9573502,test,gold,o
7826,hBNP,7,Abstract,ss_i,9573502,test,gold,i
7827,systemic vascular resistance,7,Abstract,ss_o,9573502,test,gold,o
7828,hBNP,7,Abstract,hl_i,9573502,test,gold,i
7829,systemic vascular resistance,7,Abstract,hl_o,9573502,test,gold,o
7830,hBNP,8,Abstract,ss_i,9573502,test,gold,i
7831,cardiac index,8,Abstract,ss_o,9573502,test,gold,o
7832,heart rate .,8,Abstract,ss_o,9573502,test,gold,o
7833,hBNP,8,Abstract,hl_i,9573502,test,gold,i
7834,cardiac index,8,Abstract,hl_o,9573502,test,gold,o
7835,heart rate .,8,Abstract,hl_o,9573502,test,gold,o
7836,"placebo , hBNP",9,Abstract,ss_i,9573502,test,gold,i
7837,plasma norepinephrine and aldosterone .,9,Abstract,ss_o,9573502,test,gold,o
7838,placebo,9,Abstract,hl_i,9573502,test,gold,i
7839,hBNP,9,Abstract,hl_i,9573502,test,gold,i
7840,plasma norepinephrine and aldosterone .,9,Abstract,hl_o,9573502,test,gold,o
7841,hBNP ;,10,Abstract,ss_i,9573502,test,gold,i
7842,Renal hemodynamics,10,Abstract,ss_o,9573502,test,gold,o
7843,natriuretic effect .,10,Abstract,ss_o,9573502,test,gold,o
7844,hBNP ;,10,Abstract,hl_i,9573502,test,gold,i
7845,Renal hemodynamics,10,Abstract,hl_o,9573502,test,gold,o
7846,natriuretic effect .,10,Abstract,hl_o,9573502,test,gold,o
7847,hBNP,11,Abstract,ss_i,9573502,test,gold,i
7848,hemodynamic effects,11,Abstract,ss_o,9573502,test,gold,o
7849,cardiac preload and systemic vascular resistance .,11,Abstract,ss_o,9573502,test,gold,o
7850,hBNP,11,Abstract,hl_i,9573502,test,gold,i
7851,hemodynamic effects,11,Abstract,hl_o,9573502,test,gold,o
7852,cardiac preload and systemic vascular resistance .,11,Abstract,hl_o,9573502,test,gold,o
7853,hBNP,12,Abstract,ss_i,9573502,test,gold,i
7854,cardiac output,12,Abstract,ss_o,9573502,test,gold,o
7855,heart rate .,12,Abstract,ss_o,9573502,test,gold,o
7856,hBNP,12,Abstract,hl_i,9573502,test,gold,i
7857,cardiac output,12,Abstract,hl_o,9573502,test,gold,o
7858,heart rate .,12,Abstract,hl_o,9573502,test,gold,o
7859,hBNP,13,Abstract,ss_i,9573502,test,gold,i
7860,Plasma norepinephrine and aldosterone levels,13,Abstract,ss_o,9573502,test,gold,o
7861,hBNP,13,Abstract,hl_i,9573502,test,gold,i
7862,Plasma norepinephrine and aldosterone levels,13,Abstract,hl_o,9573502,test,gold,o
7863,decompensated heart failure .,14,Abstract,ss_p,9573502,test,gold,p
7864,hBNP,14,Abstract,ss_i,9573502,test,gold,i
7865,hBNP,14,Abstract,hl_i,9573502,test,gold,i
7866,patients with hemodynamically decompensated heart failure .,0,Title,ss_p,9573502,test,gold,p
7867,human brain natriuretic peptide,0,Title,ss_i,9573502,test,gold,i
7868,"Systemic hemodynamic , neurohormonal , and renal effects",0,Title,ss_o,9573502,test,gold,o
7869,patients with hemodynamically decompensated heart failure .,0,Title,hl_p,9573502,test,gold,p
7870,human brain natriuretic peptide,0,Title,hl_i,9573502,test,gold,i
7871,"Systemic hemodynamic , neurohormonal",0,Title,hl_o,9573502,test,gold,o
7872,renal effects,0,Title,hl_o,9573502,test,gold,o
7874,placebo,1,Abstract,ss_i,9695300,test,gold,i
7875,salbutamol .,1,Abstract,ss_i,9695300,test,gold,i
7876,clinical response,1,Abstract,ss_o,9695300,test,gold,o
7877,salbutamol,1,Abstract,hl_i,9695300,test,gold,i
7878,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis,2,Abstract,ss_p,9695300,test,gold,p
7879,salbutamol,2,Abstract,ss_i,9695300,test,gold,i
7880,saline ;,2,Abstract,ss_i,9695300,test,gold,i
7881,saline,2,Abstract,ss_i,9695300,test,gold,i
7882,mist,2,Abstract,ss_i,9695300,test,gold,i
7883,One hundred and fifty-six infants aged between 7 weeks and 24 months,2,Abstract,hl_p,9695300,test,gold,p
7884,had an episode of wheezing and other signs and symptoms of bronchiolitis,2,Abstract,hl_p,9695300,test,gold,p
7885,salbutamol,2,Abstract,hl_i,9695300,test,gold,i
7886,saline,2,Abstract,hl_i,9695300,test,gold,i
7887,saline,2,Abstract,hl_i,9695300,test,gold,i
7888,mist,2,Abstract,hl_i,9695300,test,gold,i
7889,oxygen,3,Abstract,ss_i,9695300,test,gold,i
7890,oxygen,3,Abstract,hl_i,9695300,test,gold,i
7891,respiratory score,4,Abstract,ss_o,9695300,test,gold,o
7892,"Respiratory rate , heart rate , oxygen saturation and presence of cyanosis , wheezing , retractions",5,Abstract,ss_o,9695300,test,gold,o
7893,"Respiratory rate , heart rate , oxygen saturation and presence of cyanosis , wheezing , retractions",5,Abstract,hl_o,9695300,test,gold,o
7894,respiratory score,6,Abstract,ss_o,9695300,test,gold,o
7895,respiratory score,6,Abstract,hl_o,9695300,test,gold,o
7897,Heart rate,8,Abstract,ss_o,9695300,test,gold,o
7898,Heart rate,8,Abstract,hl_o,9695300,test,gold,o
7899,Oxygen saturation,9,Abstract,ss_o,9695300,test,gold,o
7900,Oxygen saturation,9,Abstract,hl_o,9695300,test,gold,o
7901,acute bronchiolitis .,10,Abstract,ss_p,9695300,test,gold,p
7902,Salbutamol,10,Abstract,ss_i,9695300,test,gold,i
7903,effective,10,Abstract,ss_o,9695300,test,gold,o
7904,safe,10,Abstract,ss_o,9695300,test,gold,o
7905,Salbutamol,10,Abstract,hl_i,9695300,test,gold,i
7906,effective,10,Abstract,hl_o,9695300,test,gold,o
7907,safe,10,Abstract,hl_o,9695300,test,gold,o
7908,acute bronchiolitis .,0,Title,ss_p,9695300,test,gold,p
7909,Salbutamol,0,Title,ss_i,9695300,test,gold,i
7910,mist,0,Title,ss_i,9695300,test,gold,i
7911,acute bronchiolitis .,0,Title,hl_p,9695300,test,gold,p
7912,Salbutamol,0,Title,hl_i,9695300,test,gold,i
7913,mist,0,Title,hl_i,9695300,test,gold,i
7914,inflammatory and infective markers,0,Abstract,ss_o,9730996,test,gold,o
7915,inflammatory and infective markers,0,Abstract,hl_o,9730996,test,gold,o
7916,bronchiectasis .,1,Abstract,ss_p,9730996,test,gold,p
7917,placebo-controlled,1,Abstract,ss_i,9730996,test,gold,i
7918,fluticasone,1,Abstract,ss_i,9730996,test,gold,i
7919,placebo-controlled,1,Abstract,hl_i,9730996,test,gold,i
7920,fluticasone,1,Abstract,hl_i,9730996,test,gold,i
7921,Twenty-four patients ( 12 female ; mean age 51 yr ),2,Abstract,ss_p,9730996,test,gold,p
7922,fluticasone,2,Abstract,ss_i,9730996,test,gold,i
7923,placebo .,2,Abstract,ss_i,9730996,test,gold,i
7924,Twenty-four,2,Abstract,hl_p,9730996,test,gold,p
7925,12,2,Abstract,hl_p,9730996,test,gold,p
7926,mean age 51 yr,2,Abstract,hl_p,9730996,test,gold,p
7927,fluticasone,2,Abstract,hl_i,9730996,test,gold,i
7928,placebo .,2,Abstract,hl_i,9730996,test,gold,i
7929,"spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities , and concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha ) , and leukotriene B4 ( LTB4 )",3,Abstract,ss_o,9730996,test,gold,o
7930,"spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities",3,Abstract,hl_o,9730996,test,gold,o
7931,"concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha )",3,Abstract,hl_o,9730996,test,gold,o
7932,leukotriene B4 ( LTB4 ),3,Abstract,hl_o,9730996,test,gold,o
7933,fluticasone,4,Abstract,ss_i,9730996,test,gold,i
7934,"sputum leukocyte density and IL-1beta , IL-8 , and LTB4",4,Abstract,ss_o,9730996,test,gold,o
7935,fluticasone,4,Abstract,hl_i,9730996,test,gold,i
7936,sputum leukocyte density,4,Abstract,hl_o,9730996,test,gold,o
7937,"IL-1beta , IL-8",4,Abstract,hl_o,9730996,test,gold,o
7938,LTB4,4,Abstract,hl_o,9730996,test,gold,o
7939,fluticasone,5,Abstract,ss_i,9730996,test,gold,i
7940,placebo,5,Abstract,ss_i,9730996,test,gold,i
7941,fluticasone,5,Abstract,hl_i,9730996,test,gold,i
7942,placebo,5,Abstract,hl_i,9730996,test,gold,i
7943,spirometry,6,Abstract,ss_o,9730996,test,gold,o
7944,reported adverse reactions,6,Abstract,ss_o,9730996,test,gold,o
7945,spirometry,6,Abstract,hl_o,9730996,test,gold,o
7946,adverse reactions,6,Abstract,hl_o,9730996,test,gold,o
7947,bronchiectasis .,7,Abstract,ss_p,9730996,test,gold,p
7948,fluticasone,7,Abstract,ss_i,9730996,test,gold,i
7949,sputum inflammatory indices,7,Abstract,ss_o,9730996,test,gold,o
7950,sputum inflammatory indices,7,Abstract,hl_o,9730996,test,gold,o
7951,bronchiectasis .,8,Abstract,ss_p,9730996,test,gold,p
7952,steroid,8,Abstract,ss_i,9730996,test,gold,i
7953,inflammatory components,8,Abstract,ss_o,9730996,test,gold,o
7954,bronchiectasis .,8,Abstract,hl_p,9730996,test,gold,p
7955,severe bronchiectasis .,0,Title,ss_p,9730996,test,gold,p
7956,fluticasone,0,Title,ss_i,9730996,test,gold,i
7957,sputum inflammatory indices,0,Title,ss_o,9730996,test,gold,o
7958,severe bronchiectasis .,0,Title,hl_p,9730996,test,gold,p
7959,fluticasone,0,Title,hl_i,9730996,test,gold,i
7960,sputum inflammatory indices,0,Title,hl_o,9730996,test,gold,o
7961,Amonafide,0,Abstract,ss_i,9816035,test,gold,i
7962,Amonafide,0,Abstract,hl_i,9816035,test,gold,i
7966,Amonafide,4,Abstract,ss_i,9816035,test,gold,i
7967,Amonafide,4,Abstract,hl_i,9816035,test,gold,i
7968,previously untreated metastatic breast cancer patients,5,Abstract,ss_p,9816035,test,gold,p
7969,cyclophosphamide-doxorubicin-5-fluorouracil,5,Abstract,ss_i,9816035,test,gold,i
7970,cyclophosphamide-doxorubicin-5-fluorouracil .,5,Abstract,ss_i,9816035,test,gold,i
7971,previously untreated metastatic breast cancer patients,5,Abstract,hl_p,9816035,test,gold,p
7972,"assess the difference in survival , toxicity , and overall response",6,Abstract,ss_o,9816035,test,gold,o
7973,survival,6,Abstract,hl_o,9816035,test,gold,o
7974,toxicity,6,Abstract,hl_o,9816035,test,gold,o
7975,overall response,6,Abstract,hl_o,9816035,test,gold,o
7976,amonafide,7,Abstract,ss_i,9816035,test,gold,i
7977,amonafide,7,Abstract,hl_i,9816035,test,gold,i
7978,cyclophosphamide-doxorubicin-5-fluorouracil,8,Abstract,ss_i,9816035,test,gold,i
7979,Patients had to have histologically documented measurable breast cancer and a performance status of 0-1 .,9,Abstract,ss_p,9816035,test,gold,p
7980,Patients had to have histologically documented measurable breast cancer and a performance status of 0-1 .,9,Abstract,hl_p,9816035,test,gold,p
7981,Patients could not have had prior chemotherapy for metastatic disease .,10,Abstract,ss_p,9816035,test,gold,p
7982,Patients could not have had prior chemotherapy for metastatic disease .,10,Abstract,hl_p,9816035,test,gold,p
7983,Prior adjuvant chemotherapy was permitted .,11,Abstract,ss_p,9816035,test,gold,p
7984,Prior adjuvant chemotherapy was permitted .,11,Abstract,hl_p,9816035,test,gold,p
7985,Patients could not have visceral crisis .,12,Abstract,ss_p,9816035,test,gold,p
7986,Patients could not have visceral crisis .,12,Abstract,hl_p,9816035,test,gold,p
7987,Amonafide,13,Abstract,ss_i,9816035,test,gold,i
7988,Amonafide,13,Abstract,hl_i,9816035,test,gold,i
7991,Toxicity,16,Abstract,ss_o,9816035,test,gold,o
7992,hematological,16,Abstract,ss_o,9816035,test,gold,o
7993,leukopenia,16,Abstract,ss_o,9816035,test,gold,o
7994,thrombocytopenia ;,16,Abstract,ss_o,9816035,test,gold,o
7995,leukopenia,16,Abstract,ss_o,9816035,test,gold,o
7996,thrombocytopenia .,16,Abstract,ss_o,9816035,test,gold,o
7997,Toxicity,16,Abstract,hl_o,9816035,test,gold,o
7998,leukopenia,16,Abstract,hl_o,9816035,test,gold,o
7999,thrombocytopenia,16,Abstract,hl_o,9816035,test,gold,o
8000,leukopenia,16,Abstract,hl_o,9816035,test,gold,o
8001,thrombocytopenia,16,Abstract,hl_o,9816035,test,gold,o
8002,response rate,17,Abstract,ss_o,9816035,test,gold,o
8003,response rate,17,Abstract,hl_o,9816035,test,gold,o
8004,hematological toxicity,18,Abstract,ss_o,9816035,test,gold,o
8005,leukopenia,18,Abstract,ss_o,9816035,test,gold,o
8006,hematological toxicity,18,Abstract,hl_o,9816035,test,gold,o
8007,leukopenia,18,Abstract,hl_o,9816035,test,gold,o
8008,thrombocytopenia,19,Abstract,ss_o,9816035,test,gold,o
8009,thrombocytopenia,19,Abstract,hl_o,9816035,test,gold,o
8010,amonafide,20,Abstract,ss_i,9816035,test,gold,i
8011,previously untreated breast cancer patients,20,Abstract,hl_p,9816035,test,gold,p
8012,amonafide,20,Abstract,hl_i,9816035,test,gold,i
8014,amonafide,22,Abstract,ss_i,9816035,test,gold,i
8015,Rates of responses,22,Abstract,ss_o,9816035,test,gold,o
8016,hematotoxicity ),22,Abstract,ss_o,9816035,test,gold,o
8017,Rates of responses,22,Abstract,hl_o,9816035,test,gold,o
8019,previously untreated advanced breast cancer -- a,0,Title,ss_p,9816035,test,gold,p
8020,Amonafide :,0,Title,ss_i,9816035,test,gold,i
8021,previously untreated advanced breast cancer -- a,0,Title,hl_p,9816035,test,gold,p
8022,Amonafide :,0,Title,hl_i,9816035,test,gold,i
